



US009963687B2

(12) **United States Patent**
Hsieh et al.

(10) **Patent No.:** US 9,963,687 B2
(45) **Date of Patent:** *May 8, 2018

(54) **FUSION POLYMERASE AND METHOD FOR USING THE SAME**(71) Applicant: **New England Biolabs, Inc.**, Ipswich, MA (US)(72) Inventors: **Pei-Chung Hsieh**, Topsfield, MA (US); **Luo Sun**, Hamilton, MA (US); **Thomas C. Evans, Jr.**, Topsfield, MA (US); **Theodore B. Davis**, Boxford, MA (US); **Andrew Gardner**, Manchester, MA (US)(73) Assignee: **New England Biolabs, Inc.**, Ipswich, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/046,166**(22) Filed: **Feb. 17, 2016**(65) **Prior Publication Data**

US 2016/0160193 A1 Jun. 9, 2016

Related U.S. Application Data

(63) Continuation-in-part of application No. 14/837,820, filed on Aug. 27, 2015, now Pat. No. 9,447,445.

(60) Provisional application No. 62/193,168, filed on Jul. 16, 2015, provisional application No. 62/189,599, filed on Jul. 7, 2015, provisional application No. 62/042,527, filed on Aug. 27, 2014.

(51) **Int. Cl.**

C12N 9/12	(2006.01)
C12P 19/34	(2006.01)
C12N 15/10	(2006.01)
C12N 15/64	(2006.01)
C12N 15/66	(2006.01)

(52) **U.S. Cl.**

CPC	C12N 9/1252 (2013.01); C12N 15/1027 (2013.01); C12N 15/1031 (2013.01); C12N 15/64 (2013.01); C12N 15/66 (2013.01); C12P 19/34 (2013.01); C12Y 207/07007 (2013.01); C07K 2319/00 (2013.01)
-----------	---

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,580,759 A	12/1996	Yang et al.
5,811,238 A	9/1998	Stemmer et al.
6,117,679 A	9/2000	Stemmer
6,150,111 A	11/2000	Tseng
6,261,797 B1	7/2001	Sorge et al.
6,361,974 B1	3/2002	Short et al.

6,372,429 B1	4/2002	Sharon
6,582,914 B1	6/2003	Caldwell et al.
6,635,449 B2	10/2003	Short
7,575,860 B2	8/2009	Evans et al.
7,723,077 B2	5/2010	Young et al.
7,776,532 B2	8/2010	Gibson et al.
8,435,736 B2	5/2013	Gibson et al.
8,476,045 B2	7/2013	Wang et al.
8,623,628 B2	1/2014	Barr Ost et al.
8,921,043 B2	12/2014	Gardner
8,968,999 B2	3/2015	Gibson et al.
9,447,445 B2 *	9/2016	Hsieh C12N 9/1252
2003/0194786 A1	10/2003	Sharon
2005/0112631 A1	5/2005	Piepenburg et al.
2006/0057683 A1	3/2006	Hyman
2006/0281109 A1	12/2006	Barr Ost et al.
2007/0141591 A1	6/2007	Borns
2008/0076123 A1	3/2008	Buzby
2008/0227159 A1 *	9/2008	Hogrefe C12N 9/1252
		435/91.2
2009/0048885 A1	2/2009	Bishop et al.
2010/0184187 A1	7/2010	Young et al.
2011/0053272 A1	3/2011	Benders et al.
2011/0053273 A1	3/2011	Benders et al.
2012/0053087 A1	3/2012	Gibson et al.
2013/0260422 A1	10/2013	Ong et al.
2013/0295645 A1	11/2013	Gibson et al.
2014/0220577 A1	8/2014	Wang et al.
2014/0296082 A1	10/2014	Gardner

FOREIGN PATENT DOCUMENTS

EP	1664287	9/2004
EP	1929012 A2	6/2008
EP	2239327 A2	10/2010
GB	248527	5/2012

(Continued)

OTHER PUBLICATIONS

Wilson et al. (2000) Assessing Annotation Transfer for Genomics: Quantifying the Relations between Protein Sequence, Structure and Function through Traditional and Probabilistic Scores. *Journal of Molecular Biology*, 297:233-249.*

Choli, et al., Isolation, characterization and microsequence analysis of a small basic methylated DNA-binding protein from the Archaeabacterium, Sulfolobus solfataricus, *Biochim Biophys Acta*, 1988, 950 (2):193-203.

McAfee, et al., Gene Cloning, Expression, and Characterization of the Sac7 Proteins from the Hyperthermophile Sulfolobus acidocaldarius, *Biochemistry*, 1995, 34 (31):10063-10077.

Pavlov, et al., Helix-hairpin—helix motifs confer salt resistance and processivity on chimeric DNA polymerases, *Proc. Natl. Acad. Sci.*, 2002, 99 (21):13510-13515.

(Continued)

Primary Examiner — Neil P Hammell

(74) Attorney, Agent, or Firm — New England Biolabs, Inc; Harriet M. Strimpel

(57) **ABSTRACT**

This disclosure provides, among other things, a composition comprising: comprising a fusion protein comprising: (a) a DNA polymerase; and (b) a heterologous sequence-specific DNA binding domain. A method for copying a DNA template, as well as a kit for performing the same, are also described.

(56)

References Cited**FOREIGN PATENT DOCUMENTS**

WO	1998038296	A1	9/1998
WO	1998038297	A1	9/1998
WO	1998038298	A1	9/1998
WO	1998038299	A1	9/1998
WO	9947649		9/1999
WO	0118213		3/2001
WO	WO 2001/23411		4/2001
WO	01066775	A2	9/2001
WO	2007021944		2/2007
WO	2007032837	A2	3/2007
WO	2008074346		6/2008
WO	WO 2009/131919		4/2009
WO	2009103027	A2	8/2009
WO	2010062776		6/2010
WO	2010080910		7/2010

OTHER PUBLICATIONS

- Bedford, et al., The thioredoxin binding domain of bacteriophage T7 DNA polymerase confers processivity on *Escherichia coli* DNA polymerase I, Proc. Natl. Acad. Sci., 1997, 94: 479-484.
- Zuccola, et al., The Crystal Structure of an Unusual Processivity Factor, Herpes Simplex Virus UL42, Bound to the C Terminus of Its Cognate Polymerase, Molecular Cell, 2000, 5 (2):267-278.
- Shamoo, et al., Building a Replisome from Interacting Pieces: Sliding Clamp Complexed to a Peptide from DNA Polymerase and a Polymerase Editing Complex, Cell, 1999, 99 (2):155-166.
- Wang, et al., A novel strategy to engineer DNA polymerases for enhanced processivity and improved performance in vitro, Nucleic Acids Research, 2004, 32 (3):1197-1207.
- Halford, et al., How do site-specific DNA-binding proteins find their targets?, Nucleic Acids Research, 2004, 32 (10):3040-3052.
- Schleif, DNA Binding by Proteins, Science, 1988, 241, 1182-1187.
- Ignatov, et al., A strong strand displacement activity of thermostable DNA polymerase markedly improves the results of DNA amplification, BioTechniques, 57:81-87, 2014.
- Argos, A sequence motif in many polymerases, Nucleic Acids Research, 16: 9909-9916, 1988.
- Ito, et al., Compilation and alignment of DNA polymerase sequences Nucleic Acids Research, 19: 4045-4057, 1991.
- Braithwaite, Compilation, alignment, and phylogenetic relationships of DNA polymerases, Nucleic Acids Research, 21:787-802, 1993.
- Steiz, DNA polymerases: structural diversity and common mechanisms, J. Biol. Chem., 274: 17395-8, 1999.
- Loh and Loeb, et al., Mutability of DNA polymerase I: Implications for the creation of mutant DNA polymerases, DNA Repair 4, 1390-1398, 2005.
- Matsukawa, et al., A useful strategy to construct DNA polymerases with different properties by using genetic resources from environmental DNA, Genes Genet. Syst. 84 3-13, 2009.
- Baar, et al., Molecular breeding of polymerases for resistance to environmental inhibitors, Nucleic Acids Research, 1-12, 2011.
- Hashimoto, et al., Crystal structure of DNA polymerase from hyperthermophilic archaeon Pyrococcus kodakaraensis KOD1, J. Mol. Biol., 306: 469-477, 2001.
- Biles, et al., Low-fidelity Pyrococcus furiosus DNA polymerase mutants useful in error-prone PCR, Nucleic Acids Research, vol. 32, p. e176, 2004.
- Kim, et al., Crystal structure of Pfu, the high fidelity DNA polymerase from Pyrococcus furiosus, Int. J. of Bio. Macromolecules, 42: 356-361, 2008.
- Eshwadfy, et al., DNA polymerase hybrids derived from the family-B enzymes of Pyrococcus furiosus and Thermococcus kodakarensis: improving performance in the polymerase chain reaction, Frontiers in Microbiology, 5, 224, 2014.
- Gaidamaviciute, et al., Site-directed chemical modification of archaeal Thermococcus litoralis Sh1B DNA polymerase: Acquired ability to read through template-strand uracils, Biochim Biophys Acta., 1804(6), 1385-1393, 2010.
- Hansen, et al., Engineered split in Pfu DNA polymerase fingers domain improves incorporation of nucleotide gamma-phosphate derivative, Nucleic Acids Research, 39(5), 1801-1810, 2011.
- Wynne, et al., Structures of an apo and a binary complex of an evolved archeal B family DNA polymerase capable of synthesising highly cy-dye labelled DNA, PLoS One, 8(8), e70892, 2013.
- Arezi, et al., Efficient and high fidelity incorporation of dyes-terminators by a novel archaeal DNA polymerase mutant, Journal of Molecular Biology, 322(4), 719-729, 2002.
- Brennan, et al., The winged-helix DNA-binding motif: another helix-turn-helix takeoff, Cell., 74: 773-6, 1993.
- Martinez-Hackert, Structural relationships in the OmpR family of winged-helix transcription factors, Journal of Molecular Biology, 269:301-12, 1997.
- Gajivala, et al., Winged helix proteins, Current Opinion in Structural Biology, 10: 110-116, 2000.
- Huffman, et al., Prokaryotic transcription regulators: more than just the helix-tum-helix motif, Current Opinion in Structural Biology, 12(1):98-106, 2002.
- Kenney, Structure/function relationships in OmpR and other winged-helix transcription factors, Curr. Opin. Microbiol., 5:135-41, 2002.
- Lintner, The structure of the CRISPR-associated protein Csa3 provides insight into the regulation of the CRISPR/Cas system, Journal of Molecular Biology, 405: 939-55, 2011.
- Kelman, et al., Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps, Nucleic Acids Research, 23: 3613-20, 1995.
- Wang, et al., Crystal structures of an NH2-terminal fragment of T4 DNA polymerase and its complexes with single-stranded DNA and with divalent metal ions, Biochemistry, 35: 8110-8119, 1996.
- Wang et al. "A novel strategy to engineer DNA polymerases for enhanced processivity and improved performance in vitro", Nucleic Acids Research, 2004, vol. 32, No. 3, pp. 1197-1207.
- Lee, et al., Journal of Bacteriology, 14, 3666-3667, 2011.
- Ignatov, et al., Biotechniques, 57, 2, 81-87, 2014.
- Harris, et al., Biotechniques, 54, 2, 93-97, 2013.
- Communication dated Dec. 21, 2015 from the International Searching Authority for International application No. PCT/US2015/047161.
- Zimmerman, S. et al., Macromolecular crowding accelerates the cohesion of DNA fragments with complementary termini, Nucl. Acids res., vol. 13, pp. 2241-2249 (1985).
- Lai and Masker, "Repair of double-strand breaks by incorporation of a molecule of homologous DNA", Mol. Microbiol., 36(2):437-46 (2000).
- Gibson et al., "Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome", Science, 319(5867):1215-1220 (2008).
- Gibson et al., "Enzymatic assembly of DNA molecules up to several hundred kilobases", Nat. Methods., 6(5):343-345 (2009).
- Tseng, DNA cloning without restriction enzyme and ligase, Biotechniques, 27:1240-1244 (1999).
- Kaluz, et al., 1992, Nucleic Acids Research 20:4369-4370.
- Dekker, et al., Joining of long double-stranded RNA molecules through controlled overhangs, Nucleic Acids Research, 32:E140 (2004).
- Garforth, et al., Mutagenesis of conserved lysine residues in bacteriophage T5 5'-3' exonuclease suggests separate mechanisms of endo- and exonucleolytic cleavage, PNAS, USA, 96:38-43 (1999).
- Gibson, Enzymatic assembly of overlapping DNA fragments, Methods Enzymol., 498:349-361 (2011).
- Hsiao, Exonuclease III induced ligase-free directional subcloning of PCR products, Nucleic Acids Research, 21:5528-5529 (1993).
- Jessberger, et al., A Mammalian Protein Complex That Repairs Double-strand Breaks and Deletions by Recombination, The Journal of Biological Chemistry, 268: 15070-15079 (1993).
- Joannes, et al., DNA filter retention assay for exonuclease activities. Application to the analysis of processivity of phage T5 induced 5'-exonuclease, Biochemistry, 24, 8043-8049 (1985).

(56)

References Cited**OTHER PUBLICATIONS**

- Li, et al., Ligation independent cloning irrespective of restriction site compatibility, *Nucleic Acids Research*, 25:4165-4166 (1997).
- Pickering, et al., Variation in the Steady State Kinetic Parameters of Wild Type and Mutant T5 5*-3*-Exonuclease With pH, *The Journal of Biological Chemistry*, 274, 25, 17711-17717 (1999).
- Pickering, et al., A single cleavage assay for T5 5'-3' exonuclease: determination fo the catalytic parameters for wild-type and mutant proteins, *Nucleic Acids Research*, 1999, 27, 730-735 (1999).
- Sasaki, et al., Regulation of DNA nucleases by molecular crowding, *Nucleic Acids Research*, 35, 4086-4093 (2007).
- Zimmerman, Macromolecular Crowding: Biochemical, Biophysical, and Physiological Consequences, *Ann. Rev. Biophys. Biomol. Struct.* 22:27-65 (1993).
- Yang, et al., Construction of recombinant DNA by exonuclease recession, *Nucleic Acids Research*, 21, 1889-1893 (1993).
- Yu, et al., Recombineering with overlapping single-stranded DNA oligonucleotides: Testing a recombination intermediate, *PNAS*, 100, 7207-7212 (2003).
- Zhou, et al., An improved ligase-free method for directional subcloning of PCR amplified DNA, *Nucleic Acids Research*, 23: 1089-1090 (1995).
- Declaration of Daniel G. Gibson, Ph.D. dated Nov. 13, 2014.
- WP_013748330.1 (NCBI Reference Sequence, Pyrococcus sp. NA2 DNA polymerase, GI:503513858, priority to May 27, 2013), 2 pages.
- WP_011011764.1 (NCBI Reference Sequence, Pyrococcus DNA-binding protein, priority to Jul. 18, 2013), 1 page.
- Doherty et al., "The helix-hairpin-helix DNA-binding motif: a structural basis for non-sequence-specific recognition of DNA", *Nucleic Acids Research*, 1996, 24(13):2488-2497.
- Doublet et al., "Structural insights into eukaryotic DNA replication", *Front Microbiol.*, 2014, 5:444.
- Brautigam et al., "Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes", *Curr Opin Struct Biol.*, Feb. 1998., 8(1):54-63.
- Norambuena et al., "The Protein-DNA Interface database", *BMC Bioinformatics*, 2010, 11:262.
- Luscombe et al., "An overview of the structures of protein-DNA complexes", *Genome Biology*, 2000, 1(1): REVIEWS001. Epub Jun. 9, 2000.
- Rohs et al., "Origins of specificity in protein-DNA recognition", *Annu Rev Biochem.*, 2010, 79: 233-269.
- Brennan et al., "The Helix-Turn-Helix DNA Binding Motif", *The Journal of Biological Chemistry*, 1989, 264(4): 1903-1906.
- Wintjens et al., "Structural Classification of HTH DNA-binding Domains and Protein-DNA Interaction Modes", *Journal of Molecular Biology*, 1996, 262(2):294-313.
- Schofield et al., "Patterns, puzzles and paradigms—The riddle of the homeobox", *Trends Neurosci.*, 1987, 10(1):3-6.
- Corsetti et al., "Differential DNA binding properties of three human homeodomain proteins", *Nucleic Acids Research*, 1992, 20(17): 4465-4472.
- Scott et al., "The structure and function of the homeodomain", *Biochimica et Biophysica Acta.*, 1989, 989(1): 25-48.

* cited by examiner




FIG. 1A

FIG. 1B




FIG. 1C




FIG. 1D





FIG. 1E






FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6





FIG. 7

Sequence of Single-stranded oligo:


Double-stranded vector user: GeneArt® CRISPRB Nuclease Vector with GFP Reporter Kit Catalog number A21174 (SEQ ID NO: 28)

Double-stranded vector used: GeneArt® CRISPR Nuclease Vector with OPT Reporter Kit Catalog number: A21174

EIG. 8A




三
八
一
二



80
G
上


Sequence of single stranded oligo containing degenerate bases:

FIG. 9A



၁၃၈

Sanger sequencing result from assembly pool. Partial designed ss-oligo sequence is displayed.



१०८




FIG. 10

DNA binding domains from Archaea Pyrococcus Furiosus

BD-51 MKTFTECQIQKVMLRAKGYQSEIAKIGTSRANVSILEKRAMIEKIEKARNNTLLWEQINSKVIVEIKAGEDIISIPEKEFKKADKVGVVKYSTAETITFLVEHAPVE
 DRIAKRDFVLFLDSSKNNKLIGDCLVIEEIKED (SEQ ID NO:56)
 BE-52 MPITKVTRNYQTIPAEIRKALGIKEGELLEVRENGKIIERLEKKERTKLKGKLTLEEIAKEIIEGMIQCMQ (SEQ ID NO:57)
 BD-54 TKEILRLRKEREMYAYEIWSLLGKPLKYQAVHQHQLKEELGLVEQAYRKGRVYYKITEKGRLRILQNFFEDLNI (SEQ ID NO:58)
 BD-62 MNTGAQGVSEMSRMKISVQLPQSILHGLDALYKRGIPNREARVAIRELLKKELYKEIQQEPIPEYVVK (SEQ ID NO:59)
 BD-67 NNCECMVVKEKLYTVKQASEILGVHPKTIQKW/DREGKIKTVTPGGRRIPESEIKRLLGSEEK (SEQ ID NO:61)
 BD-71 MLKDSAPKRKILEELRKGETVSGDYLASLKGVSRAVIAWKHIRELKELGYHADKKGYKLVYEPKKPPW (SEQ ID NO:62)
 BD-74 MIDERDKILELEKDARTPFTIAKKLGISETAVRKVKALEEGKIGEYGTICKPKKLGYSLVTTGVDTKPEKLFEVAEKLKE (SEQ ID NO:63)
 BD-75 MEIDDLDRKILSLLIEDSRLSYREIAKKLNIVAVGTYNRIKKLEDMGVIQGFTVKLNVEKLYGELTAIIKGKAQGKK (SEQ ID NO: 64)
 BD-81 EMLWMMYKLKKDRPMVAYEIRNEKKRKGFEPAVSSYVVLRLLEGGVVSEWESEAGRSRKYRLTEKGEKLEKGJETIEDVLNMLKS (SEQ ID NO:65)
 BD-82 MKVSKATASKVIRSLENKGIVERERRGKTYLVRLTNKGLELLEISKAGKELDEKIFAEAMSVDERIVL (SEQ ID NO:66)
 BD-85 SEDYMLQNRRKVLAKV/LENNYNPKALNISELARMFGYSDTIYNDIQQIKNVEV (SEQ ID NO:67)
 BD-86 SKEISRFELKVISNPIRYGLKMLNDRW/MCVCLISEALEIDQTLVSHHIRLKELDLLEERKEKGKLRFYRTNKEKLREYLEKVLDFNHGTGKGS (SEQ ID NO:68)
 BD-88 MCRKDVMSDPKQIKALSDPTRVKILELLRYHMPMTSEISRVIGKDSTSRYHKALEEAGLVEEVEKIGNETVYGR (SEQ ID NO:69)
 BD-89 MEPVEFKINQKGKISLIPTMEEAIMYMWEIKEATAGEVYEMTKYPEIRRSTVSILMNRLCERGLIKRRMEKGKKGIRVYYSITTTREEFERKVEKIIESLMM
 NFREATFAYSKINKK (SEQ ID NO:70)
 BD-91 MKKSNLDDILLAKAGGIEKEILTSRELSKMLNVSPTQITVRWLEKDGLIKKESRKGTLVITTEGVKFLEKLHEELSDALYR (SEQ ID NO:71)

FIG. 11A

DNA binding domains from Archaea Pyrococcus Furiosus

BBD-92
MEIPPEISHALSEIGFTKYEILTYWTLVYGPSTAKEISTKSIGIPYNRYDTISSLKLRGFVTIEGTPKVYAAYSPPRIAFFRFKKKELEDIMKKLEIEL
NNVKK (SEQ ID NO:72)

BD-93
INPQJARLPLELEIJKQKKSITITEIKEISERRKSEYPLSVSEYISRLERKGYVKKIAKGRKKFVEALI (SEQ ID NO:73)

BD-94
GIDVVVPEIKHDPIARDIVKILFDLRRANVSIARELKGRRGKASRNTVRKKLEKELEKLGVKEVPGERSVYTLSREVKKWLDLIGIPINLL
(SEQ ID NO:74)

BD-97
MTKRVKVITDPEVIKVMLEDTTRKILQLLRNREMTISQLSEILGKMPQTIHIEKLKEAGLVEVKR (SEQ ID NO:75)

BD-98
MEEIKEIMKSHTLGNPVRLGIMIYLFPRRRAPFSHIQKALDLTPGNLD SHIKVLEKHGFVRTYKVIA DRPRRTMVEITDYGMEETRKFLSHLK
TVIDAIHF (SEQ ID NO:76)

BD-100
MGEELNRLLDVIGNETRRRIIELLTKRPFVSELSRELGVGQKAVLEHRLLEAGLIESRVEKIPRGRPRKYYMIKKGLRLEILLPTLFGSEM
YEAK (SEQ ID NO:77)

BD-102
MRRRIDKVIDLQLIKLSQNSRSLTYRELAEMLGTTTRQRYARKVDKLKKLGIRKFTIIPNLEK (SEQ ID NO:78)

BD-105
MGRDKKKNTALLDIARDIGGDEAVEVVKALEKKGEATDEELAELTGVRVNTVRKLYVALYDAKLATFRRVRDDETGWYYYYWRI DTKRLPEVI
RTRKLQELEKLK (SEQ ID NO:108)

BD-109
GRKVRTQQNEILNLNEKEKAVLRAILEHGGEIKQEDLPLEVGSRPTISKVIQELENKGLIKREKSGKTFVVKIERKIKLD (SEQ ID NO:79)

FIG. 11B

Phylogenetic Tree of
DNA Binding Domains from Pyrococcus Furiosus (Archaea)




FIG. 12

DNA binding domains from Bacteria Thermotoga Maritima

BD-02 KSLQRFLRRNNTTSIKHLSLTGVARNRILSDILNGKTQKIRGETLRKIAKAFEKSNLNF (SEQ ID NO:80)
BD-03 DVIQRIKEKYDEFTNAEKKIADTILSDPKGIESSISDLSEKAGVKSEASVVKFYKKLGLNSFQQFKVLLAQSISSRAPLEIVYEDVSSEDITKTITEKIFKATVRAI
(SEQ ID NO:81)
BD-04 KIRDKILNVYTQFSPAERKVADYVLERPDDVHYSITEFAKIVGVSETTIHRMIKKLDFFEGYQAFKIALARELSGLEETIERDFIDEEDILRRLKDLD (SEQ ID
NO:82)
BD-06 MRGTVKWFDSKKGYGFITMENGEDIFVHWSAIQMDGFKTLRENETVFEVQKGTKGPQAVNVRPVR (SEQ ID NO:109)
BD-07 KRRPTINDVAKLAGVSIITVSRYLKDPGSQVSEKLGGERIREAIKKLGYPKPNKIAQGLRTGD (SEQ ID NO:83)
Bd-08 MASIKDVAKLAGVSIATVSRVINGYNVNVEETRKVIDAIRKLNYHPVVAVKGAVLKR (SEQ ID NO:84)
BD-09 MKKKYVTIRIDAEKAGVSINTVSRALNNKPDISSEETTRRKILKAQELGYVKNATASSLRSK (SEQ ID NO:85)
BD-11 MPTIEDVAKLAGVSIATVSRVINGSGVSEKTRYKWVKAIEELGYKPEISAKLLASKG (SEQ ID NO:86)
BD-12 MRIGEKLRLRLSRLGLTQEELAERTDLSRSFSIQLESDKTSPSIDTLERILEALGTDLKHF (SEQ ID NO:87)
Bd-14 MHMKTVRCERLKSKEPVSGAQLAEELSRSRQVIVQDIAYLRLSLGYNIVATPRGVVLAGG (SEQ ID NO:88)
BD-16 MNTLKKAFEILDFIVKNPGDVSVEIAEKFNMSVSNAVKYMWVLEEKGFVLRKDKRYVPGYKLEYGSEVLRRF (SEQ ID NO:89)
Bd-17 MRRRLNRKNNNEALKKLNDRQRKVLYCIVREYIENKKPVSSQRVLEVSNIEFSSATIRNDMKKLEYLGYYQPHHTSAGRIPTDKGLRFYYEEMLKISKE (SEQ ID
NO:110)

FIG. 13A

DNA binding domains from Bacteria Thermotoga Maritima

BD-18 MKISKKRROELIRKIHHEKKISNQFQIVEELKKYGIKAVQPTVARDLKEIGAVKIMDESGNYVYKLLDETPVIDPWKELKR (SEQ ID NO:90)
BD-22 MPKSVRAENISRLKRMKSPVSVELAEELGLTIVGEIAKIFLEKGIVVEEKDSPKGVRPTKSL (SEQ ID NO:111)
BD-23 MHKKLNPKSMKRENKKMVLRYLIESGPHSRVEIARKTGLAQSAIWRIEELVNEGIVEEKGTATGRRKAVTYGPTRSFTS (SEQ ID NO:91)
BD-24 NPSPLLRRENKIKILRYLKNGKTRNQLASNLNLAHSTLSIIDELDEGFLVFEIEKKKRGPRPYQILSVNPEKFATI (SEQ ID NO:92)
BD-30 MKEERLKEILDIVDRNGFISMKDQLQEQLGVSMITVRRDVAELVKRNLVKKVHG GIRKVNYFEKETDFMKRLSINREAKE (SEQ ID NO:93)
BD-32 MFTMRSEYALRLMIVMAKEYGNVLSMTEILEKAKQSVPREFAEKILYTLKKAGLVKTRRGKSGGYMLSSRPKEIKVSEIVFLDRKSKVFFDMPGC
PDELDCCVIRALWKRVENEIEKILSGVTLEDIVREQEEMKQ (SEQ ID NO:94)
BD-37 MRDTKGHLUKFLVLIISQQPSHGYYIMKKISQIGAEPSPGALPISSLRKQKYIETYNEGKRKVYRLTDKGRKYLEHKEEIKKALDFAERF (SEQ
ID NO:95)
BD-43 MRHRRGGRRGFRGWWLASTILLVAEKPSHGYELAERLAEFGIEIPGIGHMGNIYRVLADLESGLSTEWDDTTVSPRKIYRTPQGKLYLREILRSLE
DMKRRRIETLEERIKRVLQEE (SEQ ID NO:96)
BD-44 ITALNYLKEHFNESVNIMKRLAEMVGMSVSTFYQNFKILTGMPLQYQKKLRLCEARKLLMAGSDVTAAQVGYESLSQFSREYKRFVGVSPSQD
AKKLKEEPYTRILY (SEQ ID NO:112)
BD-45 MLSKRDAILKAAVEVFGKKGYDRATTDEAEKAGVAKGLIFHYFKNKEELYQAYMSVTEKLQKEFENFL (SEQ ID NO:97)

FIG. 13B

Phylogenetic Tree of DNA Binding Domains
from Thermotoga Maritima (Bacteria)





FIG. 14

Phylogenetic Tree for DNA polymerases



Sequences for fusions of DNA polymerase SP-17 (DNA polymerase family B) with binding domains SP-07, 08 and 98

SP-17-BD07

SP-17-BD08

SP-17-BD98

FIG. 16

Sequences for fusions of DNA polymerase SP-04 (DNA polymerase family A)
with binding domains SP-07, 02 and 98

SP-04-BD07

```

MARLFEDGTALRAYAYAIDRSLSLTGIPNTATGY/ARMLVRFKDHIVGKDVA/AFDKKAATFRHKLLETYKAQRKPTPDLIQQLPKVLYEAGMKVLEVEGYEADDIATLAVKGLP/LDEFIFVTGDKDMQLVNIEKIK
VWRVKGISDLELDAQKVKKEKYGVFQQIDPLLAUTGDEIDNIPGTVIGEKTAQVLLKEYLQDREKLNRDENAILSKKLAETNVPIENWEELRYQGYDREKLPLKLEFASIMKELQLYEESEPVGYR
VLDVLEFEKLIEKRESPSFAILETSDFPDCDIVSVPKPEAKYPLHHRNAQNLDEKEVLLKKELEIEDFGAKIVGQNQKEDYKVLVMNGVFPVPPHFDTMIAAYLEPNKRENLDLAIKFLGYKMSTYQEIMSFSSPLFG
FSFADVPVKAANYSCEDADITYRLYKLSLKHEADLENVFYKIELPVSLVARMELNGYVDTEFILKKSEEVYGRKLEELAEETYRAGEEPNINSPKQVSRLFEKLGIKPRGKTTKGDYSTRIVEELLAGEHIEPLULEYRKQLKS
TYDALPKMVNPPTGRIHASFNQTGTATGRSSSDPDLNQLPTESEGEKIRKAVPQDPNNWVNSADYSQELRAHISGDENILKAFEGIDVHTLTASRINVKPPEEVTMERRAGKMN/NSIYGVTPYGLSRVLGVPVKEA
EKMINVYFLYPKVDRYQRVVSEAKEKGVRVTLGRKDIQMLARDNTOAEGERAINTPQGTAADIKLAMEIDRELKERKMRSKMIIQVHDELVFPDEEKDALVELVKDRMTNVVKSVPLEVDTIGKTWSGTGGG
GKRPTINDVAKLAGVSVTSRYLKDPSQVSEKLERIREAKLGYKPKNIAQGLRTGD (SEQ ID NO:116)

```

SP-04-BD02

```

MKAWLLEDVDYTENDRAVTRLMCKGVFVAYDRNFLPYFYVIGCAEDDMVKVVRTNEGILITPLKVEETEAKSLGKPKALKVYTRHPQHVPKLREIIKKFAEVREADIPFAYRLLDIDLACMDG
TUELEPTAVKEGVULRAYEVRSVREVEKGFDPDILKLAFCEMIAQMPKPEKDIPDILATAVKGFFEEVFLHGDERBILRBFVSLIKEQDPLDVUGQNODNTDWPYVKBAKEFGLDGRBSELFRGG
RPLLAGRNUVDLDDAIKLPDYLKTLERKVAEFIGAKVVEEDLEGRDLYKCMWGEKEKFKVHLNDYLTTYRHAELLPMHYELSERMLRPLLDVARLGRKVDYFLLESEAKRNEIANPPELEES
YEGAFVLEPARGHENVACCLDASMYSIMINNISPUTLVGECEDCYVAPEVGHKERKSPDSPEKRLLKMLEKREMKRMKELDPSEDXKLLDIQCQTKVLINSFGYTGNLARWYCRCAE
AUTAWGRFRIKRAVKLAESMGATVLYGTDLSLTKKNGLNLLKOLEKECULKLLDVISKEPLQIQLDEFIKALFVEKRYAGTDDDRIVVKGLEVRRGWCELAKRVOREVIELLREENPDALKFV
KVNIELEIKGFKLLEDVLYKGULTKPKDKEYSICQAHVAALRANEMLGYPIGTRVGFVIVKGGSISDRAYPLIELIEDGENLKIRTPSGIMVKLDXYYLDHQIIPAVMRILLERFGYTEASLKT
IQTKLEIETGIGGGKSQLEPBRNTSIKHSETGVARLSDUNGQKRGTELRIKAFAEKSIII (SEQ ID NO:117)

```

SP-04-BD98

```

MARLFEDGTALRAYAYAIDRSLSLTGIPNTATGY/ARMLVRFKDHIVGKDVA/AFDKKAATFRHKLLETYKAQRKPTPDLIQQLPKVLYEAGMKVLEVEGYEADDIATLAVKGLP/LDEFIFVTGDKDMQLVNIEKIK
VWRVKGISDLELDAQKVKKEKYGVFQQIDPLLAUTGDEIDNIPGTVIGEKTAQVLLKEYLQDREKLNRDENAILSKKLAETNVPIENWEELRYQGYDREKLPLKLEFASIMKELQLYEESEPVGYR
VLDVLEFEKLIEKRESPSFAILETSDFPDCDIVSVPKPEAKYPLHHRNAQNLDEKEVLLKKELEIEDFGAKIVGQNQKEDYKVLVMNGVFPVPPHFDTMIAAYLEPNKRENLDLAIKFLGYKMSTYQEIMSFSSPLFG
FSFADVPVKAANYSCEDADITYRLYKLSLKHEADLENVFYKIELPVSLVARMELNGYVDTEFILKKSEEVYGRKLEELAEETYRAGEEPNINSPKQVSRLFEKLGIKPRGKTTKGDYSTRIVEELLAGEHIEPLULEYRKQLKS
TYDALPKMVNPPTGRIHASFNQTGTATGRSSSDPDLNQLPTESEGEKIRKAVPQDPNNWVNSADYSQELRAHISGDENILKAFEGIDVHTLTASRINVKPPEEVTMERRAGKMN/NSIYGVTPYGLSRVLGVPVKEA
EKMINVYFLYPKVDRYQRVVSEAKEKGVRVTLGRKDIQMLARDNTOAEGERAINTPQGTAADIKLAMEIDRELKERKMRSKMIIQVHDELVFPDEEKDALVELVKDRMTNVVKSVPLEVDTIGKTWSGTGGG
GEEIKEIMKSHTLGNPVRLGIMYLFRRRAPSHIOKALDITPGNLDISHKVLEKHGV/RTYKVIDRPTMVEIDYGMETRKFLSHLKTVIDAIIH (SEQ ID NO:118)

```

FIG. 17

Sequences for fusions of DNA polymerase SP-61 (DNA polymerase family B) with binding domains BD-07, 09, 23, 62, 93 and 109

SP-61-BD07

MEGWILDADITAEDGRAVVRWLWCKDFDGNTFVYDRNFQPYAFKNGLSKDEDIEKVKVSEGVKPKVFEVRRKVFGKEVEVFKIAYHPQHVKLREELKKTEREADIPFAYRLIDKDIACLMDGIRVEGV
GKVRERGKIVDAEHVERFEPKVLAFDCMELTEGMPEDKDIIIGVKCGDEEITGNEREIQDPDVIGYNQDNDFWPyIRKRAEKLISVKLNIGRDGEISFRGRPKIAGRINVDLYDIA
MKLDVKVKTLENVAEFLGRKVELAIDAEAKDVKRWTSGDKESVLYSKQDVNLYTFAELLPMHYELSMRMRPTDDVARYGRGQDVKWFLSEAKYGEIAPNPAEVESYEGHAFV
MPSIMIAYNISPDTYVGKCDDCYVAPEVGHKERKHPDFFKRKMLIEKREIKNQMSLDRNSREYLLNIKQDNLNTYFAELLPMHYELSMRMRPTDDVARYGRGQDVKWFLSEAKYGEIAPNPAEVESYEGHAFV
SIFVRKGNSLLEKIRGEVEKLEEESEKPKVQEDEVYKTIFFVKRAYAGLTEDGILVKGLEVRGGDCELAKEVQKIVMIEENPEKAAYVRKVINDIKSGVKLEDVYKGLTKRDPKYESKOAHVKAALRAMELGVIVNVGSKVGF
MELGINVVNGSKVGFVVEAGNVGDRAPIDLEFDGENLVRTRSGSIVKLDQYINHNPQSPVRLRERFGYNEASLGKATQKTLDAFW
GTGGGGRRPRTINDVAKLAGVSISITVSRYLKDPQSVEKSLGERIREAIKLGKPKNAQGLRTGD (SEQ ID NO:119)

SP-61-BD09

MEGWILDADITAEDGRAVVRWLWCKDFDGNTFVYDRNFQPYAFKNGLSKDEDIEKVKVSEGVKPKVFEVRRKVFGKEVEVFKIAYHPQHVKLREELKKTEREADIPFAYRLIDKDIACLMDGIRVEGV
REERGKIVDAEHVERFEPKVLAFDCMELTEGMPEDKDIIIGVKCGDEEITGNEREIQDPDVIGYNQDNDFWPyIRKRAEKLISVKLNIGRDGEISFRGRPKIAGRINVDLYDIA
KVKTLENVAEFLGRKVELAIDAEAKDVKRWTSGDKESVLYSKQDVNLYTFAELLPMHYELSMRMRPTDDVARYGRGQDVKWFLSEAKYGEIAPNPAEVESYEGHAFV
NISPDTYVGKCDDCYVAPEVGHKERKHPDFFKRKMLIEKREIKNQMSLDRNSREYLLNIKQDNLNTYFAELLPMHYELSMRMRPTDDVARYGRGQDVKWFLSEAKYGEIAPNPAEVESYEGHAFV
RGEVEKLEEESEKPKVQEDEVYKTIFFVKRAYAGLTEDGILVKGLEVRGGDCELAKEVQKIVMIEENPEKAAYVRKVINDIKSGVKLEDVYKGLTKRDPKYESKOAHVKAALRAMELGVIVNVGSKVGF
VVEAGNVGDRAPIDLEFDGENLVRTRSGSIVKLDQYINHNPQSPVRLRERFGYNEASLGKATQKTLDAFW
GTGGGGKKVITRDAEAKAGVSINTVSRALNNKPDISEETRKLIKIAQELGVKNAJASSRSK (SEQ ID NO:120)

SP-61-BD23

MEGWILDADITAEDGRAVVRWLWCKDFDGNTFVYDRNFQPYAFKNGLSKDEDIEKVKVSEGVKPKVFEVRRKVFGKEVEVFKIAYHPQHVKLREELKKTEREADIPFAYRLIDKDIACLMDGIRVEGV
VREERGKIVDAEHVERFEPKVLAFDCMELTEGMPEDKDIIIGVKCGDEEITGNEREIQDPDVIGYNQDNDFWPyIRKRAEKLISVKLNIGRDGEISFRGRPKIAGRINVDLYDIA
DVVKYKTLENVAEFLGRKVELAIDAEAKDVKRWTSGDKESVLYSKQDVNLYTFAELLPMHYELSMRMRPTDDVARYGRGQDVKWFLSEAKYGEIAPNPAEVESYEGHAFV
MIAV/NISPDTYVGKCDDCYVAPEVGHKERKHPDFFKRKMLIEKREIKNQMSLDRNSREYLLNIKQDNLNTYFAELLPMHYELSMRMRPTDDVARYGRGQDVKWFLSEAKYGEIAPNPAEVESYEGHAFV
NLSLEKIREVEKLEEESEKPKVQEDEVYKTIFFVKRAYAGLTEDGILVKGLEVRGGDCELAKEVQKIVMIEENPEKAAYVRKVINDIKSGVKLEDVYKGLTKRDPKYESKOAHVKAALRAMELGVIVNVGSKVGF
VGSKVGFVVEAGNVGDRAPIDLEFDGENLVRTRSGSIVKLDQYINHNPQSPVRLRERFGYNEASLGKATQKTLDAFW
GTGGGGHHKUNPKSMKRENKKMVLRIESGPHSRVEARRTGIAQSAWRIEELVNNEGIEEKTAGTRRKAVTYGPTRSFTS (SEQ ID NO:121)

FIG. 18A

Sequences for fusions of DNA polymerase SP-61 (DNA polymerase family B) with binding domains BD-07, 09, 23, 62, 93 and 109

SP-61-BD62

MEGWILDADYTAEDGRAVYRLWCKDFDGNTFWYDRNFQPYAFKNGLSKDEDIEKIVKSREGVIKPKVEEVRRKVFGKEVEVKIAYHQPQHVKLREFELKKITTEVREADIPFAYRULDKLACMDGIRVEGKVREERGLKVIAEHVERFEIPLPEKVLAFDCEMLTGMPDPKDIIGKCGDFEEITGNREILLRVEIINEQDPDVNGYNQDNDFWPIRKRAEKLSVKLINGRDSEISFRGGRPKIAGRLNVDYDIAMLKDVKVTLENVAEFLGRKVELAIEAKDINKRWTSGDKESVILKYSKQDVNTYFAELPMLHESMRMIRPTDVARIGRKQDVWFLLESAFKYGEAPNPAAEVESYGAEVLFPSRGHLKVNWLDFASMYPSIMAIYNSPDTYFGCDDCYVAPEVGHKFKHDGFKRKLMIEKRREKNQNMKSLDNSREYLNIKQQTLLKTSFYGTGWSARWCRCQAETTAWGRHLKSAVEIAKKLGFEVLYGDTDSIFVKGKGNISLEKIRGEVKLIEISEKPVQEDEVYKTFVEVKRYDGILVVKGLEVRGWDWCELAKEVQKVKVIEKEENPEKAAYVRKVINDIKSGKVKLEDVWIKGLTRPKYESKOAHKAALRAMELGIVNVGSKVGFVVVEAGNVGDRAPIDIEFPGENLVRTRSGSIVKKLDKDYTINHQIPSLRLERFGEYNEASLKGATQTKTDAFW~~GTTGGGNTGAGQYSEMRSMKISVQLPOSILHGIDALVKGVPNRSEAIRVAIRELIKELYKEOEIPEVYWK~~ (SEQ. ID NO:122)

SP-61-BD93

MEGWILDADYTAEDGRAVYRLWCKDFDGNTFWYDRNFQPYAFKNGLSKDEDIEKIVKSREGVIKPKFEVYRRLKVGKEVEVKIAYHQPQHVKLREFELKKITTEVREADIPFAYRULDKLACMDGIRVEGKVREERGLKVIAEHVERFEIPLPEKVLAFDCEMLTGMPDPKDIIGKCGDFEEITGNREILLRVEIINEQDPDVNGYNODNFDWPIRKRAEKLSVKLINGRDSEISFRGGRPKIAGRLNVDYDIAMLKDVKVTLENVAEFLGRKVELADIEAKDINKRWTSGDKESVILKYSKQDVNLVYHAELPMLHESMRMIRPTDVARIGRKQDVWFLLESAFKYGEAPNPAAEVESYGAEVLFPSRGHLKVNWLDFASMYPSIMAIYNSPDTYFGCDDCYVAPEVGHFKRHPDGFKRKLMIEKRREKNQNMKSLDNSREYLNIKQQTLLKTSFYGTGWSARMYCRCQAETTAWGRHLKSAVEIAKKLGFEVLYGDTDSIFVKGKGNISLEKIRGEVKLIEISEKPVQEDEVYKTFVEVKRYAGITEDGILVVKGLEVRGWDWCELAKEVQKVKVIEKEENPEKAAYVRKVINDIKSGKVKLEDVWIKGLTRPKYESKOAHKAALRAMELGIVNVGSKVGFVVVEAGNVGDRAPIDIEFPGENLVRTRSSIVKKLDKDYINHQIPSLRLERFGEYNEASLKGATQTKTDAFW~~GTTGGGNTGAGQYSEMRSMKISVQLPOSILHGIDALVKGVPNRSEAIRVAIRELIKELYKEOEIPEVYWK~~ (SEQ. ID NO:123)

SP-61-BD109

MEGWILDADYTAEDGRAVYRLWCKDFDGNTFWYDRNFQPYAFKNGLSKDEDIEKIVKSREGVIKPKVEEVRRKVFGKEVEVKIAYHQPQHVKLREFELKKITTEVREADIPFAYRULDKLACMDGIRVEGKVREERGLKVIAEHVERFEIPLPEKVLAFDCEMLTGMPDPKDIIGKCGDFEEITGNREILLRVEIINEQDPDVNGYNODNFDWPIRKRAEKLSVKLINGRDSEISFRGGRPKIAGRLNVDYDIAMLKDVKVTLENVAEFLGRKVELADIEAKDINKRWTSGDKESVILKYSKQDVNLVYHAELPMLHESMRMIRPTDVARIGRKQDVWFLLESAFKYGEAPNPAAEVESYGAEVLFPSRGHLKVNWLDFASMYPSIMAIYNSPDTYFGCDDCYVAPEVGHFKRHPDGFKRKLMIEKRREKNQNMKSLDNSREYLNIKQQTLLKTSFYGTGWSARMYCRCQAETTAWGRHLKSAVEIAKKLGFEVLYGDTDSIFVKGKGNISLEKIRGEVKLIEISEKPVQEDEVYKTFVEVKRYAGITEDGILVVKGLEVRGWDWCELAKEVQKVKVIEKEENPEKAAYVRKVINDIKSGKVKLEDVWIKGLTRPKYESKOAHKAALRAMELGIVNVGSKVGFVVVEAGNVGDRAPIDIEFPGENLVRTRSSIVKKLDKDYINHQIPSLRLERFGEYNEASLKGATQTKTDAFW~~GTTGGGNTGAGQYSEMRSMKISVQLPOSILHGIDALVKGVPNRSEAIRVAIRELIKELYKEOEIPEVYWK~~ (SEQ. ID NO:124)

FIG. 18B

Sequences for fusions of DNA polymerase 49 (DNA polymerase family B) with binding domains BD-07, 09, 23, 62, 93 and 109

SP-49-BD07

MILDADYTEDGKPIRLFKKENGRFKVEYDRNFRPIYIALLKDDSAIDDVRKITSERHGVVRVIDEVKKKKFLGRPIEWVKLYFEHPPQD/PAMDRCIREHPAVIDIFYDIPFAKRYLUDKGCLIPMEGNEELTFLAVDIETLYHEGEFGKGPIMISYADEGAKVITWKKIDLPYEVVANEERMIKRUKVIREKDPOVITYNGDNEDFPYLLKRAEKGIMKPLGRDNESEPKMQRQLGDSLAVEIKGRHFDLFPVIRTRNLPTYLEAVYEAFGKQKEKVVYPHEIAEAWETGKGLERVAKYSMEDAKVTYELGKFEPFMEAQLARLGQPLWDVSRSSTGNLVEWYLKAYERNELAPNKPDEREYERLRESYEGY/KEPERGLWEGLNSDFRSLEPSIIITHNVSPTDTLNKEGGHEYDEAPEVGHRECKDPGPFSLGSLEERQKIKRKMESKDPVERKLIDYRQAIIKLANSFYGYGAKARWCKEAEVTAW/GROYIELVRELEERGFKVLYIDTDGYATPGEKNWEEKRRALEFVNINSKLPGILELEYEGFYTRGFFVTKKTYALIDEFGKUTRGLENRRDWSEIAKETOAKVLEALKHGNEVAFKVKVEFTEKSNSYEPVEKLVLYEQTRPLNEYKAIGPHIVAVKLAAGKIKPGMVIGVVLRGDGPISKRAIAEFFDGKHKYDAEYYENQVLPAPERILKAFGKREDLRWQTKQVGLGAWLKVKSGTGGGGKKVYTDIRIAKAGVSINTVSLNKPDISEETRKILKIAQEGLYKVNATASSLRK (SEQ. ID NO.:125)

SP-49-BD09

MILDADYTEDGKPIRLFKKENGRFKVEYDRNFRPIYIALLKDDSAIDDVRKITSERHGVVRVIDEVKKKKFLGRPIEWVKLYFEHPPQD/PAMDRCIREHPAVIDIFYDIPFAKRYLUDKGCLIPMEGNEELTFLAVDIETLYHEGEFGKGPIMISYADEGAKVITWKKIDLPYEVVANEERMIKRUKVIREKDPOVITYNGDNEDFPYLLKRAEKGIMKPLGRDNESEPKMQRQLGDSLAVEIKGRHFDLFPVIRTRNLPTYLEAVYEAFGKQKEKVVYPHEIAEAWETGKGLERVAKYSMEDAKVTYELGKFEPFMEAQLARLGQPLWDVSRSSTGNLVEWYLKAYERNELAPNKPDEREYERLRESYEGY/KEPERGLWEGLNSDFRSLEPSIIITHNVSPTDTLNKEGGHEYDEAPEVGHRECKDPGPFSLGSLEERQKIKRKMESKDPVERKLIDYRQAIIKLANSFYGYGAKARWCKEAEVTAW/GROYIELVRELEERGFKVLYIDTDGYATPGEKNWEEKRRALEFVNINSKLPGILELEYEGFYTRGFFVTKKTYALIDEFGKUTRGLENRRDWSEIAKETOAKVLEALKHGNEVAFKVKVEFTEKSNSYEPVEKLVLYEQTRPLNEYKAIGPHIVAVKLAAGKIKPGMVIGVVLRGDGPISKRAIAEFFDGKHKYDAEYYENQVLPAPERILKAFGKREDLRWQTKQVGLGAWLKVKSGTGGGGKKVYTDIRIAKAGVSINTVSLNKPDISEETRKILKIAQEGLYKVNATASSLRK (SEQ. ID NO.:126)

SP-49-BD23

MILDADYTEDGKPIRLFKKENGRFKVEYDRNFRPIYIALLKDDSAIDDVRKITSERHGVVRVIDEVKKKKFLGRPIEWVKLYFEHPPQD/PAMDRCIREHPAVIDIFYDIPFAKRYLUDKGCLIPMEGNEELTFLAVDIETLYHEGEFGKGPIMISYADEGAKVITWKKIDLPYEVVANEERMIKRUKVIREKDPOVITYNGDNEDFPYLLKRAEKGIMKPLGRDNESEPKMQRQLGDSLAVEIKGRHFDLFPVIRTRNLPTYLEAVYEAFGKQKEKVVYPHEIAEAWETGKGLERVAKYSMEDAKVTYELGKFEPFMEAQLARLGQPLWDVSRSSTGNLVEWYLKAYERNELAPNKPDEREYERLRESYEGY/KEPERGLWEGLNSDFRSLEPSIIITHNVSPTDTLNKEGGHEYDEAPEVGHRECKDPGPFSLGSLEERQKIKRKMESKDPVERKLIDYRQAIIKLANSFYGYGAKARWCKEAEVTAW/GROYIELVRELEERGFKVLYIDTDGYATPGEKNWEEKRRALEFVNINSKLPGILELEYEGFYTRGFFVTKKTYALIDEFGKUTRGLENRRDWSEIAKETOAKVLEALKHGNEVAFKVKVEFTEKSNSYEPVEKLVLYEQTRPLNEYKAIGPHIVAVKLAAGKIKPGMVIGVVLRGDGPISKRAIAEFFDGKHKYDAEYYENQVLPAPERILKAFGKREDLRWQTKQVGLGAWLKVKSGTGGGGKKVYTDIRIAKAGVSINTVSLNKPDISEETRKILKIAQEGLYKVNATASSLRK (SEQ. ID NO.:127)

FIG. 19A

Sequences for fusions of DNA polymerase 49 (DNA polymerase family B)
with binding domains BD-07, 09, 23, 62, 93 and 109

SP-49-BD62

MILDADYTEDGKPIRLFKKENGRFKEVYDRNFRPYIYALLKDDSDADDVRKITSERHGVYRVIDVEKKKKFLIGRPievWVKLYFEHPQDPAMRDKIREHPAVIDFYDIPFAKRYLUDKGKLGPMEGNEELTFLAV/DIETLYHEG
EEFGKGPIMISYADEEGAKVITWKKIDLPVPEVANEREMIKRUKIVREKDPOVITYNGDNDFPPLKRAEKLGMKLPGRDNSEPKMQLRGDSLAVEIKGRHFDLFPVIRRTNLPTYLEAVYEAEAFGKQKERVYPHEIAEA
WETGIGLERV/AKSMSMEDAKVYELGEFFPMEAQLARIVGQPULWDVSRESTGNLVEWLLRKAYERNEALAPNKDDERERYRURESEYEGGYKPERGIGWEGVSLDRSLYSPIUTHNVSPTLNKECGEYDEAEPVGHR
FCDFPFGPSLGSLEERQKRRMKESKPVERKLIDYKRAILKANSFYYAKWYCKEASVTAWGRQVIEERGFKVLIDGLYATGPEKVNWEIKRALEFVNINSKLPGILELEYFGYTRGFVTK
TKKYLALIDEFGKVTRGLEINRWDWSEHAKETOAKVLAULKISGVNTEAKVKEVTEKSAYEVPEKLYUEQTRPINEYKAIGPHAVAVAKRLAAGKIKKPGMV/GYVVLRGDGSPIKRAIAEEDFGKKHYDAEYENIQVLP
AVERILKAFGYKREDLRWQTKQVSLGAWLKVKSGTGGGTINPQARLTPLEILEIKQKSSITITELSERKSEYPLSUSEYSLERKGTYKIAKGKKEFALL (SEQ ID NO:128)

SP-49 -BD93

MILDADYTEDGKPIRLFKKENGRFKEVYDRNFRPYIYALLKDDSDADDVRKITSERHGVYRVIDVEKKKKFLIGRPievWVKLYFEHPQDPAMRDKIREHPAVIDFYDIPFAKRYLUDKGKLGPMEGNEELTFLAV/DIETLYHEG
EEFGKGPIMISYADEEGAKVITWKKIDLPVPEVANEREMIKRUKIVREKDPOVITYNGDNDFPPLKRAEKLGMKLPGRDNSEPKMQLRGDSLAVEIKGRHFDLFPVIRRTNLPTYLEAVYEAEAFGKQKERVYPHEIAEA
WETGIGLERV/AKSMSMEDAKVYELGEFFPMEAQLARIVGQPULWDVSRESTGNLVEWLLRKAYERNEALAPNKDDERERYRURESEYEGGYKPERGIGWEGVSLDRSLYSPIUTHNVSPTLNKECGEYDEAEPVGHR
FCDFPFGPSLGSLEERQKRRMKESKPVERKLIDYKRAILKANSFYYAKWYCKEASVTAWGRQVIEERGFKVLIDGLYATGPEKVNWEIKRALEFVNINSKLPGILELEYFGYTRGFVTK
TKKYLALIDEFGKVTRGLEINRWDWSEHAKETOAKVLAULKISGVNTEAKVKEVTEKSAYEVPEKLYUEQTRPINEYKAIGPHAVAVAKRLAAGKIKKPGMV/GYVVLRGDGSPIKRAIAEEDFGKKHYDAEYENIQVLP
AVERILKAFGYKREDLRWQTKQVSLGAWLKVKSGTGGGTINPQARLTPLEILEIKQKSSITITELSERKSEYPLSUSEYSLERKGTYKIAKGKKEFALL (SEQ ID NO:129)

SP-49 -BD109

MILDADYTEDGKPIRLFKKENGRFKEVYDRNFRPYIYALLKDDSDADDVRKITSERHGVYRVIDVEKKKKFLIGRPievWVKLYFEHPQDPAMRDKIREHPAVIDFYDIPFAKRYLUDKGKLGPMEGNEELTFLAV/DIETLYHEG
EEFGKGPIMISYADEEGAKVITWKKIDLPVPEVANEREMIKRUKIVREKDPOVITYNGDNDFPPLKRAEKLGMKLPGRDNSEPKMQLRGDSLAVEIKGRHFDLFPVIRRTNLPTYLEAVYEAEAFGKQKERVYPHEIAEA
ETGKGGLERV/AKSMSMEDAKVYELGEFFPMEAQLARIVGQPULWDVSRESTGNLVEWLLRKAYERNEALAPNKDDERERYRURESEYEGGYKPERGIGWEGVSLDRSLYSPIUTHNVSPTLNKECGEYDEAEPVGHR
DPPGFGPSLGSLEERQKRRMKESKPVERKLIDYKRAILKANSFYYAKWYCKEASVTAWGRQVIEERGFKVLIDGLYATGPEKVNWEIKRALEFVNINSKLPGILELEYFGYTRGFVTK
KYLALIDEFGKVTRGLEINRWDWSEHAKETOAKVLAULKISGVNTEAKVKEVTEKSAYEVPEKLYUEQTRPINEYKAIGPHAVAVAKRLAAGKIKKPGMV/GYVVLRGDGSPIKRAIAEEDFGKKHYDAEYENIQVLP
AVERILKAFGYKREDLRWQTKQVSLGAWLKVKSGTGGGTINPQARLTPLEILEIKQKSSITITELSERKSEYPLSUSEYSLERKGTYKIAKGKKEFALL (SEQ ID NO:130)

FIG. 19B

DNA polymerase SP-17 (family B) has enhanced PCR activity
after fused to DNA binding domains
(Fusions can amplify longer DNA fragments)




FIG. 20

A Family DNA polymerase SP-04 (family A) has enhanced PCR activity after fused to DNA binding domains
(Fusions can amplify longer DNA fragments)




FIG. 21

DNA polymerase SP-61 (family B) has enhanced PCR activity after fused to DNA binding domains
(Fusions have better tolerance in different buffers during PCR)




FIG. 22

DNA polymerase SP-49 (family B) has enhanced PCR activity after fused to DNA binding domains
(Fusions have better tolerance in different buffers during PCR)




FIG. 23

1

FUSION POLYMERASE AND METHOD FOR
USING THE SAME

CROSS-REFERENCE

This application is a continuation-in-part of U.S. Ser. No. 14/837,820, filed on Aug. 27, 2015, which application claims the benefit of U.S. provisional application Ser. No. 62/042,527, filed Aug. 27, 2014, 62/189,599, filed Jul. 7, 2015 and 62/193,168, filed on Jul. 16, 2015, which applications are incorporated by reference herein.

BACKGROUND

DNA polymerases are widely used in in vitro applications. In particular, use of thermostable polymerases has revolutionized modern molecular biology. The processivity of a DNA polymerase, i.e., the length of product generated by the enzyme per binding event, is an important factor in many in vitro reactions. For example, in a PCR reaction or an in vitro sequence assembly reaction, the length of a product is largely determined by the proofreading activity and the processivity of the DNA polymerase used. Increasing the processivity of a DNA polymerase can, in theory, allow one to copy and/or amplify a template (particularly a longer template) more efficiently altering the fidelity of the polymerase. However, in practice, increasing the processivity of a DNA polymerase does not always have the desired effect because the proofreading activity of the polymerase may counteract any positive effects conferred by the increase in processivity.

One way to increase the processivity of a DNA polymerase involves adding Sso7d, a non-specific DNA binding protein, onto the polymerase (Wang et al, Nuc. Acids Res. 2004 32: 1197-1207). Because Sso7d binds DNA non-specifically, it is thought that the addition of the domain helps anchor the polymerase to its template, thereby stabilizing the interaction between the polymerase and the template.

SUMMARY

As will be described in greater detail below, the performance of many DNA polymerases can be unexpectedly increased by the addition of a sequence-specific DNA binding domain (e.g., the DNA binding domain of a transcription factor) to the N- or C-terminus of the polymerase. This increase in performance is believed to be unexpected because where a sequence-specific DNA binding domain preferentially binds to a specific sequence, it would not be expected to help the DNA polymerase to remain bound to its template. Indeed, an effect opposite to the desired one would be expected to occur, namely that the sequence-specific DNA binding domain would anchor the polymerase only to target sequences and prevent it from moving.

This disclosure provides, among other things, a composition comprising a fusion protein comprising: (a) a DNA polymerase; and (b) the DNA binding domain of a heterologous sequence-specific DNA binding domain. In some embodiments, the fusion protein may exhibit increased processivity relative to the polymerase of (a) in the absence of the DNA binding domain of (b). The sequence-specific DNA binding domain is C-terminal or N-terminal of the polymerase. In some embodiments, the DNA polymerase is a type A polymerase whereas on other embodiments, the DNA polymerase may be a type B polymerase. In some embodiments, the sequence-specific DNA binding domain

2

may a helix-loop-helix, ribbon-helix-helix, helix-turn-helix, winged helix, or homeodomain structure. In some embodiments, the sequence-specific DNA binding domain may be from a transcriptional activator. In some embodiments, the sequence-specific DNA binding domain may be at least 90% identical to a DNA binding domain of a naturally occurring transcription factor.

In some embodiments, the polymerase may have proofreading activity. In some embodiments, the polymerase may be at least 90% identical to a wild type polymerase, e.g., a bacterial or archaeabacterial polymerase such as a wild type *Pyrococcus* or *Thermococcus* polymerase. In some embodiments, the polymerase may be thermostable. In some embodiments, the sequence-specific DNA binding domain may be thermostable.

Also provided herein, among other things, is a kit comprising: (a) a composition comprising a fusion protein, as summarized above; and (b) a reaction buffer. In some embodiments, the composition may comprise glycerol. In some embodiments, the buffer may be in concentrated form.

Also described herein, among other things, is a method comprising: combining a DNA template with nucleotides and a composition comprising a fusion protein, as summarized above, to produce a reaction mix; and copying the DNA template. In some embodiments, the DNA template may be a plurality of overlapping primers. In some embodiments, the reaction mix may comprise a plurality of primers and genomic DNA. The copying step may done using isothermal conditions or thermocycling, for example.

This disclosure also provides, among other things, a composition comprising: i. a 5' exonuclease; ii. a strand-displacing polymerase; iii. a single strand (ss) DNA binding protein; and, iv. a non-naturally occurring buffering agent, wherein the composition does not comprise a crowding agent and/or a non-strand-displacing polymerase. The composition can be employed to assemble polynucleotides into a synthon. Embodiments of the composition optionally contain a ligase depending on whether assembly is performed for purposes of cloning in a bacterial cell that would contain its own ligase or whether assembly is performed for purposes which do not include a cloning step in bacteria.

Previously described assembly methods required a non-strand displacing polymerases and evolved to additionally require a crowding agent (see for example U.S. Pat. No. 8,968,999). Contrary to the prior teachings, present embodiments demonstrate that a strand displacing polymerase has advantages over a non-strand displacing polymerase when used with a 5'-3' exonuclease. This combination has a preference for including a ss binding protein over a crowding agent which is the reverse over prior art teachings which assert that use of crowding agents are four fold more effective than alternatives including the use of a single stand binding protein. Present embodiments provide compositions, methods and kits that provide increased efficiency of assembly and cloning of functional genes and synthons from oligonucleotides and polynucleotides including ds and/or ss nucleic acid molecules in a single step method and/or in a single reaction vessel. These embodiments do not rely on crowding agents nor do they require non-strand displacing polymerases for filling in gaps that are present after two molecules anneal. For example, when a 5'-3' exonuclease that acts upon ds DNA generates a 3' ss DNA overhang that can anneal effectively with a 3' ss DNA overhang from another molecule, the strand-displacing polymerase can fill-in gaps left after the molecules anneal. A combination of activities of the strand-displacing DNA polymerase and the 5'-3' exonuclease results in a duplex synthon containing a

nick at or near the site of joining. This nick can be sealed in vitro by a ligase or in vivo by an endogenous cellular ligase. Additionally, the inclusion of a ss DNA binding protein in the reaction mixture enables efficient assembly of relatively low concentrations of nucleic acid fragments, thereby providing a cost saving without loss of efficiency or loss of accuracy of joining.

In some embodiments of the compositions, the strand-displacing polymerase is a Family B polymerase. A strand-displacing polymerase should preferably have strand-displacing activity that is greater than that observed with Phusion® polymerase (Thermo Fisher, Waltham, Mass.) (which is generally described as non-strand displacing) under the same reaction conditions (for example, using an assay such as described in FIG. 1A-1E). In the present compositions, methods and kits the strand-displacing polymerase is utilized primarily for its strand-displacing activity. In some embodiments, the strand-displacing polymerase may be non-naturally occurring, for example, the strand-displacing polymerase may be a mutant. Examples of mutants include polymerases having one or more amino acid substitutions, non-naturally occurring polymerases may alternatively or in addition be fusion proteins with a moiety having an unrelated amino acid sequence where the fusion polymerase is not encountered in nature. Preferably the strand-displacing polymerase is stable at 50° C. or above and may thus be referred to as a thermostable strand-displacing polymerase. In some cases, the strand-displacing polymerase is a fusion polymerase having an unrelated or heterologous DNA binding domain. In some embodiments, the polymerase moiety may have an amino acid sequence that is at least 90% or 95%, or 98% or 99% identical to SEQ ID NO:102. In another embodiment, the polymerase may have an amino acid sequence that is at least 90% or 95% or 98% or 99% or 100% identical to SEQ ID NO:1 preferably at least 90%. In another embodiment, the polymerase may have an amino acid sequence that is at least 90% or 95% or 98% or 99% or 100% identical to any of SEQ ID NO:33-55 preferably at least 90%. In some embodiments, the DNA binding domain moiety may have an amino acid sequence that is at least 90% or 95%, or 98% or 99% identical to SEQ ID NO:2. In another embodiment, the polymerase may have an amino acid sequence that is at least 90% or 95% or 98% or 99% or 100% identical to any of SEQ ID NOs:1, 3, 56-96 or 102, preferably at least 90%. In other embodiments, any of the polymerase domain moieties described herein may be combined with any of the DNA binding domains described herein provided that the Polymerase moiety and the DNA binding domain are heterologous. For example, in other embodiments, the fusion protein may have an amino acid sequence that has at least 90% or 95% or 99% or 100% identity with SEQ ID NO:1 and SEQ ID NO:2, preferably at least 90%. In other embodiments, the fusion protein may have at least 90% or 95% or 98% or 99% or 100% sequence identity to SEQ ID NO:3 preferably at least 90%. The strand-displacing polymerase may or may not have a 3'-5' exonuclease activity. Where strand-displacing polymerases have 3'-5' exonuclease activity, polynucleotide joining may be optimized by balancing 3'-5' exonuclease activity, 5'-3' polymerization activity and strand displacement activity using the conditions that include those exemplified herein. The efficacy and accuracy of the assembly can be confirmed using the assay described herein (see for example, FIGS. 3A and 3B). In some embodiments, the polymerase is not Phusion, 9° N, Pfu or Vent, or a polymerase that has an amino acid sequence that is at least 90% identical to Phusion or wild type 9° N, Pfu or Vent. In some embodiments, the

polymerase is thermostable, i.e., active at a temperature of at least 40° C. or at least 50° C. degrees. In contrast to strand-displacing polymerases, some polymerases such as Taq DNA polymerase, degrade an encountered downstream strand via a 5'-3' exonuclease activity. This activity is utilized for nick translation protocols. Hence Taq DNA polymerase is not included in the definition of strand-displacing polymerases.

An assay to determine efficiency and accuracy of synthon formation is described in the examples and shown in FIG. 3A-3B. The designed assembled fragments encode the lacI and lacZ proteins, which yield a blue colony if DNA fragments are assembled correctly. Thus, the number of "blue" colonies from an overnight plate denotes both efficiency and accuracy of assembly. In the absence of a blue color, efficient assembly may occur but errors at the joining/extension region prevent expression. When synthons are assembled and then cloned into a host cell, efficiency and accuracy of synthon formation translates into a confidence that each clone will contain the accurately assembled synthon. With this confidence, only one or a few duplicate clones need to be sequenced to confirm the presence of a synthon. This reduces the cost and inconvenience of sequencing clones that might contain errors. In one embodiment, at least 80% or alternatively at least 90% of clones will contain accurately assembled synthons.

In some embodiments, methods utilizing the compositions described herein are capable of yields that are substantially in excess of minimum requirements. For example, as many as 5,000 or 10,000 colonies can be produced in a single transformation event. If the purpose of assembly is to create a single example of a synthon rather than a library of synthons, then lower starting amounts of nucleic acid fragments and reagents can be used even below the ranges provided herein. Examples of concentration ranges suitable for use in an assembly mixture include the following: 0.02 nM-100 nM for DNA fragment or for example 0.2 nM-10 nM DNA may be added to the reagent mixture in a reaction vessel. In one embodiment, vector DNA is included at a ratio of 1:1 with the DNA fragments although higher or lower ratios can be used. A higher concentration of ss DNA may be preferred when compared with the concentration selected for ds DNA. The reagent mixture in the reaction vessel may further include 0.0004 U/μl-0.064 U/μl of the 5'-3' exonuclease (for example 0.0004 U/μl-0.01 U/μl); 0.5 U/μl-32 U/μl of an optional ligase (for example 1 U/μl-10 U/μl); 0.0025 U/μl-0.25 U/μl of the strand-displacing polymerase (for example 0.005 U/μl-0.1 U/μl); and 0.001 μg/μl-0.1 μg/μl for the ss binding protein (for example 0.01 μg/μl-0.5 μg/μl) (units correspond with those specified by the manufacturer (New England Biolabs, Ipswich, Mass.)).

The amount of 5'-3' exonuclease can be further optimized according to the length of overlap of nucleic acid fragments and size of each fragment. For example, amounts of 5'-3' exonuclease may be increased within the range for nucleic acid fragments greater than 80 nucleotides in length. The absolute concentration of the strand-displacing polymerase within the specified range is not critical.

A ss DNA binding protein for use in the composition may be *E. coli* recA, T7 gene 2.5 product, RedB (from phage lambda) or RecT (from Rac prophage), ET SSB (extreme thermostable single-stranded DNA binding protein) or a ss binding protein with 90% sequence identity to SEQ ID NO:100 although many other ss DNA binding proteins are known and could be used in the composition. The inclusion of a ss binding protein improves the efficiency of assembly particularly for nucleic acid fragments with longer overlap

5

sequences (e.g. at least 20 nucleotides) than would be otherwise occur in the absence of ss binding protein as measured by colony number.

The optional ligase may be an NAD⁺ dependent ligase such as Taq ligase or an ATP dependent ligase such as T4 ligase. However, for PCR, it is convenient to use an NAD⁺ dependent ligase since ATP can inhibit Taq polymerase used in subsequent amplification of the synthon. Examples of a suitable ligase include a protein with at least 90% sequence identity to SEQ ID NO:101.

The 5'-3' exonuclease used here may be an enzyme that has a 5'-3' exonuclease activity as well as a ss endonuclease activity (see, for example, Garforth, et al., PNAS, 96, 38-43 (1999)). Examples of a 5'-3' exonuclease with exonuclease and ss endonuclease activity include T5 exonuclease, as well as homologs and variants thereof. In one example, the 5'-3' exonuclease has at least 90% amino acid sequence identity SEQ ID NO:98. There is no requirement to denature the 5'-3' exonuclease prior to joining the polynucleotides with the strand displacing polymerase. Hence the use of a thermostable 5'-3' exonuclease is described in the examples.

In some embodiments, the composition may further comprise dNTPs (i.e., a mixture of dGTP, dATP, dGTP and dTTP) and, in some embodiments, where T5 5'-3' exonuclease is used, the composition may further comprise potassium salt such as KCl (e.g., at a concentration in the range of 7 mM-150 mM).

In general, a method for producing a synthon is provided. In some embodiments, the method may include incubating an embodiment of the composition described herein that comprises a strand displacing polymerase as described herein and a 5'-3' exonuclease and optionally a ligase (if the reaction is in vitro or in vivo in a cell or organism that does not contain a ligase) and may also contain a ss binding protein, with a set of polynucleotides and/or oligonucleotides in which at least one or some of the members of the set have a sequence that overlaps with one or some other members of the set, under suitable reaction conditions. In some embodiments, the polynucleotides or oligonucleotides may be ds DNA, e.g., overlapping PCR products or overlapping restriction fragments. In other embodiments, the polynucleotides may be ss DNA or RNA. In some embodiments, the set of polynucleotides may comprise ss DNA or RNA. In some embodiments, the set of polynucleotides may comprise ds polynucleotides. In some embodiments, the set of polynucleotides may comprise at least one ds polynucleotide and at least one ss polynucleotide. In some embodiments, the set of polynucleotides may comprise a sub-population of polynucleotides that have identical sequences apart from a sub-sequence that varies between members of the sub-population. In other embodiments, the set of polynucleotides may comprise ss or ds polynucleotides or polynucleotides that have overlapping regions at their ends for purposes of joining but different internal sequences that form the synthon. Thus, in one embodiment of the method of the invention, the polynucleotides in the set of polynucleotides are ds; such as wherein the ds polynucleotides are overlapping PCR products or overlapping restriction fragments or assembled from ss polynucleotides. In an alternative embodiment of the method of the invention, the synthon is assembled from polynucleotides in the set of polynucleotides that are ss. In a further alternative embodiment of the method of the invention, the synthon is assembled from a set of polynucleotides that comprises a mixture of at least one ds polynucleotide and at least one ss oligonucleotide. In embodiments of the method of the invention, the synthon is assembled from a set of polynucleotides that comprise a

6

sub-population of polynucleotides that are identical to one another except for a sub-sequence that varies between the members of the sub-population.

Embodiments of the method may be used to produce a variety of synthons, including coding sequences, vectors, guide molecules for gene engineering and expression cassettes.

Prior to assembly, the initial ds polynucleotides may be in the range of 100 bases-30 kb in length, although polynucleotides outside of this range may be used in certain cases. For example, in some embodiments, individual fragment sizes can be as much as 20 kb-30 kb or longer or as short as 30 bases-500 bases. Moreover, in some embodiments, fragments of different sizes can be joined in the assembly reaction. In one example, long polynucleotides (e.g., fragments of 5 kb-20 kb in length) are joined to short polynucleotides (e.g., fragments of 100 bases-500 bases in length). Newly assembled synthons may be sequenced, either directly using single molecule sequencing methods or after cloning or amplification.

In one embodiment, the members of the set may contain overlapping sequences having a length less than 2 kb for example, in the range of 15-200 nucleotides for example, 20-100 nucleotides.

In one embodiment, a composition is provided where the composition has a 5'-3' exonuclease; a strand-displacing polymerase; and a buffer containing a potassium salt such as KCl in a concentration range of 7 mM-150 mM, for example, 20 mM-50 mM. A sodium salt (e.g., sodium chloride) in the range of 10 mM-100 mM such as 20 mM may also be used in addition to potassium salt. A ss binding protein may be included in the composition. In some embodiments, the composition does not contain a crowding agent such as polyethylene glycol (PEG), Ficoll, or dextran. In some embodiments, the composition does not contain a non-strand displacing polymerase. In another embodiment, polynucleotide and/or oligonucleotide fragments are included in the composition for forming a synthon.

In another embodiment of the method, a set of oligonucleotides may be joined using a composition that comprises a crowding agent such as polyethylene glycol (PEG), Ficoll, or dextran in addition to or instead of the ss binding protein and at least 7 mM potassium salt such as KCl together with a strand displacing polymerase and a 5'-3' exonuclease in the absence of a non-strand displacing polymerase. In one embodiment the potassium salt is at a concentration of less than 150 mM for example, 20 mM-50 mM.

Also provided is a kit for polynucleotide assembly, comprising: i. a 5'-3' exonuclease; ii. an optional ligase; iii. a strand-displacing polymerase; and iv. a ss DNA binding protein. In certain embodiments, the kit may further comprise dNTPs and/or a buffering agent, for example. The components of the kit may be in separate containers (e.g. one or more different reaction tubes), or, the components of the kit may be in a single container. The components may be lyophilized or in solution or in part lyophilized and in part in solution. The components may be immobilized in part or in whole on a solid surface such as a bead or surface of a reaction chamber or may be in solution. The components may be added to target polynucleotides that may be in part or in whole, immobilized or in solution. In some embodiments, the kit may contain one or more mixtures of the components of the kit. In some embodiments, the kit does not contain a non-strand-displacing polymerase, or a crowding agent.

In one embodiment, a polymerase having at least 80%, 85%, 90% or 95% sequence identity with SEQ ID NO:1 is

provided for the assembly mixture. In another embodiment, a polymerase having a binding domain having at least 80%, 85%, 90%, or 95% sequence identity with SEQ ID NO:2 is provided for the assembly mixture. In another embodiment, a polymerase having at least 80%, 85%, 90% or 95% sequence identity with SEQ ID NO:3 is provided for the assembly mixture. These compositions may be used in reaction conditions in which the polymerase is strand displacing. The compositions may be used in reaction conditions in which any 3' exonuclease activity associated with the polymerase activity is active.

The assembly reaction may occur using ss or ds nucleic acids. Any number of fragments e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more fragments can be assembled. Chemically synthesized ss polynucleotides can be assembled into ds overlapping fragments and hybridized and ligated to the ends of linearized vectors to form synthons suitable for cloning. Alternatively, duplex fragments can be assembled into synthons and inserted into vectors for cloning or PCR or isothermal amplification (see for example, FIG. 2A-2C). ss nucleic acid fragments can also be directly inserted into vectors (see for example, FIG. 7) by hybridizing the nucleic acid fragment to the 3' ss end of a linearized ds vector. The ss nucleic acids may be assembled through overlapping complementary ends at the same time, before, or after the a ss nucleic acid fragment has hybridized to the 3' ss end of the linearized vector. Assembled fragments may be amplified by PCR or isothermal methods before insertion into vectors for cloning. The nucleic acid fragments may contain randomized nucleotide sequences or degenerate code enabling libraries to be formed that contain representative variants at each nucleotide position of the variable region. The random sequence may be positioned between a defined sequence at each end. In one embodiment, the random sequence positioned between defined sequences may be for hybridizing to a second nucleic acid fragment (such as a second ss genomic polynucleotide) or to a linearized vector end. In one example, the random sequence hybridizes to a target genomic sequence for guiding a Cas9 protein to a target nucleic acid for gene editing (see for example, FIG. 9A-9C). Thus, in accordance with this aspect of the invention, the method may be used to hybridize at least one member of a set of polynucleotides to a second nucleic acid fragment (such as a second ss genomic polynucleotide) or to a linearized vector end. For example, the method may be for hybridization of the at least one member of the set of polynucleotides to a target genomic sequence in order to guide a Cas endonuclease such as Cas9 to a target genomic nucleic acid in a method of gene editing.

In some embodiments, a method is provided for assembling a plurality of polynucleotides into a synthon, that includes: combining the plurality of polynucleotides with a composition comprising a 5'-3' exonuclease, a strand displacing polymerase, optionally a ligase, a ss binding protein and a buffer wherein each polynucleotide has a 3' ss terminal polynucleotide sequence on one strand that can be hybridized to a complementary ss complementary sequence on a second polynucleotide and can be joined to form a continuous duplex polynucleotide optionally under isothermal conditions in a single container. The synthon can further be joined at its ends to the ends of a linearized plasmid for amplification and/or cloning.

In some embodiments, the entire assembly method may be carried out as a "one-step" reaction (in a single tube, which does not have to be opened during after the reaction is started). In one example, the components are mixed

together in a reaction vessel and incubated at a temperature of between 40° C. to 60° C. for a period of time, e.g., 5 minutes to 12 hours, thereby producing the synthon.

In one aspect, the method includes a step of strand displacement in the polynucleotides to be joined by a polymerase having at least 90% amino acid sequence identity with SEQ ID NO:1 or SEQ ID NO:102 and/or SEQ ID NO:2 or SEQ ID NO:3. In embodiments of the method, no additional steps of 3'-5' exonuclease chew back are required.

10 Another aspect further comprises enhancing the efficiency of the assembly reaction by including a potassium salt at a minimum concentration of 7 mM in the reaction mixture where the potassium salt is exemplified by KCl.

In one aspect, a method is provided, wherein the polynucleotides contain a random sequence between defined sequence ends. In another aspect, the method further comprises screening the random sequences for hybridizing activity with a genomic DNA and identifying the random sequence with the hybridizing activity. In another aspect, the method comprises performing gene editing by transcribing the random sequences with hybridizing activity to form RNA and using the RNA for gene editing in the presence of a Cas endonuclease.

In one embodiment of the composition, kit, or method of the invention, the strand-displacing polymerase used in the composition, kit, or method of the invention may be non-naturally occurring, such as a mutant or fusion protein. In the composition, kit, or method of the invention, the non-natural strand-displacing fusion polymerase may be characterized by an amino acid composition of the polymerase moiety that is at least 90% or 95% or 99% or 100% identical to any of SEQ ID NOS: 33-55 or SEQ ID NO:1 or of the DNA binding moiety that is at least 90% or 95% or 99% or 100% identical to any of SEQ ID NOS: 56-98 or SEQ ID NO:2. In one embodiment, the polymerase moiety may have an amino acid sequence that has 90% or 95% or 98% or 99% amino acid sequence identity with SEQ ID NO:102 fused to a heterologous DNA binding moiety selected from a polypeptide that has at least 90% or 95% or 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 56-98.

In general in one aspect, a preparation is provided that includes a composition having an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:3. The preparation may further comprise a 5'-3' exonuclease, for example a T5 exonuclease. The preparation may further comprise a ss DNA binding protein, for example, an ET SSB, *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT, more particularly a thermostable ss binding protein such as ET SSB. The preparation may further comprise a ligase. In one aspect, a preparation including the composition may further comprise a ss binding domain and a 5-3' exonuclease, wherein the preparation does not comprise a crowding agent and/or a non-strand-displacing polymerase. The preparation may further include a potassium salt.

In one aspect, the preparation including the composition may further comprise a plurality of polynucleotides in a set wherein at least a polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from: (i) ds polynucleotides; (ii) ss oligonucleotides; (iii) at least one ds polynucleotide and at least one ss oligonucleotide; and (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the sub-population. In one aspect the set of polynucleotides has at least 3 members or at least 4 members or at least 5 members.

In general, a method for producing a synthon, that includes: incubating a composition of claim 1 further comprising a 5'-3' exonuclease and, optionally, a ligase and a ss DNA binding protein, with a plurality of polynucleotides that form a set, wherein members of the set have sequences that overlap under suitable reaction conditions; and joining at least two of the polynucleotides to produce a synthon. In one aspect, the set of polynucleotides contains at least 3 members or at least 4 members or at least 5 members. In one aspect, the preparation further includes a ligase. In one aspect, the preparation, further includes a ss DNA binding protein. In one aspect, the polynucleotides are ds and the ds polynucleotides are overlapping PCR products, overlapping restriction fragments or assembled from ss oligonucleotides. In one aspect, the polynucleotides are ss oligonucleotides. In one aspect, the set of polynucleotides comprises at least one ds polynucleotide and at least one ss oligonucleotide.

In general, a kit is provided that includes a preparation according to claim 1 and a 5'-3' exonuclease such as for example T5 exonuclease. In one aspect, the kit may further include a ss binding protein. In another aspect, the kit may include a ligase. In another aspect, the kit may include a buffering agent. In one aspect, the kit does not include a crowding agent. In one aspect, the composition and the 5'-3' exonuclease are in the same vessel. In another aspect, the composition and the 5'-3' exonuclease are in different vessels optionally in buffers suitable for combining into a single vessel.

In general, a composition is provided for assembling a synthon, that includes: a 5'-3' exonuclease, which in one aspect has ss endonuclease activity, for example having 90% sequence identity with SEQ ID NO:98; a strand-displacing polymerase, including a Family B strand displacing polymerase that is preferably non-naturally occurring such as a mutant or a fusion protein derived from a naturally occurring polymerase that may additionally be thermostable; optionally a ss DNA binding protein, such as for example the ss DNA binding protein is ET SSB, *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT; and a non-naturally occurring buffering agent, wherein the composition does not comprise a crowding agent and/or a non strand-displacing polymerase. In one aspect, the composition further includes a ligase and/or a ss binding domain. In one aspect, the composition includes a set of at least two polynucleotides (a plurality of polynucleotides). In one aspect, the composition does not include a non-strand displacing polymerase. In another aspect, the composition does not include N⁹ N, Phusion, Vent or Pfu DNA polymerases.

In one aspect, the strand-displacing polymerase in the composition is a fusion protein wherein the polymerase moiety has an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:102, or any of SEQ ID NOs:33-55. For example, the fusion protein may have an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or 102 and SEQ ID NO:2. For example, the strand-displacing polymerase may have at least 90% sequence identity to SEQ ID NO:3. In one aspect, the composition may include a potassium salt having a concentration of at least 7 mM. In one aspect, the composition may include a set of polynucleotides in which at least one polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from: (i) ds polynucleotides; (ii) ss oligonucleotides; (iii) at least one ds polynucleotide and at least one ss oligonucleotide; and (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of

the sub-population. In one aspect, at least one member of the set of polynucleotides contains a random sequence positioned between a defined sequence at each end for hybridizing to a second ss genomic polynucleotide where for example, the random sequence is ss and is capable of hybridizing to a target genomic sequence for guiding a Cas protein to a target genomic nucleic acid for gene editing.

In general, a method for forming a synthon, is provided that includes incubating any of the compositions described above that contain a set of polynucleotides having sequences that overlap under suitable reaction conditions; and joining at least some of the polynucleotides to other polynucleotides to produce a synthon. In one aspect of the method, all or a portion of the polynucleotides in the set are ds. In another aspect, the ds polynucleotides are overlapping PCR products; overlapping restriction fragments, or synthetic ds molecules assembled from complementary ss oligonucleotides where these oligonucleotides may have been made in a synthesizer. In one aspect, all or a portion of the polynucleotides in the set are ss oligonucleotides. In one aspect, the set of polynucleotides comprises at least one ds polynucleotide and at least one ss oligonucleotide. In one aspect, the set of polynucleotides comprises a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the subpopulation. In one aspect, the overlapping sequences of the polynucleotides are less than 2 kilobases in length. In one aspect of the method, the strand-displacing polymerase comprises an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1, 2, 3, 33-96, or 102. In one aspect of the method, at least one member of the set of polynucleotides contains a random sequence between defined sequence ends. Another aspect of the method includes screening the random sequences for hybridizing activity with a genomic DNA and identifying the random sequence with the hybridizing activity. Another aspect of the method includes performing gene editing by transcribing the random sequences with hybridizing activity to form RNA and using the RNA for gene editing in the presence of a Cas protein.

In general, a kit for polynucleotide assembly is provided that includes: a 5'-3' exonuclease; a strand-displacing polymerase; and optionally a ss DNA binding protein wherein the kit optionally does not comprise a crowding agent and/or a non-strand-displacing polymerase. In one aspect, the kit includes a ligase. In another aspect, the kit includes dNTPs. In another aspect, the kit includes a buffering agent. In another aspect, the individual components of the kit may be in the same or separate containers such as one or more different storage or reaction containers.

In general, a composition is provided that includes a polymerase fusion protein, wherein the polymerase fusion protein includes an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:2, 56-96 and a heterologous polymerase domain. In one aspect, the polymerase fusion protein includes an amino acid sequence that is at least 90% identical to any of SEQ ID NO:2; and a heterologous polymerase domain.

In general, a composition is provided that includes a polymerase fusion protein is provided wherein the polymerase fusion protein includes a polymerase domain that has an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1, 33-55, or 102; and a heterologous DNA binding domain. In one aspect, the polymerase fusion protein, the polymerase domain that has an amino acid sequence that is at least 90% identical to SEQ ID NO:1; and a heterologous DNA binding domain. In one aspect, the

11

polymerase fusion protein has a polymerase domain that has an amino acid sequence that is at least 90% identical to SEQ ID NO:102; and a heterologous DNA binding domain. In one aspect, the polymerase fusion protein has an amino acid sequence that is at least 90% identical to SEQ ID NO:3.

In one aspect, the compositions above further include a 5'-3' exonuclease such as T5 exonuclease. In one aspect, the composition further includes a single-strand DNA binding protein for example a single-strand binding protein selected from an ET SSB, *E. coli* recA, T7 gene 2.5 product, phage lambda RedB or Rac prophage RecT. In one aspect, the composition may include a ligase. In one aspect, the ligase is thermostable. In one aspect, the composition does not include a crowding agent and/or a non-strand-displacing polymerase. In another aspect, the composition further includes dNTPs. In another aspect, the composition further includes a potassium salt having a concentration of at least 7 mM. One aspect of the composition includes a set of polynucleotides wherein at least a polynucleotide in the set has a sequence that overlaps with another polynucleotide in the set; and wherein the polynucleotides are selected from: (i) ds polynucleotides; (ii) ss oligonucleotides; (iii) at least one ds polynucleotide and at least one ss oligonucleotide; and (iv) a subpopulation of polynucleotides that are otherwise identical to one another except for a sequence that varies between the members of the sub-population.

In general, a method is provided for producing a synthon, that includes incubating a set of polynucleotides where individual polynucleotides contain sequences that overlap with sequences in other polynucleotides, where the overlapping sequences of different polynucleotides are capable of cross-hybridizing under suitable reaction conditions, and where for example the overlapping region is less than 2 kilobases, with a composition comprising a polymerase characterized above, wherein the composition further includes a 5'-3' exonuclease and, optionally, a ligase and a ss DNA binding protein; and joining the polynucleotides to produce a synthon.

In different aspects, the composition includes a ligase; and/or a ss DNA binding protein. In another aspect, one or more polynucleotides in the set are ds, where the ds polynucleotides are PCR products, overlapping restriction fragments or assembled from ss oligonucleotides and/or one or more polynucleotides are ss oligonucleotides; and/or the set of polynucleotides includes at least one ds polynucleotide and at least one ss oligonucleotide.

In general, a kit for polynucleotide assembly is provided that includes a polymerase fusion protein, as described above and a 5'-3' exonuclease; and a ss DNA binding protein. In one aspect, the kit may include any or all of a ligase, dNTPs, and buffering agent where the components of the kit may be in the same vessel or in different vessels.

BRIEF DESCRIPTION OF THE FIGURES

The skilled artisan will understand that the drawings, described below, are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way.

FIG. 1A-1E shows how the assay described in Example 1 differentiates between a strand displacing and non-strand displacing polymerase. This assay confirms that T4 DNA polymerase is non-strand displacing and terminates synthesis of a template DNA at 44 nucleotides in length at a blocking oligonucleotide (2) (FIG. 1C) whereas Bst polymerase (FIG. 1D) and a non-natural polymerase (FIG. 1E)

12

are strand displacing and can continue DNA synthesis of a FAM primer (1) by displacing the blocking oligonucleotide (27 nucleotides in length).

FIG. 1A shows the sequence and position of the primer (1) and a blocking oligonucleotide (2) on a DNA template used in the assay for the enzymes below.

FIG. 1B shows fluorescence observed in samples obtained after capillary electrophoresis where no enzyme was added and the starting material formed a peak at a position corresponding to 24 nucleotides of the FAM primer.

FIG. 1C shows the result of adding T4 DNA polymerase. The primer was extended to a final length of 44 nucleotides (24 nucleotides plus 20 nucleotides) but was terminated by the blocking oligonucleotide.

FIG. 1D shows that Bst DNA polymerase (large fragment) strand-displaces the blocking oligonucleotide and copies template by extending the primer to a total length of 72 nucleotides (24+20+27+dA).

FIG. 1E shows a family B strand displacing DNA polymerase which is a proof reading polymerase that strand displaces blocking oligonucleotides and copies template by extending the primer by 71 nucleotides (24+20+27).

FIG. 2A-2C show the steps in a DNA assembly method.

FIG. 2A shows the incorporation of the amplicons of each 25 of 5 fragments into 5 plasmids with ampicillin resistance markers. The 5 fragments were initially amplified with primers that generated amplicons which had overlapping 30 regions as well as flanked by NotI restriction sites. The NotI cleavage produces sticky ends. NotI restriction (3) permitted 35 release of each amplicon from the vectors. The restriction enzyme cleaved fragments have an 80 base pair overlap region (4) with the adjacent fragment. In FIG. 2C, the overlap between the first fragment and an adjacent reagent vector end and a last fragment and adjacent reagent vector 40 end is 15-25 nucleotides, for example, 20 nucleotides, for convenience and cost reduction but this is not intended to be limiting.

FIG. 2B shows NotI cleaved optionally sequenced fragments (5) where the amplicon is retrieved from a vector and 45 the 5' ends of Frag. 1 are SEQ ID NO:103 and 104 and of Frag. 2 top strand is SEQ ID NO:105. These fragments were 50 then treated with an enzyme mixture that included T5/5'-3' exonuclease, DNA polymerase with 3'-5' exonuclease activity, a ss binding protein ET SSB (New England Biolabs, Ipswich, Mass.) and DNA ligase in a single reaction vessel 55 (6)-(8). Although NotI is used here, other restriction endonucleases may be used for cleavage depending on convenience. Double digestion with two or more restriction endonucleases may be used. For example, double digestion of 60 vector DNA with two restriction endonucleases has been found to reduce background from uncut vector. The overlapping ss DNA sequences hybridized to adjacent fragments. The T5 exonuclease chewed back a DNA strand from 5' to 3' on each fragment to expose a 3' ss region (6) which 65 allowed the fragments to anneal together in the presence of ss binding protein (7). Removal of the 2 base flap was achieved by means of the 3'-5' exonuclease activity associated with a strand displacing polymerase followed by extension by the strand displacing polymerase to fill the gap in the assembled product (8). Any residual nick or 5' flap may be repaired by a ligase and/or T5 exonuclease.

FIG. 2C shows the 5 fragments (Frag. 1-Frag. 5) now joined in sequence and inserted into a second plasmid carrying chloramphenicol resistance gene (Cam) for transformation into a bacterial host.

FIGS. 3A and 3B show chloramphenicol plates were used to select colonies for growth on plates and those colonies

13

that contained the lacZ gene generated blue colonies in the presence of IPTG and X-Gal. The assay provides a quantitative assessment of clones in which genes are assembled efficiently and in a functional form.

FIG. 3A shows chloramphenicol only.

FIG. 3B shows chloramphenicol+IPTG+Xgal.

FIG. 4 shows that the plasmids did in fact contain the entire gene. Amplification by PCR of assembly product shown in FIG. 2B was performed to confirm all fragments were joined and ligated prior transformation. Lane 1 and 2 are duplicate PCR results. Lane M is 2-log DNA ladder from New England Biolabs, Ipswich, Mass.

FIG. 5 shows the effect of KCl in the assembly mix as determined by the number of colonies. The increase in accuracy/efficiency of assembly using a strand displacing polymerase in an assembly mix is demonstrated using an increased concentration of KCl in the buffer. The histogram on the left (T26) does not contain KCl whereas the histogram on the right (T26K) contains 25 mM KCl showing a 1.5 fold enhancement of efficiency. This improvement occurs regardless of the assembly condition. A similar relative enhancement of efficiency is expected if PEG or other crowding agent were used in the absence of ss binding protein.

FIG. 6 shows a comparison between the mixture described in Example 2 (Strand displacing polymerase/ss binding protein/5'-3' exonuclease/ligase)(Mix1) and the commercial Gibson Assembly® Mix (GAMM) (non-strand displacing polymerase and polyethylene glycol) (Synthetic Genomics, La Jolla, Calif./New England Biolabs, Ipswich, Mass.) following the protocol provided by the manufacturer. Mix 1 results in significantly higher efficiencies of DNA assembly and transformation.

FIG. 7 shows a general diagram of DNA assembly between ss DNA oligonucleotides and ds DNA fragments. ss target DNA oligonucleotide is inserted into a DNA vector. The ss target DNA oligonucleotide has been synthesized so as to have an overlapping region of 20-30 nucleotides on each end with the 3' vector ends. However, the size of the oligonucleotide may have an overlapping region of less than 20 nucleotides for example less than 15 nucleotides or less than 10 nucleotides or alternatively more than 30 nucleotides, for example, at least 40 or 50 or 60 nucleotides or more. Beyond the overlapping regions, the oligonucleotide preferably has 1 or more nucleotides that are not overlapping positioned between the ends. The assembly master mix which contains a 5'-3' exonuclease, strand displacing polymerase, ligase and ss binding protein is added to the mixture of ss oligonucleotide and the vectors so as to permit the 5'end of the ds DNA vector to be chewed back so as to produce ss overhangs (9). The 3' end of the ss DNA is then able to anneal to a 5' end of the vector and the DNA polymerase then replicates the ss template to fill the gap and produce a blunt ended ds DNA. The nick is sealed by ligase (10). Again, the exonuclease (here T5 exonuclease) chews back the 5' end this time on the blunt end of the target DNA producing 3' ss regions so as to permit annealing of the complementary sequences and completion of the ds integration of target DNA into the DNA vector (11). Fragments can anneal with DNA polymerase filling the gap and ligase sealing the nick. (12) to produce a synthon.

FIG. 8A-8C shows the workflow for bridging ds DNA by a short ss oligonucleotide. (The protocol is described in FIG. 7).

FIG. 8A provides an example of a sequence of a short ss oligonucleotide for integration into a ds DNA vector shown here as a CRISPR Nuclease Vector with OFP Reporter.

14

FIG. 8B shows the workflow starting with a ss oligonucleotide and a ds CRISPR Nuclease Vector (9424 bp) treated with 5'-3' exonuclease, strand displacing polymerase, a ligase and a ss binding protein (13) to produce a complete ds circular DNA. This DNA was transformed into competent cells (14). After an overnight incubation, the colonies were analyzed by a mini-prep and then the plasmids sequenced (15).

FIG. 8C shows the insert and adjacent sequences (SEQ ID NO:106) of U6 promoter sequence (vector) including the designed ss oligonucleotide (71mer), and scaffold template-specific sequence (vector). The ss oligonucleotide (71mer) including an overlap region of 25 nucleotides at each end (21 nucleotides of the target DNA in bold)) was properly integrated into the vector in host cells.

FIG. 9A-9C show that a similar workflow to that in FIG. 8B can be used for an ss oligonucleotide having degenerate bases between the overlapping ends. Again the starting sequence in FIG. 9A is shown above the workflow (FIG. 9B) and the Sanger-sequencing results from colonies from assembly pool is shown below (FIG. 9C) with the solid line referring to a pool of sgRNA targeting sequences. The sgRNA targeting sequence contained 21 variable nucleotide positions providing 4^{21} variants. The pool contained every possible variant and each variant was amenable to cloning reflecting the degeneracy of the sequence between the overlapping ends and the vector. FIG. 9A shows the sequence of a ss oligonucleotide containing degenerate bases (SEQ ID NO:29). The sgRNA targeting sequence of FIG. 9A was inserted between a U6 promoter sequence and a scaffold template specific sequence of the vector (16), transformed into host cells (17) and analyzed for synthons by miniprep and sequencing (18) as described above and herein. Sanger sequencing was performed on clones from the assembly pool. An example of a sequence is provided in FIG. 9C.

FIG. 10 presents the results of 187 colonies selected from a plate after the assembly reaction products were transformed into *E. coli*. Each colony was PCR amplified and sequenced to confirm the insertion of the ss DNA and the distribution of degenerate bases were analyzed. The results shown here confirmed that indeed different colonies contained different degenerate sequences. No bias was detected. Analysis was carried out by first converting the sequences into a fastq file and then using the fastx_quality_stats tool from the fastx toolkit on github. The sequence logo was created using weblogo from Berkeley.

FIGS. 11A and 11B show the amino acid sequences from a variety of DNA binding domains from *Pyrococcus furiosus*, an Archaeabacterium.

FIG. 12 shows a phylogenetic tree of the DNA binding domains shown in FIGS. 11A and 11B.

FIGS. 13A and 13B show the amino acid sequences from a variety of DNA binding domains from *Thermotoga maritima*, a thermophilic bacterium.

FIG. 14 shows a phylogenetic tree of the DNA binding domains shown in FIGS. 13A and 13B.

FIG. 15 shows a phylogenetic tree of various DNA polymerases used herein. As shown, the polymerases are derived from a variety of different bacterial and archaeal species.

FIG. 16 shows the amino acid sequences of fusions of DNA polymerase SP-17 (DNA polymerase family B) with binding domains BD-07, 08 and 98.

FIG. 17 shows the amino acid sequences for fusions of DNA polymerase SP-04 (DNA polymerase family A) with binding domains BD-07, 02 and 98.

15

FIGS. 18A and 18B shows the amino acid sequences of fusions of DNA polymerase SP-61 (DNA polymerase family B) with binding domains BD-07, 09, 23, 62, 93 and 109.

FIGS. 19A and 19B shows the amino acid sequences for fusions of DNA polymerase SP-49 (DNA polymerase family B) with binding domains BD-07, 09, 23, 62, 93 and 109.

FIG. 20 shows data showing that DNA polymerase SP-17 (family B) has enhanced PCR activity after it is fused to various DNA binding domains. In this assay, enhanced PCR activity is the ability of the fusions to amplify longer DNA fragments. The data shown in lanes 1-8 on the left was produced using the SP-17 polymerase without a DNA binding domain. This polymerase was able to amplify longer fragments when it was fused to the BD-07, BD-08 and BD-98 DNA binding domains.

FIG. 21 shows data showing that DNA polymerase SP-04 (family A) has enhanced PCR activity after it is fused to various DNA binding domains. In this assay, enhanced PCR activity is the ability of the fusions to amplify longer DNA fragments. The data shown in lanes 1-8 on the left was produced using the SP-04 polymerase without a DNA binding domain. This polymerase was able to amplify longer fragments when it was fused to the BD-02, BD-07 and BD-98 DNA binding domains.

FIG. 22 shows data showing that DNA polymerase SP-61 (family B) has enhanced PCR activity after fused to DNA binding domains. In this assay, enhanced PCR activity is a higher tolerance to different buffers. The data shown in lanes 1-3 on the left was produced using the SP-61 polymerase without a DNA binding domain. This polymerase was able to amplify fragments in a wide variety of buffers when it was fused to the BD-07, BD-23, BD-09, BD-62, BD-93 and BD-109 DNA binding domains.

FIG. 23 shows data showing that DNA polymerase SP-49 (family B) has enhanced PCR activity after fused to DNA binding domains. In this assay, enhanced PCR activity is a higher tolerance to different buffers. The data shown in lanes 1-3 on the left was produced using the SP-49 polymerase without a DNA binding domain. This polymerase was able to amplify fragments in a wide variety of buffers when it was fused to the BD-07, BD-23, BD-09, BD-62, BD-93 and BD-109 DNA binding domains.

DESCRIPTION OF TERMS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994), and Hale & Markham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, N.Y. (1991) provide one of skill with the general meaning of many of the terms used herein. Still, certain terms are defined below for the sake of clarity and ease of reference.

As used herein, the term “synthon” as used in the field of gene synthesis refers to a polynucleotide assembly. Polynucleotide assembly may include assembling overlapping fragments of a size that can be prepared on an oligonucleotide synthesizer which at the present time is generally 2000-3000 bases for each synthetic polynucleic acid. Alternatively, overlapping fragments may be obtained by PCR from naturally occurring nucleic acid to which adaptors have been attached to provide the overlapping sequences. For assembly purposes there is no limitation on the size of each fragment. Many fragments can be assembled end to end

16

relying on overlapping sequences at the ends to enable constructs of any desirable length to be made accurately and efficiently. Preferably a synthon is a continuous longer polynucleotide that does not contain gaps or nicks that are formed from the assembly of shorter polynucleotides. The length of synthons resulting from assembly of nucleic acid fragments is not limited to any particular size however.

As used herein, the term “5'-3' exonuclease”, refers to an exonuclease that degrades DNA from the 5' end, i.e., in the 5' to 3' direction. 5'-3' exonucleases of interest can remove nucleotides from the 5' end of a strand of ds DNA at a blunt end and, in certain embodiments, at a 3' and or 5' overhang. T5 exonuclease, lambda exonuclease and T7 exonuclease are examples of 5'-3' exonucleases. In certain embodiments, T5 exonuclease is preferred. T5 exonuclease additionally has a ss endonuclease activity.

As used herein, the term “ligase”, refers to an enzyme that can covalently join a 3' end of a DNA molecule to a 5' end of another DNA molecule, particularly at a nick. Examples 20 of ligases include T7 ligase, T4 DNA ligase, *E. coli* DNA ligase and Taq ligase, although many others are known and may be used herein.

As used herein, the term “strand-displacing polymerase”, refers to a polymerase that is able to displace one or more 25 nucleotides, such as at least 10 or 100 or more nucleotides that are downstream from the enzyme. Strand displacing polymerases can be differentiated from Phusion where the art recognized definition of Phusion is a non-strand displacing polymerase. In some embodiments, the strand displacing polymerase is stable and active at a temperature of at least 50° C. or at least 55° C. (including the strand displacing activity). Taq polymerase is a nick translating polymerase and, as such, is not a strand displacing polymerase.

As used herein, the term “single strand (ss) DNA binding 35 protein”, refers to proteins that bind to ss DNA and prevent premature annealing, protect the ss DNA from being digested by nucleases, and polymerases and/or remove secondary structure from the DNA to allow other enzymes to function effectively upon it. Inclusion of a ss binding protein 40 in the compositions described herein is preferable to optimize the efficiency of synthon formation. Examples of ss DNA binding proteins are T4 gene 32 protein, *E. coli* SSB, T7 gp2.5 SSB, and phage phi29 SSB, and ET SSB although many others, e.g., RedB of lambda phage, RecT of Rac 45 prophage and the sequences listed below, are known and may be used herein. A thermostable ss DNA binding protein that is stable at 50° C. may be used in some cases. Thus, in one embodiment of the composition, kit, or method of the invention, the ss DNA binding protein is T4 gene 32 protein, 50 *E. coli* SSB, T7 gp2.5 SSB, phage phi29 SSB, ET SSB, RedB of lambda phage, or RecT of Rac prophage. In one embodiment, the ss DNA binding protein is ET SSB. In one embodiment of the composition, kit, or method of the invention, the ss DNA binding protein is thermostable (i.e. stable at 40° C.-60° C.).

As used herein, the term “buffering agent”, refers to an agent that allows a solution to resist changes in pH when acid or alkali is added to the solution. Examples of suitable 55 non-naturally occurring buffering agents that may be used in the compositions, kits, and methods of the invention include, for example, Tris, HEPES, TAPS, MOPS, tricine, or MES.

The term “non-naturally occurring” refers to a composition that does not exist in nature.

Any protein described herein may be non-naturally occurring, 60 where the term “non-naturally occurring” refers to a protein that has an amino acid sequence and/or a post-translational modification pattern that is different to the

protein in its natural state. For example, a non-naturally occurring protein may have one or more amino acid substitutions, deletions or insertions at the N-terminus, the C-terminus and/or between the N- and C-termini of the protein. A “non-naturally occurring” protein may have an amino acid sequence that is different to a naturally occurring amino acid sequence (i.e., having less than 100% sequence identity to the amino acid sequence of a naturally occurring protein) but that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% identical to the naturally occurring amino acid sequence. In certain cases, a non-naturally occurring protein may contain an N-terminal methionine or may lack one or more post-translational modifications (e.g., glycosylation, phosphorylation, etc.) if it is produced by a different (e.g., bacterial) cell. A “mutant” protein may have one or more amino acid substitutions relative to a wild-type protein and may include a “fusion” protein. The term “fusion protein” refers to a protein composed of a plurality of polypeptide components that are unjoined in their native state. Fusion proteins may be a combination of two, three or even four or more different proteins. The term polypeptide includes fusion proteins, including, but not limited to, a fusion of two or more heterologous amino acid sequences, a fusion of a polypeptide with: a heterologous targeting sequence, a linker, an immunologically tag, a detectable fusion partner, such as a fluorescent protein, β -galactosidase, luciferase, etc., and the like. A fusion protein may have one or more heterologous domains added to the N-terminus, C-terminus, and/or the middle portion of the protein. If two parts of a fusion protein are “heterologous”, they are not part of the same protein in its natural state.

In the context of a nucleic acid, the term “non-naturally occurring” refers to a nucleic acid that contains: a) a sequence of nucleotides that is different to a nucleic acid in its natural state (i.e. having less than 100% sequence identity to a naturally occurring nucleic acid sequence), b) one or more non-naturally occurring nucleotide monomers (which may result in a non-natural backbone or sugar that is not G, A, T or C) and/or c) may contain one or more other modifications (e.g., an added label or other moiety) to the 5'-end, the 3' end, and/or between the 5'- and 3'-ends of the nucleic acid.

In the context of a preparation, the term “non-naturally occurring” refers to: a) a combination of components that are not combined by nature, e.g., because they are at different locations, in different cells or different cell compartments; b) a combination of components that have relative concentrations that are not found in nature; c) a combination that lacks something that is usually associated with one of the components in nature; d) a combination that is in a form that is not found in nature, e.g., dried, freeze dried, crystalline, aqueous; and/or e) a combination that contains a component that is not found in nature. For example, a preparation may contain a “non-naturally occurring” buffering agent (e.g., Tris, HEPES, TAPS, MOPS, tricine or MES), a detergent, a dye, a reaction enhancer or inhibitor, an oxidizing agent, a reducing agent, a solvent or a preservative that is not found in nature.

It may be desirable to use a strand displacing polymerase that has 3' exonuclease activity. While not wishing to be limited by theory, the 3' exonuclease activity is desirable to remove a flap sequence on the 3' end of a duplex where the flap sequence may be the result of enzyme cleavage to extract the target polynucleotide from the plasmid in which it is placed. This is the case when NotI is used as described in the examples. However, if a restriction endonuclease is

used that creates a blunt end on the excised fragment, 3'exonuclease activity may not be required.

The 3' exonuclease activity can be routinely determined by using a standard DNA template and primers where the primers either have or do not have non-hybridized 3' nucleotides. If the polymerase has 3' exonuclease activity, an amplicon will be detected using either primer pair. If the polymerase lacks the 3' exonuclease activity, no amplicon will be detected using those primers having a non-hybridized 3' nucleotide.

As used herein, the term “potassium salt”, refers to a salt of potassium including, but not limited to, KCl. The term “sodium salt”, refers to a salt of sodium including, but not limited to, NaCl.

As used herein, the term “polynucleotide” encompasses oligonucleotides and refers to a nucleic acid of any length. Polynucleotides may be DNA or RNA. Polynucleotides may be ss or ds unless specified. Polynucleotides may be synthetic, for example, synthesized in a DNA synthesizer, or naturally occurring, for example, extracted from a natural source, or derived from cloned or amplified material. Polynucleotides referred to herein may contain modified bases.

As used herein, the term “set of polynucleotides”, refers to a collection of at least 2 polynucleotides. In some embodiments, a set of polynucleotides may comprise at least 5, at least 10, at least 12 or at least 15 or more polynucleotides.

As used herein, the term “overlapping sequence”, refers to a sequence that is complementary in two polynucleotides and where the overlapping sequence is ss, on one polynucleotide it can be hybridized to another overlapping complementary ss region on another polynucleotide. By way of example, the overlapping sequence may be complementary in at least 5, 10, 15, or more polynucleotides in a set of polynucleotides. An overlapping sequence may be at or close to (e.g., within about 5, 10, 20 nucleotides of) the 3' ends of two distinct molecules (e.g., the 3' ends of two ss oligonucleotides, or the 3' end of the top strand of first ds polynucleotide and the 3' end of the bottom strand of a second ds molecule), where, if the non-overlapping sequence is at the 3' ends then the non-overlapping sequence may be removed using a 3'-5' exonuclease activity of a polymerase. An overlapping sequence may vary in length and, in some cases, may be at least 12 nucleotides in length (e.g. at least 15, 20 or more nucleotides in length) and/or may be up 100 nucleotides in length (e.g., up to 50, up to 30, up to 20 or up to 15 nucleotides in length). Alternatively, overlapping sequences in the set of polynucleotides may be 2 kb or less, or 1 kb or less or less than 900 bases, 800 bases, 700 bases, 600 bases, 500 bases, 400 bases, 300 bases, 200 bases or 100 bases. Preferably the overlapping sequence length is in the range of 15 nucleotides-80 nucleotides for example up to 20, up to 25, up to 30, up to 35, up to 40, up to 45, up to 50, up to 55, up to 60, up to 65, up to 70, up to 75, or up to 80 nucleotides. The minimum length of the overlap may be defined by a T_m that is preferably equal to or greater than 48° C.

As used herein, the term “polynucleotide assembly”, refers to a reaction in which two or more, four or more, six or more, eight or more, ten or more, 12 or more 15 or more polynucleotides, e.g., four or more polynucleotides are joined to another to make a longer polynucleotide. The product of a polynucleotide assembly reaction, i.e., the “assembled polynucleotide” or “synthon” in many embodiments should contain one copy of each of the overlapping sequences.

As used herein, the term “incubating under suitable reaction conditions”, refers to maintaining a reaction a suitable

19

temperature and time to achieve the desired results, i.e., polynucleotide assembly. Reaction conditions suitable for the enzymes and reagents used in the present method are known (e.g. as described in the Examples herein) and, as such, suitable reaction conditions for the present method can be readily determined. These reaction conditions may change depending on the enzymes used (e.g., depending on their optimum temperatures, etc.).

As used herein, the term "isothermal" refers to temperature conditions that do not require active modulation of temperature for assembly to occur. Insignificant variations in the temperature of a water bath or heating block are within the scope of the meaning of the term isothermal. By way of example, the term "isothermal", may refer to reaction conditions that do not require a heat denaturation step after the reaction has started. More specifically, isothermal methods do not involve thermocycling, i.e., cycling between a denaturation temperature of above 90° C. and an annealing/extension temperature. Isothermal conditions usually involve incubation at a temperature that is below 90° C. for a period of time (e.g., 5 minutes to 12 hours or more). In one embodiment, isothermal amplification reactions were performed at a temperature in the range of 30° C.-75° C., for example, 40° C.-60° C.

As used herein, the term "joining", refers to the production of covalent linkage between two sequences.

As used herein, the term "composition" refers to a combination of reagents that may contain other reagents, e.g., glycerol, salt, dNTPs, etc., in addition to those listed. A composition may be in any form, e.g., aqueous or lyophilized, and may be at any state (e.g., frozen or in liquid form).

As used herein a "vector" is a suitable DNA into which a fragment or a synthon may be integrated such that the engineered vector can be replicated in a host cell. A linearized vector may be created restriction endonuclease digestion of a circular vector or by PCR. The concentration of fragments and/or linearized vectors can be determined by gel electrophoresis or other means.

Any one or more of the proteins (e.g., the ligase, SSBP, 5'-3' exonuclease or polymerase, etc.) used herein may be temperature sensitive or thermostable where, as used herein, the term "temperature sensitive" refers to an enzyme that loses at least 95% of its activity after 10 minutes at a temperature of 65° C., and the term "thermostable" refers to an enzyme that retains at least 95% of its activity after 10 minutes at a temperature of 65° C.

The term "domain" refers to a structurally conserved part of a larger protein, the sequence and tertiary structure of which that can evolve, function, and exist independently of the rest of the protein. A "domain" can be transferred to another protein with the expectation that it will still function.

The term "sequence-specific DNA binding domain" refers to a domain that, based on its predicted tertiary structure and/or sequence identity to other proteins, is predicted to bind double stranded DNA in a sequence-specific manner. Sequence-specific DNA binding domains are commonly found in transcription factors, e.g., transcriptional activators or repressors. Sequence-specific DNA binding domains have much higher affinity (e.g., at least 1000× more affinity) for specific DNA sequences (which may be composed of a sequence of 4, 5, 6, 7 or 8 or more continuous or discontinuous nucleotides) and do not bind to all sequences with the same affinity. The sequence-specific DNA binding domain, when it is present in a longer protein, e.g., a transcription factor, is sufficient to anchor the protein at a particular nucleotide sequence in double stranded DNA,

20

thereby allowing the longer protein to affect another process that is local to the binding site, e.g., activate transcription, inhibit transcription, effect recombination or transposition, etc. A sequence-specific DNA binding domain may have an amino acid sequence that is at least 80%, at least 90%, at least 95%, or at least 98%, identical to a naturally occurring sequence that based on its predicted tertiary structure and/or sequence identity to other proteins, is predicted to bind double stranded DNA in a sequence-specific manner.

The term "heterologous", when used in the context of a fusion protein that contains a first domain and a second "heterologous" second domain, refers to a combination of elements that are not usually found together naturally. In the context of a fusion protein, the two domains may be from different distinct proteins, which proteins may be from the same species (in which case the proteins may be expressed in the same cell) or different species.

DETAILED DESCRIPTION OF EMBODIMENTS

Before various embodiments are described in greater detail, it is to be understood that the teachings of this disclosure are not limited to the particular embodiments described, and as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present teachings will be limited only by the appended claims.

While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the present disclosure.

Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present teachings, the some exemplary methods and materials are now described.

The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present claims are not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided can be different from the actual publication dates which can need to be independently confirmed.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims can be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which can be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present

teachings. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Fusion Proteins

In some embodiments, the fusion protein may be a fusion between a DNA polymerase and a sequence-specific DNA binding domain, where the sequence-specific DNA binding domain may be N-terminal or C-terminal to the DNA polymerase. In other words, the fusion protein has a polymerase domain and a heterologous sequence-specific DNA binding domain. The fusion protein has a polymerase activity and, as would be apparent, such a fusion protein does not exist in nature, i.e., is non-naturally occurring.

As noted above, the polymerase may be a family A polymerase or a family B polymerase. Family A polymerases, which includes bacterial, archaeal and bacteriophage polymerases, share significant similarity to *Escherichia coli* polymerase I and have an exonuclease activity, which is usually provided by the N-terminal portion of the protein. Family A polymerases are classed as being replicative polymerases or repair polymerases. The repair polymerases “proofread” the new strands created and rectify any mistakes in the base pairing. The replicative members of family A include the T7 DNA polymerase as well as the eukaryotic mitochondrial DNA polymerase γ. The repair polymerases include DNA pol I from *E. coli*, pol I from *Thermus aquaticus* and pol I from *Bacillus stearothermophilus*. Family B polymerases have six regions of similarity (numbered from I to VI). The most conserved region (I) includes a conserved tetrapeptide with two aspartate residues. Its function is not yet known, but it has been suggested that it may be involved in binding a magnesium ion. All sequences in the B family contain a characteristic DTDS motif, and possess many functional domains, including a 5'-3' elongation domain, a 3'-5' exonuclease domain, a DNA binding domain, and binding domains for both dNTP's and pyrophosphate. If the polymerase is a family A polymerase, then the DNA binding domain of a sequence-specific DNA binding protein can be N-terminal or C-terminal to the polymerase in the fusion protein. If the polymerase is a family B polymerase, then the DNA binding domain of a sequence-specific DNA binding protein can be N- or C-terminal to the polymerase in the fusion protein. In certain embodiments, the fusion protein may further comprise a flexible linker between the polymerase domain and the DNA binding domain. Several examples of fusion proteins that work are shown in FIGS. 16, 17, 18A, 18B, 19A and 19B. Further fusion proteins can be readily designed using these examples.

In some embodiments, the DNA polymerase is an A family DNA polymerase selected from the group consisting of a Pol I-type DNA polymerase such as *E. coli* DNA polymerase, the Klenow fragment of *E. coli* DNA polymerase, Bst DNA polymerase, Taq DNA polymerase, Platinum Taq DNA polymerase series, Omni Klen Taq DNA polymerase series, Klen Taq DNA polymerase series, T7 DNA polymerase, and Tth DNA polymerase. In some embodiments, the DNA polymerase is Bst DNA polymerase. In other embodiments, the DNA polymerase is *E. coli* DNA polymerase I. In some embodiments, the DNA polymerase is the Klenow fragment of *E. coli* DNA polymerase. In some embodiments, the polymerase is Taq DNA polymerase. In some embodiments, the polymerase is T7 DNA polymerase.

In other embodiments, the DNA polymerase is a B family DNA polymerase selected from the group consisting of Bst polymerase, Tli polymerase, Pfu polymerase, Pfu turbo polymerase, Pyrobest polymerase, Pwo polymerase, KOD

polymerase, Sac polymerase, Sso polymerase, Poc polymerase, Pab polymerase, Mth polymerase, Pho polymerase, ES4 polymerase, VENT polymerase, DEEPVENT polymerase, Therminator polymerase, phage Phi29 polymerase, and phage B103 polymerase. In some embodiments, the polymerase is KOD polymerase. In some embodiments, the polymerase is Therminator polymerase. In some embodiments, the polymerase is phage Phi29 DNA polymerase. In some embodiments the polymerase is phage B103 polymerase, including, for example, the variants disclosed in U.S. Patent Publication No. 2011/0014612 which is incorporated by reference herein.

In some embodiments, the amino acid sequence of the polymerase may be at least 90% identical to (e.g., at least 95% identical to, at least 98% identical to or at least 99% identical to) the amino acid sequence of a naturally occurring bacterial or archaeabacterial polymerase such as a polymerase from *Pyrococcus* or *Thermococcus*. Exemplary archaeal DNA polymerases include without limitation the thermostable and/or thermophilic DNA polymerases such as, for example, DNA polymerases isolated from *Thermus aquaticus* (Taq) DNA polymerase, *Thermus filiformis* (Tfi) DNA polymerase, *Thermococcus zilligi* (Tzi) DNA polymerase, *Thermus thermophilus* (Tth) DNA polymerase, *Thermus flavus* (Tfl) DNA polymerase, *Pyrococcus woesei* (Pwo) DNA polymerase, *Pyrococcus furiosus* (Pfu) DNA polymerase as well as Turbo Pfu DNA polymerase, *Thermococcus litoralis* (Tli) DNA polymerase or Vent DNA polymerase, *Pyrococcus* sp. GB-D polymerase, “Deep Vent” DNA polymerase (New England Biolabs), *Thermotoga maritima* (Tma) DNA polymerase, *Bacillus stearothermophilus* (Bst) DNA polymerase, *Pyrococcus Kodakaraensis* (KOD) DNA polymerase, Pfx DNA polymerase, *Thermococcus* sp. JDF-3 (JDF-3) DNA polymerase, *Thermococcus gorgonarius* (Tgo) DNA polymerase, *Thermococcus acidophilum* DNA polymerase; *Sulfolobus acidocaldarius* DNA polymerase; *Thermococcus* sp. 9° N-7 DNA polymerase; *Thermococcus* sp. NA1; *Pyrodictium occultum* DNA polymerase; *Methanococcus voltae* DNA polymerase; *Methanococcus thermoautotrophicum* DNA polymerase; *Methanococcus jannaschii* DNA polymerase; *Desulfurococcus* strain TOK DNA polymerase (D. Tok Pol); *Pyrococcus abyssi* DNA polymerase; *Pyrococcus horikoshii* DNA polymerase; *Thermococcus fumicolans* DNA polymerase; *Aeropyrum pernix* DNA polymerase; the heterodimeric DNA polymerase DP1/DP2, etc.

As would be apparent, the polymerase may be a thermostable polymerase, where the term “thermostable” refers to a polymerase that has an optimal activity at a temperature above 45° C., e.g., above 60° C. The polymerase may be strand-displacing, not strand displacing and, in certain embodiments it may or may not have a proofreading activity. Fusions of strand-displacing polymerases are of particular interest.

The sequence-specific DNA binding domain of the fusion protein should be capable of autonomously binding its target sequence as a discrete unit and may be obtained from any type of sequence-specific DNA binding protein, e.g., a transcription factor such as a transcriptional activator or transcriptional repressor or the like. As would be apparent, if the sequence-specific DNA binding domain is from a transcription factor, then other domains of the transcription factor (e.g., the transcriptional activation or repression domain) may not be in the fusion protein. In particular embodiments, the DNA binding domain may have a helix-loop-helix structure, a ribbon-helix-helix structure, helix-

turn-helix structure (e.g., from the lambda or repressor and lacI), a winged helix structure or a homeodomain structure or the like. As for the polymerase, the amino acid sequence of the sequence-specific DNA binding domain may be at least 90% identical to (e.g., at least 95% identical to, at least 98% identical to or at least 99% identical to) the amino acid sequence of the DNA binding domain of a naturally occurring bacterial or archaeabacterial transcription factor, e.g., from *Pyrococcus* or *Thermococcus* or any of the other species listed above or below. The sequence-specific DNA binding domain used should not be the DNA binding domain of a non-specific DNA binding protein, e.g., a topoisomerase, HMG protein, histone, gyrase, transposase or the DNA binding domain of Sso7D or an ortholog thereof (including Sac7d) or a variant thereof, as described in Choli (Biochim. Biophys. Acta 1988 950: 193-203), McAfee (Biochemistry 1995 34: 10063-10077) and Pavlov (Proc. Natl Acad. Sci. 2002 99 13510-13515). These proteins have no known sequence preference and are not transcription factors. Likewise, the DNA binding domain does not form a DNA sliding clamp structure, as described in thioredoxin and UL42 (see Bedford Proc. Natl Acad. 1997 Sci. USA, 94: 479-484; Zuccola, Mol. Cell 2000 5: 267-278; and Shamoo Cell 1999 99: 155-166).

In certain embodiments, the sequence-specific DNA binding domain of the fusion protein has a winged helix motif, which has a compact α/β structure that consists of two wings (W1 and W2), three α helices (H1, H2 and H3) and three β strands (S1, S2 and S3), arranged in order H1-S1-H2-H3-S2-W1-S3-W2. This domain is approximately 90-120 amino acids in length. The N-terminal half of the motif is believed to be helical, whereas the C-terminal half is believed to be composed of two of the three strands forming the twisted antiparallel β sheet and the two large loops or wings, W1 and W2. Wing W1 connects strands S2 and S3, and wing W2 extends from strand S3 to the C terminus of the DBD. HFH proteins are members of the helix-turn-helix (HTH) superfamily, but differ from canonical HTH proteins in the length of the 'turn' connecting helices H2 and H3. The DNA-recognition helix makes sequence-specific DNA contacts with the major groove of DNA, while the wings make different DNA contacts, often with the minor groove or the backbone of DNA. Several winged-helix proteins display an exposed patch of hydrophobic residues thought to mediate protein-protein interactions. Many proteins contain a winged helix DNA-binding domain, including transcriptional repressors (e.g., the biotin repressor, LexA repressor and the arginine repressor), transcription factors (e.g., the hepatocyte nuclear factor-3 protein, heat-shock transcription factor, and the general transcription factors TFIIE and TFIIF) and endonucleases (e.g., FokI and TnsA). Winged helix proteins are reviewed in Gajjivala (Current Opinion in Structural Biology 2000 10: 110-116).

In some embodiments, the polymerase activity of the fusion protein has an improvement in one or more biochemical characteristics relative to the polymerase portion of the fusion protein on its own, i.e., in the absence of the DNA binding domain. The improved biochemical characteristic may be an increase in processivity, an increase in thermal stability, an increase in salt tolerance, an increase in tolerance to impurities or an increase in speed, an increase to amplify GC rich template, an increase in PCR DNA product specificity (e.g., an increase of at least 10%, an increase of at least 20%, an increase of at least 50%, an increase of at least 100% or an increase of at least 200%), without effecting the fidelity of the polymerase. In particular embodiments, the polymerase activity of the fusion protein has an

improvement in PCR efficiency relative to the polymerase portion of the fusion protein on its own, i.e., in the absence of the DNA binding domain. Polymerase efficiency may be measured by measuring the amount of amplicon produced under a given set of thermocycling conditions, where the product may be at least 1 kb, at least 2 kb, at least 3 kb, at least 5 kb, at least 10 kb or at least 15 kb in length. In certain cases, the fusion protein may allow products to be amplified using a shorter extension time (e.g., a 10% shorter, a 20% shorter, a 50% shorter or an 80% shorter extension time), relative to the polymerase portion of the fusion protein on its own, i.e., in the absence of the sequence-specific DNA binding domain.

Methods

Also provided herein are a variety of methods that generally comprise combining a DNA template with nucleotides and a composition comprising a fusion protein, as described above, to produce a reaction mix, and incubating the reaction mix in order to copy the DNA template. As would be apparent, the reaction mix may contain, in some embodiments, one or more primers (e.g., a single primer, a random primer, a single or several pairs of PCR primers, or a set of overlapping oligonucleotides as described elsewhere herein). In some cases, the DNA template itself may be a plurality of overlapping primers. In other embodiments, the reaction mix may comprise a plurality of primers and genomic DNA (e.g., mammalian genomic DNA).

Depending on the desired result, the copying step may be done using isothermal conditions, (e.g., by incubating the reaction at one or more temperatures that are above 50° C., such as a temperature in the range of 60° C. to 75° C. In other embodiments, the copying may be done using thermocycling conditions, e.g., 8 to 50 cycles of an annealing temperature, an extension temperature, and a denaturation temperature. In some cases, the annealing temperature and the extension temperature may be the same. In some cases, the reaction mix may comprise a plurality of overlapping primers as well as other reagents (as described elsewhere herein), and the copying step may result in the assembly of a synthon. Synthon assembly is usually done using thermocycling conditions. In some cases, the copying may be done by PCR, in which case, the reaction mix may contain one or more pairs of PCR primers. Depending on the desired application, the length of the amplicon or synthon produced by this method may vary greatly and, in some cases, may be 50 bp to 40 kb in length, e.g., 50 bp to 10 kb. In certain embodiments, the template may be genomic DNA.

Further compositions and methods are described below.

The sequences that overlap in the set of polynucleotides may be of any suitable length such as 2 kb or less, or 1 kb or less or less than 900 bases, 800 bases, 700 bases, 600 bases, 500 bases, 400 bases, 300 bases, 200 bases or 100 bases. The overlapping region may be as few as 8 nucleotides. Preferably the overlapping sequence length is in the range of 15 nucleotides-80 nucleotides for example up to 20, up to 25, up to 30, up to 35, up to 40, up to 45, up to 50, up to 55, up to 60, up to 65, up to 70, up to 75, or up to 80 nucleotides. For example, the minimum length of the overlap may be defined by a Tm that is preferably equal to or greater than 48° C.

Synthetic oligonucleotides and polynucleotides may contain errors created during their synthesis prior to their use in synthon assembly. To correct these errors prior to assembly, it is desirable to perform a mismatch repair step. To this end, various methods have been described to achieve mismatch repair of the synthetic nucleic acids prior to assembly. A population of synthetic nucleic acids may have random

errors so that denaturation and renaturation of the preparation may reveal mismatches. Proteins that have been isolated from nature such as mutHLS, cel-1 nuclease, T7 endo 1, uvrD, T4 EndoVII, *E. coli* EndoV, (see U.S. Pat. No. 7,851,192 and U.S. Pat. No. 8,048,664) that can bind selectively to DNA duplexes containing mismatches; cleave nucleic acids at the mismatched bases and optionally replace with correct bases based on the nucleotide sequences of the templates.

Despite teaching in the art that a non-strand displacing polymerase must be utilized with a ss binding protein, 5'-3'-exonuclease and ligase to assemble fragments of DNA, it has been surprisingly shown herein that a strand displacing polymerase may be used under conditions where strand displacement occurs and that this is efficient at surprising low concentrations of starting polynucleotide fragments to effectively generate a single nucleic acid from a plurality of fragments.

Examples of strand displacing polymerases that may be used in embodiments of an assembly mixture, composition, kit, or method of the invention include members of family B polymerases, such as (but not limited to) any of those identified in Table 1 (SEQ ID NOS:33-55). In addition, fusions of such polymerases may be used, for example fusions between a plurality of polymerases and/or ss binding domains (such as shown in Table 2) (SEQ ID NOS: 56-97). In embodiments any of the polymerase moieties in Table 1 or proteins having at least 80%, 85%, 90%, 95% 98%, 99% or 100% amino acid sequence identity to any of these protein moieties in Table 1 may be fused at the N-terminal end or the C-terminal end to any of the DNA binding domains described in Table 2 or a protein moiety have at least 80%, 85%, 90%, 95% 98%, 99% or 100% amino acid sequence identity to any of the DNA binding moieties in Table 2 to form a strand displacing fusion polymerase for use herein. The DNA binding domain may optionally be fused to the N-terminal end or the C-terminal end of the polymerase.

Variants of other polymerases or novel isolates that are revealed to be strand displacing as determined by the assay provided herein (see for example, FIG. 1A-1E and Example

1) may also be used. Sequences of the polymerases found
from these sources are readily accessible through Gen Bank.
Because of the high degree of conservation of strand dis-
placing sequences, any variant having 80%, 85%, 90%, or
5 95% amino acid sequence identity with such wild type
polymerases might be expected to have strand displacing
properties that can be quickly and easily verified in the assay
provided in Example 1 in a preselected buffer without undue
experimentation.

10 In one embodiment, the reaction mixture, composition, kit, or method of the invention comprises or uses a strand displacing polymerase having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:1 or SEQ ID NO:102 (e.g. 100% sequence identity with SEQ ID NO:1 or SEQ ID NO:102). In another embodiment, the reaction mixture, composition, kit, or method of the invention comprises or uses a polymerase having a binding domain having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:2 (e.g. 100% sequence identity with SEQ ID NO:2). In another embodiment, the reaction mixture, composition, kit, or method of the invention comprises or uses a polymerase having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity 20 with SEQ ID NO:1, or SEQ ID NO:102 and SEQ ID NO:2, or SEQ ID NO:3 or any of SEQ ID NOs:33-97 (e.g. 100% sequence identity with SEQ ID NO:1 or SEQ ID NO: 102, and SEQ ID NO:2 or SEQ ID NO:3 or any of SEQ ID NOs:33-97). These compositions may be used in reaction 30 conditions in which the polymerase is strand displacing. The compositions may be used in reaction conditions in which any 3'-5' exonuclease activity associated with the polymerase activity is active. This may be helpful when a restriction enzyme is used in the reaction such as NotI. In this case, the 3'-5' exonuclease may remove a flap sequence on the 3' end of the duplex. However, if a restriction endonuclease is used that creates a blunt end on the excised fragment, 3'-5' exonuclease activity may not be required. 35 The assembly reaction may be performed under isothermal conditions. In one embodiment the isothermal conditions are 40 50° C.

TABLE 1

Table of polymerases

<i>Methanocaldococcus vulcanius</i> M7	SP-13	gi 502573182	SEQ ID NO: 33
<i>Archaeoglobus fulgidus</i> DSM 4304	SP-16	gi 499180464	SEQ ID NO: 34
<i>Archaeoglobus profundus</i> DSM 5631	SP-17	gi 502704426	SEQ ID NO: 35
<i>Caldicellulosiruptor hydrothermalis</i> 108	SP-19	gi 503168530	SEQ ID NO: 36
<i>Desulfococcus mucosus</i> DSM 2162	SP-27	gi 503328138	SEQ ID NO: 37
<i>Pyrolobus fumarii</i>	SP-29	gi 503791850	SEQ ID NO: 38
<i>Pyrobaculum oguniense</i> CH	SP-30	gi 379003208	SEQ ID NO: 39
<i>Staphylothermus marinus</i> F1	SP-33	gi 500164563	SEQ ID NO: 40
<i>Pyrococcus yataosii</i> CH1	SP-42	gi 503672202	SEQ ID NO: 41
<i>Thermococcus</i> sp. AM4-del	SP-43	gi 503888003	SEQ ID NO: 42
<i>Thermococcus hydrothermalis</i>	SP-44	gi 17375628	SEQ ID NO: 43
<i>Thermococcus thioreducens</i>	SP-45	gi 117958105	SEQ ID NO: 44
<i>Thermococcus waiotapuensis</i>	SP-46	gi 378813034	SEQ ID NO: 45
<i>Thermococcus sibiricus</i> MM 739	SP-47	gi 506329477	SEQ ID NO: 46
<i>Pyrococcus glycovorans</i>	SP-48	gi 7288074	SEQ ID NO: 47
<i>Pyrococcus</i> sp. NA2	SP-49	gi 503513858	SEQ ID NO: 48
<i>Ferroglobus placidus</i> DSM 10642	SP-61	gi 502730992	SEQ ID NO: 49
<i>Palaeococcus ferrophilus</i> DSM 13482	SP-5	gi 851288004	SEQ ID NO: 50
<i>Thermococcus gammatolerans</i> EJ3	SP-50	gi 506339349	SEQ ID NO: 51
<i>Thermococcus celericrescens</i>	SP-51	gi 332308985	SEQ ID NO: 52
<i>Vulcanisaeta distributa</i> DSM 14429	SP-60	gi 503101260	SEQ ID NO: 53
<i>Methanopyrus kandleri</i> AV19	SP-7	gi 20094475	SEQ ID NO: 54
<i>Thermoproteus neutrophilus</i> V24Sta	SP-9	gi 171185774	SEQ ID NO: 55

TABLE 2

DNA binding proteins			
DNA-binding protein Tfx	BD-51	gi 499321160	SEQ ID NO: 56
AbrB/MazE/MraZ-like	BD-52	gi 499321199	SEQ ID NO: 57
"Winged helix" DNA-binding domain	BD-54	gi 499322061	SEQ ID NO: 58
Ribbon-helix-helix protein, copG family	BD-62	gi 499321149	SEQ ID NO: 59
lambda repressor-like DNA-binding domains	BD-63	gi 499322443	SEQ ID NO: 60
Resolvase-like	BD-67	gi 499322676	SEQ ID NO: 61
"Winged helix" DNA-binding domain	BD-71	gi 499322676	SEQ ID NO: 62
"Winged helix" DNA-binding domain	BD-74	gi 499322255	SEQ ID NO: 63
"Winged helix" DNA-binding domain	BD-75	gi 499322388	SEQ ID NO: 64
"Winged helix" DNA-binding domain	BD-81	gi 499322131	SEQ ID NO: 65
"Winged helix" DNA-binding domain	BD-82	gi 499321342	SEQ ID NO: 66
"Winged helix" DNA-binding domain	BD-85	gi 499321130	SEQ ID NO: 67
"Winged helix" DNA-binding domain	BD-86	gi 499322705	SEQ ID NO: 68
"Winged helix" DNA-binding domain	BD-88	gi 499320855	SEQ ID NO: 69
"Winged helix" DNA-binding domain	BD-89	gi 499322250	SEQ ID NO: 70
"Winged helix" DNA-binding domain	BD-91	gi 499321633	SEQ ID NO: 71
"Winged helix" DNA-binding domain	BD-92	gi 490170077	SEQ ID NO: 72
"Winged helix" DNA-binding domain	BD-93	gi 499321272	SEQ ID NO: 73
"Winged helix" DNA-binding domain	BD-94	gi 499320919	SEQ ID NO: 74
"Winged helix" DNA-binding domain	BD-97	gi 499320853	SEQ ID NO: 75
"Winged helix" DNA-binding domain	BD-98	gi 499321734	SEQ ID NO: 76
"Winged helix" DNA-binding domain	BD-100	gi 499322439	SEQ ID NO: 77
"Winged helix" DNA-binding domain	BD-102	gi 499322707	SEQ ID NO: 78
"Winged helix" DNA-binding domain	BD-109	gi 499321112	SEQ ID NO: 79
HCP-like	BD-02	gi 351675391	SEQ ID NO: 80
Helix-turn-helix domain, rpiR family	BD-03	gi 500479591	SEQ ID NO: 81
Helix-turn-helix domain, rpiR family	BD-04	gi 15643984	SEQ ID NO: 82
Bacterial regulatory proteins, lacI family	BD-07	gi 15643711	SEQ ID NO: 83
Bacterial regulatory proteins, lacI family	BD-08	gi 15643974	SEQ ID NO: 84
Bacterial regulatory proteins, lacI family	BD-09	gi 15643956	SEQ ID NO: 85
Bacterial regulatory proteins, lacI family	BD-11	gi 500480095	SEQ ID NO: 86
lambda repressor-like DNA-binding domains	BD-12	gi 15643421	SEQ ID NO: 87
"Winged helix" DNA-binding domain	BD-14	gi 15644350	SEQ ID NO: 88
"Winged helix" DNA-binding domain	BD-16	gi 24159093	SEQ ID NO: 89
"Winged helix" DNA-binding domain	BD-18	gi 15643139	SEQ ID NO: 90
"Winged helix" DNA-binding domain	BD-23	gi 15642807	SEQ ID NO: 91
"Winged helix" DNA-binding domain	BD-24	gi 15643159	SEQ ID NO: 92
"Winged helix" DNA-binding domain	BD-30	gi 15643333	SEQ ID NO: 93
"Winged helix" DNA-binding domain	BD-32	gi 15643055	SEQ ID NO: 94
"Winged helix" DNA-binding domain	BD-37	gi 15643827	SEQ ID NO: 95
"Winged helix" DNA-binding domain	BD-43	gi 15643699	SEQ ID NO: 96
Homeodomain-like	BD-45	gi 15643788	SEQ ID NO: 97

In an embodiment of the invention, the reaction mixture, composition, kit or method may include or use a 5'-3' exonuclease such as T5/5'-3'-exonuclease that is temperature sensitive and can be inactivated by raising the temperature above 50° C. In one embodiment, the 5'-3' exonuclease has exonuclease activity and ss endonuclease activity. In some embodiments, a reaction mixture may further include a ligase for example, an NAD⁺ requiring ligase and/or a thermostable ligase, for example Taq ligase. In preferred embodiments, the reaction mixture may include a ss binding protein. The ss binding protein may be thermostable for example, ET SSB. The assembly reaction may be performed under isothermal conditions.

In certain embodiments, the use of a ligase is optional. For example, where an assembled fragment is introduced directly into a vector for transformation of a host cell, a ligase is not required as the host cell such as *E. coli* may be capable of repairing nicks in vivo. However, if the assembled fragment is amplified for purposes of confirming correct assembly prior to transformation, it is desirable to use a ligase to close nicks and enable a polymerase to amplify the entire target DNA.

Cloning of individual fragments may use chemically synthesized polynucleotide fragments with sequences obtained from any database or publication where the polynucleotide fragments have overlapping sequences. These can be cloned in a plasmid by inserting the polynucleotide

40 into a site in the plasmid adjacent to restriction enzyme sites suitable for excision of the inserted polynucleotide.

Any plasmid may be used. The present examples utilize the commercially available pACYC184 that contains the chloramphenicol gene as a selectable marker. Any selectable 45 marker may be used in place of chloramphenicol resistance gene. Similarly a specific recognition site for any cleavage enzyme capable of specifically cleaving at the ends of the oligonucleotide to generate either staggered ends or blunt ends may be selected where the specific cleavage site does not occur in the fragments of interest in addition to the engineered position adjacent to the ends of the fragment of interest. In the present examples, the recognition site for the eight base cutter NotI (CGCCGGCG) that produces staggered ends has been introduced adjacent to the polynucleotide of interest by means of DNA synthesis. However, this site may be present in a plasmid of choice or added to the synthetic oligonucleotide of interest by a primer for amplification. Examples of specific cleavage enzymes include restriction endonucleases and homing endonucleases.

Once the oligonucleotide or DNA fragment of interest has been chemically synthesized cloned or amplified from an existing DNA and cloned into a vector with a selectable marker, it is excised preferably by enzyme cleavage. The fragments or oligonucleotides that have been synthesized or 60 amplified so as to incorporate overlapping sequence with an adjacent fragment or oligonucleotide to which it is intended to be joined are then assembled in an assembly reaction.

29

Under the hybridization conditions selected, the 5'-3' exonuclease in the reaction mixture (for example, at a concentration in the range of 0.004-0.016 U/μl) chews back any ss region at the 5' end of the fragment or oligonucleotide and continues to chew back through the region of overlapping sequences and may continue further continues for a limited distance (for example, at least 100 bases) to provide a 3' ss region (see for example, FIGS. 2A-2C and 7). At the same time, the strand-displacing polymerase as defined by the assay in FIG. 1A-1E and Example 1 (for example, at a concentration in the range of 0.005 U/μl-0.5 U/μl) repairs the gap remaining between the hybridized ds region and any residual ss region. Since the polymerase is strand-displacing, it may displace additional downstream sequences to form an ss flap. However, T5 exonuclease ss endonuclease activity will remove this flap and any associated nick may be repaired by a ligase (for example, at a concentration in the range of 0.001 U/μl-20 U/μl).

Once fragments are assembled into a larger piece of DNA which are cloned in colonies of host cells under selective pressure, the DNA from these colonies can be rescued from the vectors and again assembled with other fragments and transformed into host cells thus expanding the size of the DNA many times. The host cell may be a competent bacterial cell or may be a yeast cell or other eukaryotic cell.

The assembly process as described herein has been found to be very efficient. For example, 0.02 nM-100 nM of oligonucleotide (ss) or DNA fragment (ds) may be utilized to assemble a larger fragment where the concentration of ss oligonucleotides used in a reaction can be up to approximately 50 times more than the amount of ds DNA fragments used in a similar assembly reaction. Similarly, equal molarity of plasmid containing a single fragment and a selectable marker and a similar amount of the vector containing the assembled fragments with a different selectable marker may be used. These amounts are intended as guides but can be reduced whether the efficiency of the assembly is enhanced. For example, addition of the potassium salt, KCl can increase efficiency of productive assembly by 1.5 fold as determined by the number of colonies using the assembly of lac1Z as an indicator (see for example FIG. 5).

The assembly process for ss target oligonucleotides between two ds DNA molecules or into a linearized vector is also very efficient. An example is provided herein which is not intended to be limiting that uses specific/random sequences to identify guide RNAs for CRISPR-Cas gene editing protocols that can be introduced into cells to determine an altered phenotype. At the outset, it may not be known what sequence might be suitable for achieving this goal. The generation of a library containing degenerate sequences makes this type of analysis possible. CRISPR/Cas9-based gene editing is quickly growing in popularity in the field of genome editing. Due to the size of most commonly used Cas9-containing plasmids, construction of a sgRNA or sgRNA library into a Cas9/sgRNA expression vector can be cumbersome. This approach solves this problem, using ss DNA oligonucleotides.

In a separate embodiment, any DNA binding domain from Table 2 may be fused to a Bst polymerase, Bst large fragment or mutant thereof (see for example, U.S. Pat. No. 8,993,298 and US 2015/0152396 including all the Bst variants described and claimed therein).

Kits

Also provided by the present disclosure are kits for practicing the subject method as described above. In certain embodiments, a subject kit may contain: i. a 5'-3' exonuclease, ii. an optional a ligase, iii. a strand-displacing poly-

30

merase; and iv. a ss DNA binding protein. The components of the kit may be combined in one container, or each component may be in its own container. For example, the components of the kit may be combined in a single reaction tube or in one or more different reaction tubes. Further details of the components of this kit are described above. The kit may also contain other reagents described above and below that may be employed in the method, e.g., a mismatch repair enzyme such as mutHLS, cel-1 nuclease, T7 endo 1, uvrD, T4 EndoVII, *E. coli* EndoV, a buffer, dNTPs, plasmids into which to insert the synthon and/or competent cells to receive the plasmids, controls etc., depending on how the method is going to be implemented. In some embodiments, the kit does not contain a non-strand displacing polymerase and/or a crowding agent.

In certain embodiments, the kit may comprise a composition comprising a fusion protein, as described above, and a reaction buffer. The fusion protein itself may be in a storage buffer that contains a stabilizing agent, e.g., glycerol. The reaction buffer may be formulated to provide optimal conditions for the polymerase activity of the fusion protein, or a concentrated form thereof (e.g., at a 5x or 10x concentrate). In certain embodiments, the buffer may contain a buffering agent (e.g., Tris or the like), salt (e.g., NaCl₂ or the like), the salt of a divalent cation (MgCl or the like) and other necessary components.

In addition to above-mentioned components, the subject kit further includes instructions for using the components of the kit to practice the subject method. The instructions for practicing the subject method are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

Compositions, kits and methods for assembling fragments and forming synthons as described herein result in a product that is a ds fully sealed DNA that can serve as a template for PCR, RCA or a variety of other molecular biology applications including direct transformation or transfection of a competent bacterial or eukaryotic host cell.

In order to further illustrate the present invention, the following specific examples are given with the understanding that they are being offered to illustrate the present invention and should not be construed in any way as limiting its scope.

All references cited herein including U.S. Ser. No. 14/837,820, filed on Aug. 27, 2015, US Provisional Serial Nos.: 62/042,527, filed Aug. 27, 2014, 62/189,599, filed Jul. 7, 2015 plus 62/193,168, filed on Jul. 16, 2015, are incorporated by reference.

EXAMPLES

Example 1: Assay to Establish Strand Displacement Properties of a Polymerase

The data shown in FIGS. 3A, 3B, 4, 5, 6, 8C, 9C and 10, was produced using the polymerase of SEQ ID NO: 3.

31

An assay was developed to differentiate between strand-displacing and non-strand displacing polymerases-A 10 μ l reaction containing 10 nM FAM-primer/Template/blocking oligonucleotide, 1 \times THERMOPOL® buffer (New England Biolabs, Ipswich, Mass.) (FIG. 1A) and 0.1 mM dNTP was prepared. FIG. 1B is the control which is the FAM labeled primer absent any polymerase. When a strand displacing DNA polymerase was added to the reaction, and incubated at 50° C. for 30 minutes with 1 μ l of sample diluted 10 fold and analyzed by capillary electrophoresis, the FAM primer was extended through the blocking oligonucleotide which was displaced. The results are shown in FIG. 1D-1E. The position of the peak in FIG. 2D for Bst polymerase, an established strand displacing polymerase corresponds to the peak observed for a non-natural polymerase, SPB49F. The small size shift results from a blunt end generated by SPB49F resulting from 3'-5' exonuclease activity which is absent in Bst polymerase such that the product of Bst polymerase replication has a 3'dA. FIG. 1C shows the product of a non-strand displacing polymerase-T4DNA polymerase where synthesis is terminated at the blocking primer.

Example 2: Synthesis of a Large DNA Molecule from 6 Fragments Using a Strand Displacing Polymerase and Confirmation that Assembly was Efficient Using Strand Displacing Polymerases

Plasmid A, B, C, D and E were constructed separately from PCR products (fragments (Frgs) 1, 2, 3, 4, 5 that together cover the region of LacI- and LacZ gene) using NEB® PCR Cloning Kit (New England Biolabs, Ipswich, Mass.).

In this experiment, the 5 different fragments integrated into separate plasmids were used in the following concentrations-50 ng of each PCR (source of "fragments") and 25 ng of pMiniTT™ vector (NEB # E1202) was the ampicillin containing plasmid. The 5 fragments for assembly were first amplified using PCR. Primers used in the preparation of LacI-lacZ DNA fragments assembly system as follows:

32

-continued

Not-IZ F5	GCGGCCGCaatacgttccgtcatag cgat (SEQ ID NO: 14)
5 Not-IZ R5	GCGGCCGCTcattttgacaccagacca actgg (SEQ ID NO: 15)

The amplified fragments were cloned and sequenced to confirm that no errors during amplification had been introduced.

Sequence of PCR amplified fragment 1
(SEQ ID NO: 16) :

US 9,963,687 B2

33

-continued

tatgcgactcctgcattaggaagcagcccagttaggttgaggccg
 ttgagcacgcgcggcccaaggaatggtgcatacgcaaggagatggcgcc
 caacagtccccggccacggggctgccaccataccacgcccggaaac
 aagcgtcatgagccccaaagtggcgagccgatctccccatcggtg
 atgtcggtcgatataggcgccagcaaccgcacctgtggcgccgggtat
 gccggccacgcgtcgccggcgataggatcgagatctcgatccccgc
 gaaattaatacgactactataagggaatttgtgagcggataacaatt
 cccctctagaataatttgttaacttaagaaggagatatacata
 tgaccatgattacggattactggcgctgtttacaacgtcgac
 tggggaaaaccctggcgtaatccaaacttaatcgccgtcagcacatcc
 cccttcgcccagctggcgtaatagcgaagaggcccgcacccatcgcc
 ctcccaacagtgcgcagccGCGGCCG

Sequence of PCR fragment 3 (SEQ ID NO: 18) :
 GCGGCCGCTgcagcacatcccccttcgcgcagctggcgtaatagcga
 agaggccgcaccgcgtcgcccttccaacagtgcgcagccgtatgc
 gcaatggcgcttgcgtgtttccggcaccagaagcggtgcggaa
 agctggcgagtgcgatcttcgtggccgatactgtcgctgtccc
 ctcaaaactggcagatgcacgggtacgtgcgcacatctacaccaacg
 tgacctaattccattacggtaatccgcgttgcgttccacggagaat
 ccgcacgggttactcgctcacatthaatgtgtgaaagctgg
 acaggaggccagacgcgaattatgttgcgttactcggt
 ttcatctgtggcgtaacggcgctggcggtacggccaggacagt
 cggttgcgtctgaatttgacccgtggcgatcttgcgcggaga
 aaacccgcctgggtatggcgatggcgatggcgatggcgatgg
 tggaaatgcaggatatgtggcgatggcgatggcgatggcgatgg
 tcgttgcataaaccgactacacaaatcagcgatttccatgttgc
 cactcgatataatgtgatattcagccgcgtgtactggaggctgaag
 ttcaaatgtgcggcgagttgcgtgactacccgtggtaacagttct
 ttatggcagggtgaaacgcaggatcgccgcaggccgcgccttcgg
 cggtaaattatcgatgagcgtgggtatggcgatcggtcacac
 tacgtctgaacgtcgaaacccgaaactgtggcgccgaaatcccg
 aatcttatcgccgtgggtgaaactgcacacccgcacggcagcgt
 gattgaagcagaagcgtcgatgtcggttccgcgagggtcggt
 aaaatggctgtgtgtgaaacggcaagccgtgtgtgattcgaggc
 gttaacccgtcagcgcacatcgccGCGGCCG

Sequence of PCR fragment 4 (SEQ ID NO: 19) :
 GCGGCCGCGaggcgattgaaatggctgtgtgtgaaacggca
 agccgttgcgtattcgaggcgtaaccgtcagcgcacatcatcc
 catggtcaggatcgatggatgagcagacgtggcgaggatatcc
 gatgaagcagaacaaacttacgcgtcgctgtgtgtatgtg
 accatccgtgtggtacacgcgtgtcgaccgcgtacggccgtatgtg

34

-continued

gtggatgaagccaatattgaaaccacggcatggcgccatgaatcg
 tctgaccatgtccgcgtggctaccggcgatgagcgaacgcgtaa
 5 cgcaatggtgcagcgcgtatgcatacaccgcgtgtatcatctgg
 tcgctgggaatgaatcaggccacggcgctaatcagcgcgtgt
 tcgctggatcaaactgtcgatcctcccgcccggtcgactatgaag
 10 gggcgagccacaccacggccaccatatttgcgtatgtac
 gcgcgctggatgaagaccagccctcccgctgtgcgaaatggtc
 cataaaaatggcttcgtacttgcgatggagagacgcgcggcgtatcc
 15 ttgcgataacgcacgcgtggtaacagtcttgcgttgcgt
 aaatactggcaggcgttcgtcgtatcccgatccaggcggtt
 cgtctggactgggtggatcgtcgctgatataatgtgaaac
 20 gcaaccctggctggcttacggcggtgatttggcgatgcgcgaac
 gatgcgcgatccgtatgaacggctgttgcgcaccgcacgc
 gcatccagcgtacggaaacaccagcagcagtttccag
 25 tccgttacccggcaaccatcgaaatgcgttgcgcac
 cgtcatagcgataacgacgtccgtcactggatggcgctggatgg
 taagccgtggcaagcggtgaGCGGCCG

Sequence of PCR fragment 5 (SEQ ID NO: 20) :
 30 GCGGCCGCaataatcgatccgtcatgcataacgcgatctccgcac
 tggatggcgctggatgtaagccgtggcaagcggtgaagtgc
 tctggatgtcgatccacaaggtaacagttgtgattgcgt
 35 taccgcggccggagagccggccactctggctacagtcgcgt
 gtgcacccgacgcgcacccgtggcataageccggcacatcgcc
 ctggcagcgtggcgctggcgaaaacccgtgtgacgcgtcccc
 40 cccgcgtccacgcacccgtatcgaccaccagcgaatggat
 tgcatacgatggtaataagcgatggcaatccgcgtcagg
 ctttcttcacagatgtggatggcgataaaaacaactgcgt
 45 cgctgcgcgtatccgtgcaccgcgtggataacgcacattgg
 gtaagtgaagcgacccgcattgaccctaacgcctggcgac
 50 cggcagatacttgcgtatgcggcgatccgcgtacgc
 tggcagcatcaggaaaacccattttatcagccggaaaaccc
 gattgtgtatggtaatggcgattaccgttgcgt
 55 cgacgcgtatccgcgtccgcggatggcgatggcgact
 ggcgcaggtagcagagccgtaaaactggcgatggcgcaaga
 aaactatccgcgcctactgcgcgttgcgttgcgt
 tgccatgtcagacatgtatacccgatcgatccgcgt
 60 ggtctgcgtgcggacgcgcgaaattgaaattatggcc
 gcgccgcgacttccaggatccacatcgccgtacagtc
 tgcgtggaaaccgcgcacccgtatcgacgcggaaaggcaca
 65 tggctgaatatcgacggatccatatggggatggcgacgcactc

35

-continued
 ctggagcccgtaagtatcgccgaaattccagctgagcgcggctcgct
 accattaccaggatggctgggtcaaaaatgagCGGGCCGC

The 5 fragments each had an overlapping region of 80 bp with an adjacent fragment in order of the final assembly by design (between fragment **1** and **2**, **2** and **3**, **3** and **4**, **4** and **5**). Fragment **1** and **5** also shared 20 bp overlap with the ends of vector. Any available vector may be used such as for example pACYC184 (New England Biolabs, Ipswich, Mass.). pACYC184 vector was prepared by the method of inverse PCR, which permitted assembly of fragments **1-5** in the presence of the assembly mix described above after treatment with NotI-HF® (New England Biolabs, Ipswich, Mass.) and heat-inactivation (see FIG. 2A-2C).

During assembly, the nucleotides extending from the shaded region were degraded by T5 exonuclease while nucleotides in grey were removed by the polymerase. After the fragments are assembled and transformed into *E. coli*, productive assembly determined by blue/white selection were recorded on a plate with IPTG and X-Gal.

T5 exonuclease, Taq ligase, a strand displacing DNA polymerase, and a ss binding domain (ET SSB) were combined in a reaction mixture in a buffer to form Mix 1. These enzymes were all obtained from New England Biolabs, Ipswich, Mass. Five of 150 ng of NotI-HF-digested plasmids (plasmid A, B, C, D and E) were mixed with 105 ng of vector and either with Mix 1 or GAMM in a total volume of 20 µl. The reactions were incubated at 50° C. for 60 minutes. 2 µl of the assembled products were used to transform into NEB 5-alpha (New England Biolabs, Ipswich, Mass.) competent cells. Cells were then spread on plates containing chloramphenicol. Positive assembly can be identified as a blue colony on a plate with chloramphenicol+IPTG+X-Gal and incubated at 37° C. overnight.

PCR of assembly product to confirm all fragments are joined and ligated prior transformation involved the following steps: 1 µl of assembled products were used in a PCR to ensure 5 fragments and vector are ligated together. Pairs of PCR primers that anneal on the vector were used to amplify the whole assembled LacIZ gene (5.3 kb). Lane 1 and 2 are duplicate PCR results. Lane M is 2-log DNA ladder from New England Biolabs, Ipswich, Mass. (see FIG. 4).

Sequencing results were obtained from 8 colonies that were picked and the plasmid DNA purified for the purpose of Sanger sequencing. 6 primers were used to sequence the 4.8 kb. The junction sequence between fragments as well as extension regions from the overlap region showed less than 2% sequence errors.

Primers used for sequencing the assembled DNA:

Seq Not-IZ-M0
 aaaaccacccctggcgcccaatacgc
 Seq Not-IZ-M1
 cccggactcggtaatggcgcgcat
 Seq Not-IZ-M2
 ggaagcagccccagtagtaggttga
 Seq Not-IZ-M3
 ggtgtcgctggagtgacggcag

36

-continued
 Seq Not-IZ-M4
 (SEQ ID NO: 25)
 cggccaccgatattttgccga

Seq Not-IZ-M5
 (SEQ ID NO: 26)
 gattagggccgcaagaaaactatc

Example 3: Assembly of Single Strand Oligonucleotides into a Linearized Vector or Two Distinct Ds DNAs

An oligonucleotide corresponding to sgRNA for targeting a gene from *H. sapiens* was designed as follows:

1. A PAM sequence was scanned for the desired target sequence. For example NGG in

(SEQ ID NO: 27)
 5' GCGAAGAACCTCTTCCAAGANGG3'

2. A 71-base, ss DNA oligonucleotide, containing a 21 nucleotide target sequence flanked by a partial U6 promoter sequence and scaffold RNA sequence was designed.

See for example FIG. 8A-8C in which the ss oligonucleotide is defined as

(SEQ ID NO: 28)
 5' ATCTTGAAAGGACGAAACACCGN₂GTTTAGAGCTAGAA
 AAGAGTTTAGAGCTAGAAATAGCAAGTT3'

or FIG. 9A-9C where the ss oligonucleotide is designed to create a random library:

(SEQ ID NO: 29)
 5' ATCTTGAAAGGACGAAACACCGN₂GTTTAGAGCTAGAA
 ATAGCAAGTT3'

3. The ss DNA oligonucleotide was prepared in 1× NEBuffer 2 (New England Biolabs, Ipswich, Mass.) to a final concentration of 0.2 µM.
4. A 10 µl reaction mix containing 5 µl of ss DNA oligonucleotide (0.2 µM), 30 ng of restriction enzyme-linearized vector and ddH₂O was formed.
5. A suitable vector for use in the above method is a ds vector from Life Technology (GeneArt® CRISPR Nuclease Vector with OFP Reporter Kit Catalog number: A21174). Other vectors are provided by Addgene plasmid #42230, pX330-U6-Chimeric_BB-CBh-hSpCas9. Alternatively, any plasmid containing an sgRNA scaffold under the control of a U6 promoter can be used.
6. 10 µl of a master mix containing an ss binding protein, a ligase, an exonuclease and a polymerase was added to the reaction mix, and the assembly reaction was incubated for 1 hour at 50° C.
7. NEB 10-beta Competent *E. coli* were transformed with 2 µl of the assembled product and the manufacturer's protocol followed (New England Biolabs).
8. 100 µl of transformed cells were spread on a plate with ampicillin antibiotic, and incubate overnight at 37° C.
9. 10 colonies were picked to grow, and the plasmid DNA was purified for sequencing.

Unlike traditional cloning methods, in which two oligonucleotides must be synthesized and re-annealed, this example offers a simple way to design an oligonucleotide

and assemble it with the desired vector and represents a substantial improvement over traditional methods, specifically in time savings, ease-of-use and cost.

Example 4: Production and Screening of Fusion Proteins

The sequences of several hundred DNA binding domains, most of which are expected to be sequence-specific based on their predicted structure (e.g., whether they have an HLH, LTH or WH structure, etc.) or similarity to known DNA binding proteins that are known to specifically bind DNA were identified by screening public and other databases using word searches and by sequence comparisons. Most, if not all, of the identified DNA binding domains were already annotated as being DNA binding domains and, on further analysis, could be identified as transcription factors. Further sequences were selected based on their annotation. Approximately a hundred DNA binding domains were selected for further analysis. The amino acid sequences of representative DNA binding domains from *Pyrococcus furiosus* and *Thermotoga maritima* are shown in FIGS. 11A, 11B, 13A and 13B, respectively. FIGS. 12 and 14 show that the selected DNA binding domains are diverse both in terms of sequence but also in their structure.

In addition, several DNA polymerases from a diverse range of bacterial and archaeal species were identified by performing sequence comparisons on public and other databases. Most, if not all, of the identified polymerases were already annotated as being a polymerase. A phylogenetic tree of a representative number of polymerases is shown in FIG. 15. As shown, the polymerases are from family A as well as family B.

Approximately 300 fusion proteins were made and tested for an enhanced performance in a variety of PCR conditions. The selected polymerases were from family A and family B, and the DNA binding domains were diverse in sequence. The amino acid sequences of 18 exemplary polymerases are shown in FIGS. 16, 17, 18A, 18B, 19A and 19B. These sequences can be used to guide the construction of other fusion proteins.

The fusion proteins were compared to the polymerase portion of the fusion protein in a battery of PCR-related tests that included, but were not limited to, assays to determine the length of the fragments that can be amplified using a short extension cycle (e.g., 5 seconds to 30 seconds), the ability of the polymerase to tolerate different buffers (e.g., NEB Thermopol buffer, Phusion HF buffer, OneTag Standard Reaction buffer), as well as the ability to amplify DNA template with higher GC content (>60% GC), ability to generate DNA template with better purity, ability to increase polymerase strand displacement activity. In general, these tests involved setting up a PCR reaction with genomic DNA as a template (e.g., human or bacterial genomic DNA, plasmid DNA), and then subjecting the reaction to the following thermocycling conditions: an initial denaturation step of 95° C., followed by 25-35 cycles of 15 seconds at 95° C., 20 seconds at 55° C. and 10 seconds-1 minute at 72° C.

Some polymerase fusions were inactive in the PCR assay. In these cases, many of the polymerases on their own (i.e., without the DNA binding domain) were also inactive. However, a significant portion of the polymerase fusions retained activity, some having increased activity and some having reduced activity, relative to the polymerase on its own (i.e.,

without the DNA binding domain). Collectively, more than 30% of the fusion proteins that either contained DNA polymerase SP-04 or the SP-17 DNA binding domain exhibited an enhanced performance relative to the polymerase domain of the fusion protein on its own, in at least one of the conditions tested. The data shown in FIGS. 20-23 shows data from the 18 fusion proteins shown in FIGS. 16, 17, 18A, 18B, 19A and 19B.

FIG. 20 show that BD-07 (a lambda repressor-like DNA binding domain from *T. maritima*), BD-08 (a lambda repressor-like DNA binding domain from *T. maritima*), and BD-98 (a winged helix domain from *P. furiosus*) enhance the ability of the SP-17 polymerase (an Archaeal family B polymerase from *Archaeoglobus profundus*) to amplify longer fragments.

FIG. 21 show that BD-02 (an HCP-like Crol-C1-type HTL-type DNA binding domain from *T. maritima*), BD-07 (a lambda repressor-like DNA binding domain from *T. maritima*), and BD-98 (a winged helix domain from *P. furiosus*) enhance the ability of the SP-04 polymerase to amplify longer fragments.

FIG. 22 show that BD-07 (a lambda repressor-like DNA binding domain from *T. maritima*), BD-23 (a winged helix domain from *T. maritima*), BD-09 (a lambda repressor-like DNA binding domain from *T. maritima*), BD-62 (a ribbon-helix helix DNA-binding domain from *P. furiosus*) and BD-93 (a winged helix DNA-binding domain from *P. furiosus*) and BD-109 (another winged helix DNA-binding domain from *P. furiosus*) enhance the ability of the SP-61 polymerase (an Archaeal family B polymerase from *Archaeoglobus profundus*) to tolerate different buffers.

FIG. 23 show that BD-07 (a lambda repressor-like DNA binding domain from *T. maritima*), BD-23 (a winged helix domain from *T. maritima*), BD-09 (a lambda repressor-like DNA binding domain from *T. maritima*), BD-62 (a ribbon-helix helix DNA-binding domain from *P. furiosus*) and BD-93 (a winged helix DNA-binding domain from *P. furiosus*) and BD-109 (another winged helix DNA-binding domain from *P. furiosus*) enhance the ability of the SP-04 polymerase to tolerate different buffers.

The data shown in FIGS. 20-23 is representative only.

```

SEQ ID NO: 1
MILDADYITEDGKPIIRLFKKENGRFKVEYDRNFRPYIYALLKDD
AIDDVRKITSERHGKVVRVIDVEVKVKKFLGRPIEVWKLYFEHPQD
VPAMRDKIREHPAVIDIFEYDIPFAKRYLIDKGILPMEGNEELTFL
AVDIETLYHEGEFGKGPIMISYADEEGAKVITWKKIDLPYVEVV
ANEREMIKRLIKVIREKDPVIITYNGDNDFPYLLKRAEKLGMKL
PLGRDNSEPKMQLRGDSLAVEIKGRIHFDFPVIRRTINLPTYTLE
AVYEAIFGKQKEKVYPHEIAEAWETGKGLERVAKYSMEDAKVTYEL
GKEFFPMEAQLARLVGQPLWDVRSSTGNLVEWYLLRKAYERNELA
PNKPDEREYERRLRESYEGGYVKPERGLWEGIVSLDFRSLYPSII
ITHNVSPDTLNKEGCHEYDEAPEVGHRFCKDFPGFIPSLLGSLEE
RQKIKKRMKESKDPVERKLLDYRQRAIKILANSFYGGYGYAKARWY
CKECAESVTAWGRQYIELVRRELERGFKVLYIDTDGLYATIPGEK
NWEEIKRRALEFVNINSKLPGILELEYEGBFYTRGFFVTKKKYALI
DEEGKIVTRGLEIVRRDWSEIAKETQAKVLEAILKHGNVEEAVKIV

```

US 9,963,687 B2

39

-continued

KEVTEKLSNYEIPVEKLVIYEQITRPLNEYKAIGPHVAVAKRLAAK
GIKIKPGMVIGYVVLRGDGPISKRAIAIEFDGKKHKYDAEYYIEN
QVLPAPERILKAFGYKREDLRWQTKQVGLGAWLKVKK5

SEQ ID NO: 2 IINPQARLTPLELEILEIIKQKKSITITEIKEILSERRKSEYPLSL

VSEYISRLERKGYVKKIAKGRKKFVEALI

SEQ ID NO: 3 MILDADYITEDGKPIIRLFKKENGFRKVEYDRNFRPYIYALLKDDS

AIDDVRKITSERHGKVVRVIDVEKVKKKFLGRPIEVWKLYFEHPQD

VPAMRDKIREHPAVIDIFYEYDIPFAKRYLIDKGLIPMEGNEELTFL

AVDIETLYHEGEFFGKGPIMISYADEEGAKVITWKKIDLPYVEVV

ANEREMIKRLIKVIREKDPMVITYNGDNFDFPYLLKRAEKGML

PLGRDNSEPQMQLGDLSAVEIKGRIHFPLFPVIRRTINLPTYTL

AVYEAIFGKQKEKVYPHEIAEAWETGKGLERVAKYSMEDAKVTYEL

GKEFFPMEAQLARLVGQPLWDVSRSSTGMLVEWYLLRKAYERNELA

PNKPDEREYERRLRESYEGGYVKEPERGLWEGIVSLDFRSLYPSII

I THNVPDTLNKEGCHEYDEAPEGVGHFRCKDFPGFIPSLLGSLEE

RQKIKKRMKESKDPVERKLLDYRQRAIKILANSFYGGYAKARWY

CKECAESVTAWGRQYIELVRELEERGFKVLYIDTDGLYATIPGEK

NWEEIKRRALEFVNINSKLPGILELEYEGFYTRGFFVTKKYALI

DEEGKIVTRGLEIVRRDWSEIAKETQAKVLEAILKHGNVEEAKIV

KEVTEKLSNYEIPVEKLVIYEQITRPLNEYKAIGPHVAVAKRLAAK

GIKIKPGMVIGYVVLRGDGPISKRAIAIEFDGKKHKYDAEYYIEN

QVLPAPERILKAFGYKREDLRWQTKQVGLGAWLKVKKSGTGGGI

INPQARLTPLELEILEIIKQKKSITITEIKEILSERRKSEYPLSLV

SEYISRLERKGYVKKIAKGRKKFVEALI

SEQ ID NO: 33 MKEKAPKIDALIDCTYKTEDNRRAVIYLYLLENILKREFSPYFYVE

MLKDRIEKEDIDKIKEFLLKEDLLKFVENLEVNNKTIKKEKEIVK

IIATHPQRVPKLRKIKECDIVKEIYEHDIPFAKRYLIDSIVPMTY

WDFENRKQVSIEIPKLKTVSFDMEVYNRDTEPDPEKDPILMASFWD

DNGGVITYKHFDSNIEVVNSEKDLIKKIVEMLRQYDVIFTYNGD

NFDPPYLKARAKIYGIDIKLGRDGEELKIKRGGMFERSYIPGRVHI

DLYPISRLLKLTKEYTLEDVYVNLFGIEKLKIPHTKIVDYWANNDK

ILIEYSLQDAKYTHKIGKYFFPLEVMFSRIVNQTPFEITRMSSQGM

VEYLLMKNNAKENMIVPNPKDEKEYRKRLLTSYEGGYVKEPEKGMF

EDIISMDFRCHPRGTKVIVKNNGLTDIENVKVGDYVLGIDGWQKV

RVWKYPNGFLNVNGLKSTPNHKIPVIKKENGKDRVIDVSSIYLL

NLKGCCKILKIKNFESIGMFGKIFKKDTKIKVKGLLEKIAYIDPRE

GLVIKVKNEEKEDIFPKTVIPILKELNLYKQVDEKTIIDSIDGLLK

YIVTIGFNDKNEEKIKEIIKEKSLEFKLEDEDIKISIEEYEGYVYD

LITTLEGRPYYFANGILTHNSLYPSIIAYNISPETLDCECKDISEK

40

-continued

ILGHWFCKKREGGLIPKTLRGLIERRNIKKNMKMSEKEINEEYN

LLDYEQRSLKILANSVYGYLAFPARFYSRECAEVITYLGRKYILE

TIEEAEKFGFKVIYADSVVKDAKVIKEDGKIKEKIEDLFKKVDY

TIGDKEYCILNNVETLTIEDTKLWWRKVPYIMRHTRNKKIYRVKV

DRYVDITEDHSIIGVKNKLVELKPTEIKDDETKLIILNKDLKSYN

FASVIEINCICKSDYVYDIEVENTHFFANGILVHNTDGFYAWKE

KISKDDLIKALEFVKYINSKLPGTMELEFEGYFKRGIFITKKRYA

LIDENGDRVIVKGLEFVRRDWSNLARITQRVRLAEALLLEGDINKAKK

AIQDVIKDLREKKIKKEDLIYTQLTKNPNEYKTTAPHVEIAKMM

REGKKIKIGDVIGYIIVKGSKSISERAKLPPEEVSEEIDVNYYIDN

QILPPVLRIMEAVGVSKNELKKEGTQLTDRFLK

SEQ ID NO: 34 MERVEGLIDADYETIGGKAVVRLWCKDDQGFVAYDYNFDPYFYV

IGVDEDILKNAATSTRREVIKLKSFEKAQLKTLGREVEGYIVYAH

PQHVPKLRDYLSQLFGDVREADIPFAYRYLIDKDLACMDGIAIEGEK

QGGVIRSYKIEKVERIPRMEEPELKMLVFDCEMLSSFGMPEPEKD

IIVISVKTNDDEIILTGDERKIISDFVKLIKSYDPDIIVGYNQDA

FDWPYLRKRAERWNIPLDVGRDGSNVFRGGRPKITGRLNVLDYD

AMRISDIKIKKLENVAEFLGKIEIA DIEAKDIYRYWSRGEKEKVL

NYARQDAINTYLIAKELLPMHYELSKMIRLPVDDVTRMGRGKQVDW

LLLSEAKKIGEAPNPPEHAESYEGAFVLEPERGLHENVACLDFAS

MYP SIMIAFNISPDTYGRDDCYEAPEVGHKFRKSPDGFFKRILRM

LIEKRRELKVELKNLSPESSEYKLLDIKQQLTKVLTNSFYGYMGWN

LARWYCHPCABATTAWGRHFIRTSAKIAESMGFKVLYGDTDSIFVT

KAGMTKEDVDRIDLKHEELPIQIEVDEYYSAIFFVEKKRYAGLT

DGR LVVKGLEVRRGDWCELAKKVQREVIEVILKEKNPEKALSLVKD

VILRIKEGKVSLEEVVYKGLTKPKSKYESMQAHVKAALKAREMG

IYPVSSKIGYVIVKGSGNIGDRAYPIDLIEDFDGENLRIKTKSGIE

IKKLDKDDYIDNQIIPSVRLILERFGYTEASLGKSSQMSLDSFPS

SEQ ID NO: 35 MIKA WLLD D VYVTENDRAVIRLWCKDDKGV FVAYDRNFLPYFYVIG

CKAEDVMKVVRTNEGIITPLKVEEIEAKSLGKPIKALKVYTRHQ

HVPKLREEIKKFAEVREADIPFAYRYLIDKDLACMDGIEIEPIAVK

EGVLRAYEVRSVRRVKEKGFPDLKILA FDCEMLAQFMPDPEKDPII

AI AVKCGDFEEVLHGDERDILRRFVSIIKEQDPDIIVGYNQDNFDW

PYVKKRAEKFGIRLDIGRDRSEISFRGGRPKIAGRGLNVLDYDIALK

I PDVKIKTLKKVAEFLGAKV EEE DIEGRDIYKCWMRGEKEKVFKH

LNDVLTTYRLAELLPMHYELSRMIRPLDDVARLGRGKQVDYFLL

SEAKKINEIAPNPPEI EESYEGAFVLEPARGLHENVA CLDFAS MYP

SIMINFNI SPDTLVKGECEDCYVAPEVGHKFRKSPDGFFKRILKML

IEKRREMKRQMKE LDPSEDYKLLDIKQQLTKVLTNSFYGYTGWL

US 9,963,687 B2

41

-continued

ARWYCRECAEATTAWGRYFIKRAVKIAESMGFEVLYGDTDSLFIKK
NKLNLKDLEKECLKLIDVISKEPLIQLEIDEFYKAIFFVEKKRYAG
LTDDDRIVVKVGLEVRRGDWCELAKRQVREVIEWIILRERNPDKALKF
VKNVIEEIKEGKFKLEDYVIYKGLTKPDKYESQAHVKAALRAME
MGIYYPIGTKVGFIVVKGGGSISDRAYPIELIEEFDGENLKIRTPS
GIMVKKIDKYYIDHQIIPAVMRILERFGYTEASLKTIIQKTLFDF
T

SEQ ID NO: 36

KMLVIFDGNISLYRAFFALPELTTSNIPNTNAIYGFINVILKYLEQ
EKPDYIAVAFDKRGREARKSEYQEYKANRKPMPPDNLQVQIPIVREI
LYALNIPIVEFEGYEADDVIGSLVNKFKNGLDIVIITGDRDTLQL
LDKNVVVKIVSTKFDRTMEDLYTIENIKEKYGVWANQVPDYKALVG
DQSDNIPGVKGIGEKSQAQKLLEEYSSLEEIQNLDKIKGSIREKLE
AGKDMAFLSKRLATIVCDLPLNVNLEDLRTKEWNKERLYEILVQLE
FKSIIKRLGLSENIQFEFVQQRDTIPDVEQRELESISRIRSKEIPL
MFVQDEKCFYLYDQESNTVFVTRDRHLVEEILKSDTVKIVYDLKNI
FHQLNLEDTDNIKNCEDVMIASYVLDSTRSSYELETLFVSYLNTDI
EAVKKDKKMVSVVLKLRLWDDLLRLIDLNSCQFLYENIERPLIPVL
YEMEKTGFKVDRDALLQYTKEIENKILKLETQIYQIAGEWFNINSP
KQLSYILFEKLKLPVIKKTKTGYSTDAEVLEEFDKHEIVPLILDYR
MYTKILTTYCQGLLQAINPSSGRVHTTFIGTGTATGRЛАSSDPNLQ
NIPVKYDEGKLIRKVFPVEGHVLIDADYSQIELRILAHISEDERL
INAFKNNIDIHSQTAAEFGVDIADVTPEMRSQAKAVNFGIVYGIS
DYGLARDIKISRKEAAEFINKYFERYPKVKEYLDNIVRFARENGYV
LTLFNRKRYVKDIKSANRNARSAYAERIAMNSPIQGSAADIMKLAMI
KVYQKLKENNLKSKIIQLQVHDELLIEAPYEEKDIVKRIVKREMENA
VALKVPVLVVEVKEGLNWYETK

SEQ ID NO: 3
MEKRVYLVDTYGLVGNSPEIRMFGVDENGEKVVILDRGFRPYFYV

PEEGFEDQVARIGKMQNVIKADVERTRLPGKP1KVVKVTVTPD
KVRELDRVKSIQHVKEVLEADIRFYIRYIMDNDRPGWLMSFLNK
PVDNKIGGVSNVLTETPPSTSLLGIMPRLNLYMADIEVYNPRGTP
DPKRDP1IIIALANSNGDVKLTLNDNYKHREMLNDMMSVIKEWDP
DVLFGYNSNKFDMPLYLVNRADALNVKLQLSKYGTPEQSVDGHWSI
IGRAHIDLYNFIEDMTDVKKRSLDYVAEYFGVMKRSERVNIPGHRI
YQYWDEGKRSQLIKYARDVLSLTLGLGKILLPYAMQLASVSGPL
DQVGPASVGSRVEMMIMHEAYKMGE LAPNRVERPYETYKGAI VLEP
KPGIHYNIAVLDFSSMYPNIMLKYNIS PDTLVLDSSEGDDYTAPENV
GYRFRKSPRGLYASLLQKLI EARRA DEMRNYPEGSFEVULLNER
QRALKIMANAMYGYCGWLGARWYIREVAESVTAWGRYLLKTAMSMA
KERGLTVIYGDTDLSFVTDYDKDKVADIISRINEMGFEVKIDKVYSK
LIFTESKRYIGLTADGEVDIVGFEAVRGDWSELARNVQERVAELV

42

-continued

LRESVDEAVKYVKSVIDDLRNYRFTIDDVIWKTLDKDINEYKAIQ
PHVVAARRLMEKGYVVNKGDTVGFIVKDSGDKLTQRAYPYVFIND
VKEIDVDYYVEKQVIPAALRILEFGVNEAALLGKGTGKSILDYFH

SEQ ID NO: 38

ALLAPGADPKQVAQRIRALSRPKSPIIGVEDDKRKYFGRPRRLVRI
RTVLPEAVREYRELVKNVNDGVEDVLEADIRFAMRYLIDHDLFPFTW
YRVEAEPLENKMGFRVDKVLVKSREPPLYGEALAPTKLPDLRILA
FDIEVYSKQGSPRPERDPVIVIAVKTDDGDEVLFIAEGKDDRKPIR
EFVEYVVKRYDPDIIVGYNNNHFWDWPYLLRRARILGIKLDVTRRVGA
EPTTSVHGHSVPGLRNVDLYDYAEMPEIKIKSLEEVABYLGVMK
KSERVIINWWEIPDYWDDPKRPLLQYARDDV RATYGLAEKILPF
AIQLSYVTGLPLDQVGAMS VGFRLWEWLIRAAFKMKEVPNRVERP
EETYRGAI VLEPLRGVHENIAVLFSSMYPNIMIKYNVGPDTLVRP
GEECGECGCWEAPEVKHRFRRCPPGFFKTVLERLLELRKRVRAEMK
KYPPDSPEYRLLDERQKALKVLANASYGYGMWSGARWCYCRECAEAV
TAWGRHLIRTAINIARKLGLKVIYGDTDSLFTYDPEKVEKFII
EEELGFEIKLEKVKYKRVFFFTEAKKR YAGLLEDGRIDIVGFEAVRGD
WCELAKEVQTKVVEIVLKTS DVNKAVEYVRKIVKELEEGKVPIEKL
VIWKTLSKRLEYYTTEAPHVVAAKRLMSAGYRVSPGDKIGYVIVKG
GGRISQRRAWPYFMVKDPSQIDVTYYVDHQIIPAALRILGYFGITEK
KLKASATGQKTLFDFLAKKSK

SEQ ID NO: 39
MEIRVWPLDVTYIVVGGVPEVRVFGIAEGGERVVLADRSFRPYFVV
DCAGCDPHAVKTHLGRATPVEGVELVERRFLGRPRQFLKVVAKIP
DVRLRREAATIPIGVRGVYEADIRFYMRVIDMGVVPCSNVAEVE
VADEKLGSVPYRVVKWGGAVEGFPPLRVLAFDIEVYNERGTPDP
ARDPIVMIAVQSSDGRLEVFEASGRDDRGVLRSFVEYVRSFDPDVV
VGYNNSNNFDWPYLAERAKAVGVPLRVDRLLGGAPQQSVYGHWSVLGR
ANVDLYNIVDEFPEIKLKTLDRVAEYFGVMRRDERVLIPGHKIYEY
WRDPSKRPLLQRQYVIDDVRSTYGLAERLLPFLIQLSSVSGLPLDQV
AAASVGNRVEWMLLRAYGLGEVAPNREEREYEYPKGAIVLEPKPG
LYSDVLVLFSSMYPNVMMRNYNLSPDTYLEPGEPPDPPEGVYVAPEV
GHRFRKEPPGFIPQVLRRLVALRAVREEMKKYQPDTPBEYRVLDER
QKALKIMANAMYGYTGWVGARWYKKEVAESVTAFARAILKDVIDYA
RRLGIVVIYGDTDLSLVKKGGDLEKLARYVDEKYGIEIKVDKDYEK
VLFTEAKKRYAGLLRDGRIDIVGFEVVRGDWSELAKEVQLKVIELI
LKARDLSEARQRVIKYVKDVIERLKSGKFDLDDLIIWKTLDKDLGE
YKAYPPHVRAALILKKKGYKVGRGTTIGYVVVKGGEKVRSERSLPYI
LVDDLAKIDVDYYIEKQVIPAALRIAEVIGVKEGDLRAGRSEKSLL
DFFE

US 9,963,687 B2

43

- continued

<p>SEQ ID NO: 40 MSEKINLEFYFLDNSYEVIGNEPHIIIWGITRDGRRVLLRDRFRP YFYAILDKVNIEDLARKIRTYSDPKSPIIGVEPVEKKYFGRKVSA LKIITMIPPEVRYREKIKSLPEVLEVVEADIRFSIRYIIDHDLRP CGWHAEEVVEVPKKPIYRVDAAEYEIIIGDIKPLEQTLQPDRLIIAFD IEVYNKSGTPRPQTDPIIIIGIMNNNGDIKQFLANKYDDKISVEEF VNYVKTFDPDIIVGYNNTGFDWPYLIERSKYIVGKLDVTRRGATP RTSTYGHISVPGLNNTDLYHFAEEIPEVKVKSLENVAEYLGMKKS ERVIIEYIDIPKYWDDEKLRLPKLQLQYNNIDDVKSTYGLAEKFPLFAM QLSNITGLPLDQVGAASVGFRLEWYLMREAFRYGELVPMRVERAAE SYRGAVVLPVKVGVHENIAVLDFSSMYPNIMIKYNVGPDTIVRNKEK CNPDKHNIAPVGHCFRKEPPGFFKRVLETLLRLRKQIKSEMCKYP PTSYEYRLLDERQAKVAKVLANATYGYMGWIHARWYCRAEAEAVTAW GRQTIKSAILARKLGLKVIYGDTDSLFTYDCKVEKLIELIQT LGFEIKIDKIYKRVFFTEAKKRYAGLLEDGRIDIVGFEAVRGDWA IAKEVQEKTIELLKENSIDKAIYVRQVIADLKAGKIPLDKLI KTL SKR IEE Y SVDAPHVVA KLIKAGIKVSTNDKIGYVILKGGK ISSRAEPYIFVKDPKLIDTEYYVDHQIVPAALRILNYFGVTETQLK RAAASAGQKSLFDFGGKK</p> <p>SEQ ID NO: 41 MILDADYITENGKPVVRIFKKENGEFKVEYDRSFRPYIYALLRDDS AIEDIKKITAERHGKVVRVVAEKVRKKFLGRPIEVWKLYFEHPQD VPAIREKIREHPAVIDIFEYDIPFAKRYLIDKGKIPMEGNEELKLL AFDIETLYHEGDEFGSGPIMISYADEGAKVITWKGVDPYVEVV SSEREMIKRFLRVIREKDPTDVIITYNGDNPDFPYLLKRAEKGML PIGRDGSEPKMQRMDGFAVEVKGRHFIDYIPVIRRTINLPTYTLE AVYEAVFGPKVYPNEIARAWENCKGLERVAKYSMEDAKVTYEL GREFFPMEAQLARLVGQPWVDSRSSTGNLVEWFLRKAYERNELA PNRPDEREYERRLRESYEGGYVKEPEKGLWEGIYIYLDFRSLYPSII ITHNISPDTLNKEGCSYDVAVKVGHFRCKDFPGFIPSLQGLLDE RQKIKRKMATAIDPIERKLLDYRQRAIKILANSYYGGYAKARWY CKEAEVTAWGREGYIELVSRELEKRGFKVLYIDTDGLYATIPGSR EWDKIKERALEFVKYINARLPGLLELEYEGFYKRGFFVTKKKYALI DEEGKIITRGLIEVRRDWSEIAKETQARVLEAILKEGNLEKAVKIV KEVTEKLSKYEVPPPEKLVIEQITRDLKDYKAVGPHVAVAKRLAAR GIKVRPGMIVGYLVLRGDGPISRRAIPAAEFDPSRHKYDAEYYIEN QVLPAVRLILEAFGYRKEDLRYQKTRQAGLDAWLKRKASL</p> <p>SEQ ID NO: 42 MILDADYITENGKPVVRIFKKENGEFKIEYDRTFEPYFYALLRDDS AIEDVKKVTAKRHGTVVRVKRAEKVQRKFLGRPIEVWKLYFTHPQD VPAIRDKIRAHPAVIDIYEYDIPFAKRYLIDKGKIPMEGDEELTML AFDIETLYHEGEEFGTGPILMISYADGSEARVITWKKIDLPYVDDV</p>	<p>5 10 15 20 25 30 35 40 45 50 55 60 65</p>
--	--

44

- continued

<p>STEKEMIKRFLRIVKEKDPDVLIITYNGDNDFAYLKKRCEKLGIF TLGRDGSEPKIORMGDRFAVEVKGRHFIDLYPVIRRTINLPTYTLE AVYEAVFGPKEKVYAAEIAQAWESGEGLERVARYSMEDAKVTYEL GREFFPMEAQLSRLIGQSLWDVSRSSSTGNLVEWFLRKAYERNELA PNKPDEKELARRGGYAGGYVKEPERGLWDNIVYLDFRSLYPSII THNVSPDTLNREGCKEYDVAPEVGHFKCKDFPGFIPSLLGDLLEER QKIKRKMATAVDPLEKKLLDYRQRAIKILANSYYGGYAKARWYC RECAESVTAWGREGYIETTIREIEKPGFKVLYADTDGFFATIPGAD AETVKKAKEPLKYINAKLPGGLELEYEGFYVRGFFVTKKYAVID EEGKITTRGLEIVRRDWSEIAKETQARVLEAILKHDVVEAVRIVK EVTEKLSKYEVPPPEKLVHIEQITRDLRDYKATGPHVAVAKRLAARG VKIRPGTVISYIVLKGSGRIGDRAIPDEFDPKHYDABYYIENQ VLPAPERILKAFCYRKEDLRYQKTKVQVGLGAWLKVKK</p> <p>SEQ ID NO: 43 MILDADYITENGKPVVRIFKKENGEFKIEYDREFEPYIYALLRDDS AIEEVKKITAGRHGRVVKVRAEKVKKFLGRPIEVWKLYFTHPQD VPAIRDEIRRHSAVVDIYEYDIPFAKRYLIDKGKIPMEGDEELKMM SFDIETLYHEGEEFGTGPILMISYADEGEARVITWKKIDLPYVEVV STEKEMIKRFLKVVKEKDPDVLIITYNGDNDFAYLKKRCEKIGIF TLRRDGSEPKIORMGDRFAVEVKGRHFIDLYPVIRRTINLPTYTLE AVYEAVFGTPKEVYPEEITTAWETGEGLERVARYSMEDAKVTYEL GREFFPMEAQLSRLIGQSLWDVSRSSSTGNLVEWFLRKAYERNEIA PNKPDERELEARRGGYAGGYVKEPERGLWDNIVYLDFMSLYPSII THNVSPDTFNREGCKEYDTAPQVGHFKCKDVQGFIPSLLGALLDER QKIKRKMATAVDPLEKKLLDYRQRAIKILANSYYGGYAKARWYC KECAESVTAWGRDYIETTIHEIEERFGFKVLYADTDGFFATIPGAD AETVKKAKEPLKYINAKLPGGLELEYEGFYVRGFFVTKKYAVID EEGKITTRGLEIVRRDWSEIAKETQARVLEAILRHDVVEAVRIVK DVTEKLSKYEVPPPEKLVHIEQITRELKDYKATGPHVAVAKRLAARG IKIRPGTVISYIVLKGSGRIGDRAIPDEFDPKHYDABYYIENQ VLPAPERILKAFCYKKEELRYQKTRQVGLGAWLKLKGKK</p> <p>SEQ ID NO: 44 MILDADYITENGKPVVRIFKKENGEFKIEYDREFEPYIYALLRDDS AIEEIKKITADRHKVVKVRAEKVKKFLGRPIEVWKLYFTHPQD VPAIRDEIRKHPAVVVDIYEYDIPFAKRYLIDKGKIPMEGDEELKML AFDIETLYHEGEEFGTGPILMISYADEGEDARVITWKKIDLPYVDDV STEKEMIKRFLKVVKEKDPDVLIITYNGDNDFAYLKKRCEKLGIF TLGRDGSEPKIORMGDRFAVEVKGRHFIDLYPLIRRTINLPTYTLE AVYEAVFGPKEKVYAAEIALAWESGEGLERVARYSMEDAKVTFEL GREFFPMEAQLSRLIGQSLWDVSRSSSTGNLVEWFLRKAYERNELA PNKPNERELEARRGGYAGGYVKEPERGLWDNIVYLDFRSLYPSII THNVSPDTLNREGCKEYDRAPOVGHFKCKDVPGFIPSLLGSSLDER</p>	
--	--

US 9,963,687 B2

45

- continued

QKIKRKMKTIDPIEKLLDYRQRAIKILANSYYGGYARARWYC
RECAESVTAWGREYIEMAIREELEKFGFKVLYADTDGLHATIPGAD
AETVKKKAMEFLKYINPKLPGLELEYEGFYARGFFVTKKYAVID
EEGKITTRGLEIVRRDWSEIAKETQARVLEAILRGDVEEAIRVK
EVTEKLSKYEVPPPEKLVIHQITRELKDYRATGPHVIAKRLAKRG
IKIRPGTVISYIVLKGSGRIGDRAIPDFDPTKHKYDAEYYIENO
VLPAPERVLKAFGYRKDDLRYQKTRQVGLGAWLKVKR

SEQ ID NO: 45
MILDADYITEDGKPVIRVFKEKGEFKINYDRDPEPYIYALLKDD
AIEDIKKITAERHGTTVRVTRAERVKKFLGRPVEVWKLYFTHPQD
VPAIRDKIREHPAVVDIYEYDIPFAKRYLIDKGLIPMEGNEELRML
AFDIETLYHEGEEFGEPPMAQLSRLVGQPLWDVSRSSTGNLVEWYLLRKAYERNELA
STEKEMIKRPLKVIQEKKDPDVILITYNGDNPDFAYLKKRSETLGK
ILGRDGSEPKIQRMGDRFAVEVKGRIRHFDLYPVIRRTINLPTYTLE
TVYEAFGQPKEKVYAEETIAQAWESGEGLERVARYSMEDAKATYEL
GKEFPMPMEAQLSRLVGQSLWVDSRSSTGNLVEWYLLRKAYERNELA
PNKPDERELARRAESYAGGYVKEPEKGLWENIVYLDYKSLYPSII
THNVSPDTLNREGCREYDVAPQVGHRFCKDFPGFIPSLLGDLLER
QKVKKMKATVDPIERKLLDYRQRAIKILANSYYGGYANARWYC
RECAESVTAWGRQYIETTMREIEEKFGFKVLYADTDGFFATIPGAD
AETVKKKTKEFLNYINPRPLGLLELEYEGFYRGGFFVTKKYAVID
EEDKITTRGLEIVRRDWSEIAKETQARVLEAILKHGDVEEAIRVK
EVTEKLSRYEVPPPEKLVIHQITRNLDRYRATGPHVAVAKRLAARG
IKIRPGTVISYIVLKGPGRVGDRAIIPDFDPAKHYDAEYYIENO
VLPAPERILRAFGYRKEDLRYQKTKQAGLGAWLKPKT

SEQ ID NO: 46
MILGADYITEDGKPVIRIFKKENGEFKIELDPHPQPYIYALLSEDS
AIDEIKQIKGERHGKTVRIVDAVKVEKKFLKPVKWKLILEHPQD
VPAIRNKIREHPAVQDIYEYDIPFAKRYLIDNGLIPMEGDEELKML
AFDIETFYHEGDEFKGGEIIMISYADEEGARVITWKNIDL PYDVVV
SNEREMIKRPIQIIKEKDPDVITYNGDNPDFPYLIKRAEKLGLRL
ILSRDNENPVPKIQRMGNSFAVEIKGRIRHDFLPVVKRAVNLPYT
LEAVYETVLGKHKSKLGAEIAIAIWETEEGLKLLAQYSMEDAKATY
ELGREFFPMEVELAKLIGQSVDWSRSSTGNLVEWYMLRVAYERNE
LAPNRPSDEEYKRLRRTYLGGVKEPERGLWENIIYLDFRSLYPS
IIVTHNVSPDTLERKGQCQNYDVAPIVGYKFCDFSGFIPSILEDLI
ETRQKIKKEMKSTIDPIKKMLDYRQRAVKLLANSYYGYMGYPKAR
WYSKECAESVTAWGRHYIEMTIREIEEKFGFKVLYADTDGFYATIP
GADPETIKKKAKEFLNYINSKLPGLLELEYEGFYLRGFFVTKKRYA
VIDEEEEKITTRGLEVVRRDWSEIAKETQARVLEAILREGSVEKAVE
IVKEVVEAITKYKVPLEKLIHEQITRELRDYKAVGPHVIAKRLA

46

- continued

AKGIKIKPGTIISYIVLRGSGKISDRVVLLTEYDPRKHKYDPDYYI
ENQVLPAVLRLIEAFGYRKEDLKYQSSQQTGLESWLKK

SEQ ID NO: 47
MILDADYITEDGKPVIRIFKKENGEFKVEYDRNFRPYIYALLKDD
QIDEVKKIATAERHGKIVRIVDVEVKVKKFLGRPIEVWKLYFEHPQD
VPAIRDKIREHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKLL
AFDIETLYHEGEEFAKGPIIMISYADEEGAKVITWKKVDSL PYVEVV
SSEREMIKRFLKVIKEKDPDVITYNGDSFDLPLVKAELGIKL
PLGRDGSEPKMQRLGDMTAVEIKGRIRHFDLYHVIRRTINLPTYTLE
AVYEAFGKPKEKVYAEHEIAEWETGKGLERVAKYSMEDAKVTYEL
GREFFPMMEAQLSRLVGQPLWDVSRSSTGNLVEWYLLRKAYERNELA
PNKPDEREYERRLRESYAGGYVKEPEKGLWEGLVSLDFRSLYPSII
IITHNVSPDTLNREGCMYEDVAPEVKHFCKDFPGFIPSLLKRLDE
RQEIKRMMASKDPIEKKMLDYRQRAIKILANSYYGGYAKARWY
CKECAESVTAWGREYIEFVKELEEKFGFKVLYIDTDGLYATIPGA
KPEEIKRKALEFVEYINA KLPGLLELEYEGFYVRGFFVTKKYALI
DEEGKIIITRGLIEVRRDWSEIAKETQAKVLEAILKHGNVEEAIV
KEVTEKLSKYEIIPPEKLVIYEQITRPLHEYKAIGPHVAVAKRLAAR
GVKVRPGMVIGYIVLRGDGPI SKRAILAEEDFPRKHKYDAEYYIEN
QVLPAPERLRLIEAFGYRKEDLWRQKTKQGLTAWLNVKK

SEQ ID NO: 48
MILDADYITEDGKPVIRIFKKENGEFKVEYDRNFRPYIYALLKDD
AIDDVRKITSERHGKVVVIDVEVKVKKFLGRPIEVWKLYFEHPQD
VPAIRDKIREHPAVDIYEYDIPFAKRYLIDKGLIPMEGNEELTFL
AFDIETLYHEGEEFGKGPIIMISYADEEGAKVITWKKIDLPYVEVV
ANEREMIKRLIKVIREKDPDVITYNGDNDFPYLLKRAEKLGMKL
PLGRDNSEPKMQRLGDSLAVEIKGRIRHFDLFPVIRRTINLPTYTLE
AVYEAFGKQKEKVYPHEIAEWETGKGLERVAKYSMEDAKVTYEL
GKEFPMPMEAQLSRLVGQPLWDVSRSSTGNLVEWYLLRKAYERNELA
PNKPDEREYERRLRESYEGGYVKEPERGLWEGIVSLDFRSLYPSII
IITHNVSPDTLNKEGCHEYDEAPEVGHRFCKDFPGFIPSLLGSLEE
RQKIKRMMESKDPVERKL LDYRQRAIKILANSFYGGYAKARWY
CKECAESVTAWGRQYIELVRREREERGFKVLYIDTDGLYATIPGK
NWEEIKRRALEFVNINSKLPGILELEYEGFYTRGFFVTKKYALI
DEEGKIVTRGLEIVRRDWSEIAKETQAKVLEAILKHGNVEEAIV
KEVTEKLSNYEIPEVKEKLVIYEQITRPLNEYKAIGPHVAVAKRLAAK
GIKIKPGMVIGYVLRGDPISKRAIAIEEDGKKH KYDAEYYIEN
QVLPAPERILKAFGYKREDLWRQKTKQVGLGAWLKVK

SEQ ID NO: 49
MEGWLLDADYITAEDGRAVVRLWCKDFDGNTFVVFYDRNFQPYAF
KNGLSKEDIEKIVVKSREGVIKPFKVEEVRRKVFKEVEVFKIYAY
HPQHVPKLREELKKITEVREADIPFAYRLIDKDLACMDGIRVEGK

47

-Continued

VREERGLKVIDAEHVERFEIPLPEPKVLAFDCEMLTELGMPDPEKD
 KIIIGVKCGDFEEIITGNEREILLRFVIEIKEQDPDVIVGYNQDN
 FDWPYIIRKRAEKLSVKLNIGRDGEISFRGGRPKIAGRNLNVLDYDI
 AMKLDVVKVTLLENVAEFLGRKVELADIEAKDIYKRWTSGDKESV р
 YSKQDVLNTYFIAEELLPMHYELSRMIRIPTDDVARIGRKQVDWF
 LLSEAYKIGEIAPNPAEVEESEYEGAFVLEPSRGLHKNVCLDFASM
 YPSIMIAYNISPDTYVFGKDDCYVAPEVGHKFRKHPDGFFKRILK
 MLIЕKRREIKNQMSLDRNSREYLLNIKQOTLKILTNFSYGTGW
 SGARWYCRQCAEATTAWGRHLIKSAVEIAKKLGPEVLYGDTD SIFV
 KKGNLSLEKIRGEVEKLIEEISEKFPVQIEVDEYYKTIFFVEKKRY
 AGLTEDGILVVKGLEVRRGDWCELAKEVQKKVIEIILKEENPEKA
 EYVRKVINDIKSGKVLEDVVIYKGLTKRPDKYESKQAHVKAALRA
 MELGIVNVNGSKVGVVVVEAGAGNVDRAYPIDLIEEFGENLVIRT
 RSGSIVKKLDKDYIINHQIIPSVLRILERFGYNEASLKGATQKTLD
 AFW

SEQ ID NO: 50

MILDADYITENGKPVVRIPKKENGEFKVYEDRNPEPYIYALLKDDS
 AIEEIKKITAERHGTVVRIKAEKVERKFLGRPVEVWKLYFTHPQD
 VPAIRDKIRSHPAVVDIYEDIPFAKRYLIDKGLVPMEGDEELKML
 AFDIETLYHEGEEFAEGPILMISYADESEARVITWKKVDPYDAV
 STEKDMIKAFLRVVKEKDРDVЛITYNGDMFDAYLKKRCEKLGK
 ILGRDGSEPKIQRMGDRFAVDVKGRIHFDLYPVIRRTINLP
 AVYEAIIFGRPKEKVYAEIQAQAWETNEGLERVARYSMEDA
 GKEFFPMEAQLSRLIGQPLWDVSRSSTGNLVEWFLRKAYERNELA
 PNKPSGREYDERGGYAGGYVKEPEKGLWENIVYLDYKSLYP
 THNVPDTLNREGCKEYDVAPQVGHFCKDFPGFIPSLLGD
 QKIKRKMATIDPIERRLLDYRQRAIKILANSYYGGYARWYC
 KECAESVTAWGREYIEMSIREIEEKYGFVLYADTDGFHATIP
 AETIKKKAMEFLKYINSKLPGALELEYEGFYRRGFFV
 EEGKITTRGLEIVRRDWSEIAKETQARVLEALLKDG
 EVTEKLSKYEVPPKEVLVIHEQITRELKDYKATGPHV
 VKIRPGTVISYIVLKGSGRIGDRAIPFDEFDP
 VLPAVERILKAFGYRKEDLRYQKTRQVGLGAWL
 SEQ ID NO: 51

MILDADYITENGKPVVRIPKKENGEFKVYEDRNPEPYIYALLKDDS
 AIEDVKKVTAHRGAVVKVRAEKVQRKFLGRPVEVWKLYFTHPQD
 VPAIRDKIRHAPAVVDIYEDIPFAKRYLIDKGLVPMEGDEEL
 AFDIETLYHEGEEFGTPILMISYADENEARVITWKK
 STEKEMIKRFLRVVKEKDРDVЛITYNGDMFDAYLKKRCEK
 ILGRDGSEPKIQRMGDRFAVEVKGRIHFDLYPVIRRTINLP
 AVYEAVFGPKEKVYAEIITEAWESGEGLERVARYSMEDA
 KVTYEL

48

-continued

GREFFPMEAQLSRLIGQSLWDVSRSSTGNLVEWFLRKAYERNELA
 PNKPDERELARRRESYAGGYVKEPERGLWDNIVYLDFRSLYP
 THNVPDTLNREGCKEYDVAPV р GHFCKDFPGFIPSLLGD
 LEER QKIKRKMATIDPLEKKLDYRQRAIKILANSFYGGYAK
 KECAESVTAWGREYIETTIREIEEKFGFKVLYADTDGF
 AETVKKAKEFLKYINAKLPGLELEYEGFYVRGFFV р K
 EGGKITTRGLEIVRRDWSEIAKETQARVLEA
 LKHGDVEEAVRIVK EVTEKLSKYEVPPKEVLVIHEQIT
 RDLRDYKATGPHVAVAKRLAAG VKIRPGTVISYIVLKG
 SGSGRIGDRAIPADEFDPTKHYDAEYYIENQ VLPAVERIL
 KAFGYRKEDLRYQKTRQVGLGAWLKVKGKK

SEQ ID NO: 52

MILDADYITENGKPVVRIPKKENGEFKVYEDRNPEPYIYALLRDDS
 AIEDVKKVTAERHGRVVVKVRAEKVKKFLGPVEVWKLYF
 TRPQD VPAIRDRIRAHPAVVDIYEDIPFAKRYLIDKG
 IIPMEGDEELKML AFDIETLYHEGEEFAEGPILMISYAD
 ENEARVITWKKIDLPFVDVV STEKEMIKRFLKV
 IKEKDРDVЛITYNGDMFDAYLKKRCEKFGIKF TLGRGSD
 PKIORMGDRFAVEVKGRHF DLYPVILRTVNLP
 TYLE AVYEAIIFGTPKEKVYPEEITTAWETGEGL
 ERVARYSMEDA
 KVTFEL GREFFPMEAQLSRLVGQS
 FWDSRSSTGNLVEWFLRKAYERNELA PNKPDEREL
 VRRNSYTGGYVKEPERGLWDNIVYLDFRSLYP
 THNVPDTLNREGCKEYDEAPV р GHFCKDFPGFIPS
 LLGNLLDER QKIKRKMATIDPLEKKLDYRQRAIKILANS
 YYGGYARWYC KECAESVTAWGREYIEMSIREIEEKY
 GFVLYADTDGFHATIP AETVKKAMEFLKYINAKL
 PGALELEYEGFYKRGFFV р K
 EGGKITTRGLEIVRRDWSEIAKETQARVLE
 ALLKDG
 NVEEAVSIVK EVTEKLGKYEVPPKEVLVIHEQIT
 RELKDYKATGPHV
 AIAKRLAARG VKIRPGTVISYIVLKGSGRIGDRAIP
 FDEFDP
 VLPAVERILKAFGYRAEDL
 RYQKTRQVGLGVWLQPKGKK

SEQ ID NO: 53

MELAFWLLDITYGVIGNTP
 ERLFGITDDGKRV
 VLDRSFRPYFV
 VV
 IPSGDVNAVFNNVKR
 LEGKVLN
 NEV
 I
 KRMFG
 NEV
 DAIRV
 TATIP
 EKVREL
 RELAA
 E
 VPG
 VED
 V
 LEAD
 IRFS
 Q
 RY
 L
 DMGV
 K
 PSN
 W
 V
 DQ
 C
 EEV
 V
 Q
 V
 D
 L
 V
 CL
 A
 K
 S
 R
 P
 R
 M
 I
 E
 H
 K
 L
 P
 S
 F
 R
 V
 L
 A
 F
 D
 I
 E
 V
 Y
 N
 P
 R
 G
 M
 P
 N
 P
 D
 R
 P
 V
 I
 I
 S
 T
 M
 T
 K
 E
 D
 G
 V
 K
 M
 F
 V
 V
 D
 D
 N
 K
 N
 D
 A
 K
 I
 I
 R
 E
 F
 L
 D
 Y
 F
 R
 K
 Y
 D
 P
 I
 V
 V
 G
 Y
 N
 N
 N
 G
 F
 D
 P
 Y
 L
 V
 N
 R
 S
 R
 V
 G
 V
 R
 L
 A
 L
 S
 R
 M
 G
 N
 P
 P
 E
 P
 S
 V
 Y
 G
 H
 W
 S
 I
 I
 G
 R
 A
 N
 V
 D
 L
 Y
 N
 F
 I
 E
 E
 I
 S
 E
 I
 K
 V
 K
 S
 L
 D
 R
 A
 E
 F
 F
 G
 I
 M
 K
 R
 S
 E
 R
 V
 L
 I
 P
 G
 H
 R
 I
 H
 E
 Y
 W
 D
 D
 K
 N
 K
 R
 D
 L
 L
 K
 Y
 A
 R
 D
 D
 V
 V
 S
 T
 Y
 G
 L
 A
 E
 K
 L
 L
 P
 F
 A
 I
 Q
 L
 S
 S
 I
 S
 G
 L
 P
 L
 D
 Q
 V
 G
 A
 S
 V
 G
 A
 R
 V
 E
 M
 I
 F
 Y
 A
 E
 V
 K
 R
 G
 E
 L
 A
 P
 N
 R
 E
 R
 P
 Y
 E
 T
 Y
 G
 A
 V
 V
 L
 E
 P
 R
 G
 L
 H
 E
 N
 I
 A
 V
 I
 D
 F
 S
 S
 M
 Y
 P
 S
 I
 M
 M
 K
 Y
 N
 V
 S
 P
 D
 T
 L
 V
 L
 G
 D
 C
 G
 C
 Y
 V
 A
 P
 E
 V
 N
 Y
 K
 F
 R
 R
 S
 P
 E
 G
 L
 Y
 P
 G
 L
 L
 R
 I
 L
 V
 E
 S
 R
 R
 V
 D
 L
 M
 K
 K
 P
 E
 N
 S
 P
 E
 W
 V
 L
 N
 E
 R

US 9,963,687 B2

49

- continued

QRALKVMANAMYGYCGWLGARWYRREVAEAVTAWGRNLLRTVIEKA
RSLGLPPIIYGDTDSLFRVNISDKDALINYVNNELGFEVKVDKVYR
RVLFTEAKKRYVGLTVEGEVDIVGFEAVRGDWAEIAKDQENVAEI
VLTTGDVGKAISYVKSVIDKVKAYQFDIDDDVIIWKTLDKSLNEYKV
LTPHVAACKQLVEAGYKGKGMIGYVVVKGGAKLAYKVKPYILI
KDIREVDVDYYVEKQIVPAAMRILEVLGVKESQLMEGKAGKSILDY
FS

SEQ ID NO: 54

MLRTVWVDYARKGEPDVILVGRREDGNPAALVVKGFRPYFYAEVED
GFDPSEVERLSGVVEVEEVILLEHPYGGDRVELLRIVATYPKVPKL
REQVKKLDGVKEVYEAIDIYFVRRAAVDLNLPPASEVDVSQDLDGSW
SGLPAYFADVEDARELDHRYPYPIEDLVVASFDLEVLAEPGTTIKGA
SGPIIAISFAYSTPDGERRNYVITWKGEDESFEVDGVETEVICRS
EAAALRRFFDEFRRVPDVVFTYNGDEFDLPLYLQHRAGKLGIDVSP
LARPAGKRGIILKHGGGRYASDIFGRAHVLDYHTARKNLKLERFTL
EEAVKDVLGVEKEEMELADINEAWKRGNLDELMRYSADEAHYTEL
GLELAQVELELSYLTRLPLPDATRSFGQLAEWRAYIKARQEDILV
PNKPTRDEYKRRRKAYKGAIVFEPEIGLHENVVCVDFASLYPNVM
VAHNISPDTDCDCPRTVVEEVDDPTDATVAPDVGHKPKCKRKG
FPRLVEGLIERRELKRLRKLDTESHPHEAKILDVRQQAYKVLAN
SYYGYMGWANARWFCRECAESVTAWGRYYISEVRRIAEEKYGLKV
YGDTSFLVLPDADEETIERVKEFLKEVNGLPVELELEDAYKR
ILFVTKKYAGYTEDGKIVTKGLEVVRRDWAPIRETQRRLKRL
ADNDPEAALKEIHEVLERLKSGDVEDIDEALAVTSQLTCKPSEYVQKG
PHVRAALRLARHLGVEPEPGTIVRYVIVRPGPSVSDKAPVVELVRE
EGKEPDVDYYIEHQILPAVERIMRAIGYSRGQIVGETASQKLDQF
FG

SEQ ID NO: 55 45

MELKIWPLDVTYAVVGGYPEVRVPGLTEGGGRVVLVDRSFKPYFYV
DCPTCEVGVKSSLSRVAPDEVSAERRFLGRPRRFMLVVARVPE
DVRRLREAAAQIPGVAGVYEADIRFYMRYMIDVGLLPCSWNRRAEVE
GGGVGGGLPQYTUVQWLGPGAGFPPLRLVAFDIEVYNERGTPDPA
RDPVVMIAVKTDDGREEVFEAEGRDRGVLSFVEFVKSYPDVVV
GYNNSNGFDWPYLAGRARAIYGVPLRVDRLGGLPQQSVYGHWSIVGRA
NVDLYGIVEEFPEIKLKTLDRVAYFGVMRREERVLIPGHKIYEYW
RDPGKRPLLQYVLDVRSTLGLADKLLPFLIQLSSVSLGPLDQVA
AASVGNRVEWMLLRYAYRLGEVAPNREEREYEPEYKGAIYLEPKPGM
YEDVLVLFSSMYPNIMMKYNLSPDTYLEPGEPPPEGVNAAPEVG
HRFRRSPLGFVPQVLKSLVELRKAVREEAKRPPDSPEFRILDERQ
RALKVMANAMYGYLGWVGARWYKREVAESVTAFARAILKDVIEQAR
RLGIVVVYGDTSFLVKKHNVNDKLIQYVEEKYGIEIKVDKDYAKV

50

- continued

LFTEAKKRYAGLLRDGRIDIVGFVVGRDWSELAKEVQLKVVEIL
NSRDAEARRRTQYVREIIERLREYKFNVDDLIIWKTLDKELGEY
KAYPPHVHAALILKRHGYKGKGNMVGYVVVKGGKISEKALPYIL
LDDVKKIDVEYYIERQIIPAAALRIAEVIGVKEADLKTGKSERSLLD
FF

SEQ ID NO: 56

MKTFLTEQQIKVLMRLAKGYKQSEIAKILGTSRANVSILEKRAMEK
IEKARNLTLLEWEQINSKVIVEIKAGEDIFSIEPKFFFKADKVGKV
PYSTAEEITFLVEHAPVEDRLAKRDFVLFLDSKNKLIGDCLVIEE
IKED

SEQ ID NO: 57

MPITKVTRNYQITIPAEIRKALGIKEGELLEVRELENGKIIERLKK
ERKTLKLGKKLTLEEIEKAIEEGMKQCMQ

SEQ ID NO: 58

TKIEILRLKEREMYAYEIWSSLGKPLKYQAVHQHIKELLELGLVE
QAYRKGRVYYKITEKGLRILQNFEDELENI

SEQ ID NO: 59

MNTGAQGVSEMSRMKIIISVQLPQSLIHGLDALVKRGYIYPNRSEAIR
VAIRELLKKELYKEEIQEEIPEYVVK

SEQ ID NO: 60

VIIIPRIDPRDIRRIRKELGITQEEELARKAGVTQAYIAKLEAGKVD
PRLSTFNKILRALIECQKAKI

SEQ ID NO: 61

NNCECMVVKEKLYTVKQASEILGVHPKTIQKWDREGKIKTVRTPGG
RRRIPESEIKRLLGISEEK

SEQ ID NO: 62

MLKDSAPKRKILEELRKGETVSGDYLASKLGVSRAVIAWKHRELKE
LGYGIIADKKGYKLVYEPKKPYPPWE

SEQ ID NO: 63

MIDERDKIILEILEKDARTPFTEIAKKGISETAVRKRVKALEEGK
IIEGYTIKINPKKLGYSLVTITGVDTKPEKLFVAEKLKE

SEQ ID NO: 64

MEIDDLDRKILSLLIEDSRLSYREIAKKLNVAVGTYNRIKKLED
GVIQGFTVKLNYEKLGYELTAIIIGIKAQGKK

SEQ ID NO: 65

EMLWMYILKLLKDRPMYAYEIRNELKKRGFEPATVSSYVVLRYLE
EGGYVSSEWHESEAGRPSRKYYRLTEKGEKLLEKGIFTIEDVLNML
KS

SEQ ID NO: 66

MKVSKATASKVLSLENKGITVERERRGKTYLVRLTNKGLELLEIS
KAGKELDEKIFAEMSVDERIVL

SEQ ID NO: 67

SEDYMLQNRKVLAKVLELLNNYNPKALNISELARMFGVSRTIYND
IQQIIKNVEV

US 9,963,687 B2

51

-continued

SEQ ID NO: 68	SKEISRFLKVISNPIRGILKMLNDRMCVCLISEALEIDQTLVSH	
	HIRILKELDLLEERKEGKLRFYRTNKEKLREYLEKVLEDNFNHGTSK	5
GS		
SEQ ID NO: 69	MCRKDVMISDPKQIKALSDPTRVKILELLRYHPTVSEISRIGK	
	DKSTIYRHAKLEEAGLVEEVEKIGNETVYGR	10
SEQ ID NO: 70	MEPVEFKLNQKGKISILPTMMEAEIFMEYMWEIFAKEATAGEVVEYMKT	
YPEIRRSTSILMNRLCERGLLKRRMEKGKGIRYVYSITTTREEF	15	
ERKVVEKIIESLMMNFREATFAYLSKINKK		
SEQ ID NO: 71	MKKSNLDDLILLAKAGGIKEILTTSRELSKMLNVSPQTIVRWED	
	LEKDGLIKSESRKGTLVTITEEGVKFLEKLHEELSDALYR	20
SEQ ID NO: 72	MEIPPEISHALSEIGFTKYEILTYWTLVYGPSTAKEISTKSGIPY	
NRVYDTISSLKLRGFVTEIEGTPKVYAAYSPIAFFRKKELEDIM	25	
KKLEIELNNVKK		
SEQ ID NO: 73	IINPQARLTPLELEILEIIKQKKSITITEIKEILSERRKSEYPLSL	
VSEYISRLERKGYVKKIAKGRKKPVEALI	30	
SEQ ID NO: 74	GIDVVIPEIKHDPIARDIVKILFDLRRANVSQIARELKGRRGKASR	
NTVRKKLKELEKLGVVKEVPGERGSVYTLSREVVKWLIDLIGIPIN	35	
LL		
SEQ ID NO: 75	MTKRVKVITDPEVIKVMLEDTRRKILQLLRNREMTISQLSEILGKM	
PQTIYHHIEKLKEAGLVEVKR	40	
SEQ ID NO: 76	MEEIKEIMKSHTLGNPVRLGIMIYLFPRRRAPFSHQKALDLTPGN	
LD SHIKVLEKHGFVRTYKVIADPRTMVEITDYGMEETRKFLSHLK	45	
TVIDAIHF		
SEQ ID NO: 77	MGEELNRLDVLGNETRRRILFLLTKRPYFVSELSRELGVGQKAVL	
EHLRILEEAGLIESRVEKIPRGRPRKYYMIKKGLRLEILLPTLFG	50	
SEMYEAK		
SEQ ID NO: 78	MRRMDKVDLQLIKILSQNSRLTYRELAEMLGTTQRVARKVDKLKK	55
LGIIRKFTIIPNLEK		
SEQ ID NO: 79	GRKVRTQQNEILNLLNEKEKAVLRAILEHGGEIKQEDLPELVGYSR	
PTISKVIELENKGLIKREKSGKTFVVKIERKIKLD	60	
SEQ ID NO: 80	KSLQRFLRNTTSIKHLSEITGVARNRLSDILNGKTQKIRGETLRK	
IAKAFEKSNILSF	65	

52

-continued

SEQ ID NO: 81	DVIQRIKEKYDEFTNAEKKIADTILSDPKGIIESSISDLSEKAGVK	
SEASVVFKYKGLNSFQQFKVLLAQSISRAPLEIVYEDVSEDDT		
KTITEKIFKATVRAI		
SEQ ID NO: 82	KIRDKILNVYTQFSPAERKVADYVLERPDDVIHYSITEFAKIVGVS	
ETTIHRMIKKLDFEQYQAFKIALARELSGLEETIERRDFIDEEDI		
LRRLKDTLD		
SEQ ID NO: 83	KRRPTINDVAKLAGVSISTVSRYLKDPSPQVSEKLERIREAIKKLG	
YKPNKIAQGLRTGD		
SEQ ID NO: 84	MASIKDVAKLAGVSIAATSRVINGYNNVSEETRKVIDAIRKLYNH	
PVYAVKGAVLKR		
SEQ ID NO: 85	MKKKYVTIRDIAEKAGVSINTVSRALNNKPDISEETRRKILKIAQE	
LGYVKNATASSLRSK		
SEQ ID NO: 86	MPTIEDVAKLAGVSIAATSRVINGSGYVSEKTRYKVWKAIIEELGYK	
PEISAKLLASKG		
SEQ ID NO: 87	MRIGEKLRLRSRGLTQEELAERTDLSRSFISQLESDKTPSPIDT	
LERILEALGTDLKHF		
SEQ ID NO: 88	MHMKTVRQERLKSIVRILERSKEPVSGAQLAEELSVSRQIVQDIA	
YLRSLGYNIVATPRGYVLAGG		
SEQ ID NO: 89	MNTLKKAFEILDIVKNPGDVSVSEIAEKFNMSVSNAYKYMVLE	
KGFVLRKKDKRYVPGYKLIYEYGSFVLRFF		
SEQ ID NO: 90	MKISKRRQELIRKIIHEKKISNQFQIVEELKKYGIKAVQPTVARD	
LKEIGAVKIMDESGNYVYKLLDETPVIDPWKELKR		
SEQ ID NO: 91	MHKKLNPKSMKRENKKMVLRYLIESGPHSRVEIARKTGLAQSIAWR	
TIEELVNEGIVEEKGTATGRERRKAVTYGPTRSFITS		
SEQ ID NO: 92	MPSPLLRENKIKILRYILKNGKTRNQLASNLNLAHSTLSYIIDE	
LLDEGFLVFEIICKRGRPYQILSVNPEKFTAI		
SEQ ID NO: 93	MKEERLKEILDIVDRNGFISMKDLQEQOLGVSMITVRRDVAELVKRN	
LVKKVHGGIRKVNYFEKETDFMKRLSINREAKE		
SEQ ID NO: 94	MFTMRSEYALRLMIVMAKEYGNYLSMTEILEKAKQSVPREFAEKIL	
YTLKKAGLVKTRRGKSGGYMLSRRPPKEIKVSEIVFLDRKSKVFFD		
MPGCPDELDCVIRALWKRVENEIEKILSGVTLEDLVREQEEMKQ		

US 9,963,687 B2

55**56**

-continued

35 40 45

Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
 50 55 60

Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
 85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125

Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190

Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
 275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
 385 390 395 400

Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415

His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
 420 425 430

Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445

Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile
 450 455 460

US 9,963,687 B2

57

-continued

Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
465 470 475 480

Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
485 490 495

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
500 505 510

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
645 650 655

Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
675 680 685

Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
705 710 715 720

Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
740 745 750

Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
755 760 765

Trp Leu Lys Val Lys Lys Ser
770 775

<210> SEQ_ID NO 2

<211> LENGTH: 75

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 2

Ile Ile Asn Pro Gln Ala Arg Leu Thr Pro Leu Glu Leu Glu Ile Leu
1 5 10 15

Glu Ile Ile Lys Gln Lys Lys Ser Ile Thr Ile Thr Glu Ile Lys Glu
20 25 30

Ile Leu Ser Glu Arg Arg Lys Ser Glu Tyr Pro Leu Ser Leu Val Ser
35 40 45

Glu Tyr Ile Ser Arg Leu Glu Arg Lys Gly Tyr Val Lys Lys Ile Ala

58

US 9,963,687 B2

59**60**

-continued

50 55 60

Lys Gly Arg Lys Lys Phe Val Glu Ala Leu Ile
 65 70 75

<210> SEQ_ID NO 3
 <211> LENGTH: 856
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 3

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15

Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
 20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45

Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
 50 55 60

Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
 85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125

Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190

Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
 275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu

US 9,963,687 B2

61**62**

-continued

340	345	350
Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365
Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser		
370	375	380
Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly		
385	390	395
Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr		
405	410	415
His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr		
420	425	430
Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly		
435	440	445
Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile		
450	455	460
Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu		
465	470	475
Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly		
485	490	495
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu		
500	505	510
Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu		
515	520	525
Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu		
530	535	540
Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg		
545	550	555
Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu		
565	570	575
Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys		
580	585	590
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly		
595	600	605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
610	615	620
Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala		
625	630	635
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile		
645	650	655
Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn		
660	665	670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala		
675	680	685
Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val		
690	695	700
Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu		
705	710	715
Phe Asp Gly Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn		
725	730	735
Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys		
740	745	750
Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala		
755	760	765

-continued

Trp Leu Lys Val Lys Lys Ser Gly Thr Gly Gly Gly Ile Ile Asn
 770 775 780

Pro Gln Ala Arg Leu Thr Pro Leu Glu Leu Glu Ile Leu Glu Ile Ile
 785 790 795 800

Lys Gln Lys Lys Ser Ile Thr Ile Thr Glu Ile Lys Glu Ile Leu Ser
 805 810 815

Glu Arg Arg Lys Ser Glu Tyr Pro Leu Ser Leu Val Ser Glu Tyr Ile
 820 825 830

Ser Arg Leu Glu Arg Lys Gly Tyr Val Lys Lys Ile Ala Lys Gly Arg
 835 840 845

Lys Lys Phe Val Glu Ala Leu Ile
 850 855

<210> SEQ ID NO 4

<211> LENGTH: 40

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 4

ttggtctgggt gtcaaaaatg aatcgtcacg gcgattttagt 40

<210> SEQ ID NO 5

<211> LENGTH: 39

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 5

gggtcatttt cggcgaggac tgcatacaacg catatacg 39

<210> SEQ ID NO 6

<211> LENGTH: 32

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 6

gcggccgcgt cctcgccgaa aatgacccag ag 32

<210> SEQ ID NO 7

<211> LENGTH: 32

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 7

gcggccgcgtg gtgtcgatgg tagaacgaag cg 32

<210> SEQ ID NO 8

<211> LENGTH: 32

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 8

gcggccgcggc cactgacgcg ttgcgcgaga ag 32

-continued

<210> SEQ ID NO 9
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 9

gccccggcg ctgcgcaact gttgggaagg gc

32

<210> SEQ ID NO 10
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 10

gccccggctg cagcacatcc cccttcgcc ag

32

<210> SEQ ID NO 11
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 11

gccccgcat gatgctcgtg acggtaacg cc

32

<210> SEQ ID NO 12
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 12

gccccgcag gtgcggattt aaaatggct gc

32

<210> SEQ ID NO 13
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 13

gccccgctc accgcttgcc agcggttac ca

32

<210> SEQ ID NO 14
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 14

gccccgcga atacctgttc cgtcatagcg at

32

<210> SEQ ID NO 15
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

-continued

<400> SEQUENCE: 15

gccccggcgc attttgaca ccagaccaac tgg 33

<210> SEQ ID NO 16

<211> LENGTH: 1016

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 16

gccccggcgt cctcgccaa aatgacccag aegcgtgcgg gcacctgtcc tacgagttgc 60

atgataaaga agacagtcat aagtgcggcg acgatagtca tgcccgccgc ccacccgaaag 120

gagctgactg ggttgaaggc tctcaaggc atcggtcgag atcccggtgc ctaatgagtg 180

agctaactta cattaattgc gttgcgcctca ctgcccgtt tccagtcggg aaacctgtcg 240

tgccagctgc attaatgaat cggccaaacgc gccccggagag ggggtttgcg tattggcgc 300

cagggtggtt tttctttca ccagttagac gggcaacagc tgattgcctt tcaccgcctg 360

gcctcgagag agttgcagca agcggtccac gctgggttgc cccagcaggc gaaaatcctg 420

tttgcgtgt gttaacggcg ggtatataacc aacgcgcagc cggactcg taatatccca 480

ctaccgagat atccgcacca acgwgccagcc cggactcgat aatggcgccg attgegcaca 540

gccccatctg atcggtggca accagcatcg cagtggaaac gatgcctca ttccgcattt 600

gcatggttt tgaaaaccg gacatggcac tccagtcggc ttcccggttcc gctatcggt 660

gaatttgatt gcgagtgaga tatttatgcc agccagccag acgcagacgc gcccggac 720

aacttaatgg gccccgttaac agcgccgattt gctgggtacc caatgcgacc agatgctcca 780

cgcccgatcg cgtaccgtct tcatggaga aaataatact gttgatgggt gtctggcgt 840

agacatcaag aaataacgccc ggaacattag tgcaggcagc ttccacagca atggcatct 900

ggtcatcccg cggatagttt atgatcagcc cactgacgcg ttgcgcgaga agattgtgca 960

ccggccgttt acagggttcg acggccgttc gttctaccat cgacaccacg ggccgc 1016

<210> SEQ ID NO 17

<211> LENGTH: 1016

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 17

gccccggccc cactgacgcg ttgcgcgaga agattgtgca ccggccgttt acagggttcg 60

acggccgttc gttctaccat cgacaccac acgctggcac ccagttgtac ggcgcgagat 120

ttaatcgccg cgacaatttg cgacggcgccg tgcagggcca gactggaggt ggcaacgcca 180

atcagcaacg actgtttgcc cgccagttgt tgcgcacgc gggtggaaat gtaattcagc 240

tccgcacatcg ccgttccac ttttccgc gtttgcag aaacgtggct ggcctggtc 300

accacgcggg aaacggctcg ataagagaca cccgcataact ctgcgcacatc gtataacgtt 360

actggttca cattcaccac cctgaattga ctctcttccg ggcgcstatca tgccataccg 420

cgaaagggtt tgcgcattc gatggtgtcc gggatctcg cgcctccct tatgcgactc 480

ctgcattagg aaggccca gtagtaggtt gaggccgtt agcaccgcg ccgcaaggaa 540

tggtgcatgc aaggagatgg cgcccaacag tccccggcc acggggcctg ccaccatacc 600

-continued

cacggccgaaa	caagegctca	tgagccgaa	gtggcgagcc	cgatcttccc	catcggtat	660
gtcggcgata	taggegccag	caaccgcacc	tgtggcgccg	gtgatgccgg	ccacgatcg	720
tccggcgtag	aggatcgaga	tctcgatccc	cgaaattaa	tacgactcac	tatagggaa	780
ttgtgagcg	ataacaattc	ccctctagaa	ataatttgt	ttaactttaa	gaaggagata	840
tacatatgac	catgattacg	gattcaactgg	ccgtcggtt	acaacgtcgt	gactgggaaa	900
accctggcg	tacccaactt	aatcgccctg	cagcacatcc	cccttcgccc	agctggcgta	960
atagcgaaga	ggccgcacc	gategcctt	ccaaacagt	gcccgcgc	ggccgc	1016

<210> SEQ ID NO 18

<211> LENGTH: 1016

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 18

gccccgcctg	cagcacatcc	cccttcgccc	agctggcgta	atagcgaaga	ggccgcacc	60
gatgcgcctt	cccaacagt	gcccgcctg	aatggcgaat	ggcgcttgc	ctggttccg	120
gcaccagaag	cggtgcccga	aagctggctg	gagtgcgatc	tccctgaggc	cgataactgtc	180
gtcgccccct	caaactggca	gatgcacgg	tacgatgcgc	ccatctacac	caacgtgacc	240
tatcccatta	cggtaatcc	gccgtttgtt	cccacggaga	atccgacggg	ttgttactcg	300
ctcacattna	atgttgcata	aagctggcta	caggaaggc	agacgcgaat	tattttgat	360
ggcggttaact	ggcggttca	tctgtggtgc	aacggggcgt	gggtcggtt	cgccaggac	420
agtcgttgc	cgtctgaaatt	tgacctgagc	gcattttac	gcccggaga	aaaccgcctc	480
gccccgtatgg	tgctgcgtg	gagtgcggc	agtttatctgg	aagatcagg	tatgtggcg	540
atgagcggca	tttccgtga	cgtctcggt	ctgcataaac	cgactacaca	aatcagcgat	600
ttccatgttg	ccactcgctt	taatgtat	ttcagccgc	ctgtactgga	ggctgaagtt	660
cagatgtgcg	gccccgtcg	tgactaccta	cggtaacag	tttctttatg	gcagggtgaa	720
acgcaggctg	ccagcggcac	cgcgccttc	ggcggtgaaa	ttatcgatg	gccccgttgt	780
tatgccgatc	gcgtcacact	acgtctgaa	gtcgaaaacc	cgaaactgtg	gagcgcgc	840
atccccgaaatc	tctatcggtc	ggtgggtgaa	ctgcacaccg	ccgacggcac	gctgtattgaa	900
gcagaaggct	gccccgtcg	tttccgcgag	gtgcggattt	aaaatggct	gctgtgtcg	960
acggcaagc	cgttgcgtat	tcgaggcg	tttccgcgat	acccgtc	agcatcatgc	1016

<210> SEQ ID NO 19

<211> LENGTH: 1016

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 19

ggggccgcag	gtgcggattt	aaaatggct	gctgtgtcg	aacggcaagc	cgttgcgtat	60
tcgaggcgat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	120
gatgggtcag	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	180
ttatccgaaatc	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	240
tgaaggccat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	300
ctggctaccg	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	tttccgcgat	360

-continued

gagtggtgatc atctggtcgc tggggaatga atcaggccac ggcgctaatac acgacgcgct	420
gtatcgctgg atcaaatctg tcgatcccttc ccgcgggtg cagttatgaag gcggcggagc	480
cgacaccacg gccaccgata ttatttgccc gatgtacgcg cgctggatg aagaccagcc	540
cttcccggtt gtggccaaat ggtccatcaa aaaatggctt tcgtacttgc gagagacgcg	600
cccgctgatc ctggcgaat acgcccacgc gatggtaac agtcttggcg gtttcgtta	660
atactggcag gcgttgcgtc agtatccccg tttacagggc ggcttcgtct gggactgggt	720
ggatcagtgc ctgattaaat atgatgaaaa cggcaacccg tggteggctt acggcggtga	780
ttttggcgat acgcccgaacg atcccgatgtt ctgtatgaac ggtctggctt ttggccgaccg	840
cacgcgcacat ccagegctga cggaaagcaaa acaccagcag cagttttcc agttccgttt	900
atccggccaa accatcgaag tgaccagcga atacctgttc cgtcatagcg ataacgagct	960
cctgcactgg atggtggcgc tggatggtaa gcccgtggca agcggtgagc ggccgc	1016

<210> SEQ ID NO 20

<211> LENGTH: 1168

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 20

ggggccgcga atacctgttc cgtcatagcg ataacgagct cctgcactgg atggtggcgc	60
tggatggtaa gccgcgtggca agcgggtgaag tgcctctggta tgcgtgtcca caaggtaaac	120
agttgattga actgcgtgaa ctaccgcgc cggagagcgc cggcaactc tggctcacag	180
tacgcgttagt gcaaccgaac gcgaccgcac ggtcagaacg cgggcacatc agcgcctggc	240
agcagtggcg tctggcgaa aacctcagtg tgacgcgtccc cgccgcgtcc cagccatcc	300
cgcacatgcg caccagcgaa atggatttt gcatcgagct ggtaataag cgttggcaat	360
ttaaccgcga gtcaggcttt ctggcacaga tggatggattgg cgataaaaaaa caactgctga	420
cgccgcgtgc cgatcgttgc accegtgcac cgctggataa cgacattggc gtaagtgaag	480
cgcacccgcac tgaccctaac gcctgggtcg aacgctggaa ggcgggggc cattaccagg	540
ccgaaggcgc gttgttgcag tgcacggcag atacacttgc tggatgggtg ctgattacga	600
cgcgtcacgc gtggcagcat cagggaaaa ctttattat cagccggaaa acctaccgga	660
ttgatggtag tggcaatg gcgattaccg ttgatgttgta agtggcgagc gatacaccgc	720
atccggcgcg gattggcctg aactgccagc tggcgaggt agcagagcgg gtaaactggc	780
tccgattagg gccgcaagaa aactatccc accgccttac tggatgggtt tttgaccgt	840
gggatctgcc attgtcagac atgtatacccg cgtacgtctt cccgagcgaa aacggcttc	900
gctgcggcgc ggcgcgaaattt aattatggcc cacaccgtg ggcggggc ttccagttca	960
acatcagccg ctacagtcaa cagcaactga tggaaaccag ccacgcacat ctgctgcacg	1020
cggaaagaagg cacaatggctg aatatcgacg gttccatat ggggatttgtt ggcgacgact	1080
cctggagccc gtcagttatcg gccgaaattcc agctgagcgc cggcgtatc cattaccgt	1140
tggatggatgg tcaaaaatga gccgcgc	1168

<210> SEQ ID NO 21

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 21

aaaaccaccc tggcgccaa tacg

24

<210> SEQ ID NO 22

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 22

cccggaactcg gtaatggcgc gcat

24

<210> SEQ ID NO 23

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 23

ggaagcagcc cagtagtagg ttga

24

<210> SEQ ID NO 24

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 24

ggtgctgcgc tggagtgacg gcag

24

<210> SEQ ID NO 25

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 25

cggccaccga tattatttgc ccga

24

<210> SEQ ID NO 26

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 26

gattagggcc gcaagaaaaac tatac

24

<210> SEQ ID NO 27

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (22)..(22)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 27

-continued

gccaagaacc tttcccaag angg	24
---------------------------	----

<210> SEQ ID NO 28	
<211> LENGTH: 71	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic construct	
 <400> SEQUENCE: 28	

atcttgttga aaggacgaaa caccggcgaa gaaaccttcc caaagagtt tagagctaga	60
aatagcaagt t	71

<210> SEQ ID NO 29	
<211> LENGTH: 71	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic construct	
<220> FEATURE:	
<221> NAME/KEY: misc_feature	
<222> LOCATION: (26)..(46)	
<223> OTHER INFORMATION: n is a, c, g, or t	
 <400> SEQUENCE: 29	

atcttgttga aaggacgaaa cacggnnnn nnnnnnnnnn nnnnnngtt tagagctaga	60
aatagcaagt t	71

<210> SEQ ID NO 30	
<211> LENGTH: 24	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic construct	
 <400> SEQUENCE: 30	

cggcagggtt ttcccagtca cgac	24
----------------------------	----

<210> SEQ ID NO 31	
<211> LENGTH: 27	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic construct	
 <400> SEQUENCE: 31	

gcgaagcttg catgcctgca ggtcgac	27
-------------------------------	----

<210> SEQ ID NO 32	
<211> LENGTH: 71	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic construct	
 <400> SEQUENCE: 32	

gtcgacotgc aggcatgcaa gcttggcaact ggccgtcggtt ttacaacgtc gtgactggta	60
aaaccctggc g	71

<210> SEQ ID NO 33	
<211> LENGTH: 1184	
<212> TYPE: PRT	
<213> ORGANISM: Methanocaldococcus vulcanius	

US 9,963,687 B2

77

78

-continued

<400> SEQUENCE: 33

Met Lys Glu Lys Ala Pro Lys Ile Asp Ala Leu Ile Asp Cys Thr Tyr
 1 5 10 15

Lys Thr Glu Asp Asn Arg Ala Val Ile Tyr Leu Tyr Leu Leu Glu Asn
 20 25 30

Ile Leu Lys Asp Arg Glu Phe Ser Pro Tyr Phe Tyr Val Glu Met Leu
 35 40 45

Lys Asp Arg Ile Glu Lys Glu Asp Ile Asp Lys Ile Lys Glu Phe Leu
 50 55 60

Leu Lys Glu Asp Leu Leu Lys Phe Val Glu Asn Leu Glu Val Val Asn
 65 70 75 80

Lys Thr Ile Leu Lys Lys Glu Lys Glu Ile Val Lys Ile Ile Ala Thr
 85 90 95

His Pro Gln Arg Val Pro Lys Leu Arg Lys Ile Lys Glu Cys Asp Ile
 100 105 110

Val Lys Glu Ile Tyr Glu His Asp Ile Pro Phe Ala Lys Arg Tyr Leu
 115 120 125

Ile Asp Ser Asp Ile Val Pro Met Thr Tyr Trp Asp Phe Glu Asn Arg
 130 135 140

Lys Gln Val Ser Ile Glu Ile Pro Lys Leu Lys Thr Val Ser Phe Asp
 145 150 155 160

Met Glu Val Tyr Asn Arg Asp Thr Glu Pro Asp Pro Glu Lys Asp Pro
 165 170 175

Ile Leu Met Ala Ser Phe Trp Asp Asn Gly Gly Lys Val Ile Thr
 180 185 190

Tyr Lys His Phe Asp His Ser Asn Ile Glu Val Val Asn Ser Glu Lys
 195 200 205

Asp Leu Ile Lys Lys Ile Val Glu Met Leu Arg Gln Tyr Asp Val Ile
 210 215 220

Phe Thr Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Lys Ala Arg
 225 230 235 240

Ala Lys Ile Tyr Gly Ile Asp Ile Lys Leu Gly Arg Asp Gly Glu Glu
 245 250 255

Leu Lys Ile Lys Arg Gly Gly Met Glu Phe Arg Ser Tyr Ile Pro Gly
 260 265 270

Arg Val His Ile Asp Leu Tyr Pro Ile Ser Arg Arg Leu Leu Lys Leu
 275 280 285

Thr Lys Tyr Thr Leu Glu Asp Val Val Tyr Asn Leu Phe Gly Ile Glu
 290 295 300

Lys Leu Lys Ile Pro His Thr Lys Ile Val Asp Tyr Trp Ala Asn Asn
 305 310 315 320

Asp Lys Ile Leu Ile Glu Tyr Ser Leu Gln Asp Ala Lys Tyr Thr His
 325 330 335

Lys Ile Gly Lys Tyr Phe Phe Pro Leu Glu Val Met Phe Ser Arg Ile
 340 345 350

Val Asn Gln Thr Pro Phe Glu Ile Thr Arg Met Ser Ser Gly Gln Met
 355 360 365

Val Glu Tyr Leu Leu Met Lys Asn Ala Phe Lys Glu Asn Met Ile Val
 370 375 380

Pro Asn Lys Pro Asp Glu Lys Glu Tyr Arg Lys Arg Leu Leu Thr Ser
 385 390 395 400

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Met Phe Glu Asp
 405 410 415

-continued

Ile Ile Ser Met Asp Phe Arg Cys His Pro Arg Gly Thr Lys Val Ile
420 425 430

Val Lys Asn Asn Gly Leu Thr Asp Ile Glu Asn Val Lys Val Gly Asp
435 440 445

Tyr Val Leu Gly Ile Asp Gly Trp Gln Lys Val Lys Arg Val Trp Lys
450 455 460

Tyr Pro Tyr Asn Gly Phe Leu Val Asn Val Asn Gly Leu Lys Ser Thr
465 470 475 480

Pro Asn His Lys Ile Pro Val Ile Lys Lys Glu Asn Gly Lys Asp Arg
485 490 495

Val Ile Asp Val Ser Ser Ile Tyr Leu Leu Asn Leu Lys Gly Cys Lys
500 505 510

Ile Leu Lys Ile Lys Asn Phe Glu Ser Ile Gly Met Phe Gly Lys Ile
515 520 525

Phe Lys Lys Asp Thr Lys Ile Lys Lys Val Lys Gly Leu Leu Glu Lys
530 535 540

Ile Ala Tyr Ile Asp Pro Arg Glu Gly Leu Val Ile Lys Val Lys Asn
545 550 555 560

Glu Lys Glu Asp Ile Phe Lys Thr Val Ile Pro Ile Leu Lys Glu Leu
565 570 575

Asn Ile Leu Tyr Lys Gln Val Asp Glu Lys Thr Ile Ile Ile Asp Ser
580 585 590

Ile Asp Gly Leu Leu Lys Tyr Ile Val Thr Ile Gly Phe Asn Asp Lys
595 600 605

Asn Glu Glu Lys Ile Lys Glu Ile Ile Lys Glu Lys Ser Phe Leu Glu
610 615 620

Phe Lys Glu Leu Glu Asp Ile Lys Ile Ser Ile Glu Glu Tyr Glu Gly
625 630 635 640

Tyr Val Tyr Asp Leu Thr Leu Glu Gly Arg Pro Tyr Tyr Phe Ala Asn
645 650 655

Gly Ile Leu Thr His Asn Ser Leu Tyr Pro Ser Ile Ile Ala Tyr
660 665 670

Asn Ile Ser Pro Glu Thr Leu Asp Cys Glu Cys Cys Lys Asp Ile Ser
675 680 685

Glu Lys Ile Leu Gly His Trp Phe Cys Lys Lys Arg Glu Gly Leu Ile
690 695 700

Pro Lys Thr Leu Arg Gly Leu Ile Glu Arg Arg Ile Asn Ile Lys Asn
705 710 715 720

Lys Met Lys Met Glu Ser Glu Lys Glu Ile Asn Glu Glu Tyr Asn
725 730 735

Leu Leu Asp Tyr Glu Gln Arg Ser Leu Lys Ile Leu Ala Asn Ser Val
740 745 750

Tyr Gly Tyr Leu Ala Phe Pro Arg Ala Arg Phe Tyr Ser Arg Glu Cys
755 760 765

Ala Glu Val Ile Thr Tyr Leu Gly Arg Lys Tyr Ile Leu Glu Thr Ile
770 775 780

Glu Glu Ala Glu Lys Phe Gly Phe Lys Val Ile Tyr Ala Asp Ser Val
785 790 795 800

Val Lys Asp Ala Lys Val Ile Ile Lys Glu Asp Gly Lys Ile Lys Glu
805 810 815

Ile Lys Ile Glu Asp Leu Phe Lys Lys Val Asp Tyr Thr Ile Gly Asp
820 825 830

US 9,963,687 B2

81**82**

-continued

Lys Glu Tyr Cys Ile Leu Asn Asn Val Glu Thr Leu Thr Ile Glu Asp
835 840 845

Thr Lys Leu Val Trp Arg Lys Val Pro Tyr Ile Met Arg His Arg Thr
850 855 860

Asn Lys Lys Ile Tyr Arg Val Lys Val Lys Asp Arg Tyr Val Asp Ile
865 870 875 880

Thr Glu Asp His Ser Ile Ile Gly Val Lys Asn Asn Lys Leu Val Glu
885 890 895

Leu Lys Pro Thr Glu Ile Lys Asp Asp Glu Thr Lys Leu Ile Ile Leu
900 905 910

Asn Lys Asp Leu Lys Ser Tyr Asn Phe Ala Ser Val Glu Glu Ile Asn
915 920 925

Cys Ile Lys Tyr Ser Asp Tyr Val Tyr Asp Ile Glu Val Glu Asn Thr
930 935 940

His Arg Phe Phe Ala Asn Gly Ile Leu Val His Asn Thr Asp Gly Phe
945 950 955 960

Tyr Ala Val Trp Lys Glu Lys Ile Ser Lys Asp Asp Leu Ile Lys Lys
965 970 975

Ala Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Thr Met
980 985 990

Glu Leu Glu Phe Glu Gly Tyr Phe Lys Arg Gly Ile Phe Ile Thr Lys
995 1000 1005

Lys Arg Tyr Ala Leu Ile Asp Glu Asn Gly Arg Val Ile Val Lys
1010 1015 1020

Gly Leu Glu Phe Val Arg Arg Asp Trp Ser Asn Leu Ala Arg Ile
1025 1030 1035

Thr Gln Arg Arg Val Leu Glu Ala Leu Leu Leu Glu Gly Asp Ile
1040 1045 1050

Asn Lys Ala Lys Lys Ala Ile Gln Asp Val Ile Lys Asp Leu Arg
1055 1060 1065

Glu Lys Lys Ile Lys Lys Glu Asp Leu Ile Ile Tyr Thr Gln Leu
1070 1075 1080

Thr Lys Asn Pro Asn Glu Tyr Lys Thr Thr Ala Pro His Val Glu
1085 1090 1095

Ile Ala Lys Lys Met Met Arg Glu Gly Lys Lys Ile Lys Ile Gly
1100 1105 1110

Asp Val Ile Gly Tyr Ile Ile Val Lys Gly Ser Lys Ser Ile Ser
1115 1120 1125

Glu Arg Ala Lys Leu Pro Glu Glu Val Ser Ile Glu Glu Ile Asp
1130 1135 1140

Val Asn Tyr Tyr Ile Asp Asn Gln Ile Leu Pro Pro Val Leu Arg
1145 1150 1155

Ile Met Glu Ala Val Gly Val Ser Lys Asn Glu Leu Lys Lys Glu
1160 1165 1170

Gly Thr Gln Leu Thr Leu Asp Arg Phe Leu Lys
1175 1180

<210> SEQ ID NO 34
<211> LENGTH: 781
<212> TYPE: PRT
<213> ORGANISM: Archaeoglobus fulgidus

<400> SEQUENCE: 34

Met Glu Arg Val Glu Gly Trp Leu Ile Asp Ala Asp Tyr Glu Thr Ile
1 5 10 15

-continued

Gly Gly Lys Ala Val Val Arg Leu Trp Cys Lys Asp Asp Gln Gly Ile
20 25 30

Phe Val Ala Tyr Asp Tyr Asn Phe Asp Pro Tyr Phe Tyr Val Ile Gly
35 40 45

Val Asp Glu Asp Ile Leu Lys Asn Ala Ala Thr Ser Thr Arg Arg Glu
50 55 60

Val Ile Lys Leu Lys Ser Phe Glu Lys Ala Gln Leu Lys Thr Leu Gly
65 70 75 80

Arg Glu Val Glu Gly Tyr Ile Val Tyr Ala His His Pro Gln His Val
85 90 95

Pro Lys Leu Arg Asp Tyr Leu Ser Gln Phe Gly Asp Val Arg Glu Ala
100 105 110

Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys
115 120 125

Met Asp Gly Ile Ala Ile Glu Gly Glu Lys Gln Gly Gly Val Ile Arg
130 135 140

Ser Tyr Lys Ile Glu Lys Val Glu Arg Ile Pro Arg Met Glu Phe Pro
145 150 155 160

Glu Leu Lys Met Leu Val Phe Asp Cys Glu Met Leu Ser Ser Phe Gly
165 170 175

Met Pro Glu Pro Glu Lys Asp Pro Ile Ile Val Ile Ser Val Lys Thr
180 185 190

Asn Asp Asp Asp Glu Ile Ile Leu Thr Gly Asp Glu Arg Lys Ile Ile
195 200 205

Ser Asp Phe Val Lys Leu Ile Lys Ser Tyr Asp Pro Asp Ile Ile Val
210 215 220

Gly Tyr Asn Gln Asp Ala Phe Asp Trp Pro Tyr Leu Arg Lys Arg Ala
225 230 235 240

Glu Arg Trp Asn Ile Pro Leu Asp Val Gly Arg Asp Gly Ser Asn Val
245 250 255

Val Phe Arg Gly Arg Pro Lys Ile Thr Gly Arg Leu Asn Val Asp
260 265 270

Leu Tyr Asp Ile Ala Met Arg Ile Ser Asp Ile Lys Ile Lys Lys Leu
275 280 285

Glu Asn Val Ala Glu Phe Leu Gly Thr Lys Ile Glu Ile Ala Asp Ile
290 295 300

Glu Ala Lys Asp Ile Tyr Arg Tyr Trp Ser Arg Gly Glu Lys Glu Lys
305 310 315 320

Val Leu Asn Tyr Ala Arg Gln Asp Ala Ile Asn Thr Tyr Leu Ile Ala
325 330 335

Lys Glu Leu Leu Pro Met His Tyr Glu Leu Ser Lys Met Ile Arg Leu
340 345 350

Pro Val Asp Asp Val Thr Arg Met Gly Arg Gly Lys Gln Val Asp Trp
355 360 365

Leu Leu Leu Ser Glu Ala Lys Lys Ile Gly Glu Ile Ala Pro Asn Pro
370 375 380

Pro Glu His Ala Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Glu
385 390 395 400

Arg Gly Leu His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr
405 410 415

Pro Ser Ile Met Ile Ala Phe Asn Ile Ser Pro Asp Thr Tyr Gly Cys
420 425 430

-continued

Arg Asp Asp Cys Tyr Glu Ala Pro Glu Val Gly His Lys Phe Arg Lys
435 440 445

Ser Pro Asp Gly Phe Phe Lys Arg Ile Leu Arg Met Leu Ile Glu Lys
450 455 460

Arg Arg Glu Leu Lys Val Glu Leu Lys Asn Leu Ser Pro Glu Ser Ser
465 470 475 480

Glu Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr
485 490 495

Asn Ser Phe Tyr Gly Tyr Met Gly Trp Asn Leu Ala Arg Trp Tyr Cys
500 505 510

His Pro Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Phe Ile Arg
515 520 525

Thr Ser Ala Lys Ile Ala Glu Ser Met Gly Phe Lys Val Leu Tyr Gly
530 535 540

Asp Thr Asp Ser Ile Phe Val Thr Lys Ala Gly Met Thr Lys Glu Asp
545 550 555 560

Val Asp Arg Leu Ile Asp Lys Leu His Glu Glu Leu Pro Ile Gln Ile
565 570 575

Glu Val Asp Glu Tyr Tyr Ser Ala Ile Phe Phe Val Glu Lys Lys Arg
580 585 590

Tyr Ala Gly Leu Thr Glu Asp Gly Arg Leu Val Val Lys Gly Leu Glu
595 600 605

Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Lys Val Gln Arg Glu
610 615 620

Val Ile Glu Val Ile Leu Lys Glu Lys Asn Pro Glu Lys Ala Leu Ser
625 630 635 640

Leu Val Lys Asp Val Ile Leu Arg Ile Lys Glu Gly Lys Val Ser Leu
645 650 655

Glu Glu Val Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro Ser Lys Tyr
660 665 670

Glu Ser Met Gln Ala His Val Lys Ala Ala Leu Lys Ala Arg Glu Met
675 680 685

Gly Ile Ile Tyr Pro Val Ser Ser Lys Ile Gly Tyr Val Ile Val Lys
690 695 700

Gly Ser Gly Asn Ile Gly Asp Arg Ala Tyr Pro Ile Asp Leu Ile Glu
705 710 715 720

Asp Phe Asp Gly Glu Asn Leu Arg Ile Lys Thr Lys Ser Gly Ile Glu
725 730 735

Ile Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asp Asn Gln Ile Ile Pro
740 745 750

Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu Ala Ser Leu
755 760 765

Lys Gly Ser Ser Gln Met Ser Leu Asp Ser Phe Phe Ser
770 775 780

<210> SEQ ID NO 35

<211> LENGTH: 783

<212> TYPE: PRT

<213> ORGANISM: Archaeoglobus profundus

<400> SEQUENCE: 35

Met Ile Lys Ala Trp Leu Leu Asp Val Asp Tyr Val Thr Glu Asn Asp
1 5 10 15

Arg Ala Val Ile Arg Leu Trp Cys Lys Asp Asp Lys Gly Val Phe Val
20 25 30

-continued

Ala Tyr Asp Arg Asn Phe Leu Pro Tyr Phe Tyr Val Ile Gly Cys Lys
 35 40 45
 Ala Glu Asp Val Met Lys Val Lys Val Arg Thr Asn Glu Gly Ile Ile
 50 55 60
 Thr Pro Leu Lys Val Glu Glu Ile Glu Ala Lys Ser Leu Gly Lys Pro
 65 70 75 80
 Ile Lys Ala Leu Lys Val Tyr Thr Arg His Pro Gln His Val Pro Lys
 85 90 95
 Leu Arg Glu Glu Ile Lys Lys Phe Ala Glu Val Arg Glu Ala Asp Ile
 100 105 110
 Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys Met Asp
 115 120 125
 Gly Ile Glu Ile Glu Pro Ile Ala Val Lys Glu Gly Val Leu Arg Ala
 130 135 140
 Tyr Glu Val Arg Ser Val Arg Arg Val Glu Lys Lys Gly Phe Pro Asp
 145 150 155 160
 Leu Lys Ile Leu Ala Phe Asp Cys Glu Met Leu Ala Gln Phe Met Pro
 165 170 175
 Asp Pro Glu Lys Asp Pro Ile Ile Ala Ile Ala Val Lys Cys Gly Asp
 180 185 190
 Phe Glu Glu Val Leu His Gly Asp Glu Arg Asp Ile Leu Arg Arg Phe
 195 200 205
 Val Ser Ile Ile Lys Glu Gln Asp Pro Asp Ile Ile Val Gly Tyr Asn
 210 215 220
 Gln Asp Asn Phe Asp Trp Pro Tyr Val Lys Lys Arg Ala Glu Lys Phe
 225 230 235 240
 Gly Ile Arg Leu Asp Ile Gly Arg Asp Arg Ser Glu Ile Ser Phe Arg
 245 250 255
 Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp Leu Tyr Asp
 260 265 270
 Ile Ala Leu Lys Ile Pro Asp Val Lys Ile Lys Thr Leu Lys Lys Val
 275 280 285
 Ala Glu Phe Leu Gly Ala Lys Val Glu Glu Asp Ile Glu Gly Arg
 290 295 300
 Asp Ile Tyr Lys Cys Trp Met Arg Gly Glu Lys Glu Lys Val Phe Lys
 305 310 315 320
 His Val Leu Asn Asp Val Leu Thr Thr Tyr Arg Leu Ala Leu Glu Leu
 325 330 335
 Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Leu Pro Leu Asp
 340 345 350
 Asp Val Ala Arg Leu Gly Arg Gly Lys Gln Val Asp Tyr Phe Leu Leu
 355 360 365
 Ser Glu Ala Lys Lys Ile Asn Glu Ile Ala Pro Asn Pro Pro Glu Ile
 370 375 380
 Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ala Arg Gly Leu
 385 390 395 400
 His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr Pro Ser Ile
 405 410 415
 Met Ile Asn Phe Asn Ile Ser Pro Asp Thr Leu Val Lys Gly Glu Cys
 420 425 430
 Glu Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg Lys Ser
 435 440 445

US 9,963,687 B2

89**90**

-continued

Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu Lys Arg
450 455 460

Arg Glu Met Lys Arg Gln Met Lys Glu Leu Asp Pro Asp Ser Glu Asp
465 470 475 480

Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr Asn
485 490 495

Ser Phe Tyr Gly Tyr Thr Gly Trp Asn Leu Ala Arg Trp Tyr Cys Arg
500 505 510

Glu Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg Tyr Phe Ile Lys Arg
515 520 525

Ala Val Lys Ile Ala Glu Ser Met Gly Phe Glu Val Leu Tyr Gly Asp
530 535 540

Thr Asp Ser Leu Phe Ile Lys Lys Asn Lys Leu Asn Leu Lys Asp Leu
545 550 555 560

Glu Lys Glu Cys Leu Lys Leu Ile Asp Val Ile Ser Lys Glu Leu Pro
565 570 575

Ile Gln Leu Glu Ile Asp Glu Phe Tyr Lys Ala Ile Phe Phe Val Glu
580 585 590

Lys Lys Arg Tyr Ala Gly Leu Thr Asp Asp Asp Arg Ile Val Val Lys
595 600 605

Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Arg Val
610 615 620

Gln Arg Glu Val Ile Glu Ile Ile Leu Arg Glu Arg Asn Pro Asp Lys
625 630 635 640

Ala Leu Lys Phe Val Lys Asn Val Ile Glu Glu Ile Lys Glu Gly Lys
645 650 655

Phe Lys Leu Glu Asp Tyr Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro
660 665 670

Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu Arg Ala
675 680 685

Met Glu Met Gly Ile Tyr Tyr Pro Ile Gly Thr Lys Val Gly Phe Val
690 695 700

Ile Val Lys Gly Gly Ser Ile Ser Asp Arg Ala Tyr Pro Ile Glu
705 710 715 720

Leu Ile Glu Phe Asp Gly Glu Asn Leu Lys Ile Arg Thr Pro Ser
725 730 735

Gly Ile Met Val Lys Lys Ile Asp Lys Asp Tyr Tyr Ile Asp His Gln
740 745 750

Ile Ile Pro Ala Val Met Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu
755 760 765

Ala Ser Leu Lys Thr Thr Ile Gln Lys Thr Leu Phe Asp Phe Thr
770 775 780

<210> SEQ ID NO 36

<211> LENGTH: 849

<212> TYPE: PRT

<213> ORGANISM: Caldicellulosiruptor hydrothermalis

<400> SEQUENCE: 36

Met Lys Leu Val Ile Phe Asp Gly Asn Ser Ile Leu Tyr Arg Ala Phe
1 5 10 15

Phe Ala Leu Pro Glu Leu Thr Thr Ser Ser Asn Ile Pro Thr Asn Ala
20 25 30

Ile Tyr Gly Phe Ile Asn Val Ile Leu Lys Tyr Leu Glu Gln Glu Lys
35 40 45

US 9,963,687 B2

91**92**

-continued

Pro Asp Tyr Ile Ala Val Ala Phe Asp Lys Arg Gly Arg Glu Ala Arg
50 55 60

Lys Ser Glu Tyr Gln Glu Tyr Lys Ala Asn Arg Lys Pro Met Pro Asp
65 70 75 80

Asn Leu Gln Val Gln Ile Pro Tyr Val Arg Glu Ile Leu Tyr Ala Leu
85 90 95

Asn Ile Pro Ile Val Glu Phe Glu Gly Tyr Glu Ala Asp Asp Val Ile
100 105 110

Gly Ser Leu Val Asn Lys Phe Lys Asn Thr Gly Leu Asp Ile Val Ile
115 120 125

Ile Thr Gly Asp Arg Asp Thr Leu Gln Leu Leu Asp Lys Asn Val Val
130 135 140

Val Lys Ile Val Ser Thr Lys Phe Asp Arg Thr Met Glu Asp Leu Tyr
145 150 155 160

Thr Ile Glu Asn Ile Lys Glu Lys Tyr Gly Val Trp Ala Asn Gln Val
165 170 175

Pro Asp Tyr Lys Ala Leu Val Gly Asp Gln Ser Asp Asn Ile Pro Gly
180 185 190

Val Lys Gly Ile Gly Glu Lys Ser Ala Gln Lys Leu Leu Glu Glu Tyr
195 200 205

Ser Ser Leu Glu Glu Ile Tyr Gln Asn Leu Asp Lys Ile Lys Gly Ser
210 215 220

Ile Arg Glu Lys Leu Glu Ala Gly Lys Asp Met Ala Phe Leu Ser Lys
225 230 235 240

Arg Leu Ala Thr Ile Val Cys Asp Leu Pro Leu Asn Val Asn Leu Glu
245 250 255

Asp Leu Arg Thr Lys Glu Trp Asn Lys Glu Arg Leu Tyr Glu Ile Leu
260 265 270

Val Gln Leu Glu Phe Lys Ser Ile Ile Lys Arg Leu Gly Leu Ser Glu
275 280 285

Asn Ile Gln Phe Glu Phe Val Gln Gln Arg Thr Asp Ile Pro Asp Val
290 295 300

Glu Gln Arg Glu Leu Glu Ser Ile Ser Arg Ile Arg Ser Lys Glu Ile
305 310 315 320

Pro Leu Met Phe Val Gln Asp Glu Lys Cys Phe Tyr Leu Tyr Asp Gln
325 330 335

Glu Ser Asn Thr Val Phe Val Thr Arg Asp Arg His Leu Val Glu Glu
340 345 350

Ile Leu Lys Ser Asp Thr Val Lys Ile Val Tyr Asp Leu Lys Asn Ile
355 360 365

Phe His Gln Leu Asn Leu Glu Asp Thr Asp Asn Ile Lys Asn Cys Glu
370 375 380

Asp Val Met Ile Ala Ser Tyr Val Leu Asp Ser Thr Arg Ser Ser Tyr
385 390 395 400

Glu Leu Glu Thr Leu Phe Val Ser Tyr Leu Asn Thr Asp Ile Glu Ala
405 410 415

Val Lys Lys Asp Lys Lys Met Val Ser Val Val Leu Leu Lys Arg Leu
420 425 430

Trp Asp Asp Leu Leu Arg Leu Ile Asp Leu Asn Ser Cys Gln Phe Leu
435 440 445

Tyr Glu Asn Ile Glu Arg Pro Leu Ile Pro Val Leu Tyr Glu Met Glu
450 455 460

-continued

Lys Thr Gly Phe Lys Val Asp Arg Asp Ala Leu Leu Gln Tyr Thr Lys
465 470 475 480

Glu Ile Glu Asn Lys Ile Leu Lys Leu Glu Thr Gln Ile Tyr Gln Ile
485 490 495

Ala Gly Glu Trp Phe Asn Ile Asn Ser Pro Lys Gln Leu Ser Tyr Ile
500 505 510

Leu Phe Glu Lys Leu Lys Leu Pro Val Ile Lys Lys Thr Lys Thr Gly
515 520 525

Tyr Ser Thr Asp Ala Glu Val Leu Glu Glu Phe Asp Lys His Glu Ile
530 535 540

Val Pro Leu Ile Leu Asp Tyr Arg Met Tyr Thr Lys Ile Leu Thr Thr
545 550 555 560

Tyr Cys Gln Gly Leu Leu Gln Ala Ile Asn Pro Ser Ser Gly Arg Val
565 570 575

His Thr Thr Phe Ile Gln Thr Gly Thr Ala Thr Gly Arg Leu Ala Ser
580 585 590

Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Lys Tyr Asp Glu Gly Lys
595 600 605

Leu Ile Arg Lys Val Phe Val Pro Glu Glu Gly His Val Leu Ile Asp
610 615 620

Ala Asp Tyr Ser Gln Ile Glu Leu Arg Ile Leu Ala His Ile Ser Glu
625 630 635 640

Asp Glu Arg Leu Ile Asn Ala Phe Lys Asn Asn Ile Asp Ile His Ser
645 650 655

Gln Thr Ala Ala Glu Val Phe Gly Val Asp Ile Ala Asp Val Thr Pro
660 665 670

Glu Met Arg Ser Gln Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly
675 680 685

Ile Ser Asp Tyr Gly Leu Ala Arg Asp Ile Lys Ile Ser Arg Lys Glu
690 695 700

Ala Ala Glu Phe Ile Asn Lys Tyr Phe Glu Arg Tyr Pro Lys Val Lys
705 710 715 720

Glu Tyr Leu Asp Asn Ile Val Arg Phe Ala Arg Glu Asn Gly Tyr Val
725 730 735

Leu Thr Leu Phe Asn Arg Lys Arg Tyr Val Lys Asp Ile Lys Ser Ala
740 745 750

Asn Arg Asn Ala Arg Ser Tyr Ala Glu Arg Ile Ala Met Asn Ser Pro
755 760 765

Ile Gln Gly Ser Ala Ala Asp Ile Met Lys Leu Ala Met Ile Lys Val
770 775 780

Tyr Gln Lys Leu Lys Glu Asn Asn Leu Lys Ser Lys Ile Ile Leu Gln
785 790 795 800

Val His Asp Glu Leu Leu Ile Glu Ala Pro Tyr Glu Glu Lys Asp Ile
805 810 815

Val Lys Arg Ile Val Lys Arg Glu Met Glu Asn Ala Val Ala Leu Lys
820 825 830

Val Pro Leu Val Val Glu Val Lys Glu Gly Leu Asn Trp Tyr Glu Thr
835 840 845

Lys

<210> SEQ ID NO 37
<211> LENGTH: 781
<212> TYPE: PRT
<213> ORGANISM: Desulfurococcus mucosus

-continued

<400> SEQUENCE: 37

Met Glu Lys Arg Val Tyr Leu Val Asp Ile Thr Tyr Gly Leu Val Gly
1 5 10 15

Asn Ser Pro Glu Ile Arg Met Phe Gly Val Asp Glu Asn Gly Glu Lys
20 25 30

Val Val Ile Leu Asp Arg Gly Phe Arg Pro Tyr Phe Tyr Val Ile Pro
35 40 45

Glu Glu Gly Phe Glu Asp Gln Val Ala Arg Val Ile Gly Lys Met Gln
50 55 60

Asn Val Ile Lys Ala Asp Val Thr Glu Arg Arg Leu Phe Gly Lys Pro
65 70 75 80

Ile Lys Val Val Lys Val Thr Val Thr Val Pro Asp Lys Val Arg Glu
85 90 95

Leu Arg Asp Arg Val Lys Ser Ile Gln His Val Lys Glu Val Leu Glu
100 105 110

Ala Asp Ile Arg Phe Tyr Ile Arg Tyr Met Ile Asp Asn Asp Ile Arg
115 120 125

Pro Gly Trp Leu Met Phe Ser Asn Leu Lys Pro Val Asp Asn Lys Ile
130 135 140

Gly Gly Val Ser Asn Val Tyr Leu Thr Glu Thr Pro Pro Thr Ser Leu
145 150 155 160

Asp Leu Gly Ile Met Pro Arg Leu Asn Tyr Met Ala Leu Asp Ile Glu
165 170 175

Val Tyr Asn Pro Arg Gly Thr Pro Asp Pro Lys Arg Asp Pro Ile Ile
180 185 190

Ile Ile Ala Leu Ala Asn Ser Asn Gly Asp Val Lys Leu Leu Thr Leu
195 200 205

Asp Asn Tyr Lys His Glu Arg Glu Met Leu Asn Asp Met Met Ser Val
210 215 220

Ile Lys Glu Trp Asp Pro Asp Val Leu Phe Gly Tyr Asn Ser Asn Lys
225 230 235 240

Phe Asp Met Pro Tyr Leu Val Asn Arg Ala Asp Ala Leu Asn Val Lys
245 250 255

Leu Gln Leu Ser Lys Tyr Gly Thr Pro Pro Glu Gln Ser Val Tyr Gly
260 265 270

His Trp Ser Ile Ile Gly Arg Ala His Ile Asp Leu Tyr Asn Phe Ile
275 280 285

Glu Asp Met Thr Asp Val Lys Arg Lys Ser Leu Asp Tyr Val Ala Glu
290 295 300

Tyr Phe Gly Val Met Lys Arg Ser Glu Arg Val Asn Ile Pro Gly His
305 310 315 320

Arg Ile Tyr Gln Tyr Trp Asp Asp Glu Gly Lys Arg Ser Gln Leu Ile
325 330 335

Lys Tyr Ala Arg Asp Asp Val Leu Ser Thr Leu Gly Leu Gly Lys Ile
340 345 350

Leu Leu Pro Tyr Ala Met Gln Leu Ala Ser Val Ser Gly Leu Pro Leu
355 360 365

Asp Gln Val Gly Pro Ala Ser Val Gly Ser Arg Val Glu Met Met Ile
370 375 380

Met His Glu Ala Tyr Lys Met Gly Glu Leu Ala Pro Asn Arg Val Glu
385 390 395 400

Arg Pro Tyr Glu Thr Tyr Lys Gly Ala Ile Val Leu Glu Pro Lys Pro

US 9,963,687 B2

97**98**

-continued

405	410	415
Gly Ile His Tyr Asn Ile Ala Val Leu Asp Phe Ser Ser Met Tyr Pro		
420	425	430
Asn Ile Met Leu Lys Tyr Asn Ile Ser Pro Asp Thr Leu Val Leu Asp		
435	440	445
Ser Ser Glu Gly Asp Tyr Tyr Thr Ala Pro Glu Val Gly Tyr Arg Phe		
450	455	460
Arg Lys Ser Pro Arg Gly Leu Tyr Ala Ser Leu Leu Gln Lys Leu Ile		
465	470	475
Glu Ala Arg Arg Glu Ala Arg Asp Glu Met Arg Asn Tyr Pro Glu Gly		
485	490	495
Ser Phe Glu Trp Val Leu Leu Asn Glu Arg Gln Arg Ala Leu Lys Ile		
500	505	510
Met Ala Asn Ala Met Tyr Gly Tyr Cys Gly Trp Leu Gly Ala Arg Trp		
515	520	525
Tyr Ile Arg Glu Val Ala Glu Ser Val Thr Ala Trp Gly Arg Tyr Leu		
530	535	540
Leu Lys Thr Ala Met Ser Met Ala Lys Glu Arg Gly Leu Thr Val Ile		
545	550	555
Tyr Gly Asp Thr Asp Ser Leu Phe Val Thr Tyr Asp Lys Asp Lys Val		
565	570	575
Ala Asp Ile Ile Ser Arg Ile Asn Glu Met Gly Phe Glu Val Lys Ile		
580	585	590
Asp Lys Val Tyr Ser Lys Leu Ile Phe Thr Glu Ser Lys Lys Arg Tyr		
595	600	605
Ile Gly Leu Thr Ala Asp Gly Glu Val Asp Ile Val Gly Phe Glu Ala		
610	615	620
Val Arg Gly Asp Trp Ser Glu Leu Ala Arg Asn Val Gln Glu Arg Val		
625	630	635
Ala Glu Leu Val Leu Arg Glu Ser Val Asp Glu Ala Val Lys Tyr Val		
645	650	655
Lys Ser Val Ile Asp Asp Leu Arg Asn Tyr Arg Phe Thr Ile Asp Asp		
660	665	670
Val Ile Ile Trp Lys Thr Leu Asp Lys Asp Ile Asn Glu Tyr Lys Ala		
675	680	685
Ile Gln Pro His Val Val Ala Ala Arg Arg Leu Met Glu Lys Gly Tyr		
690	695	700
Val Val Asn Lys Gly Asp Thr Val Gly Phe Val Ile Val Lys Asp Ser		
705	710	715
Gly Asp Lys Leu Thr Gln Arg Ala Tyr Pro Tyr Val Phe Ile Asn Asp		
725	730	735
Val Lys Glu Ile Asp Val Asp Tyr Tyr Val Glu Lys Gln Val Ile Pro		
740	745	750
Ala Ala Leu Arg Ile Leu Glu Val Phe Gly Val Asn Glu Ala Ala Leu		
755	760	765
Leu Gly Lys Thr Gly Lys Ser Ile Leu Asp Tyr Phe His		
770	775	780

<210> SEQ ID NO 38

<211> LENGTH: 803

<212> TYPE: PRT

<213> ORGANISM: Pyrollobus fumarii

<400> SEQUENCE: 38

US 9,963,687 B2

99**100**

-continued

Met Thr Glu Val Val Phe Thr Val Leu Asp Ser Ser Tyr Glu Val Val
 1 5 10 15

Gly Lys Glu Pro Gln Val Ile Ile Trp Gly Ile Ala Glu Asn Gly Glu
 20 25 30

Arg Val Val Leu Ile Asp Arg Ser Phe Arg Pro Tyr Phe Tyr Ala Leu
 35 40 45

Leu Ala Pro Gly Ala Asp Pro Lys Gln Val Ala Gln Arg Ile Arg Ala
 50 55 60

Leu Ser Arg Pro Lys Ser Pro Ile Ile Gly Val Glu Asp Asp Lys Arg
 65 70 75 80

Lys Tyr Phe Gly Arg Pro Arg Arg Val Leu Arg Ile Arg Thr Val Leu
 85 90 95

Pro Glu Ala Val Arg Glu Tyr Arg Glu Leu Val Lys Asn Val Asp Gly
 100 105 110

Val Glu Asp Val Leu Glu Ala Asp Ile Arg Phe Ala Met Arg Tyr Leu
 115 120 125

Ile Asp His Asp Leu Phe Pro Phe Thr Trp Tyr Arg Val Glu Ala Glu
 130 135 140

Pro Leu Glu Asn Lys Met Gly Phe Arg Val Asp Lys Val Tyr Leu Val
 145 150 155 160

Lys Ser Arg Pro Glu Pro Leu Tyr Gly Glu Ala Leu Ala Pro Thr Lys
 165 170 175

Leu Pro Asp Leu Arg Ile Leu Ala Phe Asp Ile Glu Val Tyr Ser Lys
 180 185 190

Gln Gly Ser Pro Arg Pro Glu Arg Asp Pro Val Ile Val Ile Ala Val
 195 200 205

Lys Thr Asp Asp Gly Asp Glu Val Leu Phe Ile Ala Glu Gly Lys Asp
 210 215 220

Asp Arg Lys Pro Ile Arg Glu Phe Val Glu Tyr Val Lys Arg Tyr Asp
 225 230 235 240

Pro Asp Ile Ile Val Gly Tyr Asn Asn His Phe Asp Trp Pro Tyr
 245 250 255

Leu Leu Arg Arg Ala Arg Ile Leu Gly Ile Lys Leu Asp Val Thr Arg
 260 265 270

Arg Val Gly Ala Glu Pro Thr Thr Ser Val His Gly His Val Ser Val
 275 280 285

Pro Gly Arg Leu Asn Val Asp Leu Tyr Asp Tyr Ala Glu Glu Met Pro
 290 295 300

Glu Ile Lys Ile Lys Ser Leu Glu Val Ala Glu Tyr Leu Gly Val
 305 310 315 320

Met Lys Lys Ser Glu Arg Val Ile Ile Asn Trp Trp Glu Ile Pro Asp
 325 330 335

Tyr Trp Asp Asp Pro Lys Lys Arg Pro Leu Leu Leu Gln Tyr Ala Arg
 340 345 350

Asp Asp Val Arg Ala Thr Tyr Gly Leu Ala Glu Lys Ile Leu Pro Phe
 355 360 365

Ala Ile Gln Leu Ser Tyr Val Thr Gly Leu Pro Leu Asp Gln Val Gly
 370 375 380

Ala Met Ser Val Gly Phe Arg Leu Glu Trp Tyr Leu Ile Arg Ala Ala
 385 390 395 400

Phe Lys Met Lys Glu Leu Val Pro Asn Arg Val Glu Arg Pro Glu Glu
 405 410 415

Thr Tyr Arg Gly Ala Ile Val Leu Glu Pro Leu Arg Gly Val His Glu

US 9,963,687 B2

101**102**

-continued

420	425	430
Asn Ile Ala Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Ile Met Ile		
435	440	445
Lys Tyr Asn Val Gly Pro Asp Thr Leu Val Arg Pro Gly Glu Glu Cys		
450	455	460
Gly Glu Cys Gly Cys Trp Glu Ala Pro Glu Val Lys His Arg Phe Arg		
465	470	475
Arg Cys Pro Pro Gly Phe Phe Lys Thr Val Leu Glu Arg Leu Leu Glu		
485	490	495
Leu Arg Lys Arg Val Arg Ala Glu Met Lys Lys Tyr Pro Pro Asp Ser		
500	505	510
Pro Glu Tyr Arg Leu Leu Asp Glu Arg Gln Lys Ala Leu Lys Val Leu		
515	520	525
Ala Asn Ala Ser Tyr Gly Tyr Met Gly Trp Ser Gly Ala Arg Trp Tyr		
530	535	540
Cys Arg Glu Cys Ala Glu Ala Val Thr Ala Trp Gly Arg His Leu Ile		
545	550	555
Arg Thr Ala Ile Asn Ile Ala Arg Lys Leu Gly Leu Lys Val Ile Tyr		
565	570	575
Gly Asp Thr Asp Ser Leu Phe Val Thr Tyr Asp Pro Glu Lys Val Glu		
580	585	590
Lys Phe Ile Lys Ile Ile Glu Glu Leu Gly Phe Glu Ile Lys Leu		
595	600	605
Glu Lys Val Tyr Lys Arg Val Phe Phe Thr Glu Ala Lys Lys Arg Tyr		
610	615	620
Ala Gly Leu Leu Glu Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Ala		
625	630	635
Val Arg Gly Asp Trp Cys Glu Leu Ala Lys Glu Val Gln Thr Lys Val		
645	650	655
Val Glu Ile Val Leu Lys Thr Ser Asp Val Asn Lys Ala Val Glu Tyr		
660	665	670
Val Arg Lys Ile Val Lys Glu Leu Glu Glu Gly Lys Val Pro Ile Glu		
675	680	685
Lys Leu Val Ile Trp Lys Thr Leu Ser Lys Arg Leu Glu Glu Tyr Thr		
690	695	700
Thr Glu Ala Pro His Val Val Ala Ala Lys Arg Met Leu Ser Ala Gly		
705	710	715
Tyr Arg Val Ser Pro Gly Asp Lys Ile Gly Tyr Val Ile Val Lys Gly		
725	730	735
Gly Gly Arg Ile Ser Gln Arg Ala Trp Pro Tyr Phe Met Val Lys Asp		
740	745	750
Pro Ser Gln Ile Asp Val Thr Tyr Val Asp His Gln Ile Ile Pro		
755	760	765
Ala Ala Leu Arg Ile Leu Gly Tyr Phe Gly Ile Thr Glu Lys Lys Leu		
770	775	780
Lys Ala Ser Ala Thr Gly Gln Lys Thr Leu Phe Asp Phe Leu Ala Lys		
785	790	795
Lys Ser Lys		

<210> SEQ ID NO 39

<211> LENGTH: 786

<212> TYPE: PRT

<213> ORGANISM: Pyrobaculum oguniense

-continued

<400> SEQUENCE: 39

Met Glu Ile Arg Val Trp Pro Leu Asp Val Thr Tyr Ile Val Val Gly
 1 5 10 15

Gly Val Pro Glu Val Arg Val Phe Gly Ile Ala Glu Gly Glu Arg
 20 25 30

Val Val Leu Ala Asp Arg Ser Phe Arg Pro Tyr Phe Tyr Val Asp Cys
 35 40 45

Ala Gly Cys Asp Pro His Ala Val Lys Thr His Leu Gly Arg Thr Ala
 50 55 60

Pro Val Glu Gly Val Glu Leu Val Glu Arg Arg Phe Leu Gly Arg Pro
 65 70 75 80

Arg Gln Phe Leu Lys Val Val Ala Lys Ile Pro Glu Asp Val Arg Arg
 85 90 95

Leu Arg Glu Ala Ala Ser Thr Ile Pro Gly Val Arg Gly Val Tyr Glu
 100 105 110

Ala Asp Ile Arg Phe Tyr Met Arg Tyr Val Ile Asp Met Gly Val Val
 115 120 125

Pro Cys Ser Trp Asn Val Ala Glu Val Glu Val Ala Asp Glu Lys Leu
 130 135 140

Gly Ser Leu Pro Val Tyr Arg Val Val Lys Trp Gly Gly Ala Val Glu
 145 150 155 160

Gly Phe Pro Pro Leu Arg Val Leu Ala Phe Asp Ile Glu Val Tyr
 165 170 175

Asn Glu Arg Gly Thr Pro Asp Pro Ala Arg Asp Pro Ile Val Met Ile
 180 185 190

Ala Val Gln Ser Ser Asp Gly Arg Leu Glu Val Phe Glu Ala Ser Gly
 195 200 205

Arg Asp Asp Arg Gly Val Leu Arg Ser Phe Val Glu Tyr Val Arg Ser
 210 215 220

Phe Asp Pro Asp Val Val Val Gly Tyr Asn Ser Asn Asn Phe Asp Trp
 225 230 235 240

Pro Tyr Leu Ala Glu Arg Ala Lys Ala Val Gly Val Pro Leu Arg Val
 245 250 255

Asp Arg Leu Gly Gly Ala Pro Gln Gln Ser Val Tyr Gly His Trp Ser
 260 265 270

Val Leu Gly Arg Ala Asn Val Asp Leu Tyr Asn Ile Val Asp Glu Phe
 275 280 285

Pro Glu Ile Lys Leu Lys Thr Leu Asp Arg Val Ala Glu Tyr Phe Gly
 290 295 300

Val Met Arg Arg Asp Glu Arg Val Leu Ile Pro Gly His Lys Ile Tyr
 305 310 315 320

Glu Tyr Trp Arg Asp Pro Ser Lys Arg Pro Leu Leu Arg Gln Tyr Val
 325 330 335

Ile Asp Asp Val Arg Ser Thr Tyr Gly Leu Ala Glu Arg Leu Leu Pro
 340 345 350

Phe Leu Ile Gln Leu Ser Ser Val Ser Gly Leu Pro Leu Asp Gln Val
 355 360 365

Ala Ala Ala Ser Val Gly Asn Arg Val Glu Trp Met Leu Leu Arg Tyr
 370 375 380

Ala Tyr Gly Leu Gly Glu Val Ala Pro Asn Arg Glu Glu Arg Glu Tyr
 385 390 395 400

Glu Pro Tyr Lys Gly Ala Ile Val Leu Glu Pro Lys Pro Gly Leu Tyr
 405 410 415

US 9,963,687 B2

105**106**

-continued

Ser Asp Val Leu Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Val Met
 420 425 430
 Met Arg Tyr Asn Leu Ser Pro Asp Thr Tyr Leu Glu Pro Gly Glu Pro
 435 440 445
 Asp Pro Pro Glu Gly Val Tyr Val Ala Pro Glu Val Gly His Arg Phe
 450 455 460
 Arg Lys Glu Pro Pro Gly Phe Ile Pro Gln Val Leu Arg Arg Leu Val
 465 470 475 480
 Ala Leu Arg Arg Ala Val Arg Glu Glu Met Lys Lys Tyr Gln Pro Asp
 485 490 495
 Thr Pro Glu Tyr Arg Val Leu Asp Glu Arg Gln Lys Ala Leu Lys Ile
 500 505 510
 Met Ala Asn Ala Met Tyr Gly Tyr Thr Gly Trp Val Gly Ala Arg Trp
 515 520 525
 Tyr Lys Lys Glu Val Ala Glu Ser Val Thr Ala Phe Ala Arg Ala Ile
 530 535 540
 Leu Lys Asp Val Ile Asp Tyr Ala Arg Arg Leu Gly Ile Val Val Ile
 545 550 555 560
 Tyr Gly Asp Thr Asp Ser Leu Phe Val Lys Lys Gly Gly Asp Leu Glu
 565 570 575
 Lys Leu Ala Arg Tyr Val Asp Glu Lys Tyr Gly Ile Glu Ile Lys Val
 580 585 590
 Asp Lys Asp Tyr Glu Lys Val Leu Phe Thr Glu Ala Lys Lys Arg Tyr
 595 600 605
 Ala Gly Leu Leu Arg Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Val
 610 615 620
 Val Arg Gly Asp Trp Ser Glu Leu Ala Lys Glu Val Gln Leu Lys Val
 625 630 635 640
 Ile Glu Leu Ile Leu Lys Ala Arg Asp Leu Ser Glu Ala Arg Gln Arg
 645 650 655
 Val Ile Lys Tyr Val Lys Asp Val Ile Glu Arg Leu Lys Ser Gly Lys
 660 665 670
 Phe Asp Leu Asp Asp Leu Ile Ile Trp Lys Thr Leu Asp Lys Asp Leu
 675 680 685
 Gly Glu Tyr Lys Ala Tyr Pro Pro His Val Arg Ala Ala Leu Ile Leu
 690 695 700
 Lys Lys Lys Gly Tyr Lys Val Gly Arg Gly Thr Thr Ile Gly Tyr Val
 705 710 715 720
 Val Val Lys Gly Glu Lys Val Ser Glu Arg Ser Leu Pro Tyr Ile
 725 730 735
 Leu Val Asp Asp Leu Ala Lys Ile Asp Val Asp Tyr Tyr Ile Glu Lys
 740 745 750
 Gln Val Ile Pro Ala Ala Leu Arg Ile Ala Glu Val Ile Gly Val Lys
 755 760 765
 Glu Gly Asp Leu Arg Ala Gly Arg Ser Glu Lys Ser Leu Leu Asp Phe
 770 775 780
 Phe Glu
 785

<210> SEQ ID NO 40

<211> LENGTH: 801

<212> TYPE: PRT

<213> ORGANISM: Staphylothermus marinus

US 9,963,687 B2

107**108**

-continued

<400> SEQUENCE: 40

Met Ser Glu Lys Ile Asn Leu Glu Phe Tyr Phe Leu Asp Asn Ser Tyr
 1 5 10 15

Glu Val Ile Gly Asn Glu Pro His Ile Ile Ile Trp Gly Ile Thr Arg
 20 25 30

Asp Gly Arg Arg Val Leu Leu Arg Asp Arg Arg Phe Arg Pro Tyr Phe
 35 40 45

Tyr Ala Ile Leu Lys Asp Lys Val Asn Ile Glu Asp Leu Ala Arg Lys
 50 55 60

Ile Arg Thr Tyr Ser Asp Pro Lys Ser Pro Ile Ile Gly Val Glu Pro
 65 70 75 80

Val Glu Lys Tyr Phe Gly Arg Lys Val Ser Ala Leu Lys Ile Ile
 85 90 95

Thr Met Ile Pro Glu Tyr Val Arg Lys Tyr Arg Glu Lys Ile Lys Ser
 100 105 110

Leu Pro Glu Val Leu Glu Val Val Glu Ala Asp Ile Arg Phe Ser Ile
 115 120 125

Arg Tyr Ile Ile Asp His Asp Leu Arg Pro Cys Gly Trp His Val Ala
 130 135 140

Glu Val Val Glu Val Pro Lys Lys Pro Ile Tyr Arg Val Asp Ala Glu
 145 150 155 160

Tyr Glu Ile Ile Gly Asp Ile Lys Pro Leu Glu Gln Thr Leu Gln Pro
 165 170 175

Asp Leu Arg Ile Ile Ala Phe Asp Ile Glu Val Tyr Asn Lys Ser Gly
 180 185 190

Thr Pro Arg Pro Gln Thr Asp Pro Ile Ile Ile Gly Ile Met Asn
 195 200 205

Asn Asn Gly Asp Ile Lys Gln Phe Leu Ala Asn Lys Tyr Asp Asp Lys
 210 215 220

Ile Ser Val Glu Glu Phe Val Asn Tyr Val Lys Thr Phe Asp Pro Asp
 225 230 235 240

Ile Ile Val Gly Tyr Asn Thr Asp Gly Phe Asp Trp Pro Tyr Leu Ile
 245 250 255

Glu Arg Ser Lys Tyr Ile Gly Val Lys Leu Asp Val Thr Arg Arg Val
 260 265 270

Gly Ala Thr Pro Arg Thr Ser Thr Tyr Gly His Ile Ser Val Pro Gly
 275 280 285

Arg Leu Asn Thr Asp Leu Tyr His Phe Ala Glu Glu Ile Pro Glu Val
 290 295 300

Lys Val Lys Ser Leu Glu Asn Val Ala Glu Tyr Leu Gly Val Met Lys
 305 310 315 320

Lys Ser Glu Arg Val Ile Ile Glu Tyr Ile Asp Ile Pro Lys Tyr Trp
 325 330 335

Asp Asp Glu Lys Leu Arg Pro Lys Leu Leu Gln Tyr Asn Ile Asp Asp
 340 345 350

Val Lys Ser Thr Tyr Gly Leu Ala Glu Lys Phe Leu Pro Phe Ala Met
 355 360 365

Gln Leu Ser Asn Ile Thr Gly Leu Pro Leu Asp Gln Val Gly Ala Ala
 370 375 380

Ser Val Gly Phe Arg Leu Glu Trp Tyr Leu Met Arg Glu Ala Phe Arg
 385 390 395 400

Tyr Gly Glu Leu Val Pro Asn Arg Val Glu Arg Ala Ala Glu Ser Tyr
 405 410 415

US 9,963,687 B2

109**110**

-continued

Arg Gly Ala Val Val Leu Lys Pro Val Lys Gly Val His Glu Asn Ile
 420 425 430
 Ala Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Ile Met Ile Lys Tyr
 435 440 445
 Asn Val Gly Pro Asp Thr Ile Val Arg Asn Glu Lys Cys Asn Pro Asp
 450 455 460
 Lys His Asn Ile Ala Pro Glu Val Gly His Cys Phe Arg Lys Glu Pro
 465 470 475 480
 Pro Gly Phe Phe Lys Arg Val Leu Glu Thr Leu Leu Arg Leu Arg Lys
 485 490 495
 Gln Ile Lys Ser Glu Met Lys Lys Tyr Pro Pro Thr Ser Tyr Glu Tyr
 500 505 510
 Arg Leu Leu Asp Glu Arg Gln Lys Ala Val Lys Val Leu Ala Asn Ala
 515 520 525
 Thr Tyr Gly Tyr Met Gly Trp Ile His Ala Arg Trp Tyr Cys Arg Glu
 530 535 540
 Cys Ala Glu Ala Val Thr Ala Trp Gly Arg Gln Thr Ile Lys Ser Ala
 545 550 555 560
 Ile Glu Leu Ala Arg Lys Leu Gly Leu Lys Val Ile Tyr Gly Asp Thr
 565 570 575
 Asp Ser Leu Phe Val Thr Tyr Asp Lys Asp Lys Val Glu Lys Leu Ile
 580 585 590
 Glu Leu Ile Gln Thr Lys Leu Gly Phe Glu Ile Lys Ile Asp Lys Ile
 595 600 605
 Tyr Lys Arg Val Phe Phe Thr Glu Ala Lys Lys Arg Tyr Ala Gly Leu
 610 615 620
 Leu Glu Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Ala Val Arg Gly
 625 630 635 640
 Asp Trp Ala Glu Ile Ala Lys Glu Val Gln Glu Lys Val Thr Glu Ile
 645 650 655
 Leu Leu Lys Glu Asn Ser Ile Asp Lys Ala Ile Glu Tyr Val Arg Gln
 660 665 670
 Val Ile Ala Asp Leu Lys Ala Gly Ile Pro Leu Asp Lys Leu Ile
 675 680 685
 Ile Trp Lys Thr Leu Ser Lys Arg Ile Glu Glu Tyr Ser Val Asp Ala
 690 695 700
 Pro His Val Val Ala Ala Lys Lys Leu Ile Lys Ala Gly Ile Lys Val
 705 710 715 720
 Ser Thr Asn Asp Lys Ile Gly Tyr Val Ile Leu Lys Gly Gly Lys
 725 730 735
 Ile Ser Ser Arg Ala Glu Pro Tyr Ile Phe Val Lys Asp Pro Lys Leu
 740 745 750
 Ile Asp Thr Glu Tyr Tyr Val Asp His Gln Ile Val Pro Ala Ala Leu
 755 760 765
 Arg Ile Leu Asn Tyr Phe Gly Val Thr Glu Thr Gln Leu Lys Arg Ala
 770 775 780
 Ala Ala Ser Ala Gly Gln Lys Ser Leu Phe Asp Phe Phe Gly Gly Lys
 785 790 795 800
 Lys

<210> SEQ ID NO 41
 <211> LENGTH: 776
 <212> TYPE: PRT

-continued

<213> ORGANISM: Pyrococcus yayaosii

<400> SEQUENCE: 41

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Val			
1	5	10	15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg		
20	25	30

Ser Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile		
35	40	45

Glu Asp Ile Lys Lys Ile Thr Ala Glu Arg His Gly Lys Val Val Arg		
50	55	60

Val Val Glu Ala Glu Lys Val Arg Lys Phe Leu Gly Arg Pro Ile			
65	70	75	80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile		
85	90	95

Arg Glu Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr		
100	105	110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro		
115	120	125

Met Glu Gly Asn Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr		
130	135	140

Leu Tyr His Glu Gly Asp Glu Phe Gly Ser Gly Pro Ile Ile Met Ile			
145	150	155	160

Ser Tyr Ala Asp Glu Lys Gly Ala Lys Val Ile Thr Trp Lys Gly Val		
165	170	175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys		
180	185	190

Arg Phe Leu Arg Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr		
195	200	205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu		
210	215	220

Lys Leu Gly Met Lys Leu Pro Ile Gly Arg Asp Gly Ser Glu Pro Lys			
225	230	235	240

Met Gln Arg Met Gly Asp Gly Phe Ala Val Glu Val Lys Gly Arg Ile		
245	250	255

His Phe Asp Ile Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr		
260	265	270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Arg Pro Lys Glu		
275	280	285

Lys Val Tyr Pro Asn Glu Ile Ala Arg Ala Trp Glu Asn Cys Lys Gly		
290	295	300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr			
305	310	315	320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu		
325	330	335

Val Gly Gln Pro Val Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
340	345	350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365

Pro Asn Arg Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser		
370	375	380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly			
385	390	395	400

-continued

Ile Ile Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr			
405	410	415	
His Asn Ile Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Asn Ser Tyr			
420	425	430	
Asp Val Ala Pro Lys Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly			
435	440	445	
Phe Ile Pro Ser Leu Leu Gly Gln Leu Leu Asp Glu Arg Gln Lys Ile			
450	455	460	
Lys Arg Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Lys Leu Leu			
465	470	475	480
Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly			
485	490	495	
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu			
500	505	510	
Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Leu Val Ser Arg Glu			
515	520	525	
Leu Glu Lys Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu			
530	535	540	
Tyr Ala Thr Ile Pro Gly Ser Arg Glu Trp Asp Lys Ile Lys Glu Arg			
545	550	555	560
Ala Leu Glu Phe Val Lys Tyr Ile Asn Ala Arg Leu Pro Gly Leu Leu			
565	570	575	
Glu Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys			
580	585	590	
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly			
595	600	605	
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln			
610	615	620	
Ala Arg Val Leu Glu Ala Ile Leu Lys Glu Gly Asn Leu Glu Lys Ala			
625	630	635	640
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val			
645	650	655	
Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asp Leu Lys			
660	665	670	
Asp Tyr Lys Ala Val Gly Pro His Val Ala Val Ala Lys Arg Leu Ala			
675	680	685	
Ala Arg Gly Ile Lys Val Arg Pro Gly Met Val Ile Gly Tyr Leu Val			
690	695	700	
Leu Arg Gly Asp Gly Pro Ile Ser Arg Arg Ala Ile Pro Ala Glu Glu			
705	710	715	720
Phe Asp Pro Ser Arg His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn			
725	730	735	
Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg			
740	745	750	
Lys Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Ala Gly Leu Asp Ala			
755	760	765	
Trp Leu Lys Arg Lys Ala Ser Leu			
770	775		

<210> SEQ ID NO 42

<211> LENGTH: 773

<212> TYPE: PRT

<213> ORGANISM: Thermococcus sp.AM4-del

<400> SEQUENCE: 42

-continued

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Ile
 1 5 10 15
 Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
 20 25 30
 Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Glu Asp Val Lys Lys Val Thr Ala Lys Arg His Gly Thr Val Val Arg
 50 55 60
 Val Lys Arg Ala Glu Lys Val Gln Arg Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Lys Ile Arg Ala His Pro Ala Val Ile Asp Ile Tyr Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asp Glu Glu Leu Thr Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Gly Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Arg Ile Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Ser Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Lys Glu Leu Ala Arg Arg Gly Gly Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415

-continued

Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
420 425 430

Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
435 440 445

Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
450 455 460

Arg Lys Met Lys Ala Thr Val Asp Pro Leu Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Thr Thr Ile Arg Glu Ile
515 520 525

Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Lys Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Arg Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Val Lys Lys
770

<210> SEQ ID NO 43

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus hydrothermalis

<400> SEQUENCE: 43

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1 5 10 15

US 9,963,687 B2

119

-continued

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
20 25 30

Glu Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Glu Glu Val Lys Lys Ile Thr Ala Gly Arg His Gly Arg Val Val Lys
50 55 60

Val Lys Arg Ala Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Glu Ile Arg Arg His Ser Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Met Met Ser Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Gly Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Thr Glu Lys Glu Met Ile Lys
180 185 190

Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
210 215 220

Lys Ile Gly Ile Lys Phe Thr Leu Arg Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Thr Pro Lys Glu
275 280 285

Lys Val Tyr Pro Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Gly
290 295 300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Ile Ala
355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Gly Gly Tyr
370 375 380

Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
385 390 395 400

Val Tyr Leu Asp Phe Met Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
405 410 415

Asn Val Ser Pro Asp Thr Phe Asn Arg Glu Gly Cys Lys Glu Tyr Asp
420 425 430

120

-continued

Thr Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Val Gln Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Ala Leu Leu Asp Glu Arg Gln Lys Ile Lys
 450 455 460
 Lys Arg Met Lys Ala Ser Ile Asp Pro Leu Glu Lys Lys Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Lys Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Asp Tyr Ile Glu Thr Thr Ile His Glu Ile
 515 520 525
 Glu Glu Arg Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
 530 535 540
 Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
 545 550 555 560
 Lys Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620
 Arg Val Leu Glu Ala Ile Leu Arg His Gly Asp Val Glu Glu Ala Val
 625 630 635 640
 Arg Ile Val Lys Asp Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
 645 650 655
 Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
 660 665 670
 Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala
 675 680 685
 Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
 690 695 700
 Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
 705 710 715 720
 Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
 725 730 735
 Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys Lys
 740 745 750
 Glu Glu Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp
 755 760 765
 Leu Lys Leu Lys Gly Lys Lys
 770 775

<210> SEQ ID NO 44

<211> LENGTH: 774

<212> TYPE: PRT

<213> ORGANISM: Thermococcus thioreducens

<400> SEQUENCE: 44

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Val
 1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
 20 25 30

-continued

Glu Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
 35 40 45
 Glu Glu Ile Lys Lys Ile Thr Ala Asp Arg His Gly Lys Val Val Lys
 50 55 60
 Val Lys Arg Ala Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Glu Ile Arg Lys His Pro Ala Val Val Asp Ile Tyr Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Asp Gly Ala Arg Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Leu Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Ala Leu Ala Trp Glu Ser Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Phe
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asn Glu Arg Glu Leu Ala Arg Arg Gly Gly Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
 420 425 430
 Arg Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Val Pro Gly Phe
 435 440 445

-continued

Ile Pro Ser Leu Leu Gly Ser Leu Leu Asp Glu Arg Gln Lys Ile Lys
450 455 460

Arg Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Lys Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Ala Ile Arg Glu Leu
515 520 525

Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Leu
530 535 540

His Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Met Glu Phe Leu Lys Tyr Ile Asn Pro Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Ala Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Arg His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
660 665 670

Tyr Arg Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Lys
675 680 685

Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Val Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Asp Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Val Lys Lys Arg
770

<210> SEQ ID NO 45

<211> LENGTH: 773

<212> TYPE: PRT

<213> ORGANISM: Thermococcus waiotapuensis

<400> SEQUENCE: 45

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1 5 10 15

Arg Val Phe Lys Lys Glu Lys Gly Glu Phe Lys Ile Asn Tyr Asp Arg
20 25 30

Asp Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

-continued

Glu Asp Ile Lys Lys Ile Thr Ala Glu Arg His Gly Thr Thr Val Arg
 50 55 60
 Val Thr Arg Ala Glu Arg Val Lys Lys Phe Leu Gly Arg Pro Val
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asn Glu Glu Leu Arg Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Phe Gly Glu Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile
 165 170 175
 Asp Leu Pro Tyr Val Glu Ser Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Lys Val Ile Gln Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu
 210 215 220
 Thr Leu Gly Val Lys Phe Ile Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Thr Val Tyr Glu Ala Ile Phe Gly Gln Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Ser Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Val Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Ala Glu Ser Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Tyr Lys Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Arg Glu Tyr Asp
 420 425 430
 Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Val Lys
 450 455 460

US 9,963,687 B2

129

130

-continued

Lys Lys Met Lys Ala Thr Val Asp Pro Ile Glu Arg Lys Leu Leu Asp
465 470 475 480

Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
485 490 495

Tyr Gly Tyr Ala Asn Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
500 505 510

Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Thr Thr Met Arg Glu Ile
515 520 525

Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Thr
545 550 555 560

Lys Glu Phe Leu Asn Tyr Ile Asn Pro Arg Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Arg Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Asp Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Arg Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asn Leu Arg Asp
660 665 670

Tyr Arg Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Pro Gly Arg Val Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Ala Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Ala Gly Leu Gly Ala Trp
755 760 765

Leu Lys Pro Lys Thr
770

<210> SEQ ID NO 46
<211> LENGTH: 774
<212> TYPE: PRT
<213> ORGANISM: Thermococcus sibiricus

<400> SEQUENCE: 46

Met Ile Leu Gly Ala Asp Tyr Ile Thr Lys Asp Gly Lys Pro Ile Val
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Leu Asp Pro
20 25 30

His Phe Gln Pro Tyr Ile Tyr Ala Leu Leu Ser Glu Asp Ser Ala Ile
35 40 45

Asp Glu Ile Lys Gln Ile Lys Gly Glu Arg His Gly Lys Thr Val Arg
50 55 60

-continued

Ile Val Asp Ala Val Lys Val Glu Lys Lys Phe Leu Lys Lys Pro Val
65 70 75 80

Lys Val Trp Lys Leu Ile Leu Glu His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asn Lys Ile Arg Glu His Pro Ala Val Gln Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Asn Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
130 135 140

Phe Tyr His Glu Gly Asp Glu Phe Gly Lys Gly Glu Ile Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile
165 170 175

Asp Leu Pro Tyr Val Asp Val Val Ser Asn Glu Arg Glu Met Ile Lys
180 185 190

Arg Phe Ile Gln Ile Ile Lys Glu Lys Asp Pro Asp Val Ile Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Leu Pro Tyr Leu Ile Lys Arg Ala Glu
210 215 220

Lys Leu Gly Leu Arg Leu Ile Leu Ser Arg Asp Asn Glu Asn Pro Val
225 230 235 240

Pro Lys Ile Gln Arg Met Gly Asn Ser Phe Ala Val Glu Ile Lys Gly
245 250 255

Arg Ile His Phe Asp Leu Phe Pro Val Val Lys Arg Ala Val Asn Leu
260 265 270

Pro Thr Tyr Thr Leu Glu Ala Val Tyr Glu Thr Val Leu Gly Lys His
275 280 285

Lys Ser Lys Leu Gly Ala Glu Glu Ile Ala Ala Ile Trp Glu Thr Glu
290 295 300

Glu Gly Leu Lys Lys Leu Ala Gln Tyr Ser Met Glu Asp Ala Lys Ala
305 310 315 320

Thr Tyr Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Val Glu Leu Ala
325 330 335

Lys Leu Ile Gly Gln Ser Val Trp Asp Val Ser Arg Ser Ser Thr Gly
340 345 350

Asn Leu Val Glu Trp Tyr Met Leu Arg Val Ala Tyr Glu Arg Asn Glu
355 360 365

Leu Ala Pro Asn Arg Pro Ser Asp Glu Glu Tyr Lys Arg Arg Leu Arg
370 375 380

Thr Thr Tyr Leu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp
385 390 395 400

Glu Asn Ile Ile Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile
405 410 415

Val Thr His Asn Val Ser Pro Asp Thr Leu Glu Arg Lys Gly Cys Gln
420 425 430

Asn Tyr Asp Val Ala Pro Ile Val Gly Tyr Lys Phe Cys Lys Asp Phe
435 440 445

Ser Gly Phe Ile Pro Ser Ile Leu Glu Asp Leu Ile Glu Thr Arg Gln
450 455 460

Lys Ile Lys Lys Glu Met Lys Ser Thr Ile Asp Pro Ile Lys Lys Lys
465 470 475 480

-continued

Met Leu Asp Tyr Arg Gln Arg Ala Val Lys Leu Leu Ala Asn Ser Tyr
 485 490 495
 Tyr Gly Tyr Met Gly Tyr Pro Lys Ala Arg Trp Tyr Ser Lys Glu Cys
 500 505 510
 Ala Glu Ser Val Thr Ala Trp Gly Arg His Tyr Ile Glu Met Thr Ile
 515 520 525
 Arg Glu Ile Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr
 530 535 540
 Asp Gly Phe Tyr Ala Thr Ile Pro Gly Ala Asp Pro Glu Thr Ile Lys
 545 550 555 560
 Lys Lys Ala Lys Glu Phe Leu Asn Tyr Ile Asn Ser Lys Leu Pro Gly
 565 570 575
 Leu Leu Glu Leu Glu Tyr Glu Gly Phe Tyr Leu Arg Gly Phe Phe Val
 580 585 590
 Thr Lys Lys Arg Tyr Ala Val Ile Asp Glu Glu Lys Ile Thr Thr
 595 600 605
 Arg Gly Leu Glu Val Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu
 610 615 620
 Thr Gln Ala Arg Val Leu Glu Ala Ile Leu Arg Glu Gly Ser Val Glu
 625 630 635 640
 Lys Ala Val Glu Ile Val Lys Glu Val Val Glu Ala Ile Thr Lys Tyr
 645 650 655
 Lys Val Pro Leu Glu Lys Leu Ile His Glu Gln Ile Thr Arg Glu
 660 665 670
 Leu Arg Asp Tyr Lys Ala Val Gly Pro His Val Ala Ile Ala Lys Arg
 675 680 685
 Leu Ala Ala Lys Gly Ile Lys Ile Lys Pro Gly Thr Ile Ile Ser Tyr
 690 695 700
 Ile Val Leu Arg Gly Ser Gly Lys Ile Ser Asp Arg Val Val Leu Leu
 705 710 715 720
 Thr Glu Tyr Asp Pro Arg Lys His Lys Tyr Asp Pro Asp Tyr Tyr Ile
 725 730 735
 Glu Asn Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly
 740 745 750
 Tyr Arg Lys Glu Asp Leu Lys Tyr Gln Ser Ser Lys Gln Thr Gly Leu
 755 760 765
 Glu Ser Trp Leu Lys Lys
 770

<210> SEQ ID NO 47
 <211> LENGTH: 775
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus glycovorans

<400> SEQUENCE: 47

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15
 Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
 20 25 30
 Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Gln Ile
 35 40 45
 Asp Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Lys Ile Val Arg
 50 55 60
 Ile Val Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

-continued

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asp Glu Glu Leu Lys Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Ala Lys Gly Pro Ile Ile Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Val
 165 170 175
 Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205
 Tyr Asn Gly Asp Ser Phe Asp Leu Pro Tyr Leu Val Lys Arg Ala Glu
 210 215 220
 Lys Leu Gly Ile Lys Leu Pro Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Met Gln Arg Leu Gly Asp Met Thr Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr His Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300
 Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Ala Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly
 385 390 395 400
 Leu Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Met Glu Tyr
 420 425 430
 Asp Val Ala Pro Glu Val Lys His Lys Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Lys Arg Leu Leu Asp Glu Arg Gln Glu Ile
 450 455 460
 Lys Arg Arg Met Lys Ala Ser Lys Asp Pro Ile Glu Lys Lys Met Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly
 485 490 495

-continued

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
500 505 510

Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Phe Val Arg Lys Glu
515 520 525

Leu Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly
530 535 540

Leu Tyr Ala Thr Ile Pro Gly Ala Lys Pro Glu Glu Ile Lys Arg Lys
545 550 555 560

Ala Leu Glu Phe Val Glu Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile
645 650 655

Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu His
660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
675 680 685

Ala Arg Gly Val Lys Val Arg Pro Gly Met Val Ile Gly Tyr Ile Val
690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Leu Ala Glu Glu
705 710 715 720

Phe Asp Pro Arg Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg
740 745 750

Lys Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Thr Gly Leu Thr Ala
755 760 765

Trp Leu Asn Val Lys Lys Lys
770 775

<210> SEQ ID NO 48
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus sp. NA2

<400> SEQUENCE: 48

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
50 55 60

Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
85 90 95

US 9,963,687 B2

139**140**

-continued

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190
 Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220
 Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240
 Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
 275 280 285
 Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300
 Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335
 Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
 385 390 395 400
 Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
 420 425 430
 Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Arg Gln Lys Ile
 450 455 460
 Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510

US 9,963,687 B2

141

142

-continued

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
645 650 655

Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
675 680 685

Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
705 710 715 720

Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
740 745 750

Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
755 760 765

Trp Leu Lys Val Lys Lys Ser
770 775

<210> SEQ ID NO 49

<211> LENGTH: 785

<212> TYPE: PRT

<213> ORGANISM: Ferroglobus placidus

<400> SEQUENCE: 49

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly
1 5 10 15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe
20 25 30

Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn
35 40 45

Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu
50 55 60

Gly Val Ile Lys Pro Phe Lys Val Glu Glu Val Arg Arg Lys Val Phe
65 70 75 80

Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His
85 90 95

Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu
100 105 110

-continued

Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala
 115 120 125
 Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly
 130 135 140
 Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu
 145 150 155 160
 Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu
 165 170 175
 Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Ile Gly Val Lys
 180 185 190
 Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu
 195 200 205
 Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val
 210 215 220
 Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala
 225 230 235 240
 Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile
 245 250 255
 Ser Phe Arg Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp
 260 265 270
 Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu
 275 280 285
 Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu
 290 295 300
 Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val
 305 310 315 320
 Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu
 325 330 335
 Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro
 340 345 350
 Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe
 355 360 365
 Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala
 370 375 380
 Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg
 385 390 395 400
 Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro
 405 410 415
 Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly
 420 425 430
 Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg
 435 440 445
 Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
 450 455 460
 Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
 465 470 475 480
 Arg Glu Tyr Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
 485 490 495
 Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
 500 505 510
 Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile
 515 520 525

-continued

Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr
530 535 540

Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu
545 550 555 560

Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys
565 570 575

Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe
580 585 590

Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val
595 600 605

Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys
610 615 620

Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro
625 630 635 640

Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser
645 650 655

Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys
660 665 670

Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu
675 680 685

Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
690 695 700

Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
705 710 715 720

Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
725 730 735

Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
740 745 750

His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr
755 760 765

Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe
770 775 780

Trp
785

<210> SEQ ID NO 50
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: Palaeococcus ferrophilus

<400> SEQUENCE: 50

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Val
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Glu Glu Ile Lys Lys Ile Thr Ala Glu Arg His Gly Thr Val Val Arg
50 55 60

Ile Thr Lys Ala Glu Lys Val Glu Arg Lys Phe Leu Gly Arg Pro Val
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Lys Ile Arg Ser His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

-continued

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Val Pro
 115 120 125
 Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Val
 165 170 175
 Asp Leu Pro Tyr Val Asp Ala Val Ser Thr Glu Lys Asp Met Ile Lys
 180 185 190
 Ala Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Leu Gly Val Lys Phe Ile Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Asp Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Arg Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Thr Asn Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Ile Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Ser Gly Arg Glu Tyr Asp Glu Arg Arg Gly Gly Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Tyr Lys Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
 420 425 430
 Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
 450 455 460
 Arg Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Arg Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Ser Ile Arg Glu Ile
 515 520 525

US 9,963,687 B2

149**150**

-continued

Glu	Glu	Lys	Tyr	Gly	Phe	Lys	Val	Leu	Tyr	Ala	Asp	Thr	Asp	Gly	Phe
530					535					540					
His Ala Thr Ile Pro Gly Glu Asp Ala Glu Thr Ile Lys Lys Lys Ala															
545					550			555							560
Met Glu Phe Leu Lys Tyr Ile Asn Ser Lys Leu Pro Gly Ala Leu Glu															
565					570			575							
Leu Glu Tyr Glu Gly Phe Tyr Arg Arg Gly Phe Phe Val Thr Lys Lys															
580					585			590							
Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu															
595					600			605							
Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala															
610					615			620							
Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asn Val Glu Glu Ala Val															
625					630			635							640
Ser Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro															
645					650			655							
Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp															
660					665			670							
Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala															
675					680			685							
Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu															
690					695			700							
Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe															
705					710			715							720
Asp Pro Ala Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln															
725					730			735							
Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys															
740					745			750							
Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp															
755					760			765							
Leu Lys Pro Lys Gly Lys Lys															
770					775										

<210> SEQ ID NO 51

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus gammatolerans

<400> SEQUENCE: 51

Met	Ile	Leu	Asp	Thr	Asp	Tyr	Ile	Thr	Glu	Asn	Gly	Lys	Pro	Val	Ile
1							5		10					15	
Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg															
							20		25					30	
Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile															
							35		40					45	
Glu Asp Val Lys Lys Val Thr Ala Lys Arg His Gly Ala Val Val Lys															
							50		55					60	
Val Lys Arg Ala Glu Lys Val Gln Arg Lys Phe Leu Gly Arg Pro Ile															
							65		70					80	
Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile															
							85		90					95	
Arg Asp Lys Ile Arg Ala His Pro Ala Val Val Asp Ile Tyr Glu Tyr															
							100		105					110	
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro															
							115		120					125	

US 9,963,687 B2

151**152**

-continued

Met Glu Gly Asp Glu Glu Leu Arg Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Asn Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Thr Glu Ala Trp Glu Ser Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Arg Glu Ser Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
 420 425 430
 Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
 450 455 460
 Arg Lys Met Lys Ala Thr Ile Asp Pro Leu Glu Lys Lys Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Thr Thr Ile Arg Glu Ile
 515 520 525
 Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
 530 535 540

US 9,963,687 B2

153

154

-continued

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
545 550 555 560

Lys Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
565 570 575

Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
580 585 590

Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
595 600 605

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
610 615 620

Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
625 630 635 640

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Arg Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
675 680 685

Lys Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Ala Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Val Lys Gly Lys Lys
770 775

<210> SEQ ID NO 52
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: Thermococcus celericrescens

<400> SEQUENCE: 52

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1 5 10 15

Arg Ile Phe Lys Lys Asp Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
20 25 30

Asn Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
35 40 45

Glu Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Arg Val Val Lys
50 55 60

Val Lys Arg Ala Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Val
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Thr Arg Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Arg Ile Arg Ala His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Ile Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
130 135 140

US 9,963,687 B2

155

-continued

Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Asn Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Phe Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Lys Val Ile Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Phe Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Asp Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Leu Arg Thr Val Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Thr Pro Lys Glu
 275 280 285
 Lys Val Tyr Pro Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Phe
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Val Gly Gln Ser Phe Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Leu Val Arg Arg Arg Asn Ser Tyr
 370 375 380
 Thr Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
 420 425 430
 Glu Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asn Leu Leu Asp Glu Arg Gln Lys Ile Lys
 450 455 460
 Lys Arg Met Lys Ala Thr Ile Asp Pro Leu Glu Lys Lys Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
 485 490 495
 Tyr Ala Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Ser Ile Arg Glu Ile
 515 520 525
 Glu Glu Lys Tyr Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
 530 535 540
 His Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
 545 550 555 560

156

US 9,963,687 B2

157

-continued

Met Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Ala Leu Glu
 565 570 575

 Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590

 Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
 595 600 605

 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620

 Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asn Val Glu Glu Ala Val
 625 630 635 640

 Ser Ile Val Lys Glu Val Thr Glu Lys Leu Gly Lys Tyr Glu Val Pro
 645 650 655

 Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
 660 665 670

 Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala
 675 680 685

 Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
 690 695 700

 Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
 705 710 715 720

 Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
 725 730 735

 Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Ala
 740 745 750

 Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Val Trp
 755 760 765

 Leu Gln Pro Lys Gly Lys Lys
 770 775

<210> SEQ_ID NO 53

<211> LENGTH: 784

<212> TYPE: PRT

<213> ORGANISM: Vulcanisaeta distributa

<400> SEQUENCE: 53

Met Glu Leu Ala Phe Trp Leu Leu Asp Ile Thr Tyr Gly Val Ile Gly
 1 5 10 15

 Asn Thr Pro Glu Leu Arg Leu Phe Gly Ile Thr Asp Asp Gly Lys Arg
 20 25 30

 Val Leu Val Leu Asp Arg Ser Phe Arg Pro Tyr Phe Tyr Val Ile Pro
 35 40 45

 Ser Gly Asp Val Asn Ala Val Phe Asn Asn Val Lys Arg Lys Leu Glu
 50 55 60

 Gly Lys Val Leu Asn Val Glu Val Ile Lys Arg Lys Met Phe Gly Asn
 65 70 75 80

 Glu Val Asp Ala Ile Arg Val Thr Ala Thr Ile Pro Glu Lys Val Arg
 85 90 95

 Glu Leu Arg Glu Leu Ala Ala Glu Val Pro Gly Val Glu Asp Val Leu
 100 105 110

 Glu Ala Asp Ile Arg Phe Ser Gln Arg Tyr Leu Leu Asp Met Gly Val
 115 120 125

 Lys Pro Ser Asn Trp Ile Val Val Asp Gln Cys Glu Glu Val Lys Gly
 130 135 140

 Asn Tyr Gln Val Asp Leu Val Cys Leu Ala Lys Ser Arg Pro Arg Met
 145 150 155 160

158

US 9,963,687 B2

159

-continued

Ile Glu Glu His Lys Leu Pro Ser Phe Arg Val Leu Ala Phe Asp Ile
165 170 175

Glu Val Tyr Asn Pro Arg Gly Met Pro Asn Pro Asp Arg Asp Pro Val
180 185 190

Ile Ile Ile Ser Thr Met Thr Lys Glu Asp Gly Val Lys Met Phe Val
195 200 205

Val Asp Asp Asn Lys Asn Asp Ala Lys Ile Ile Arg Glu Phe Leu Asp
210 215 220

Tyr Phe Arg Lys Tyr Asp Pro Asp Ile Val Val Gly Tyr Asn Asn Asn
225 230 235 240

Gly Phe Asp Trp Pro Tyr Leu Val Asn Arg Ser Ser Arg Val Gly Val
245 250 255

Arg Leu Ala Leu Ser Arg Met Gly Asn Pro Pro Glu Pro Ser Val Tyr
260 265 270

Gly His Trp Ser Ile Ile Gly Arg Ala Asn Val Asp Leu Tyr Asn Phe
275 280 285

Ile Glu Glu Ile Ser Glu Ile Lys Val Lys Ser Leu Asp Arg Ala Ala
290 295 300

Glu Phe Phe Gly Ile Met Lys Arg Ser Glu Arg Val Leu Ile Pro Gly
305 310 315 320

His Arg Ile His Glu Tyr Trp Asp Asp Lys Asn Lys Arg Asp Leu Leu
325 330 335

Leu Lys Tyr Ala Arg Asp Asp Val Val Ser Thr Tyr Gly Leu Ala Glu
340 345 350

Lys Leu Leu Pro Phe Ala Ile Gln Leu Ser Ser Ile Ser Gly Leu Pro
355 360 365

Leu Asp Gln Val Gly Ala Ala Ser Val Gly Ala Arg Val Glu Trp Met
370 375 380

Ile Phe Tyr Glu Ala Val Lys Arg Gly Glu Leu Ala Pro Asn Arg Glu
385 390 395 400

Glu Arg Pro Tyr Glu Thr Tyr Lys Gly Ala Val Val Leu Glu Pro Arg
405 410 415

Pro Gly Leu His Glu Asn Ile Ala Val Ile Asp Phe Ser Ser Met Tyr
420 425 430

Pro Ser Ile Met Met Lys Tyr Asn Val Ser Pro Asp Thr Leu Val Leu
435 440 445

Gly Asp Cys Gly Asp Cys Tyr Val Ala Pro Glu Val Asn Tyr Lys Phe
450 455 460

Arg Arg Ser Pro Glu Gly Leu Tyr Pro Gly Leu Leu Arg Ile Leu Val
465 470 475 480

Glu Ser Arg Arg Val Arg Asp Leu Met Lys Lys Tyr Pro Glu Asn
485 490 495

Ser Pro Glu Trp Val Leu Leu Asn Glu Arg Gln Arg Ala Leu Lys Val
500 505 510

Met Ala Asn Ala Met Tyr Gly Tyr Cys Gly Trp Leu Gly Ala Arg Trp
515 520 525

Tyr Arg Arg Glu Val Ala Glu Ala Val Thr Ala Trp Gly Arg Asn Leu
530 535 540

Leu Arg Thr Val Ile Glu Lys Ala Arg Ser Leu Gly Leu Pro Ile Ile
545 550 555 560

Tyr Gly Asp Thr Asp Ser Leu Phe Val Arg Asn Ile Ser Asp Lys Val
565 570 575

160

-continued

Asp Ala Leu Ile Asn Tyr Val Asn Asn Glu Leu Gly Phe Glu Val Lys
 580 585 590
 Val Asp Lys Val Tyr Arg Arg Val Leu Phe Thr Glu Ala Lys Lys Arg
 595 600 605
 Tyr Val Gly Leu Thr Val Glu Gly Glu Val Asp Ile Val Gly Phe Glu
 610 615 620
 Ala Val Arg Gly Asp Trp Ala Glu Ile Ala Lys Asp Val Gln Glu Asn
 625 630 635 640
 Val Ala Glu Ile Val Leu Thr Thr Gly Asp Val Gly Lys Ala Ile Ser
 645 650 655
 Tyr Val Lys Ser Val Ile Asp Lys Val Lys Ala Tyr Gln Phe Asp Ile
 660 665 670
 Asp Asp Val Ile Ile Trp Lys Thr Leu Asp Lys Ser Leu Asn Glu Tyr
 675 680 685
 Lys Val Leu Thr Pro His Val Ala Ala Ala Lys Gln Leu Val Glu Ala
 690 695 700
 Gly Tyr Lys Val Gly Lys Gly Asp Met Ile Gly Tyr Val Val Val Lys
 705 710 715 720
 Gly Gly Ala Lys Leu Ala Tyr Lys Val Lys Pro Tyr Ile Leu Ile
 725 730 735
 Lys Asp Ile Arg Glu Val Asp Val Asp Tyr Tyr Val Glu Lys Gln Ile
 740 745 750
 Val Pro Ala Ala Met Arg Ile Leu Glu Val Leu Gly Val Lys Glu Ser
 755 760 765
 Gln Leu Met Glu Gly Lys Ala Gly Lys Ser Ile Leu Asp Tyr Phe Ser
 770 775 780

<210> SEQ ID NO 54
 <211> LENGTH: 830
 <212> TYPE: PRT
 <213> ORGANISM: Methanopyrus kandleri
 <400> SEQUENCE: 54

Met Leu Arg Thr Val Trp Val Asp Tyr Ala Arg Lys Gly Glu Pro Asp
 1 5 10 15
 Val Ile Leu Val Gly Arg Arg Glu Asp Gly Asn Pro Ala Ala Leu Val
 20 25 30
 Val Lys Gly Phe Arg Pro Tyr Phe Tyr Ala Glu Val Glu Asp Gly Phe
 35 40 45
 Asp Pro Ser Glu Val Glu Arg Leu Ser Gly Val Val Glu Val Glu Glu
 50 55 60
 Val Leu Leu Glu His Pro Tyr Gly Gly Asp Arg Val Glu Leu Leu Arg
 65 70 75 80
 Ile Val Ala Thr Tyr Pro Lys Val Val Pro Lys Leu Arg Glu Gln Val
 85 90 95
 Lys Lys Leu Asp Gly Val Lys Glu Val Tyr Glu Ala Asp Ile Pro Phe
 100 105 110
 Val Arg Arg Ala Ala Val Asp Leu Asn Leu Pro Pro Ala Ser Glu Val
 115 120 125
 Asp Val Ser Asp Leu Asp Thr Gly Ser Trp Ser Gly Leu Pro Ala Tyr
 130 135 140
 Phe Ala Asp Val Glu Asp Ala Arg Glu Leu Asp His Arg Pro Tyr Pro
 145 150 155 160
 Ile Glu Asp Leu Val Val Ala Ser Phe Asp Leu Glu Val Leu Ala Glu
 165 170 175

Pro Gly Thr Thr Ile Lys Gly Ala Ser Gly Pro Ile Ile Ala Ile Ser
 180 185 190
 Phe Ala Tyr Ser Thr Pro Asp Gly Glu Arg Arg Asn Tyr Val Ile Thr
 195 200 205
 Trp Lys Gly Glu Asp Glu Ser Phe Glu Val Asp Gly Val Glu Thr Glu
 210 215 220
 Val Ile Val Cys Arg Ser Glu Ala Ala Ala Leu Arg Arg Phe Phe Asp
 225 230 235 240
 Glu Phe Arg Arg Val Asp Pro Asp Val Val Phe Thr Tyr Asn Gly Asp
 245 250 255
 Glu Phe Asp Leu Pro Tyr Leu Gln His Arg Ala Gly Lys Leu Gly Ile
 260 265 270
 Asp Val Ser Pro Leu Ala Arg Pro Ala Gly Lys Arg Gly Ile Ile Leu
 275 280 285
 Lys His Gly Gly Arg Tyr Ala Ser Asp Ile Phe Gly Arg Ala His
 290 295 300
 Val Asp Leu Tyr His Thr Ala Arg Lys Asn Leu Lys Leu Glu Arg Phe
 305 310 315 320
 Thr Leu Glu Ala Val Lys Asp Val Leu Gly Val Glu Lys Glu Glu
 325 330 335
 Met Glu Leu Ala Asp Ile Asn Glu Ala Trp Lys Arg Gly Asn Leu Asp
 340 345 350
 Glu Leu Met Arg Tyr Ser Ala Glu Asp Ala His Tyr Thr Leu Glu Leu
 355 360 365
 Gly Leu Glu Leu Ala Gln Val Glu Leu Glu Leu Ser Tyr Leu Thr Arg
 370 375 380
 Leu Pro Leu Pro Asp Ala Thr Arg Phe Ser Phe Gly Gln Leu Ala Glu
 385 390 395 400
 Trp Arg Ala Ile Tyr Lys Ala Arg Gln Glu Asp Ile Leu Val Pro Asn
 405 410 415
 Lys Pro Thr Arg Asp Glu Tyr Lys Arg Arg Arg Lys Ala Tyr Lys
 420 425 430
 Gly Ala Ile Val Phe Glu Pro Glu Ile Gly Leu His Glu Asn Val Val
 435 440 445
 Cys Val Asp Phe Ala Ser Leu Tyr Pro Asn Val Met Val Ala His Asn
 450 455 460
 Ile Ser Pro Asp Thr Phe Asp Cys Asp Cys Cys Pro Arg Val Thr Val
 465 470 475 480
 Glu Glu Val Asp Asp Pro Thr Asp Ala Thr Val Ala Pro Asp Val Gly
 485 490 495
 His Lys Phe Cys Lys Arg Arg Lys Gly Phe Phe Pro Arg Leu Val Glu
 500 505 510
 Gly Leu Ile Glu Arg Arg Arg Glu Leu Lys Arg Arg Leu Arg Lys Leu
 515 520 525
 Asp Thr Glu Ser His Pro His Glu Ala Lys Ile Leu Asp Val Arg Gln
 530 535 540
 Gln Ala Tyr Lys Val Leu Ala Asn Ser Tyr Tyr Gly Tyr Met Gly Trp
 545 550 555 560
 Ala Asn Ala Arg Trp Phe Cys Arg Glu Cys Ala Glu Ser Val Thr Ala
 565 570 575
 Trp Gly Arg Tyr Tyr Ile Ser Glu Val Arg Arg Ile Ala Glu Glu Lys
 580 585 590

US 9,963,687 B2

165

-continued

Tyr Gly Leu Lys Val Val Tyr Gly Asp Thr Asp Ser Leu Phe Val Lys
595 600 605

Leu Pro Asp Ala Asp Leu Glu Glu Thr Ile Glu Arg Val Lys Glu Phe
610 615 620

Leu Lys Glu Val Asn Gly Arg Leu Pro Val Glu Leu Glu Leu Glu Asp
625 630 635 640

Ala Tyr Lys Arg Ile Leu Phe Val Thr Lys Lys Tyr Ala Gly Tyr
645 650 655

Thr Glu Asp Gly Lys Ile Val Thr Lys Gly Leu Glu Val Val Arg Arg
660 665 670

Asp Trp Ala Pro Ile Ala Arg Glu Thr Gln Arg Arg Val Leu Lys Arg
675 680 685

Ile Leu Ala Asp Asn Asp Pro Glu Ala Ala Leu Lys Glu Ile His Glu
690 695 700

Val Leu Glu Arg Leu Lys Ser Gly Asp Val Asp Ile Asp Glu Leu Ala
705 710 715 720

Val Thr Ser Gln Leu Thr Lys Lys Pro Ser Glu Tyr Val Gln Lys Gly
725 730 735

Pro His Val Arg Ala Ala Leu Arg Leu Ala Arg His Leu Gly Val Glu
740 745 750

Pro Glu Pro Gly Thr Ile Val Arg Tyr Val Ile Val Arg Gly Pro Gly
755 760 765

Ser Val Ser Asp Lys Ala Tyr Pro Val Glu Leu Val Arg Glu Glu Gly
770 775 780

Lys Glu Pro Asp Val Asp Tyr Tyr Ile Glu His Gln Ile Leu Pro Ala
785 790 795 800

Val Glu Arg Ile Met Arg Ala Ile Gly Tyr Ser Arg Gly Gln Ile Val
805 810 815

Gly Glu Thr Ala Ser Gln Lys Thr Leu Asp Gln Phe Phe Gly
820 825 830

<210> SEQ ID NO 55

<211> LENGTH: 784

<212> TYPE: PRT

<213> ORGANISM: Thermoproteus neutrophilus

<400> SEQUENCE: 55

Met Glu Leu Lys Ile Trp Pro Leu Asp Val Thr Tyr Ala Val Val Gly
1 5 10 15

Gly Tyr Pro Glu Val Arg Val Phe Gly Leu Thr Glu Gly Gly Arg
20 25 30

Val Val Leu Val Asp Arg Ser Phe Lys Pro Tyr Phe Tyr Val Asp Cys
35 40 45

Pro Thr Cys Glu Val Gly Val Val Lys Ser Ser Leu Ser Arg Val Ala
50 55 60

Pro Val Asp Glu Val Ser Ala Ala Glu Arg Arg Phe Leu Gly Arg Pro
65 70 75 80

Arg Arg Phe Leu Met Val Val Ala Arg Val Pro Glu Asp Val Arg Arg
85 90 95

Leu Arg Glu Ala Ala Ala Gln Ile Pro Gly Val Ala Gly Val Tyr Glu
100 105 110

Ala Asp Ile Arg Phe Tyr Met Arg Tyr Met Ile Asp Val Gly Leu Leu
115 120 125

Pro Cys Ser Trp Asn Arg Ala Glu Val Glu Gly Gly Lys Val Gly
130 135 140

166

US 9,963,687 B2

167

-continued

Gly Leu Pro Gln Tyr Thr Val Val Gln Trp Leu Gly Pro Ala Gly Gly
145 150 155 160

Phe Pro Pro Pro Leu Arg Val Leu Ala Phe Asp Ile Glu Val Tyr Asn
165 170 175

Glu Arg Gly Thr Pro Asp Pro Ala Arg Asp Pro Val Val Met Ile Ala
180 185 190

Val Lys Thr Asp Asp Gly Arg Glu Glu Val Phe Glu Ala Glu Gly Arg
195 200 205

Asp Asp Arg Gly Val Leu Arg Ser Phe Val Glu Phe Val Lys Ser Tyr
210 215 220

Asp Pro Asp Val Val Gly Tyr Asn Ser Asn Gly Phe Asp Trp Pro
225 230 235 240

Tyr Leu Ala Gly Arg Ala Arg Ala Ile Gly Val Pro Leu Arg Val Asp
245 250 255

Arg Leu Gly Gly Leu Pro Gln Gln Ser Val Tyr Gly His Trp Ser Ile
260 265 270

Val Gly Arg Ala Asn Val Asp Leu Tyr Gly Ile Val Glu Glu Phe Pro
275 280 285

Glu Ile Lys Leu Lys Thr Leu Asp Arg Val Ala Glu Tyr Phe Gly Val
290 295 300

Met Arg Arg Glu Glu Arg Val Leu Ile Pro Gly His Lys Ile Tyr Glu
305 310 315 320

Tyr Trp Arg Asp Pro Gly Lys Arg Pro Leu Leu Arg Gln Tyr Val Leu
325 330 335

Asp Asp Val Arg Ser Thr Leu Gly Leu Ala Asp Lys Leu Leu Pro Phe
340 345 350

Leu Ile Gln Leu Ser Ser Val Ser Gly Leu Pro Leu Asp Gln Val Ala
355 360 365

Ala Ala Ser Val Gly Asn Arg Val Glu Trp Met Leu Leu Arg Tyr Ala
370 375 380

Tyr Arg Leu Gly Glu Val Ala Pro Asn Arg Glu Glu Arg Glu Tyr Glu
385 390 395 400

Pro Tyr Lys Gly Ala Ile Val Leu Glu Pro Lys Pro Gly Met Tyr Glu
405 410 415

Asp Val Leu Val Leu Asp Phe Ser Ser Met Tyr Pro Asn Ile Met Met
420 425 430

Lys Tyr Asn Leu Ser Pro Asp Thr Tyr Leu Glu Pro Gly Glu Pro Asp
435 440 445

Pro Pro Glu Gly Val Asn Ala Ala Pro Glu Val Gly His Arg Phe Arg
450 455 460

Arg Ser Pro Leu Gly Phe Val Pro Gln Val Leu Lys Ser Leu Val Glu
465 470 475 480

Leu Arg Lys Ala Val Arg Glu Glu Ala Lys Arg Tyr Pro Pro Asp Ser
485 490 495

Pro Glu Phe Arg Ile Leu Asp Glu Arg Gln Arg Ala Leu Lys Val Met
500 505 510

Ala Asn Ala Met Tyr Gly Tyr Leu Gly Trp Val Gly Ala Arg Trp Tyr
515 520 525

Lys Arg Glu Val Ala Glu Ser Val Thr Ala Phe Ala Arg Ala Ile Leu
530 535 540

Lys Asp Val Ile Glu Gln Ala Arg Arg Leu Gly Ile Val Val Val Tyr
545 550 555 560

168

US 9,963,687 B2

169**170**

-continued

Gly Asp Thr Asp Ser Leu Phe Val Lys Lys His Val Asn Val Asp Lys
565 570 575

Leu Ile Gln Tyr Val Glu Glu Lys Tyr Gly Ile Glu Ile Lys Val Asp
580 585 590

Lys Asp Tyr Ala Lys Val Leu Phe Thr Glu Ala Lys Lys Arg Tyr Ala
595 600 605

Gly Leu Leu Arg Asp Gly Arg Ile Asp Ile Val Gly Phe Glu Val Val
610 615 620

Arg Gly Asp Trp Ser Glu Leu Ala Lys Glu Val Gln Leu Lys Val Val
625 630 635 640

Glu Ile Ile Leu Asn Ser Arg Asp Val Ala Glu Ala Arg Arg Arg Val
645 650 655

Thr Gln Tyr Val Arg Glu Ile Ile Glu Arg Leu Arg Glu Tyr Lys Phe
660 665 670

Asn Val Asp Asp Leu Ile Ile Trp Lys Thr Leu Asp Lys Glu Leu Gly
675 680 685

Glu Tyr Lys Ala Tyr Pro Pro His Val His Ala Ala Leu Ile Leu Lys
690 695 700

Arg His Gly Tyr Lys Val Gly Lys Gly Asn Met Val Gly Tyr Val Val
705 710 715 720

Val Lys Gly Gly Lys Ile Ser Glu Lys Ala Leu Pro Tyr Ile Leu
725 730 735

Leu Asp Asp Val Lys Lys Ile Asp Val Glu Tyr Tyr Ile Glu Arg Gln
740 745 750

Ile Ile Pro Ala Ala Leu Arg Ile Ala Glu Val Ile Gly Val Lys Glu
755 760 765

Ala Asp Leu Lys Thr Gly Lys Ser Glu Arg Ser Leu Leu Asp Phe Phe
770 775 780

<210> SEQ_ID NO 56
<211> LENGTH: 142
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 56

Met Lys Thr Phe Leu Thr Glu Gln Ile Lys Val Leu Met Leu Arg
1 5 10 15

Ala Lys Gly Tyr Lys Gln Ser Glu Ile Ala Lys Ile Leu Gly Thr Ser
20 25 30

Arg Ala Asn Val Ser Ile Leu Glu Lys Arg Ala Met Glu Lys Ile Glu
35 40 45

Lys Ala Arg Asn Thr Leu Leu Trp Glu Gln Ile Asn Ser Lys Val
50 55 60

Ile Val Glu Ile Lys Ala Gly Glu Asp Ile Phe Ser Ile Pro Glu Lys
65 70 75 80

Phe Phe Lys Lys Ala Asp Lys Val Gly Val Lys Val Pro Tyr Ser Thr
85 90 95

Ala Glu Ile Ile Thr Phe Leu Val Glu His Ala Pro Val Glu Asp Arg
100 105 110

Leu Ala Lys Arg Asp Phe Val Leu Phe Leu Asp Ser Lys Asn Lys Leu
115 120 125

Arg Ile Gly Asp Cys Leu Val Ile Glu Glu Ile Lys Glu Asp
130 135 140

<210> SEQ_ID NO 57

US 9,963,687 B2

171

172

-continued

<211> LENGTH: 75
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 57

Met	Pro	Ile	Thr	Lys	Val	Thr	Arg	Asn	Tyr	Gln	Ile	Thr	Ile	Pro	Ala
1															15
Glu	Ile	Arg	Lys	Ala	Leu	Gly	Ile	Lys	Glu	Gly	Glu	Leu	Leu	Glu	Val
															30
Arg	Leu	Glu	Asn	Gly	Lys	Ile	Ile	Glu	Arg	Leu	Lys	Glu	Glu	Arg	
															45
Lys	Thr	Leu	Lys	Leu	Gly	Lys	Lys	Leu	Thr	Leu	Glu	Glu	Ile	Glu	Lys
															60
Ala	Ile	Glu	Glu	Gly	Met	Lys	Gln	Cys	Met	Gln					
															75

<210> SEQ ID NO 58
<211> LENGTH: 76
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 58

Thr	Lys	Ile	Glu	Ile	Leu	Arg	Leu	Leu	Lys	Glu	Arg	Glu	Met	Tyr	Ala
1															15
Tyr	Glu	Ile	Trp	Ser	Leu	Leu	Gly	Lys	Pro	Leu	Lys	Tyr	Gln	Ala	Val
															30
His	Gln	His	Ile	Lys	Glu	Leu	Leu	Glu	Leu	Gly	Leu	Val	Glu	Gln	Ala
															45
Tyr	Arg	Lys	Gly	Lys	Arg	Val	Tyr	Tyr	Lys	Ile	Thr	Glu	Lys	Gly	Leu
															60
Arg	Ile	Leu	Gln	Asn	Phe	Glu	Asp	Leu	Glu	Asn	Ile				
															75

<210> SEQ ID NO 59
<211> LENGTH: 72
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 59

Met	Asn	Thr	Gly	Ala	Gln	Gly	Val	Ser	Glu	Met	Ser	Arg	Met	Lys	Ile
1															15
Ile	Ser	Val	Gln	Leu	Pro	Gln	Ser	Leu	Ile	His	Gly	Leu	Asp	Ala	Leu
															30
Val	Lys	Arg	Gly	Ile	Tyr	Pro	Asn	Arg	Ser	Glu	Ala	Ile	Arg	Val	Ala
															45
Ile	Arg	Glu	Leu	Leu	Lys	Lys	Glu	Leu	Tyr	Lys	Glu	Glu	Ile	Gln	Glu
															60
Glu	Ile	Pro	Glu	Tyr	Val	Val	Lys								
															70

<210> SEQ ID NO 60
<211> LENGTH: 67
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 60

Val	Ile	Ile	Pro	Arg	Pro	Ile	Asp	Pro	Arg	Asp	Ile	Arg	Arg	Ile	Arg
1															15
Lys	Glu	Leu	Gly	Ile	Thr	Gln	Glu	Glu	Leu	Ala	Arg	Lys	Ala	Gly	Val

US 9,963,687 B2

173**174**

-continued

20 25 30

Thr Gln Ala Tyr Ile Ala Lys Leu Glu Ala Gly Lys Val Asp Pro Arg
 35 40 45

Leu Ser Thr Phe Asn Lys Ile Leu Arg Ala Leu Ile Glu Cys Gln Lys
 50 55 60

Ala Lys Ile
 65

<210> SEQ ID NO 61
 <211> LENGTH: 65
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 61

Asn Asn Cys Glu Cys Met Val Val Lys Glu Lys Leu Tyr Thr Val Lys
 1 5 10 15

Gln Ala Ser Glu Ile Leu Gly Val His Pro Lys Thr Ile Gln Lys Trp
 20 25 30

Asp Arg Glu Gly Lys Ile Lys Thr Val Arg Thr Pro Gly Gly Arg Arg
 35 40 45

Arg Ile Pro Glu Ser Glu Ile Lys Arg Leu Leu Gly Ile Ser Glu Glu
 50 55 60

Lys
 65

<210> SEQ ID NO 62
 <211> LENGTH: 71
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 62

Met Leu Lys Asp Ser Ala Pro Lys Arg Lys Ile Leu Glu Glu Leu Arg
 1 5 10 15

Lys Gly Glu Thr Val Ser Gly Asp Tyr Leu Ala Ser Lys Leu Gly Val
 20 25 30

Ser Arg Val Ala Ile Trp Lys His Ile Arg Glu Leu Lys Glu Leu Gly
 35 40 45

Tyr Gly Ile Ile Ala Asp Lys Lys Gly Tyr Lys Leu Val Tyr Glu Pro
 50 55 60

Lys Lys Pro Tyr Pro Trp Glu
 65 70

<210> SEQ ID NO 63
 <211> LENGTH: 86
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 63

Met Ile Asp Glu Arg Asp Lys Ile Ile Leu Glu Ile Leu Glu Lys Asp
 1 5 10 15

Ala Arg Thr Pro Phe Thr Glu Ile Ala Lys Lys Leu Gly Ile Ser Glu
 20 25 30

Thr Ala Val Arg Lys Arg Val Lys Ala Leu Glu Glu Lys Gly Ile Ile
 35 40 45

Glu Gly Tyr Thr Ile Lys Ile Asn Pro Lys Lys Leu Gly Tyr Ser Leu
 50 55 60

Val Thr Ile Thr Gly Val Asp Thr Lys Pro Glu Lys Leu Phe Glu Val
 65 70 75 80

-continued

Ala Glu Lys Leu Lys Glu
85

<210> SEQ ID NO 64
<211> LENGTH: 77
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 64

Met	Glu	Ile	Asp	Asp	Leu	Asp	Arg	Lys	Ile	Leu	Ser	Leu	Leu	Ile	Glu
1									10						15

Asp	Ser	Arg	Leu	Ser	Tyr	Arg	Glu	Ile	Ala	Lys	Lys	Leu	Asn	Val	Ala
			20					25							30

Val	Gly	Thr	Ile	Tyr	Asn	Arg	Ile	Lys	Lys	Leu	Glu	Asp	Met	Gly	Val
	35				40										45

Ile	Gln	Gly	Phe	Thr	Val	Lys	Leu	Asn	Tyr	Glu	Lys	Leu	Gly	Tyr	Glu
	50					55									60

Leu	Thr	Ala	Ile	Ile	Gly	Ile	Lys	Ala	Gln	Gly	Lys	Lys			
65					70										

<210> SEQ ID NO 65
<211> LENGTH: 94
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 65

Glu	Met	Leu	Trp	Met	Tyr	Ile	Leu	Lys	Leu	Leu	Lys	Asp	Arg	Pro	Met
1									10						15

Tyr	Ala	Tyr	Glu	Ile	Arg	Asn	Glu	Leu	Lys	Lys	Arg	Phe	Gly	Phe	Glu
		20						25							30

Pro	Ala	Thr	Val	Ser	Ser	Tyr	Val	Val	Leu	Tyr	Arg	Leu	Glu	Gly	
							35		40						45

Gly	Tyr	Val	Ser	Ser	Glu	Trp	His	Glu	Ser	Glu	Ala	Gly	Arg	Pro	Ser
	50				55										60

Arg	Lys	Tyr	Tyr	Arg	Leu	Thr	Glu	Lys	Gly	Glu	Lys	Leu	Leu	Glu	Lys
65					70				75						80

Gly	Ile	Glu	Thr	Ile	Glu	Asp	Val	Leu	Asn	Met	Leu	Lys	Ser		
							85			90					

<210> SEQ ID NO 66
<211> LENGTH: 68
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus
<400> SEQUENCE: 66

Met	Lys	Val	Ser	Lys	Ala	Thr	Ala	Ser	Lys	Val	Leu	Arg	Ser	Leu	Glu
1										10					15

Asn	Lys	Gly	Ile	Val	Glu	Arg	Glu	Arg	Arg	Gly	Lys	Thr	Tyr	Leu	Val
			20					25							30

Arg	Leu	Thr	Asn	Lys	Gly	Leu	Glu	Leu	Glu	Glu	Ile	Ser	Lys	Ala	
						35		40							45

Gly	Lys	Glu	Leu	Asp	Glu	Lys	Ile	Phe	Ala	Glu	Met	Ser	Val	Asp	Glu
	50						55								60

Arg	Ile	Val	Leu												
65															

<210> SEQ ID NO 67
<211> LENGTH: 56

-continued

<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 67

```

Ser Glu Asp Tyr Met Leu Gln Asn Arg Arg Lys Val Leu Ala Lys Val
1           5          10          15

Leu Glu Leu Leu Asn Tyr Asn Pro Lys Ala Leu Asn Ile Ser Glu Leu
20          25          30

Ala Arg Met Phe Gly Val Ser Arg Asp Thr Ile Tyr Asn Asp Ile Gln
35          40          45

Gln Ile Ile Lys Asn Val Glu Val
50          55

```

<210> SEQ ID NO 68

<211> LENGTH: 94

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 68

```

Ser Lys Glu Ile Ser Arg Phe Leu Lys Val Ile Ser Asn Pro Ile Arg
1           5          10          15

Tyr Gly Ile Leu Lys Met Leu Asn Asp Arg Trp Met Cys Val Cys Leu
20          25          30

Ile Ser Glu Ala Leu Glu Ile Asp Gln Thr Leu Val Ser His His Ile
35          40          45

Arg Ile Leu Lys Glu Leu Asp Leu Leu Glu Arg Lys Glu Gly Lys
50          55          60

Leu Arg Phe Tyr Arg Thr Asn Lys Glu Lys Leu Arg Glu Tyr Leu Glu
65          70          75          80

Lys Val Leu Glu Asp Phe Asn His Gly Thr Ser Lys Gly Ser
85          90

```

<210> SEQ ID NO 69

<211> LENGTH: 78

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 69

```

Met Cys Arg Lys Asp Val Met Ile Ile Ser Asp Pro Lys Gln Ile Lys
1           5          10          15

Ala Leu Ser Asp Pro Thr Arg Val Lys Ile Leu Glu Leu Leu Arg Tyr
20          25          30

His Pro Met Thr Val Ser Glu Ile Ser Arg Val Ile Gly Lys Asp Lys
35          40          45

Ser Thr Ile Tyr Arg His Ile Lys Ala Leu Glu Ala Gly Leu Val
50          55          60

Glu Glu Val Glu Lys Ile Gly Asn Glu Thr Val Tyr Gly Arg
65          70          75

```

<210> SEQ ID NO 70

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 70

```

Met Glu Pro Val Glu Phe Lys Leu Asn Gln Lys Gly Ile Lys Ser Ile
1           5          10          15

Leu Pro Thr Met Glu Ala Glu Ile Met Glu Tyr Met Trp Glu Ile Lys
20          25          30

```

-continued

Glu Ala Thr Ala Gly Glu Val Tyr Glu Tyr Met Lys Thr Lys Tyr Pro
 35 40 45

Glu Ile Arg Arg Ser Thr Val Ser Ile Leu Met Asn Arg Leu Cys Glu
 50 55 60

Arg Gly Leu Leu Lys Arg Arg Met Glu Lys Gly Lys Gly Ile Arg
 65 70 75 80

Tyr Val Tyr Ser Ile Thr Thr Arg Glu Glu Phe Glu Arg Lys Val
 85 90 95

Val Glu Lys Ile Ile Glu Ser Leu Met Met Asn Phe Arg Glu Ala Thr
 100 105 110

Phe Ala Tyr Leu Ser Lys Ile Asn Lys Lys
 115 120

<210> SEQ ID NO 71

<211> LENGTH: 87

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 71

Met Lys Lys Ser Asn Leu Asp Leu Leu Ile Leu Leu Ala Lys Ala Gly
 1 5 10 15

Gly Ile Glu Lys Glu Ile Leu Thr Thr Ser Arg Glu Leu Ser Lys Met
 20 25 30

Leu Asn Val Ser Pro Gln Thr Ile Val Arg Trp Leu Glu Asp Leu Glu
 35 40 45

Lys Asp Gly Leu Ile Lys Lys Ser Glu Ser Arg Lys Gly Thr Leu Val
 50 55 60

Thr Ile Thr Glu Glu Gly Val Lys Phe Leu Glu Lys Leu His Glu Glu
 65 70 75 80

Leu Ser Asp Ala Leu Tyr Arg
 85

<210> SEQ ID NO 72

<211> LENGTH: 104

<212> TYPE: PRT

<213> ORGANISM: Thermococcaceae

<400> SEQUENCE: 72

Met Glu Ile Pro Pro Glu Ile Ser His Ala Leu Ser Glu Ile Gly Phe
 1 5 10 15

Thr Lys Tyr Glu Ile Leu Thr Tyr Trp Thr Leu Leu Val Tyr Gly Pro
 20 25 30

Ser Thr Ala Lys Glu Ile Ser Thr Lys Ser Gly Ile Pro Tyr Asn Arg
 35 40 45

Val Tyr Asp Thr Ile Ser Ser Leu Lys Leu Arg Gly Phe Val Thr Glu
 50 55 60

Ile Glu Gly Thr Pro Lys Val Tyr Ala Ala Tyr Ser Pro Arg Ile Ala
 65 70 75 80

Phe Phe Arg Phe Lys Lys Glu Leu Glu Asp Ile Met Lys Lys Leu Glu
 85 90 95

Ile Glu Leu Asn Asn Val Lys Lys
 100

<210> SEQ ID NO 73

<211> LENGTH: 75

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

US 9,963,687 B2

181**182**

-continued

<400> SEQUENCE: 73

Ile	Ile	Asn	Pro	Gln	Ala	Arg	Leu	Thr	Pro	Leu	Glu	Leu	Glu	Ile	Leu
1				5				10						15	

Glu	Ile	Ile	Lys	Gln	Lys	Lys	Ser	Ile	Thr	Ile	Thr	Glu	Ile	Lys	Glu
	20				25					30					

Ile	Leu	Ser	Glu	Arg	Arg	Lys	Ser	Glu	Tyr	Pro	Leu	Ser	Leu	Val	Ser
	35				40					45					

Glu	Tyr	Ile	Ser	Arg	Leu	Glu	Arg	Lys	Gly	Tyr	Val	Lys	Lys	Ile	Ala
	50				55				60						

Lys	Gly	Arg	Lys	Lys	Phe	Val	Glu	Ala	Leu	Ile					
65					70				75						

<210> SEQ_ID NO 74

<211> LENGTH: 94

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 74

Gly	Ile	Asp	Val	Val	Ile	Pro	Glu	Ile	Lys	His	Asp	Pro	Ile	Ala	Arg
1				5			10		15						

Asp	Ile	Val	Lys	Ile	Leu	Phe	Asp	Leu	Arg	Arg	Ala	Asn	Val	Ser	Gln
	20				25				30						

Ile	Ala	Arg	Glu	Leu	Lys	Gly	Arg	Arg	Gly	Lys	Ala	Ser	Arg	Asn	Thr
	35				40				45						

Val	Arg	Lys	Lys	Leu	Lys	Glu	Leu	Glu	Lys	Leu	Gly	Val	Val	Lys	Glu
	50				55			60							

Val	Pro	Gly	Glu	Arg	Gly	Ser	Val	Tyr	Thr	Leu	Ser	Arg	Glu	Val	Val
65				70			75		80						

Lys	Lys	Trp	Leu	Asp	Leu	Ile	Gly	Ile	Pro	Ile	Asn	Leu	Leu		
				85			90								

<210> SEQ_ID NO 75

<211> LENGTH: 67

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 75

Met	Thr	Lys	Arg	Val	Lys	Val	Ile	Thr	Asp	Pro	Glu	Val	Ile	Lys	Val
1				5			10		15						

Met	Leu	Glu	Asp	Thr	Arg	Arg	Lys	Ile	Leu	Gln	Leu	Leu	Arg	Asn	Arg
	20				25				30						

Glu	Met	Thr	Ile	Ser	Gln	Leu	Ser	Glu	Ile	Leu	Gly	Lys	Met	Pro	Gln
	35				40			45							

Thr	Ile	Tyr	His	His	Ile	Glu	Lys	Leu	Lys	Glu	Ala	Gly	Leu	Val	Glu
	50				55			60							

Val	Lys	Arg													
65															

<210> SEQ_ID NO 76

<211> LENGTH: 100

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 76

Met	Glu	Glu	Ile	Lys	Glu	Ile	Met	Lys	Ser	His	Thr	Leu	Gly	Asn	Pro
1				5			10		15						

Val	Arg	Leu	Gly	Ile	Met	Ile	Tyr	Leu	Phe	Pro	Arg	Arg	Ala	Pro	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	--

-continued

20 25 30

Phe Ser His Ile Gln Lys Ala Leu Asp Leu Thr Pro Gly Asn Leu Asp
35 40 45

Ser His Ile Lys Val Leu Glu Lys His Gly Phe Val Arg Thr Tyr Lys
50 55 60

Val Ile Ala Asp Arg Pro Arg Thr Met Val Glu Ile Thr Asp Tyr Gly
65 70 75 80

Met Glu Glu Thr Arg Lys Phe Leu Ser His Leu Lys Thr Val Ile Asp
85 90 95

Ala Ile His Phe
100

<210> SEQ ID NO 77

<211> LENGTH: 99

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 77

Met Gly Glu Glu Leu Asn Arg Leu Leu Asp Val Leu Gly Asn Glu Thr
1 5 10 15

Arg Arg Arg Ile Leu Phe Leu Leu Thr Lys Arg Pro Tyr Phe Val Ser
20 25 30

Glu Leu Ser Arg Glu Leu Gly Val Gly Gln Lys Ala Val Leu Glu His
35 40 45

Leu Arg Ile Leu Glu Glu Ala Gly Leu Ile Glu Ser Arg Val Glu Lys
50 55 60

Ile Pro Arg Gly Arg Pro Arg Lys Tyr Tyr Met Ile Lys Lys Gly Leu
65 70 75 80

Arg Leu Glu Ile Leu Leu Thr Pro Thr Leu Phe Gly Ser Glu Met Tyr
85 90 95

Glu Ala Lys

<210> SEQ ID NO 78

<211> LENGTH: 61

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 78

Met Arg Arg Met Asp Lys Val Asp Leu Gln Leu Ile Lys Ile Leu Ser
1 5 10 15

Gln Asn Ser Arg Leu Thr Tyr Arg Glu Leu Ala Glu Met Leu Gly Thr
20 25 30

Thr Arg Gln Arg Val Ala Arg Lys Val Asp Lys Leu Lys Lys Leu Gly
35 40 45

Ile Ile Arg Lys Phe Thr Ile Ile Pro Asn Leu Glu Lys
50 55 60

<210> SEQ ID NO 79

<211> LENGTH: 82

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 79

Gly Arg Lys Val Arg Thr Gln Gln Asn Glu Ile Leu Asn Leu Asn
1 5 10 15

Glu Lys Glu Lys Ala Val Leu Arg Ala Ile Leu Glu His Gly Gly Glu
20 25 30

-continued

Ile Lys Gln Glu Asp Leu Pro Glu Leu Val Gly Tyr Ser Arg Pro Thr
 35 40 45

Ile Ser Lys Val Ile Gln Glu Leu Glu Asn Lys Gly Leu Ile Lys Arg
 50 55 60

Glu Lys Ser Gly Lys Thr Phe Val Val Lys Ile Glu Arg Lys Ile Lys
 65 70 75 80

Leu Asp

<210> SEQ ID NO 80

<211> LENGTH: 59

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 80

Lys Ser Leu Gln Arg Phe Leu Arg Arg Asn Thr Thr Ser Ile Lys His
 1 5 10 15

Leu Ser Glu Ile Thr Gly Val Ala Arg Asn Arg Leu Ser Asp Ile Leu
 20 25 30

Asn Gly Lys Thr Gln Lys Ile Arg Gly Glu Thr Leu Arg Lys Ile Ala
 35 40 45

Lys Ala Phe Glu Lys Ser Asn Ile Leu Ser Phe
 50 55

<210> SEQ ID NO 81

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Thermotoga

<400> SEQUENCE: 81

Asp Val Ile Gln Arg Ile Lys Glu Lys Tyr Asp Glu Phe Thr Asn Ala
 1 5 10 15

Glu Lys Lys Ile Ala Asp Thr Ile Leu Ser Asp Pro Lys Gly Ile Ile
 20 25 30

Glu Ser Ser Ile Ser Asp Leu Ser Glu Lys Ala Gly Val Lys Ser Glu
 35 40 45

Ala Ser Val Val Lys Phe Tyr Lys Lys Leu Gly Leu Asn Ser Phe Gln
 50 55 60

Gln Phe Lys Val Leu Ala Gln Ser Ile Ser Arg Ala Pro Leu Glu
 65 70 75 80

Ile Val Tyr Glu Asp Val Ser Ser Glu Asp Asp Thr Lys Thr Ile Thr
 85 90 95

Glu Lys Ile Phe Lys Ala Thr Val Arg Ala Ile
 100 105

<210> SEQ ID NO 82

<211> LENGTH: 101

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 82

Lys Ile Arg Asp Lys Ile Leu Asn Val Tyr Thr Gln Phe Ser Pro Ala
 1 5 10 15

Glu Arg Lys Val Ala Asp Tyr Val Leu Glu Arg Pro Asp Asp Val Ile
 20 25 30

His Tyr Ser Ile Thr Glu Phe Ala Lys Ile Val Gly Val Ser Glu Thr
 35 40 45

Thr Ile His Arg Met Ile Lys Lys Leu Asp Phe Glu Gly Tyr Gln Ala
 50 55 60

-continued

Phe Lys Ile Ala Leu Ala Arg Glu Leu Ser Gly Leu Glu Glu Thr Ile
 65 70 75 80
 Glu Arg Arg Asp Phe Ile Asp Glu Glu Ile Asp Ile Leu Arg Arg Leu
 85 90 95
 Lys Asp Thr Leu Asp
 100

<210> SEQ ID NO 83
<211> LENGTH: 60
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima
<400> SEQUENCE: 83

Lys Arg Arg Pro Thr Ile Asn Asp Val Ala Lys Leu Ala Gly Val Ser
 1 5 10 15
 Ile Ser Thr Val Ser Arg Tyr Leu Lys Asp Pro Ser Gln Val Ser Glu
 20 25 30
 Lys Leu Gly Glu Arg Ile Arg Glu Ala Ile Lys Lys Leu Gly Tyr Lys
 35 40 45
 Pro Asn Lys Ile Ala Gln Gly Leu Arg Thr Gly Asp
 50 55 60

<210> SEQ ID NO 84
<211> LENGTH: 58
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima
<400> SEQUENCE: 84

Met Ala Ser Ile Lys Asp Val Ala Lys Leu Ala Gly Val Ser Ile Ala
 1 5 10 15
 Thr Val Ser Arg Val Ile Asn Gly Tyr Asn Asn Val Ser Glu Glu Thr
 20 25 30
 Arg Lys Lys Val Ile Asp Ala Ile Arg Lys Leu Asn Tyr His Pro Val
 35 40 45
 Tyr Ala Val Lys Gly Ala Val Leu Lys Arg
 50 55

<210> SEQ ID NO 85
<211> LENGTH: 61
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima
<400> SEQUENCE: 85

Met Lys Lys Tyr Val Thr Ile Arg Asp Ile Ala Glu Lys Ala Gly
 1 5 10 15
 Val Ser Ile Asn Thr Val Ser Arg Ala Leu Asn Asn Lys Pro Asp Ile
 20 25 30
 Ser Glu Glu Thr Arg Arg Lys Ile Leu Lys Ile Ala Gln Glu Leu Gly
 35 40 45
 Tyr Val Lys Asn Ala Thr Ala Ser Ser Leu Arg Ser Lys
 50 55 60

<210> SEQ ID NO 86
<211> LENGTH: 58
<212> TYPE: PRT
<213> ORGANISM: Thermotoga
<400> SEQUENCE: 86

Met Pro Thr Ile Glu Asp Val Ala Lys Leu Ala Gly Val Ser Ile Ala

US 9,963,687 B2

189**190**

-continued

1	5	10	15
Thr Val Ser Arg Val Ile Asn Gly Ser Gly Tyr Val Ser Glu Lys Thr			
20	25	30	
Arg Tyr Lys Val Trp Lys Ala Ile Glu Glu Leu Gly Tyr Lys Pro Glu			
35	40	45	
Ile Ser Ala Lys Leu Leu Ala Ser Lys Gly			
50	55		

<210> SEQ ID NO 87
<211> LENGTH: 61
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 87

Met Arg Ile Gly Glu Lys Leu Arg Lys Leu Arg Leu Ser Arg Gly Leu			
1	5	10	15
Thr Gln Glu Glu Leu Ala Glu Arg Thr Asp Leu Ser Arg Ser Phe Ile			
20	25	30	
Ser Gln Leu Glu Ser Asp Lys Thr Ser Pro Ser Ile Asp Thr Leu Glu			
35	40	45	
Arg Ile Leu Glu Ala Leu Gly Thr Asp Leu Lys His Phe			
50	55	60	

<210> SEQ ID NO 88
<211> LENGTH: 67
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 88

Met His Met Lys Thr Val Arg Gln Glu Arg Leu Lys Ser Ile Val Arg			
1	5	10	15
Ile Leu Glu Arg Ser Lys Glu Pro Val Ser Gly Ala Gln Leu Ala Glu			
20	25	30	
Glu Leu Ser Val Ser Arg Gln Val Ile Val Gln Asp Ile Ala Tyr Leu			
35	40	45	
Arg Ser Leu Gly Tyr Asn Ile Val Ala Thr Pro Arg Gly Tyr Val Leu			
50	55	60	
Ala Gly Gly			
65			

<210> SEQ ID NO 89
<211> LENGTH: 75
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 89

Met Asn Thr Leu Lys Lys Ala Phe Glu Ile Leu Asp Phe Ile Val Lys			
1	5	10	15
Asn Pro Gly Asp Val Ser Val Glu Ile Ala Glu Lys Phe Asn Met			
20	25	30	
Ser Val Ser Asn Ala Tyr Lys Tyr Met Val Val Leu Glu Lys Gly			
35	40	45	
Phe Val Leu Arg Lys Lys Asp Lys Arg Tyr Val Pro Gly Tyr Lys Leu			
50	55	60	
Ile Glu Tyr Gly Ser Phe Val Leu Arg Arg Phe			
65	70	75	

<210> SEQ ID NO 90

US 9,963,687 B2

191**192**

-continued

<211> LENGTH: 81
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 90

Met	Lys	Ile	Ser	Lys	Lys	Arg	Arg	Gln	Glu	Leu	Ile	Arg	Lys	Ile	Ile
1				5				10				15			

His	Glu	Lys	Lys	Ile	Ser	Asn	Gln	Phe	Gln	Ile	Val	Glu	Glu	Leu	Lys
	20					25				30					

Lys	Tyr	Gly	Ile	Lys	Ala	Val	Gln	Pro	Thr	Val	Ala	Arg	Asp	Leu	Lys
	35					40				45					

Glu	Ile	Gly	Ala	Val	Lys	Ile	Met	Asp	Glu	Ser	Gly	Asn	Tyr	Val	Tyr
	50				55				60						

Lys	Leu	Leu	Asp	Glu	Thr	Pro	Val	Ile	Asp	Pro	Trp	Lys	Glu	Leu	Lys
65				70				75				80			

Arg

<210> SEQ ID NO 91
<211> LENGTH: 82
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 91

Met	His	Lys	Lys	Leu	Asn	Pro	Lys	Ser	Met	Lys	Arg	Glu	Asn	Lys	Lys
1				5				10			15				

Met	Val	Leu	Arg	Tyr	Leu	Ile	Glu	Ser	Gly	Pro	His	Ser	Arg	Val	Glu
	20					25				30					

Ile	Ala	Arg	Lys	Thr	Gly	Leu	Ala	Gln	Ser	Ala	Ile	Trp	Arg	Ile	Ile
	35				40				45						

Glu	Glu	Leu	Val	Asn	Glu	Gly	Leu	Val	Glu	Glu	Lys	Gly	Thr	Ala	Thr
	50				55				60						

Gly	Arg	Arg	Arg	Lys	Ala	Val	Thr	Tyr	Gly	Pro	Thr	Arg	Ser	Phe	Ile
65				70				75			80				

Thr Ser

<210> SEQ ID NO 92
<211> LENGTH: 79
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 92

Met	Pro	Ser	Pro	Leu	Leu	Arg	Arg	Glu	Asn	Lys	Ile	Lys	Ile	Leu	Arg
1				5				10			15				

Tyr	Ile	Leu	Lys	Asn	Gly	Lys	Thr	Thr	Arg	Asn	Gln	Leu	Ala	Ser	Asn
	20				25				30						

Leu	Asn	Leu	Ala	His	Ser	Thr	Leu	Ser	Tyr	Ile	Ile	Asp	Glu	Leu	Leu
	35				40				45						

Asp	Glu	Gly	Phe	Leu	Val	Phe	Glu	Glu	Ile	Lys	Lys	Lys	Arg	Gly	Arg
	50				55				60						

Pro	Tyr	Gln	Ile	Leu	Ser	Val	Asn	Pro	Glu	Lys	Phe	Thr	Ala	Ile	
65				70				75							

<210> SEQ ID NO 93
<211> LENGTH: 79
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 93

-continued

Met Lys Glu Glu Arg Leu Lys Glu Ile Leu Asp Ile Val Asp Arg Asn
 1 5 10 15

Gly Phe Ile Ser Met Lys Asp Leu Gln Glu Gln Leu Gly Val Ser Met
 20 25 30

Ile Thr Val Arg Arg Asp Val Ala Glu Leu Val Lys Arg Asn Leu Val
 35 40 45

Lys Lys Val His Gly Gly Ile Arg Lys Val Asn Tyr Phe Glu Lys Glu
 50 55 60

Thr Asp Phe Met Lys Arg Leu Ser Ile Asn Arg Glu Ala Lys Glu
 65 70 75

<210> SEQ ID NO 94
 <211> LENGTH: 137
 <212> TYPE: PRT
 <213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 94

Met Phe Thr Met Arg Ser Glu Tyr Ala Leu Arg Leu Met Ile Val Met
 1 5 10 15

Ala Lys Glu Tyr Gly Asn Tyr Leu Ser Met Thr Glu Ile Leu Glu Lys
 20 25 30

Ala Lys Gln Ser Val Pro Arg Glu Phe Ala Glu Lys Ile Leu Tyr Thr
 35 40 45

Leu Lys Lys Ala Gly Leu Val Lys Thr Arg Arg Gly Lys Ser Gly Gly
 50 55 60

Tyr Met Leu Ser Arg Pro Pro Lys Glu Ile Lys Val Ser Glu Ile Val
 65 70 75 80

Phe Leu Leu Asp Arg Lys Ser Lys Val Phe Phe Asp Met Pro Gly Cys
 85 90 95

Pro Asp Glu Leu Asp Cys Val Ile Arg Ala Leu Trp Lys Arg Val Glu
 100 105 110

Asn Glu Ile Glu Lys Ile Leu Ser Gly Val Thr Leu Glu Asp Leu Val
 115 120 125

Arg Glu Gln Glu Glu Lys Met Lys Gln
 130 135

<210> SEQ ID NO 95
 <211> LENGTH: 95
 <212> TYPE: PRT
 <213> ORGANISM: Thermotoga naphthophila

<400> SEQUENCE: 95

Met Arg Asp Thr Lys Gly His Leu Lys Phe Leu Val Leu His Ile Ile
 1 5 10 15

Ser Gln Gln Pro Ser His Gly Tyr Tyr Ile Met Lys Lys Ile Ser Gln
 20 25 30

Ile Ile Gly Ala Glu Pro Pro Ser Pro Gly Ala Leu Tyr Pro Ile Leu
 35 40 45

Ser Ser Leu Arg Lys Gln Lys Tyr Ile Glu Thr Tyr Asn Glu Gly Lys
 50 55 60

Arg Lys Val Tyr Arg Leu Thr Asp Lys Gly Arg Lys Tyr Leu Glu Glu
 65 70 75 80

His Lys Glu Glu Ile Lys Lys Ala Leu Asp Phe Ala Glu Arg Phe
 85 90 95

<210> SEQ ID NO 96
 <211> LENGTH: 118

US 9,963,687 B2

195**196**

-continued

<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 96

```

Met Arg His Arg Gly Gly Arg Gly Phe Arg Gly Trp Trp Leu Ala Ser
1           5          10          15

Thr Ile Leu Leu Leu Val Ala Glu Lys Pro Ser His Gly Tyr Glu Leu
20          25          30

Ala Glu Arg Leu Ala Glu Phe Gly Ile Glu Ile Pro Gly Ile Gly His
35          40          45

Met Gly Asn Ile Tyr Arg Val Leu Ala Asp Leu Glu Glu Ser Gly Phe
50          55          60

Leu Ser Thr Glu Trp Asp Thr Thr Val Ser Pro Pro Arg Lys Ile Tyr
65          70          75          80

Arg Ile Thr Pro Gln Gly Lys Leu Tyr Leu Arg Glu Ile Leu Arg Ser
85          90          95

Leu Glu Asp Met Lys Arg Arg Ile Glu Thr Leu Glu Glu Arg Ile Lys
100         105         110

Arg Val Leu Gln Glu Glu
115

```

<210> SEQ ID NO 97
<211> LENGTH: 70
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 97

```

Met Leu Ser Lys Arg Asp Ala Ile Leu Lys Ala Ala Val Glu Val Phe
1           5          10          15

Gly Lys Lys Gly Tyr Asp Arg Ala Thr Thr Asp Glu Ile Ala Glu Lys
20          25          30

Ala Gly Val Ala Lys Gly Leu Ile Phe His Tyr Phe Lys Asn Lys Glu
35          40          45

Glu Leu Tyr Tyr Gln Ala Tyr Met Ser Val Thr Glu Lys Leu Gln Lys
50          55          60

Glu Phe Glu Asn Phe Leu
65          70

```

<210> SEQ ID NO 98
<211> LENGTH: 291
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 98

```

Met Ser Lys Ser Trp Gly Lys Phe Ile Glu Glu Glu Ala Glu Met
1           5          10          15

Ala Ser Arg Arg Asn Leu Met Ile Val Asp Gly Thr Asn Leu Gly Phe
20          25          30

Arg Phe Lys His Asn Asn Ser Lys Lys Pro Phe Ala Ser Ser Tyr Val
35          40          45

Ser Thr Ile Gln Ser Leu Ala Lys Ser Tyr Ser Ala Arg Thr Thr Ile
50          55          60

Val Leu Gly Asp Lys Gly Lys Ser Val Phe Arg Leu Glu His Leu Pro
65          70          75          80

Glu Tyr Lys Gly Asn Arg Asp Glu Lys Tyr Ala Gln Arg Thr Glu Glu
85          90          95

```

US 9,963,687 B2

197**198**

-continued

Glu Lys Ala Leu Asp Glu Gln Phe Phe Glu Tyr Leu Lys Asp Ala Phe
100 105 110

Glu Leu Cys Lys Thr Thr Phe Pro Thr Phe Thr Ile Arg Gly Val Glu
115 120 125

Ala Asp Asp Met Ala Ala Tyr Ile Val Lys Leu Ile Gly His Leu Tyr
130 135 140

Asp His Val Trp Leu Ile Ser Thr Asp Gly Asp Trp Asp Thr Leu Leu
145 150 155 160

Thr Asp Lys Val Ser Arg Phe Ser Phe Thr Thr Arg Arg Glu Tyr His
165 170 175

Leu Arg Asp Met Tyr Glu His His Asn Val Asp Asp Val Glu Gln Phe
180 185 190

Ile Ser Leu Lys Ala Ile Met Gly Asp Leu Gly Asp Asn Ile Arg Gly
195 200 205

Val Glu Gly Ile Gly Ala Lys Arg Gly Tyr Asn Ile Ile Arg Glu Phe
210 215 220

Gly Asn Val Leu Asp Ile Ile Asp Gln Leu Pro Leu Pro Gly Lys Gln
225 230 235 240

Lys Tyr Ile Gln Asn Leu Asn Ala Ser Glu Glu Leu Leu Phe Arg Asn
245 250 255

Leu Ile Leu Val Asp Leu Pro Thr Tyr Cys Val Asp Ala Ile Ala Ala
260 265 270

Val Gly Gln Asp Val Leu Asp Lys Phe Thr Lys Asp Ile Leu Glu Ile
275 280 285

Ala Glu Gln
290

<210> SEQ ID NO 99
<211> LENGTH: 53
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (17)..(37)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 99

tttctagctc taaaacnnnn nnnnnnnnnn nnnnnnnncgg tgtttcgtcc ttt 53

<210> SEQ ID NO 100
<211> LENGTH: 148
<212> TYPE: PRT
<213> ORGANISM: Sulfolobus solfataricus

<400> SEQUENCE: 100

Met Glu Glu Lys Val Gly Asn Leu Lys Pro Asn Met Glu Ser Val Asn
1 5 10 15Val Thr Val Arg Val Leu Glu Ala Ser Glu Ala Arg Gln Ile Gln Thr
20 25 30Lys Asn Gly Val Arg Thr Ile Ser Glu Ala Ile Val Gly Asp Glu Thr
35 40 45Gly Arg Val Lys Leu Thr Leu Trp Gly Lys His Ala Gly Ser Ile Lys
50 55 60Glu Gly Gln Val Val Lys Ile Glu Asn Ala Trp Thr Thr Ala Phe Lys
65 70 75 80

US 9,963,687 B2

199**200**

-continued

Gly	Gln	Val	Gln	Leu	Asn	Ala	Gly	Ser	Lys	Thr	Lys	Ile	Ala	Glu	Ala
				85				90							95

Ser	Glu	Asp	Gly	Phe	Pro	Glu	Ser	Ser	Gln	Ile	Pro	Glu	Asn	Thr	Pro
				100				105							110

Thr	Ala	Pro	Gln	Gln	Met	Arg	Gly	Gly	Gly	Arg	Gly	Phe	Arg	Gly	Gly
					115		120								125

Gly	Arg	Arg	Tyr	Gly	Arg	Arg	Gly	Gly	Arg	Arg	Gln	Glu	Asn	Glu	Glu
					130		135								140

Gly	Glu	Glu	Glu												
					145										

<210> SEQ ID NO 101

<211> LENGTH: 673

<212> TYPE: PRT

<213> ORGANISM: Thermus thermophilus

<400> SEQUENCE: 101

Met	Thr	Leu	Glu	Glu	Ala	Arg	Lys	Arg	Val	Asn	Glu	Leu	Arg	Asp	Leu
1									5						15

Ile	Arg	Tyr	His	Asn	Tyr	Arg	Tyr	Tyr	Val	Leu	Ala	Asp	Pro	Ile	Ser
									20						30

Asp	Ala	Glu	Tyr	Asp	Arg	Leu	Leu	Arg	Glu	Leu	Lys	Glu	Leu	Glu	Glu
									35						45

Arg	Phe	Pro	Glu	Leu	Lys	Ser	Pro	Asp	Ser	Pro	Thr	Leu	Gln	Val	Gly
									50						60

Ala	Arg	Pro	Leu	Glu	Ala	Thr	Phe	Arg	Pro	Val	Arg	His	Pro	Thr	Arg
									65						80

Met	Tyr	Ser	Leu	Asp	Asn	Ala	Phe	Asn	Leu	Asp	Glu	Leu	Lys	Ala	Phe
									85						95

Glu	Glu	Arg	Ile	Glu	Arg	Ala	Leu	Gly	Arg	Lys	Gly	Pro	Phe	Ala	Tyr
									100						110

Thr	Val	Glu	His	Lys	Val	Asp	Gly	Leu	Ser	Val	Asn	Leu	Tyr	Tyr	Glu
									115						125

Glu	Gly	Val	Leu	Val	Tyr	Gly	Ala	Thr	Arg	Gly	Asp	Gly	Glu	Val	Gly
									130						140

Glu	Glu	Val	Thr	Gln	Asn	Leu	Leu	Thr	Ile	Pro	Thr	Ile	Pro	Arg	Arg
									145						160

Leu	Lys	Gly	Val	Pro	Glu	Arg	Leu	Glu	Val	Arg	Gly	Glu	Met	Pro	Ile
									165						175

Glu	Ala	Phe	Leu	Arg	Leu	Asn	Glu	Glu	Leu	Glu	Glu	Arg	Gly	Glu	Arg
									180						190

Ile	Phe	Lys	Asn	Pro	Arg	Asn	Ala	Ala	Ala	Gly	Ser	Leu	Arg	Gln	Lys
									195						205

Asp	Pro	Arg	Ile	Thr	Ala	Lys	Arg	Gly	Leu	Arg	Ala	Thr	Phe	Tyr	Ala
									210						220

Leu	Gly	Leu	Gly	Leu	Glu	Val	Glu	Arg	Glu	Gly	Val	Ala	Thr	Gln	
									225						240

Phe	Ala	Leu	Leu	His	Trp	Leu	Lys	Glu	Lys	Gly	Phe	Pro	Val	Glu	His
									245						255

Gly	Tyr	Ala	Arg	Ala	Val	Gly	Ala	Glu	Gly	Val	Glu	Ala	Val	Tyr	Gln
									260						270

Asp	Trp	Leu	Lys	Lys	Arg	Arg	Ala	Leu	Pro	Phe	Glu	Ala	Asp	Gly	Val
									275						285

Val	Val	Lys	Leu	Asp	Glu	Leu	Ala	Leu	Trp	Arg	Glu	Leu	Gly	Tyr	Thr
									290						300

US 9,963,687 B2

201

202

-continued

Ala Arg Ala Pro Arg Phe Ala Ile Ala Tyr Lys Phe Pro Ala Glu Glu
 305 310 315 320
 Lys Glu Thr Arg Leu Leu Asp Val Val Phe Gln Val Gly Arg Thr Gly
 325 330 335
 Arg Val Thr Pro Val Gly Ile Leu Glu Pro Val Phe Leu Glu Gly Ser
 340 345 350
 Glu Val Ser Arg Val Thr Leu His Asn Glu Ser Tyr Ile Glu Glu Leu
 355 360 365
 Asp Ile Arg Ile Gly Asp Trp Val Leu Val His Lys Ala Gly Gly Val
 370 375 380
 Ile Pro Glu Val Leu Arg Val Leu Lys Glu Arg Arg Thr Gly Glu Glu
 385 390 395 400
 Arg Pro Ile Arg Trp Pro Glu Thr Cys Pro Glu Cys Gly His Arg Leu
 405 410 415
 Leu Lys Glu Gly Lys Val His Arg Cys Pro Asn Pro Leu Cys Pro Ala
 420 425 430
 Lys Arg Phe Glu Ala Ile Arg His Phe Ala Ser Arg Lys Ala Met Asp
 435 440 445
 Ile Gln Gly Leu Gly Glu Lys Leu Ile Glu Arg Leu Leu Glu Lys Gly
 450 455 460
 Leu Val Lys Asp Val Ala Asp Leu Tyr Arg Leu Arg Lys Glu Asp Leu
 465 470 475 480
 Val Gly Leu Glu Arg Met Gly Glu Lys Ser Ala Gln Asn Leu Leu Arg
 485 490 495
 Gln Ile Glu Glu Ser Lys Lys Arg Gly Leu Glu Arg Leu Leu Tyr Ala
 500 505 510
 Leu Gly Leu Pro Gly Val Gly Glu Val Leu Ala Arg Asn Leu Ala Ala
 515 520 525
 Arg Phe Gly Asn Met Asp Arg Leu Leu Glu Ala Ser Leu Glu Glu Leu
 530 535 540
 Leu Glu Val Glu Val Gly Glu Leu Thr Ala Arg Ala Ile Leu Glu
 545 550 555 560
 Thr Leu Lys Asp Pro Ala Phe Arg Asp Leu Val Arg Arg Leu Lys Glu
 565 570 575
 Ala Gly Val Glu Met Glu Ala Lys Glu Lys Gly Glu Ala Leu Lys
 580 585 590
 Gly Leu Thr Phe Val Ile Thr Gly Glu Leu Ser Arg Pro Arg Glu Glu
 595 600 605
 Val Lys Ala Leu Leu Arg Arg Leu Gly Ala Lys Val Thr Asp Ser Val
 610 615 620
 Ser Arg Lys Thr Ser Tyr Leu Val Val Gly Glu Asn Pro Gly Ser Lys
 625 630 635 640
 Leu Glu Lys Ala Arg Ala Leu Gly Val Pro Thr Leu Thr Glu Glu Glu
 645 650 655
 Leu Tyr Arg Leu Leu Glu Ala Arg Thr Gly Lys Lys Ala Glu Glu Leu
 660 665 670
 Val

```

<210> SEQ ID NO 102
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
  
```

-continued

<400> SEQUENCE: 102

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
 20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45

Asp Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Lys Val Val Arg
 50 55 60

Val Val Asp Val Glu Lys Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile
 85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125

Met Glu Gly Asn Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Val
 165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
 180 185 190

Arg Phe Leu Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu
 275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly
 385 390 395 400

Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr

US 9,963,687 B2

205**206**

-continued

405	410	415
His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr		
420	425	430
Asp Val Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly		
435	440	445
Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Asp Glu Arg Gln Lys Ile		
450	455	460
Lys Arg Arg Met Lys Ala Ser Lys Asp Pro Ile Glu Arg Lys Leu Leu		
465	470	475
Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly		
485	490	495
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu		
500	505	510
Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Leu Val Arg Arg Glu		
515	520	525
Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu		
530	535	540
Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg		
545	550	555
Ala Leu Glu Phe Val Asn Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu		
565	570	575
Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys		
580	585	590
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly		
595	600	605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
610	615	620
Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala		
625	630	635
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile		
645	650	655
Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn		
660	665	670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala		
675	680	685
Ala Arg Gly Ile Lys Val Arg Pro Gly Met Val Ile Gly Tyr Val Val		
690	695	700
Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ala Glu Glu		
705	710	715
Phe Asp Pro Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn		
725	730	735
Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg		
740	745	750
Lys Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala		
755	760	765
Trp Leu Lys Val Lys Lys Ser		
770	775	

<210> SEQ ID NO 103

<211> LENGTH: 10

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

-continued

<400> SEQUENCE: 103

ggccgcaacc 10

<210> SEQ ID NO 104
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 104

ggccgcgaat at 12

<210> SEQ ID NO 105
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 105

ggccgcattc at 12

<210> SEQ ID NO 106
<211> LENGTH: 148
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 106

cgtaacttga aagtatttcg atttcttggc tttatataatc ttgtggaaag gacgaaacac 60
cggcgaagaa cctcttccca agagtttag agctagaaat agcaaggtaa aataaggcta 120
gtccgttatac aacttgaaaa agtggcac 148

<210> SEQ ID NO 107
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (27)..(47)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 107

taacttgcta tttctagctc taaaacnnnn nnnnnnnnnn nnnnnnnncgg tgtttgcgtcc 60
tttccacaag ata 73

<210> SEQ ID NO 108
<211> LENGTH: 104
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 108

Met Gly Arg Asp Lys Lys Asn Thr Ala Leu Leu Asp Ile Ala Arg Asp
1 5 10 15Ile Gly Gly Asp Glu Ala Val Glu Val Val Lys Ala Leu Glu Lys Lys
20 25 30Gly Glu Ala Thr Asp Glu Glu Leu Ala Glu Leu Thr Gly Val Arg Val
35 40 45

-continued

Asn	Thr	Val	Arg	Lys	Ile	Leu	Tyr	Ala	Leu	Tyr	Asp	Ala	Lys	Leu	Ala
50					55			60							

Thr	Phe	Arg	Arg	Val	Arg	Asp	Asp	Glu	Thr	Gly	Trp	Tyr	Tyr	Tyr	Tyr
65					70			75			80				

Trp	Arg	Ile	Asp	Thr	Lys	Arg	Leu	Pro	Glu	Val	Ile	Arg	Thr	Arg	Lys
					85			90			95				

Leu	Gln	Glu	Leu	Glu	Lys	Leu	Lys								
					100										

<210> SEQ ID NO 109
<211> LENGTH: 66
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 109

Met	Arg	Gly	Thr	Val	Lys	Trp	Phe	Asp	Ser	Lys	Lys	Gly	Tyr	Gly	Phe
1					5			10				15			

Ile	Thr	Met	Glu	Asn	Gly	Glu	Asp	Ile	Phe	Val	His	Trp	Ser	Ala	Ile
					20			25			30				

Gln	Met	Asp	Gly	Phe	Lys	Thr	Leu	Arg	Glu	Asn	Glu	Thr	Val	Glu	Phe
					35			40			45				

Glu	Val	Gln	Lys	Gly	Thr	Lys	Gly	Pro	Gln	Ala	Val	Asn	Val	Arg	Pro
					50			55			60				

Val	Arg														
	65														

<210> SEQ ID NO 110
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 110

Met	Arg	Arg	Leu	Asn	Arg	Lys	Asn	Asn	Glu	Ala	Leu	Lys	Lys	Leu	Asn
1					5			10			15				

Asp	Arg	Gln	Arg	Lys	Val	Leu	Tyr	Cys	Ile	Val	Arg	Glu	Tyr	Ile	Glu
					20			25			30				

Asn	Lys	Pro	Val	Ser	Ser	Gln	Arg	Val	Leu	Glu	Val	Ser	Asn	Ile	
					35			40			45				

Glu	Phe	Ser	Ser	Ala	Thr	Ile	Arg	Asn	Asp	Met	Lys	Lys	Leu	Glu	Tyr
					50			55			60				

Leu	Gly	Tyr	Ile	Tyr	Gln	Pro	His	Thr	Ser	Ala	Gly	Arg	Ile	Pro	Thr
					65			70			75			80	

Asp	Lys	Gly	Leu	Arg	Phe	Tyr	Tyr	Glu	Glu	Met	Leu	Lys	Ile	Ser	Lys
					85			90			95				

Glu

<210> SEQ ID NO 111
<211> LENGTH: 68
<212> TYPE: PRT
<213> ORGANISM: Thermotoga Maritima

<400> SEQUENCE: 111

Met	Pro	Lys	Ser	Val	Arg	Ala	Glu	Asn	Ile	Ser	Arg	Ile	Leu	Lys	Arg
1					5			10			15				

Ile	Met	Lys	Ser	Pro	Val	Ser	Arg	Val	Glu	Leu	Ala	Glu	Glu	Leu	Gly
					20			25			30				

Leu	Thr	Lys	Thr	Thr	Val	Gly	Glu	Ile	Ala	Lys	Ile	Phe	Leu	Glu	Lys
					35			40			45				

-continued

Gly Ile Val Val Glu Glu Lys Asp Ser Pro Lys Gly Val Gly Arg Pro
50 55 60

Thr Lys Ser Leu
65

<210> SEQ ID NO 112

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Thermotoga maritima

<400> SEQUENCE: 112

Ile Thr Ala Leu Asn Tyr Leu Lys Glu His Phe Asn Glu Ser Val Asn
1 5 10 15

Met Lys Arg Leu Ala Glu Met Val Gly Met Ser Val Ser Thr Phe Tyr
20 25 30

Gln Asn Phe Lys Ile Leu Thr Gly Met Thr Pro Leu Gln Tyr Gln Lys
35 40 45

Lys Leu Arg Leu Cys Glu Ala Arg Lys Leu Leu Met Ala Gly Ser Asp
50 55 60

Val Thr Thr Ala Ala Tyr Gln Val Gly Tyr Glu Ser Leu Ser Gln Phe
65 70 75 80

Ser Arg Glu Tyr Lys Arg Phe Phe Gly Val Ser Pro Ser Gln Asp Ala
85 90 95

Lys Lys Leu Lys Glu Glu Pro Tyr Thr Arg Ile Leu Tyr
100 105

<210> SEQ ID NO 113

<211> LENGTH: 849

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 113

Met Ile Lys Ala Trp Leu Leu Asp Val Asp Tyr Val Thr Glu Asn Asp
1 5 10 15

Arg Ala Val Ile Arg Leu Trp Cys Lys Asp Asp Lys Gly Val Phe Val
20 25 30

Ala Tyr Asp Arg Asn Phe Leu Pro Tyr Phe Tyr Val Ile Gly Cys Lys
35 40 45

Ala Glu Asp Val Met Lys Val Lys Val Arg Thr Asn Glu Gly Ile Ile
50 55 60

Thr Pro Leu Lys Val Glu Glu Ile Glu Ala Lys Ser Leu Gly Lys Pro
65 70 75 80

Ile Lys Ala Leu Lys Val Tyr Thr Arg His Pro Gln His Val Pro Lys
85 90 95

Leu Arg Glu Glu Ile Lys Lys Phe Ala Glu Val Arg Glu Ala Asp Ile
100 105 110

Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys Met Asp
115 120 125

Gly Ile Glu Ile Glu Pro Ile Ala Val Lys Glu Gly Val Leu Arg Ala
130 135 140

Tyr Glu Val Arg Ser Val Arg Arg Val Glu Lys Lys Gly Phe Pro Asp
145 150 155 160

Leu Lys Ile Leu Ala Phe Asp Cys Glu Met Leu Ala Gln Phe Met Pro
165 170 175

-continued

Asp Pro Glu Lys Asp Pro Ile Ile Ala Ile Ala Val Lys Cys Gly Asp
 180 185 190
 Phe Glu Glu Val Leu His Gly Asp Glu Arg Asp Ile Leu Arg Arg Phe
 195 200 205
 Val Ser Ile Ile Lys Glu Gln Asp Pro Asp Ile Ile Val Gly Tyr Asn
 210 215 220
 Gln Asp Asn Phe Asp Trp Pro Tyr Val Lys Lys Arg Ala Glu Lys Phe
 225 230 235 240
 Gly Ile Arg Leu Asp Ile Gly Arg Asp Arg Ser Glu Ile Ser Phe Arg
 245 250 255
 Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp Leu Tyr Asp
 260 265 270
 Ile Ala Leu Lys Ile Pro Asp Val Lys Ile Lys Thr Leu Lys Lys Val
 275 280 285
 Ala Glu Phe Leu Gly Ala Lys Val Glu Glu Asp Ile Glu Gly Arg
 290 295 300
 Asp Ile Tyr Lys Cys Trp Met Arg Gly Glu Lys Glu Lys Val Phe Lys
 305 310 315 320
 His Val Leu Asn Asp Val Leu Thr Thr Tyr Arg Leu Ala Leu Glu Leu
 325 330 335
 Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Leu Pro Leu Asp
 340 345 350
 Asp Val Ala Arg Leu Gly Arg Gly Lys Gln Val Asp Tyr Phe Leu Leu
 355 360 365
 Ser Glu Ala Lys Lys Ile Asn Glu Ile Ala Pro Asn Pro Pro Glu Ile
 370 375 380
 Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ala Arg Gly Leu
 385 390 395 400
 His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr Pro Ser Ile
 405 410 415
 Met Ile Asn Phe Asn Ile Ser Pro Asp Thr Leu Val Lys Gly Glu Cys
 420 425 430
 Glu Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg Lys Ser
 435 440 445
 Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu Lys Arg
 450 455 460
 Arg Glu Met Lys Arg Gln Met Lys Glu Leu Asp Pro Asp Ser Glu Asp
 465 470 475 480
 Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr Asn
 485 490 495
 Ser Phe Tyr Gly Tyr Thr Gly Trp Asn Leu Ala Arg Trp Tyr Cys Arg
 500 505 510
 Glu Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg Tyr Phe Ile Lys Arg
 515 520 525
 Ala Val Lys Ile Ala Glu Ser Met Gly Phe Glu Val Leu Tyr Gly Asp
 530 535 540
 Thr Asp Ser Leu Phe Ile Lys Lys Asn Lys Leu Asn Leu Lys Asp Leu
 545 550 555 560
 Glu Lys Glu Cys Leu Lys Leu Ile Asp Val Ile Ser Lys Glu Leu Pro
 565 570 575
 Ile Gln Leu Glu Ile Asp Glu Phe Tyr Lys Ala Ile Phe Phe Val Glu
 580 585 590
 Lys Lys Arg Tyr Ala Gly Leu Thr Asp Asp Asp Arg Ile Val Val Lys

US 9,963,687 B2

215

-continued

595	600	605
Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Arg Val		
610	615	620
Gln Arg Glu Val Ile Glu Ile Ile Leu Arg Glu Arg Asn Pro Asp Lys		
625	630	635
640		
Ala Leu Lys Phe Val Lys Asn Val Ile Glu Glu Ile Lys Glu Gly Lys		
645	650	655
Phe Lys Leu Glu Asp Tyr Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro		
660	665	670
Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu Arg Ala		
675	680	685
Met Glu Met Gly Ile Tyr Tyr Pro Ile Gly Thr Lys Val Gly Phe Val		
690	695	700
Ile Val Lys Gly Gly Ser Ile Ser Asp Arg Ala Tyr Pro Ile Glu		
705	710	715
720		
Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Lys Ile Arg Thr Pro Ser		
725	730	735
Gly Ile Met Val Lys Lys Ile Asp Lys Asp Tyr Tyr Ile Asp His Gln		
740	745	750
Ile Ile Pro Ala Val Met Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu		
755	760	765
Ala Ser Leu Lys Thr Thr Ile Gln Lys Thr Leu Phe Asp Phe Thr Gly		
770	775	780
Thr Gly Gly Gly Lys Arg Arg Pro Thr Ile Asn Asp Val Ala Lys		
785	790	795
800		
Leu Ala Gly Val Ser Ile Ser Thr Val Ser Arg Tyr Leu Lys Asp Pro		
805	810	815
Ser Gln Val Ser Glu Lys Leu Gly Glu Arg Ile Arg Glu Ala Ile Lys		
820	825	830
Lys Leu Gly Tyr Lys Pro Asn Lys Ile Ala Gln Gly Leu Arg Thr Gly		
835	840	845

Asp

<210> SEQ_ID NO 114
<211> LENGTH: 846
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<400> SEQUENCE: 114

Met Ile Lys Ala Trp Leu Leu Asp Val Asp Tyr Val Thr Glu Asn Asp		
1	5	10
15		
Arg Ala Val Ile Arg Leu Trp Cys Lys Asp Asp Lys Gly Val Phe Val		
20	25	30
30		
Ala Tyr Asp Arg Asn Phe Leu Pro Tyr Phe Tyr Val Ile Gly Cys Lys		
35	40	45
45		
Ala Glu Asp Val Met Lys Val Lys Val Arg Thr Asn Glu Gly Ile Ile		
50	55	60
60		
Thr Pro Leu Lys Val Glu Glu Ile Glu Ala Lys Ser Leu Gly Lys Pro		
65	70	75
80		
Ile Lys Ala Leu Lys Val Tyr Thr Arg His Pro Gln His Val Pro Lys		
85	90	95
95		
Lys Leu Arg Glu Glu Ile Lys Lys Phe Ala Glu Val Arg Glu Ala Asp Ile		
100	105	110

-continued

Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys Met Asp
 115 120 125
 Gly Ile Glu Ile Glu Pro Ile Ala Val Lys Glu Gly Val Leu Arg Ala
 130 135 140
 Tyr Glu Val Arg Ser Val Arg Arg Val Glu Lys Lys Gly Phe Pro Asp
 145 150 155 160
 Leu Lys Ile Leu Ala Phe Asp Cys Glu Met Leu Ala Gln Phe Met Pro
 165 170 175
 Asp Pro Glu Lys Asp Pro Ile Ile Ala Ile Ala Val Lys Cys Gly Asp
 180 185 190
 Phe Glu Glu Val Leu His Gly Asp Glu Arg Asp Ile Leu Arg Arg Phe
 195 200 205
 Val Ser Ile Ile Lys Glu Gln Asp Pro Asp Ile Ile Val Gly Tyr Asn
 210 215 220
 Gln Asp Asn Phe Asp Trp Pro Tyr Val Lys Lys Arg Ala Glu Lys Phe
 225 230 235 240
 Gly Ile Arg Leu Asp Ile Gly Arg Asp Arg Ser Glu Ile Ser Phe Arg
 245 250 255
 Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp Leu Tyr Asp
 260 265 270
 Ile Ala Leu Lys Ile Pro Asp Val Lys Ile Lys Thr Leu Lys Lys Val
 275 280 285
 Ala Glu Phe Leu Gly Ala Lys Val Glu Glu Asp Ile Glu Gly Arg
 290 295 300
 Asp Ile Tyr Lys Cys Trp Met Arg Gly Glu Lys Glu Lys Val Phe Lys
 305 310 315 320
 His Val Leu Asn Asp Val Leu Thr Thr Tyr Arg Leu Ala Leu Glu Leu
 325 330 335
 Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Leu Pro Leu Asp
 340 345 350
 Asp Val Ala Arg Leu Gly Arg Gly Lys Gln Val Asp Tyr Phe Leu Leu
 355 360 365
 Ser Glu Ala Lys Lys Ile Asn Glu Ile Ala Pro Asn Pro Pro Glu Ile
 370 375 380
 Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ala Arg Gly Leu
 385 390 395 400
 His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr Pro Ser Ile
 405 410 415
 Met Ile Asn Phe Asn Ile Ser Pro Asp Thr Leu Val Lys Gly Glu Cys
 420 425 430
 Glu Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg Lys Ser
 435 440 445
 Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu Lys Arg
 450 455 460
 Arg Glu Met Lys Arg Gln Met Lys Glu Leu Asp Pro Asp Ser Glu Asp
 465 470 475 480
 Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr Asn
 485 490 495
 Ser Phe Tyr Gly Tyr Thr Gly Trp Asn Leu Ala Arg Trp Tyr Cys Arg
 500 505 510
 Glu Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg Tyr Phe Ile Lys Arg
 515 520 525

-continued

Ala Val Lys Ile Ala Glu Ser Met Gly Phe Glu Val Leu Tyr Gly Asp
530 535 540

Thr Asp Ser Leu Phe Ile Lys Lys Asn Lys Leu Asn Leu Lys Asp Leu
545 550 555 560

Glu Lys Glu Cys Leu Lys Leu Ile Asp Val Ile Ser Lys Glu Leu Pro
565 570 575

Ile Gln Leu Glu Ile Asp Glu Phe Tyr Lys Ala Ile Phe Phe Val Glu
580 585 590

Lys Lys Arg Tyr Ala Gly Leu Thr Asp Asp Asp Arg Ile Val Val Lys
595 600 605

Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Arg Val
610 615 620

Gln Arg Glu Val Ile Glu Ile Leu Arg Glu Arg Asn Pro Asp Lys
625 630 635 640

Ala Leu Lys Phe Val Lys Asn Val Ile Glu Glu Ile Lys Glu Gly Lys
645 650 655

Phe Lys Leu Glu Asp Tyr Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro
660 665 670

Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu Arg Ala
675 680 685

Met Glu Met Gly Ile Tyr Tyr Pro Ile Gly Thr Lys Val Gly Phe Val
690 695 700

Ile Val Lys Gly Gly Ser Ile Ser Asp Arg Ala Tyr Pro Ile Glu
705 710 715 720

Leu Ile Glu Phe Asp Gly Glu Asn Leu Lys Ile Arg Thr Pro Ser
725 730 735

Gly Ile Met Val Lys Lys Ile Asp Lys Asp Tyr Tyr Ile Asp His Gln
740 745 750

Ile Ile Pro Ala Val Met Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu
755 760 765

Ala Ser Leu Lys Thr Thr Ile Gln Lys Thr Leu Phe Asp Phe Thr Gly
770 775 780

Thr Gly Gly Gly Ala Ser Ile Lys Asp Val Ala Lys Leu Ala Gly
785 790 795 800

Val Ser Ile Ala Thr Val Ser Arg Val Ile Asn Gly Tyr Asn Asn Val
805 810 815

Ser Glu Glu Thr Arg Lys Lys Val Ile Asp Ala Ile Arg Lys Leu Asn
820 825 830

Tyr His Pro Val Tyr Ala Val Lys Gly Ala Val Leu Lys Arg
835 840 845

<210> SEQ ID NO 115

<211> LENGTH: 888

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 115

Met Ile Lys Ala Trp Leu Leu Asp Val Asp Tyr Val Thr Glu Asn Asp
1 5 10 15

Arg Ala Val Ile Arg Leu Trp Cys Lys Asp Asp Lys Gly Val Phe Val
20 25 30

Ala Tyr Asp Arg Asn Phe Leu Pro Tyr Phe Tyr Val Ile Gly Cys Lys
35 40 45

-continued

Ala Glu Asp Val Met Lys Val Lys Val Arg Thr Asn Glu Gly Ile Ile
 50 55 60

Thr Pro Leu Lys Val Glu Glu Ile Glu Ala Lys Ser Leu Gly Lys Pro
 65 70 75 80

Ile Lys Ala Leu Lys Val Tyr Thr Arg His Pro Gln His Val Pro Lys
 85 90 95

Leu Arg Glu Glu Ile Lys Lys Phe Ala Glu Val Arg Glu Ala Asp Ile
 100 105 110

Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys Met Asp
 115 120 125

Gly Ile Glu Ile Glu Pro Ile Ala Val Lys Glu Gly Val Leu Arg Ala
 130 135 140

Tyr Glu Val Arg Ser Val Arg Arg Val Glu Lys Lys Gly Phe Pro Asp
 145 150 155 160

Leu Lys Ile Leu Ala Phe Asp Cys Glu Met Leu Ala Gln Phe Met Pro
 165 170 175

Asp Pro Glu Lys Asp Pro Ile Ile Ala Ile Ala Val Lys Cys Gly Asp
 180 185 190

Phe Glu Glu Val Leu His Gly Asp Glu Arg Asp Ile Leu Arg Arg Phe
 195 200 205

Val Ser Ile Ile Lys Glu Gln Asp Pro Asp Ile Ile Val Gly Tyr Asn
 210 215 220

Gln Asp Asn Phe Asp Trp Pro Tyr Val Lys Lys Arg Ala Glu Lys Phe
 225 230 235 240

Gly Ile Arg Leu Asp Ile Gly Arg Asp Arg Ser Glu Ile Ser Phe Arg
 245 250 255

Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp Leu Tyr Asp
 260 265 270

Ile Ala Leu Lys Ile Pro Asp Val Lys Ile Lys Thr Leu Lys Lys Val
 275 280 285

Ala Glu Phe Leu Gly Ala Lys Val Glu Glu Asp Ile Glu Gly Arg
 290 295 300

Asp Ile Tyr Lys Cys Trp Met Arg Gly Glu Lys Val Phe Lys
 305 310 315 320

His Val Leu Asn Asp Val Leu Thr Thr Tyr Arg Leu Ala Leu Glu Leu
 325 330 335

Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Leu Pro Leu Asp
 340 345 350

Asp Val Ala Arg Leu Gly Arg Gly Lys Gln Val Asp Tyr Phe Leu Leu
 355 360 365

Ser Glu Ala Lys Lys Ile Asn Glu Ile Ala Pro Asn Pro Pro Glu Ile
 370 375 380

Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ala Arg Gly Leu
 385 390 395 400

His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr Pro Ser Ile
 405 410 415

Met Ile Asn Phe Asn Ile Ser Pro Asp Thr Leu Val Lys Gly Glu Cys
 420 425 430

Glu Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg Lys Ser
 435 440 445

Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu Lys Arg
 450 455 460

Arg Glu Met Lys Arg Gln Met Lys Glu Leu Asp Pro Asp Ser Glu Asp

US 9,963,687 B2

223

224

-continued

465	470	475	480
Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr Asn			
485	490	495	
Ser Phe Tyr Gly Tyr Thr Gly Trp Asn Leu Ala Arg Trp Tyr Cys Arg			
500	505	510	
Glu Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg Tyr Phe Ile Lys Arg			
515	520	525	
Ala Val Lys Ile Ala Glu Ser Met Gly Phe Glu Val Leu Tyr Gly Asp			
530	535	540	
Thr Asp Ser Leu Phe Ile Lys Lys Asn Lys Leu Asn Leu Lys Asp Leu			
545	550	555	560
Glu Lys Glu Cys Leu Lys Leu Ile Asp Val Ile Ser Lys Glu Leu Pro			
565	570	575	
Ile Gln Leu Glu Ile Asp Glu Phe Tyr Lys Ala Ile Phe Phe Val Glu			
580	585	590	
Lys Lys Arg Tyr Ala Gly Leu Thr Asp Asp Asp Arg Ile Val Val Lys			
595	600	605	
Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Arg Val			
610	615	620	
Gln Arg Glu Val Ile Glu Ile Ile Leu Arg Glu Arg Asn Pro Asp Lys			
625	630	635	640
Ala Leu Lys Phe Val Lys Asn Val Ile Glu Glu Ile Lys Glu Gly Lys			
645	650	655	
Phe Lys Leu Glu Asp Tyr Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro			
660	665	670	
Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu Arg Ala			
675	680	685	
Met Glu Met Gly Ile Tyr Tyr Pro Ile Gly Thr Lys Val Gly Phe Val			
690	695	700	
Ile Val Lys Gly Gly Ser Ile Ser Asp Arg Ala Tyr Pro Ile Glu			
705	710	715	720
Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Lys Ile Arg Thr Pro Ser			
725	730	735	
Gly Ile Met Val Lys Lys Ile Asp Lys Asp Tyr Tyr Ile Asp His Gln			
740	745	750	
Ile Ile Pro Ala Val Met Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu			
755	760	765	
Ala Ser Leu Lys Thr Thr Ile Gln Lys Thr Leu Phe Asp Phe Thr Gly			
770	775	780	
Thr Gly Gly Gly Glu Glu Ile Lys Glu Ile Met Lys Ser His Thr			
785	790	795	800
Leu Gly Asn Pro Val Arg Leu Gly Ile Met Ile Tyr Leu Phe Pro Arg			
805	810	815	
Arg Arg Ala Pro Phe Ser His Ile Gln Lys Ala Leu Asp Leu Thr Pro			
820	825	830	
Gly Asn Leu Asp Ser His Ile Lys Val Leu Glu Lys His Gly Phe Val			
835	840	845	
Arg Thr Tyr Lys Val Ile Ala Asp Arg Pro Arg Thr Met Val Glu Ile			
850	855	860	
Thr Asp Tyr Gly Met Glu Glu Thr Arg Lys Phe Leu Ser His Leu Lys			
865	870	875	880
Thr Val Ile Asp Ala Ile His Phe			
885			

-continued

<210> SEQ_ID NO 116
 <211> LENGTH: 959
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic construct

 <400> SEQUENCE: 116

 Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala
 1 5 10 15

 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly Ile Pro Thr
 20 25 30

 Asn Ala Thr Tyr Gly Val Ala Arg Met Leu Val Arg Phe Ile Lys Asp
 35 40 45

 His Ile Ile Val Gly Lys Asp Tyr Val Ala Val Ala Phe Asp Lys Lys
 50 55 60

 Ala Ala Thr Phe Arg His Lys Leu Leu Glu Thr Tyr Lys Ala Gln Arg
 65 70 75 80

 Pro Lys Thr Pro Asp Leu Leu Ile Gln Gln Leu Pro Tyr Ile Lys Lys
 85 90 95

 Leu Val Glu Ala Leu Gly Met Lys Val Leu Glu Val Glu Gly Tyr Glu
 100 105 110

 Ala Asp Asp Ile Ile Ala Thr Leu Ala Val Lys Gly Leu Pro Leu Phe
 115 120 125

 Asp Glu Ile Phe Ile Val Thr Gly Asp Lys Asp Met Leu Gln Leu Val
 130 135 140

 Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu
 145 150 155 160

 Glu Leu Tyr Asp Ala Gln Lys Val Lys Glu Lys Tyr Gly Val Glu Pro
 165 170 175

 Gln Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Glu Ile Asp Asn
 180 185 190

 Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu
 195 200 205

 Glu Lys Tyr Lys Asp Leu Glu Asp Ile Leu Asn His Val Arg Glu Leu
 210 215 220

 Pro Gln Lys Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Asn Ala Ile
 225 230 235 240

 Leu Ser Lys Leu Ala Ile Leu Glu Thr Asn Val Pro Ile Glu Ile
 245 250 255

 Asn Trp Glu Glu Leu Arg Tyr Gln Gly Tyr Asp Arg Glu Lys Leu Leu
 260 265 270

 Pro Leu Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln
 275 280 285

 Leu Tyr Glu Glu Ser Glu Pro Val Gly Tyr Arg Ile Val Lys Asp Leu
 290 295 300

 Val Glu Phe Glu Lys Leu Ile Glu Lys Leu Arg Glu Ser Pro Ser Phe
 305 310 315 320

 Ala Ile Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asp Cys Asp Ile
 325 330 335

 Val Gly Ile Ser Val Ser Phe Lys Pro Lys Glu Ala Tyr Tyr Ile Pro
 340 345 350

 Leu His His Arg Asn Ala Gln Asn Leu Asp Glu Lys Glu Val Leu Lys
 355 360 365

Lys Leu Lys Glu Ile Leu Glu Asp Pro Gly Ala Lys Ile Val Gly Gln
 370 375 380
 Asn Leu Lys Phe Asp Tyr Lys Val Leu Met Val Lys Gly Val Glu Pro
 385 390 395 400
 Val Pro Pro His Phe Asp Thr Met Ile Ala Ala Tyr Leu Leu Glu Pro
 405 410 415
 Asn Glu Lys Lys Phe Asn Leu Asp Asp Leu Ala Leu Lys Phe Leu Gly
 420 425 430
 Tyr Lys Met Thr Ser Tyr Gln Glu Leu Met Ser Phe Ser Ser Pro Leu
 435 440 445
 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Glu Lys Ala Ala Asn Tyr
 450 455 460
 Ser Cys Glu Asp Ala Asp Ile Thr Tyr Arg Leu Tyr Lys Ile Leu Ser
 465 470 475 480
 Leu Lys Leu His Glu Ala Asp Leu Glu Asn Val Phe Tyr Lys Ile Glu
 485 490 495
 Met Pro Leu Val Ser Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr
 500 505 510
 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys
 515 520 525
 Leu Glu Glu Leu Ala Glu Glu Ile Tyr Arg Ile Ala Gly Glu Pro Phe
 530 535 540
 Asn Ile Asn Ser Pro Lys Gln Val Ser Arg Ile Leu Phe Glu Lys Leu
 545 550 555 560
 Gly Ile Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Asp Tyr Ser Thr
 565 570 575
 Arg Ile Glu Val Leu Glu Glu Leu Ala Gly Glu His Glu Ile Ile Pro
 580 585 590
 Leu Ile Leu Glu Tyr Arg Lys Ile Gln Lys Leu Lys Ser Thr Tyr Ile
 595 600 605
 Asp Ala Leu Pro Lys Met Val Asn Pro Lys Thr Gly Arg Ile His Ala
 610 615 620
 Ser Phe Asn Gln Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
 625 630 635 640
 Pro Asn Leu Gln Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu Ile
 645 650 655
 Arg Lys Ala Ile Val Pro Gln Asp Pro Asn Trp Trp Ile Val Ser Ala
 660 665 670
 Asp Tyr Ser Gln Ile Glu Leu Arg Ile Leu Ala His Leu Ser Gly Asp
 675 680 685
 Glu Asn Leu Leu Lys Ala Phe Glu Glu Gly Ile Asp Val His Thr Leu
 690 695 700
 Thr Ala Ser Arg Ile Phe Asn Val Lys Pro Glu Glu Val Thr Glu Glu
 705 710 715 720
 Met Arg Arg Ala Gly Lys Met Val Asn Phe Ser Ile Ile Tyr Gly Val
 725 730 735
 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly Val Pro Val Lys Glu Ala
 740 745 750
 Glu Lys Met Ile Val Asn Tyr Phe Val Leu Tyr Pro Lys Val Arg Asp
 755 760 765
 Tyr Ile Gln Arg Val Val Ser Glu Ala Lys Glu Lys Gly Tyr Val Arg
 770 775 780

US 9,963,687 B2

229**230**

-continued

Thr Leu Phe Gly Arg Lys Arg Asp Ile Pro Gln Leu Met Ala Arg Asp
 785 790 795 800
 Arg Asn Thr Gln Ala Glu Gly Glu Arg Ile Ala Ile Asn Thr Pro Ile
 805 810 815
 Gln Gly Thr Ala Ala Asp Ile Ile Lys Leu Ala Met Ile Glu Ile Asp
 820 825 830
 Arg Glu Leu Lys Glu Arg Lys Met Arg Ser Lys Met Ile Ile Gln Val
 835 840 845
 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Asp Ala Leu
 850 855 860
 Val Glu Leu Val Lys Asp Arg Met Thr Asn Val Val Lys Leu Ser Val
 865 870 875 880
 Pro Leu Glu Val Asp Val Thr Ile Gly Lys Thr Trp Ser Gly Thr Gly
 885 890 895
 Gly Gly Lys Arg Arg Pro Thr Ile Asn Asp Val Ala Lys Leu Ala
 900 905 910
 Gly Val Ser Ile Ser Thr Val Ser Arg Tyr Leu Lys Asp Pro Ser Gln
 915 920 925
 Val Ser Glu Lys Leu Gly Glu Arg Ile Arg Glu Ala Ile Lys Lys Leu
 930 935 940
 Gly Tyr Lys Pro Asn Lys Ile Ala Gln Gly Leu Arg Thr Gly Asp
 945 950 955

<210> SEQ ID NO 117
 <211> LENGTH: 848
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 117

Met Ile Lys Ala Trp Leu Leu Asp Val Asp Tyr Val Thr Glu Asn Asp
 1 5 10 15
 Arg Ala Val Ile Arg Leu Trp Cys Lys Asp Asp Lys Gly Val Phe Val
 20 25 30
 Ala Tyr Asp Arg Asn Phe Leu Pro Tyr Phe Tyr Val Ile Gly Cys Lys
 35 40 45
 Ala Glu Asp Val Met Lys Val Lys Val Arg Thr Asn Glu Gly Ile Ile
 50 55 60
 Thr Pro Leu Lys Val Glu Glu Ile Glu Ala Lys Ser Leu Gly Lys Pro
 65 70 75 80
 Ile Lys Ala Leu Lys Val Tyr Thr Arg His Pro Gln His Val Pro Lys
 85 90 95
 Leu Arg Glu Glu Ile Lys Lys Phe Ala Glu Val Arg Glu Ala Asp Ile
 100 105 110
 Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys Met Asp
 115 120 125
 Gly Ile Glu Ile Glu Pro Ile Ala Val Lys Glu Gly Val Leu Arg Ala
 130 135 140
 Tyr Glu Val Arg Ser Val Arg Arg Val Glu Lys Lys Gly Phe Pro Asp
 145 150 155 160
 Leu Lys Ile Leu Ala Phe Asp Cys Glu Met Leu Ala Gln Phe Met Pro
 165 170 175
 Asp Pro Glu Lys Asp Pro Ile Ile Ala Ile Ala Val Lys Cys Gly Asp
 180 185 190

-continued

Phe Glu Glu Val Leu His Gly Asp Glu Arg Asp Ile Leu Arg Arg Phe
195 200 205

Val Ser Ile Ile Lys Glu Gln Asp Pro Asp Ile Ile Val Gly Tyr Asn
210 215 220

Gln Asp Asn Phe Asp Trp Pro Tyr Val Lys Lys Arg Ala Glu Lys Phe
225 230 235 240

Gly Ile Arg Leu Asp Ile Gly Arg Asp Arg Ser Glu Ile Ser Phe Arg
245 250 255

Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp Leu Tyr Asp
260 265 270

Ile Ala Leu Lys Ile Pro Asp Val Lys Ile Lys Thr Leu Lys Lys Val
275 280 285

Ala Glu Phe Leu Gly Ala Lys Val Glu Glu Asp Ile Glu Gly Arg
290 295 300

Asp Ile Tyr Lys Cys Trp Met Arg Gly Glu Lys Glu Lys Val Phe Lys
305 310 315 320

His Val Leu Asn Asp Val Leu Thr Thr Tyr Arg Leu Ala Leu Glu Leu
325 330 335

Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Leu Pro Leu Asp
340 345 350

Asp Val Ala Arg Leu Gly Arg Gly Lys Gln Val Asp Tyr Phe Leu Leu
355 360 365

Ser Glu Ala Lys Lys Ile Asn Glu Ile Ala Pro Asn Pro Pro Glu Ile
370 375 380

Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ala Arg Gly Leu
385 390 395 400

His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr Pro Ser Ile
405 410 415

Met Ile Asn Phe Asn Ile Ser Pro Asp Thr Leu Val Lys Gly Glu Cys
420 425 430

Glu Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg Lys Ser
435 440 445

Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu Lys Arg
450 455 460

Arg Glu Met Lys Arg Gln Met Lys Glu Leu Asp Pro Asp Ser Glu Asp
465 470 475 480

Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr Asn
485 490 495

Ser Phe Tyr Gly Tyr Thr Gly Trp Asn Leu Ala Arg Trp Tyr Cys Arg
500 505 510

Glu Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg Tyr Phe Ile Lys Arg
515 520 525

Ala Val Lys Ile Ala Glu Ser Met Gly Phe Glu Val Leu Tyr Gly Asp
530 535 540

Thr Asp Ser Leu Phe Ile Lys Lys Asn Lys Leu Asn Leu Lys Asp Leu
545 550 555 560

Glu Lys Glu Cys Leu Lys Leu Ile Asp Val Ile Ser Lys Glu Leu Pro
565 570 575

Ile Gln Leu Glu Ile Asp Glu Phe Tyr Lys Ala Ile Phe Phe Val Glu
580 585 590

Lys Lys Arg Tyr Ala Gly Leu Thr Asp Asp Asp Arg Ile Val Val Lys
595 600 605

Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Arg Val

-continued

610	615	620
Gln Arg Glu Val Ile Glu Ile Ile Leu Arg Glu Arg Asn Pro Asp Lys		
625	630	635
640		
Ala Leu Lys Phe Val Lys Asn Val Ile Glu Glu Ile Lys Glu Gly Lys		
645	650	655
Phe Lys Leu Glu Asp Tyr Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro		
660	665	670
Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu Arg Ala		
675	680	685
Met Glu Met Gly Ile Tyr Tyr Pro Ile Gly Thr Lys Val Gly Phe Val		
690	695	700
Ile Val Lys Gly Gly Ser Ile Ser Asp Arg Ala Tyr Pro Ile Glu		
705	710	715
720		
Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Lys Ile Arg Thr Pro Ser		
725	730	735
Gly Ile Met Val Lys Lys Ile Asp Lys Asp Tyr Tyr Ile Asp His Gln		
740	745	750
Ile Ile Pro Ala Val Met Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu		
755	760	765
Ala Ser Leu Lys Thr Thr Ile Gln Lys Thr Leu Phe Asp Phe Thr Gly		
770	775	780
Thr Gly Gly Gly Lys Ser Leu Gln Arg Phe Leu Arg Arg Asn Thr		
785	790	795
800		
Thr Ser Ile Lys His Leu Ser Glu Ile Thr Gly Val Ala Arg Asn Arg		
805	810	815
Leu Ser Asp Ile Leu Asn Gly Lys Thr Gln Lys Ile Arg Gly Glu Thr		
820	825	830
Leu Arg Lys Ile Ala Lys Ala Phe Glu Lys Ser Asn Ile Leu Ser Phe		
835	840	845

<210> SEQ_ID NO 118
<211> LENGTH: 998
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct
<400> SEQUENCE: 118

Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala		
1	5	10
15		
Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly Ile Pro Thr		
20	25	30
Asn Ala Thr Tyr Gly Val Ala Arg Met Leu Val Arg Phe Ile Lys Asp		
35	40	45
His Ile Ile Val Gly Lys Asp Tyr Val Ala Val Ala Phe Asp Lys Lys		
50	55	60
Ala Ala Thr Phe Arg His Lys Leu Leu Glu Thr Tyr Lys Ala Gln Arg		
65	70	75
80		
Pro Lys Thr Pro Asp Leu Leu Ile Gln Gln Leu Pro Tyr Ile Lys Lys		
85	90	95
Leu Val Glu Ala Leu Gly Met Lys Val Leu Glu Val Glu Gly Tyr Glu		
100	105	110
Ala Asp Asp Ile Ile Ala Thr Leu Ala Val Lys Gly Leu Pro Leu Phe		
115	120	125
Asp Glu Ile Phe Ile Val Thr Gly Asp Lys Asp Met Leu Gln Leu Val		

US 9,963,687 B2

235

-continued

130	135	140
Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu		
145	150	155
Glu Leu Tyr Asp Ala Gln Lys Val Lys Glu Lys Tyr Gly Val Glu Pro		
165	170	175
Gln Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Glu Ile Asp Asn		
180	185	190
Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu		
195	200	205
Glu Lys Tyr Lys Asp Leu Glu Asp Ile Leu Asn His Val Arg Glu Leu		
210	215	220
Pro Gln Lys Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Asn Ala Ile		
225	230	235
Leu Ser Lys Leu Ala Ile Leu Glu Thr Asn Val Pro Ile Glu Ile		
245	250	255
Asn Trp Glu Leu Arg Tyr Gln Gly Tyr Asp Arg Glu Lys Leu Leu		
260	265	270
Pro Leu Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln		
275	280	285
Leu Tyr Glu Glu Ser Glu Pro Val Gly Tyr Arg Ile Val Lys Asp Leu		
290	295	300
Val Glu Phe Glu Lys Leu Ile Glu Lys Leu Arg Glu Ser Pro Ser Phe		
305	310	315
Ala Ile Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asp Cys Asp Ile		
325	330	335
Val Gly Ile Ser Val Ser Phe Lys Pro Lys Glu Ala Tyr Tyr Ile Pro		
340	345	350
Leu His His Arg Asn Ala Gln Asn Leu Asp Glu Lys Glu Val Leu Lys		
355	360	365
Lys Leu Lys Glu Ile Leu Glu Asp Pro Gly Ala Lys Ile Val Gly Gln		
370	375	380
Asn Leu Lys Phe Asp Tyr Lys Val Leu Met Val Lys Gly Val Glu Pro		
385	390	395
Val Pro Pro His Phe Asp Thr Met Ile Ala Ala Tyr Leu Glu Pro		
405	410	415
Asn Glu Lys Phe Asn Leu Asp Asp Leu Ala Leu Lys Phe Leu Gly		
420	425	430
Tyr Lys Met Thr Ser Tyr Gln Glu Leu Met Ser Phe Ser Ser Pro Leu		
435	440	445
Phe Gly Phe Ser Phe Ala Asp Val Pro Val Glu Lys Ala Ala Asn Tyr		
450	455	460
Ser Cys Glu Asp Ala Asp Ile Thr Tyr Arg Leu Tyr Lys Ile Leu Ser		
465	470	475
480		
Leu Lys Leu His Glu Ala Asp Leu Glu Asn Val Phe Tyr Lys Ile Glu		
485	490	495
Met Pro Leu Val Ser Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr		
500	505	510
Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys		
515	520	525
Leu Glu Glu Leu Ala Glu Glu Ile Tyr Arg Ile Ala Gly Glu Pro Phe		
530	535	540
Asn Ile Asn Ser Pro Lys Gln Val Ser Arg Ile Leu Phe Glu Lys Leu		
545	550	555
560		

-continued

Gly Ile Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Asp Tyr Ser Thr
565 570 575

Arg Ile Glu Val Leu Glu Glu Leu Ala Gly Glu His Glu Ile Ile Pro
580 585 590

Leu Ile Leu Glu Tyr Arg Lys Ile Gln Lys Leu Lys Ser Thr Tyr Ile
595 600 605

Asp Ala Leu Pro Lys Met Val Asn Pro Lys Thr Gly Arg Ile His Ala
610 615 620

Ser Phe Asn Gln Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp
625 630 635 640

Pro Asn Leu Gln Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu Ile
645 650 655

Arg Lys Ala Ile Val Pro Gln Asp Pro Asn Trp Trp Ile Val Ser Ala
660 665 670

Asp Tyr Ser Gln Ile Glu Leu Arg Ile Leu Ala His Leu Ser Gly Asp
675 680 685

Glu Asn Leu Leu Lys Ala Phe Glu Glu Gly Ile Asp Val His Thr Leu
690 695 700

Thr Ala Ser Arg Ile Phe Asn Val Lys Pro Glu Glu Val Thr Glu Glu
705 710 715 720

Met Arg Arg Ala Gly Lys Met Val Asn Phe Ser Ile Ile Tyr Gly Val
725 730 735

Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly Val Pro Val Lys Glu Ala
740 745 750

Glu Lys Met Ile Val Asn Tyr Phe Val Leu Tyr Pro Lys Val Arg Asp
755 760 765

Tyr Ile Gln Arg Val Val Ser Glu Ala Lys Glu Lys Gly Tyr Val Arg
770 775 780

Thr Leu Phe Gly Arg Lys Arg Asp Ile Pro Gln Leu Met Ala Arg Asp
785 790 795 800

Arg Asn Thr Gln Ala Glu Gly Glu Arg Ile Ala Ile Asn Thr Pro Ile
805 810 815

Gln Gly Thr Ala Ala Asp Ile Ile Lys Leu Ala Met Ile Glu Ile Asp
820 825 830

Arg Glu Leu Lys Glu Arg Lys Met Arg Ser Lys Met Ile Ile Gln Val
835 840 845

His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Asp Ala Leu
850 855 860

Val Glu Leu Val Lys Asp Arg Met Thr Asn Val Val Lys Leu Ser Val
865 870 875 880

Pro Leu Glu Val Asp Val Thr Ile Gly Lys Thr Trp Ser Gly Thr Gly
885 890 895

Gly Gly Gly Glu Glu Ile Lys Glu Ile Met Lys Ser His Thr Leu Gly
900 905 910

Asn Pro Val Arg Leu Gly Ile Met Ile Tyr Leu Phe Pro Arg Arg Arg
915 920 925

Ala Pro Phe Ser His Ile Gln Lys Ala Leu Asp Leu Thr Pro Gly Asn
930 935 940

Leu Asp Ser His Ile Lys Val Leu Glu Lys His Gly Phe Val Arg Thr
945 950 955 960

Tyr Lys Val Ile Ala Asp Arg Pro Arg Thr Met Val Glu Ile Thr Asp
965 970 975

US 9,963,687 B2

239**240**

-continued

Tyr Gly Met Glu Glu Thr Arg Lys Phe Leu Ser His Leu Lys Thr Val
 980 985 990

Ile Asp Ala Ile His Phe
 995

<210> SEQ ID NO 119

<211> LENGTH: 851

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 119

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly
 1 5 10 15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe
 20 25 30

Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn
 35 40 45

Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu
 50 55 60

Gly Val Ile Lys Pro Phe Lys Val Glu Glu Val Arg Arg Lys Val Phe
 65 70 75 80

Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His
 85 90 95

Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu
 100 105 110

Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala
 115 120 125

Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Arg Gly
 130 135 140

Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu
 145 150 155 160

Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu
 165 170 175

Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Ile Gly Val Lys
 180 185 190

Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu
 195 200 205

Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val
 210 215 220

Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala
 225 230 235 240

Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile
 245 250 255

Ser Phe Arg Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp
 260 265 270

Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu
 275 280 285

Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu
 290 295 300

Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val
 305 310 315 320

Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu
 325 330 335

-continued

Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro
 340 345 350
 Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe
 355 360 365
 Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala
 370 375 380
 Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg
 385 390 395 400
 Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro
 405 410 415
 Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly
 420 425 430
 Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg
 435 440 445
 Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
 450 455 460
 Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
 465 470 475 480
 Arg Glu Tyr Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
 485 490 495
 Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
 500 505 510
 Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile
 515 520 525
 Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr
 530 535 540
 Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu
 545 550 555 560
 Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys
 565 570 575
 Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe
 580 585 590
 Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val
 595 600 605
 Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys
 610 615 620
 Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro
 625 630 635 640
 Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser
 645 650 655
 Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys
 660 665 670
 Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu
 675 680 685
 Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
 690 695 700
 Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
 705 710 715 720
 Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
 725 730 735
 Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
 740 745 750
 His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr

-continued

755 760 765

Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe
770 775 780

Trp Gly Thr Gly Gly Gly Lys Arg Arg Pro Thr Ile Asn Asp Val
785 790 795 800

Ala Lys Leu Ala Gly Val Ser Ile Ser Thr Val Ser Arg Tyr Leu Lys
805 810 815

Asp Pro Ser Gln Val Ser Glu Lys Leu Gly Glu Arg Ile Arg Glu Ala
820 825 830

Ile Lys Lys Leu Gly Tyr Lys Pro Asn Lys Ile Ala Gln Gly Leu Arg
835 840 845

Thr Gly Asp
850

<210> SEQ_ID NO 120

<211> LENGTH: 851

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 120

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly
1 5 10 15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe
20 25 30

Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn
35 40 45

Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu
50 55 60

Gly Val Ile Lys Pro Phe Lys Val Glu Val Arg Arg Lys Val Phe
65 70 75 80

Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His
85 90 95

Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu
100 105 110

Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala
115 120 125

Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly
130 135 140

Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu
145 150 155 160

Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu
165 170 175

Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Ile Gly Val Lys
180 185 190

Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu
195 200 205

Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val
210 215 220

Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala
225 230 235 240

Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile
245 250 255

Ser Phe Arg Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp

US 9,963,687 B2

245

-continued

246

260	265	270
Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu		
275	280	285
Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu		
290	295	300
Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val		
305	310	315
Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu		
325	330	335
Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro		
340	345	350
Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe		
355	360	365
Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala		
370	375	380
Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg		
385	390	395
Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro		
405	410	415
Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly		
420	425	430
Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg		
435	440	445
Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu		
450	455	460
Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser		
465	470	475
Arg Glu Tyr Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu		
485	490	495
Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr		
500	505	510
Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile		
515	520	525
Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr		
530	535	540
Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu		
545	550	555
Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys		
565	570	575
Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe		
580	585	590
Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val		
595	600	605
Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys		
610	615	620
Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro		
625	630	635
Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser		
645	650	655
Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys		
660	665	670
Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu		
675	680	685

-continued

Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
690 695 700

Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
705 710 715 720

Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
725 730 735

Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
740 745 750

His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr
755 760 765

Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe
770 775 780

Trp Gly Thr Gly Gly Gly Lys Lys Tyr Val Thr Ile Arg Asp
785 790 795 800

Ile Ala Glu Lys Ala Gly Val Ser Ile Asn Thr Val Ser Arg Ala Leu
805 810 815

Asn Asn Lys Pro Asp Ile Ser Glu Glu Thr Arg Arg Lys Ile Leu Lys
820 825 830

Ile Ala Gln Glu Leu Gly Tyr Val Lys Asn Ala Thr Ala Ser Ser Leu
835 840 845

Arg Ser Lys
850

<210> SEQ_ID NO 121
<211> LENGTH: 872
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 121

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly
1 5 10 15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe
20 25 30

Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn
35 40 45

Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu
50 55 60

Gly Val Ile Lys Pro Phe Lys Val Glu Glu Val Arg Arg Lys Val Phe
65 70 75 80

Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His
85 90 95

Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu
100 105 110

Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala
115 120 125

Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly
130 135 140

Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu
145 150 155 160

Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu
165 170 175

Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Gly Val Lys
180 185 190

US 9,963,687 B2

249**250**

-continued

Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu
195 200 205

Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val
210 215 220

Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala
225 230 235 240

Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile
245 250 255

Ser Phe Arg Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp
260 265 270

Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu
275 280 285

Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu
290 295 300

Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val
305 310 315 320

Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu
325 330 335

Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro
340 345 350

Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe
355 360 365

Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala
370 375 380

Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg
385 390 395 400

Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro
405 410 415

Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly
420 425 430

Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg
435 440 445

Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
450 455 460

Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
465 470 475 480

Arg Glu Tyr Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
485 490 495

Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
500 505 510

Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile
515 520 525

Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr
530 535 540

Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu
545 550 555 560

Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys
565 570 575

Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe
580 585 590

Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val
595 600 605

-continued

Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys
610 615 620

Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro
625 630 635 640

Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser
645 650 655

Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys
660 665 670

Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu
675 680 685

Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
690 695 700

Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
705 710 715 720

Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
725 730 735

Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
740 745 750

His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr
755 760 765

Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe
770 775 780

Trp Gly Thr Gly Gly Gly His Lys Lys Leu Asn Pro Lys Ser Met
785 790 795 800

Lys Arg Glu Asn Lys Lys Met Val Leu Arg Tyr Leu Ile Glu Ser Gly
805 810 815

Pro His Ser Arg Val Glu Ile Ala Arg Lys Thr Gly Leu Ala Gln Ser
820 825 830

Ala Ile Trp Arg Ile Ile Glu Glu Leu Val Asn Glu Gly Leu Val Glu
835 840 845

Glu Lys Gly Thr Ala Thr Gly Arg Arg Lys Ala Val Thr Tyr Gly
850 855 860

Pro Thr Arg Ser Phe Ile Thr Ser
865 870

<210> SEQ ID NO 122
<211> LENGTH: 862
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 122

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly
1 5 10 15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe
20 25 30

Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn
35 40 45

Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu
50 55 60

Gly Val Ile Lys Pro Phe Lys Val Glu Glu Val Arg Arg Lys Val Phe
65 70 75 80

Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His
85 90 95

-continued

Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu
100 105 110

Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala
115 120 125

Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly
130 135 140

Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu
145 150 155 160

Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu
165 170 175

Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Ile Gly Val Lys
180 185 190

Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu
195 200 205

Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val
210 215 220

Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala
225 230 235 240

Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile
245 250 255

Ser Phe Arg Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp
260 265 270

Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu
275 280 285

Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu
290 295 300

Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val
305 310 315 320

Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu
325 330 335

Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro
340 345 350

Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe
355 360 365

Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala
370 375 380

Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg
385 390 395 400

Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro
405 410 415

Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly
420 425 430

Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg
435 440 445

Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
450 455 460

Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
465 470 475 480

Arg Glu Tyr Leu Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
485 490 495

Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
500 505 510

Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile

US 9,963,687 B2

255

-continued

256

515	520	525
Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe	Glu Val Leu Tyr	
530	535	540
Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn	Leu Ser Leu Glu	
545	550	555
Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu	Ile Ser Glu Lys	
565	570	575
Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys	Thr Ile Phe Phe	
580	585	590
Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp	Gly Ile Leu Val	
595	600	605
Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys	Glu Leu Ala Lys	
610	615	620
Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys	Glu Asn Pro	
625	630	635
Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn	Asp Ile Lys Ser	
645	650	655
Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys	Gly Leu Thr Lys	
660	665	670
Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val	Lys Ala Ala Leu	
675	680	685
Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly	Ser Lys Val Gly	
690	695	700
Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp	Arg Ala Tyr Pro	
705	710	715
Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu	Val Ile Arg Thr	
725	730	735
Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp	Tyr Ile Asn	
740	745	750
His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu	Arg Phe Gly Tyr	
755	760	765
Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr	Leu Asp Ala Phe	
770	775	780
Trp Gly Thr Gly Gly Gly Asn Thr Gly Ala Gln Gly	Val Ser Glu	
785	790	795
Met Ser Arg Met Lys Ile Ile Ser Val Gln Leu Pro	Gln Ser Leu Ile	
805	810	815
His Gly Leu Asp Ala Leu Val Lys Arg Gly Ile Tyr	Pro Asn Arg Ser	
820	825	830
Glu Ala Ile Arg Val Ala Ile Arg Glu Leu Leu Lys	Glu Leu Tyr	
835	840	845
Lys Glu Glu Ile Gln Glu Ile Pro Glu Tyr Val Val	Lys	
850	855	860

<210> SEQ_ID NO 123

<211> LENGTH: 866

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 123

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr	Ala Glu Asp Gly
1	5
10	15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe

US 9,963,687 B2

257

-continued

20	25	30
Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn		
35	40	45
Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu		
50	55	60
Gly Val Ile Lys Pro Phe Lys Val Glu Glu Val Arg Arg Lys Val Phe		
65	70	75
Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His		
85	90	95
Val Pro Lys Leu Arg Glu Glu Leu Lys Ile Thr Glu Val Arg Glu		
100	105	110
Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala		
115	120	125
Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly		
130	135	140
Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu		
145	150	155
Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu		
165	170	175
Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Ile Gly Val Lys		
180	185	190
Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu		
195	200	205
Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val		
210	215	220
Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala		
225	230	235
Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile		
245	250	255
Ser Phe Arg Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp		
260	265	270
Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu		
275	280	285
Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu		
290	295	300
Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val		
305	310	315
Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu		
325	330	335
Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro		
340	345	350
Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe		
355	360	365
Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala		
370	375	380
Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg		
385	390	395
Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro		
405	410	415
Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly		
420	425	430
Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg		
435	440	445

258

US 9,963,687 B2

259**260**

-continued

Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
450 455 460

Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
465 470 475 480

Arg Glu Tyr Leu Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
485 490 495

Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
500 505 510

Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile
515 520 525

Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr
530 535 540

Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu
545 550 555 560

Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys
565 570 575

Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe
580 585 590

Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val
595 600 605

Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys
610 615 620

Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro
625 630 635 640

Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser
645 650 655

Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys
660 665 670

Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu
675 680 685

Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
690 695 700

Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
705 710 715 720

Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
725 730 735

Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
740 745 750

His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr
755 760 765

Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe
770 775 780

Trp Gly Thr Gly Gly Gly Ile Ile Asn Pro Gln Ala Arg Leu Thr
785 790 795 800

Pro Leu Glu Leu Glu Ile Leu Glu Ile Ile Lys Gln Lys Lys Ser Ile
805 810 815

Thr Ile Thr Glu Ile Lys Glu Ile Leu Ser Glu Arg Arg Lys Ser Glu
820 825 830

Tyr Pro Leu Ser Leu Val Ser Glu Tyr Ile Ser Arg Leu Glu Arg Lys
835 840 845

Gly Tyr Val Lys Lys Ile Ala Lys Gly Arg Lys Lys Phe Val Glu Ala
850 855 860

-continued

Leu Ile
865

```

<210> SEQ ID NO 124
<211> LENGTH: 873
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 124

Met Glu Gly Trp Leu Leu Asp Ala Asp Tyr Ile Thr Ala Glu Asp Gly
1           5          10          15

Arg Ala Val Val Arg Leu Trp Cys Lys Asp Phe Asp Gly Asn Thr Phe
20          25          30

Val Val Tyr Asp Arg Asn Phe Gln Pro Tyr Phe Tyr Ala Phe Lys Asn
35          40          45

Gly Leu Ser Lys Glu Asp Ile Glu Lys Ile Val Val Lys Ser Arg Glu
50          55          60

Gly Val Ile Lys Pro Phe Lys Val Glu Glu Val Arg Arg Lys Val Phe
65          70          75          80

Gly Lys Glu Val Glu Val Phe Lys Ile Tyr Ala Tyr His Pro Gln His
85          90          95

Val Pro Lys Leu Arg Glu Glu Leu Lys Lys Ile Thr Glu Val Arg Glu
100         105         110

Ala Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala
115         120         125

Cys Met Asp Gly Ile Arg Val Glu Gly Lys Val Arg Glu Glu Arg Gly
130         135         140

Leu Lys Val Ile Asp Ala Glu His Val Glu Arg Phe Glu Ile Pro Leu
145         150         155         160

Pro Glu Pro Lys Val Leu Ala Phe Asp Cys Glu Met Leu Thr Glu Leu
165         170         175

Gly Met Pro Asp Pro Glu Lys Asp Lys Ile Ile Ile Ile Gly Val Lys
180         185         190

Cys Gly Asp Phe Glu Glu Ile Ile Thr Gly Asn Glu Arg Glu Ile Leu
195         200         205

Leu Arg Phe Val Glu Ile Ile Lys Glu Gln Asp Pro Asp Val Ile Val
210         215         220

Gly Tyr Asn Gln Asp Asn Phe Asp Trp Pro Tyr Ile Arg Lys Arg Ala
225         230         235         240

Glu Lys Leu Ser Val Lys Leu Asn Ile Gly Arg Asp Gly Ser Glu Ile
245         250         255

Ser Phe Arg Gly Gly Arg Pro Lys Ile Ala Gly Arg Leu Asn Val Asp
260         265         270

Leu Tyr Asp Ile Ala Met Lys Leu Asp Val Lys Val Lys Thr Leu Glu
275         280         285

Asn Val Ala Glu Phe Leu Gly Arg Lys Val Glu Leu Ala Asp Ile Glu
290         295         300

Ala Lys Asp Ile Tyr Lys Arg Trp Thr Ser Gly Asp Lys Glu Ser Val
305         310         315         320

Leu Lys Tyr Ser Lys Gln Asp Val Leu Asn Thr Tyr Phe Ile Ala Glu
325         330         335

Glu Leu Leu Pro Met His Tyr Glu Leu Ser Arg Met Ile Arg Ile Pro
340         345         350

```

-continued

Thr Asp Asp Val Ala Arg Ile Gly Arg Gly Lys Gln Val Asp Trp Phe
 355 360 365
 Leu Leu Ser Glu Ala Tyr Lys Ile Gly Glu Ile Ala Pro Asn Pro Ala
 370 375 380
 Glu Val Glu Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Ser Arg
 385 390 395 400
 Gly Leu His Lys Asn Val Val Cys Leu Asp Phe Ala Ser Met Tyr Pro
 405 410 415
 Ser Ile Met Ile Ala Tyr Asn Ile Ser Pro Asp Thr Tyr Val Phe Gly
 420 425 430
 Lys Cys Asp Asp Cys Tyr Val Ala Pro Glu Val Gly His Lys Phe Arg
 435 440 445
 Lys His Pro Asp Gly Phe Phe Lys Arg Ile Leu Lys Met Leu Ile Glu
 450 455 460
 Lys Arg Arg Glu Ile Lys Asn Gln Met Lys Ser Leu Asp Arg Asn Ser
 465 470 475 480
 Arg Glu Tyr Leu Leu Asn Ile Lys Gln Gln Thr Leu Lys Ile Leu
 485 490 495
 Thr Asn Ser Phe Tyr Gly Tyr Thr Gly Trp Ser Gly Ala Arg Trp Tyr
 500 505 510
 Cys Arg Gln Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Leu Ile
 515 520 525
 Lys Ser Ala Val Glu Ile Ala Lys Lys Leu Gly Phe Glu Val Leu Tyr
 530 535 540
 Gly Asp Thr Asp Ser Ile Phe Val Lys Lys Gly Asn Leu Ser Leu Glu
 545 550 555 560
 Lys Ile Arg Gly Glu Val Glu Lys Leu Ile Glu Glu Ile Ser Glu Lys
 565 570 575
 Phe Pro Val Gln Ile Glu Val Asp Glu Tyr Tyr Lys Thr Ile Phe Phe
 580 585 590
 Val Glu Lys Lys Arg Tyr Ala Gly Leu Thr Glu Asp Gly Ile Leu Val
 595 600 605
 Val Lys Gly Leu Glu Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys
 610 615 620
 Glu Val Gln Lys Lys Val Ile Glu Ile Ile Leu Lys Glu Glu Asn Pro
 625 630 635 640
 Glu Lys Ala Ala Glu Tyr Val Arg Lys Val Ile Asn Asp Ile Lys Ser
 645 650 655
 Gly Lys Val Lys Leu Glu Asp Val Val Ile Tyr Lys Gly Leu Thr Lys
 660 665 670
 Arg Pro Asp Lys Tyr Glu Ser Lys Gln Ala His Val Lys Ala Ala Leu
 675 680 685
 Arg Ala Met Glu Leu Gly Ile Val Tyr Asn Val Gly Ser Lys Val Gly
 690 695 700
 Phe Val Val Val Glu Gly Ala Gly Asn Val Gly Asp Arg Ala Tyr Pro
 705 710 715 720
 Ile Asp Leu Ile Glu Glu Phe Asp Gly Glu Asn Leu Val Ile Arg Thr
 725 730 735
 Arg Ser Gly Ser Ile Val Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asn
 740 745 750
 His Gln Ile Ile Pro Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr
 755 760 765
 Asn Glu Ala Ser Leu Lys Gly Ala Thr Gln Lys Thr Leu Asp Ala Phe

US 9,963,687 B2

265

-continued

770	775	780
Trp Gly Thr Gly Gly Gly Gly Arg Lys Val Arg Thr Gln Gln Asn		
785	790	795
Glu Ile Leu Asn Leu Leu Asn Glu Lys Glu Lys Ala Val Leu Arg Ala		
805	810	815
Ile Leu Glu His Gly Gly Glu Ile Lys Gln Glu Asp Leu Pro Glu Leu		
820	825	830
Val Gly Tyr Ser Arg Pro Thr Ile Ser Lys Val Ile Gln Glu Leu Glu		
835	840	845
Asn Lys Gly Leu Ile Lys Arg Glu Lys Ser Gly Lys Thr Phe Val Val		
850	855	860
Lys Ile Glu Arg Lys Ile Lys Leu Asp		
865	870	

<210> SEQ_ID NO 125
<211> LENGTH: 841
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 125

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile		
1	5	10
Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg		
20	25	30
Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile		
35	40	45
Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg		
50	55	60
Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile		
65	70	75
Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met		
85	90	95
Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr		
100	105	110
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro		
115	120	125
Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr		
130	135	140
Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile		
145	150	155
Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile		
165	170	175
Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys		
180	185	190
Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr		
195	200	205
Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu		
210	215	220
Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys		
225	230	235
Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile		
245	250	255
His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr		

266

US 9,963,687 B2

267

-continued

260	265	270
Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu		
275	280	285
Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly		
290	295	300
Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr		
305	310	315
Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu		
325	330	335
Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
340	345	350
Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365
Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser		
370	375	380
Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly		
385	390	395
Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr		
405	410	415
His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr		
420	425	430
Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly		
435	440	445
Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile		
450	455	460
Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu		
465	470	475
480		
Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly		
485	490	495
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu		
500	505	510
Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu		
515	520	525
Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu		
530	535	540
Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg		
545	550	555
560		
Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu		
565	570	575
Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys		
580	585	590
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly		
595	600	605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
610	615	620
Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala		
625	630	635
640		
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile		
645	650	655
Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn		
660	665	670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala		
675	680	685

268

-continued

Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
 705 710 715 720
 Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735
 Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
 740 745 750
 Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
 755 760 765
 Trp Leu Lys Val Lys Ser Gly Thr Gly Gly Lys Arg Arg
 770 775 780
 Pro Thr Ile Asn Asp Val Ala Lys Leu Ala Gly Val Ser Ile Ser Thr
 785 790 795 800
 Val Ser Arg Tyr Leu Lys Asp Pro Ser Gln Val Ser Glu Lys Leu Gly
 805 810 815
 Glu Arg Ile Arg Glu Ala Ile Lys Lys Leu Gly Tyr Lys Pro Asn Lys
 820 825 830
 Ile Ala Gln Gly Leu Arg Thr Gly Asp
 835 840

<210> SEQ ID NO 126
 <211> LENGTH: 841
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic construct

 <400> SEQUENCE: 126

 Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15

 Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
 20 25 30

 Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45

 Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
 50 55 60

 Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

 Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
 85 90 95

 Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110

 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125

 Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140

 Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160

 Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175

 Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190

 Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

-continued

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355 360 365

Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
370 375 380

Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
385 390 395 400

Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
405 410 415

His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
420 425 430

Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
435 440 445

Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Arg Gln Lys Ile
450 455 460

Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
465 470 475 480

Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
485 490 495

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
500 505 510

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

-continued

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
 625 630 635 640
 Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
 645 650 655
 Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
 660 665 670
 Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685
 Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
 705 710 715 720
 Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735
 Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
 740 745 750
 Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
 755 760 765
 Trp Leu Lys Val Lys Lys Ser Gly Thr Gly Gly Gly Lys Lys Lys
 770 775 780
 Tyr Val Thr Ile Arg Asp Ile Ala Glu Lys Ala Gly Val Ser Ile Asn
 785 790 795 800
 Thr Val Ser Arg Ala Leu Asn Asn Lys Pro Asp Ile Ser Glu Glu Thr
 805 810 815
 Arg Arg Lys Ile Leu Lys Ile Ala Gln Glu Leu Gly Tyr Val Lys Asn
 820 825 830
 Ala Thr Ala Ser Ser Leu Arg Ser Lys
 835 840

<210> SEQ_ID NO 127
 <211> LENGTH: 862
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic construct

 <400> SEQUENCE: 127

 Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15
 Arg Leu Phe Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
 20 25 30
 Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
 50 55 60
 Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
 85 90 95
 Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140

-continued

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190
 Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220
 Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240
 Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
 275 280 285
 Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300
 Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335
 Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
 385 390 395 400
 Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
 420 425 430
 Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile
 450 455 460
 Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510
 Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
 515 520 525
 Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
 530 535 540
 Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
 545 550 555 560
 Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu

US 9,963,687 B2

277

278

-continued

565	570	575
Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys		
580	585	590
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly		
595	600	605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
610	615	620
Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Ala		
625	630	635
640		
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile		
645	650	655
Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn		
660	665	670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala		
675	680	685
Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val		
690	695	700
Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu		
705	710	715
720		
Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn		
725	730	735
Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys		
740	745	750
Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala		
755	760	765
Trp Leu Lys Val Lys Lys Ser Gly Thr Gly Gly Gly His Lys Lys		
770	775	780
Leu Asn Pro Lys Ser Met Lys Arg Glu Asn Lys Lys Met Val Leu Arg		
785	790	795
800		
Tyr Leu Ile Glu Ser Gly Pro His Ser Arg Val Glu Ile Ala Arg Lys		
805	810	815
Thr Gly Leu Ala Gln Ser Ala Ile Trp Arg Ile Ile Glu Glu Leu Val		
820	825	830
Asn Glu Gly Leu Val Glu Glu Lys Gly Thr Ala Thr Gly Arg Arg Arg		
835	840	845
Lys Ala Val Thr Tyr Gly Pro Thr Arg Ser Phe Ile Thr Ser		
850	855	860

<210> SEQ ID NO 128

<211> LENGTH: 852

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 128

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile		
1	5	10
15		
Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg		
20	25	30
Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile		
35	40	45
Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg		
50	55	60
Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile		

US 9,963,687 B2

279

-continued

280

65	70	75	80												
Glu	Val	Trp	Lys	Leu	Tyr	Phe	Glu	His	Pro	Gln	Asp	Val	Pro	Ala	Met
85							90							95	
Arg	Asp	Lys	Ile	Arg	Glu	His	Pro	Ala	Val	Ile	Asp	Ile	Phe	Glu	Tyr
100							105						110		
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro
115							120						125		
Met	Glu	Gly	Asn	Glu	Glu	Leu	Thr	Phe	Leu	Ala	Val	Asp	Ile	Glu	Thr
130						135					140				
Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Gly	Lys	Gly	Pro	Ile	Ile	Met	Ile
145						150				155			160		
Ser	Tyr	Ala	Asp	Glu	Glu	Gly	Ala	Lys	Val	Ile	Thr	Trp	Lys	Lys	Ile
165						170				175					
Asp	Leu	Pro	Tyr	Val	Glu	Val	Val	Ala	Asn	Glu	Arg	Glu	Met	Ile	Lys
180						185							190		
Arg	Leu	Ile	Lys	Val	Ile	Arg	Glu	Lys	Asp	Pro	Asp	Val	Ile	Ile	Thr
195						200							205		
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Phe	Pro	Tyr	Leu	Leu	Lys	Arg	Ala	Glu
210						215						220			
Lys	Leu	Gly	Met	Lys	Leu	Pro	Leu	Gly	Arg	Asp	Asn	Ser	Glu	Pro	Lys
225						230				235			240		
Met	Gln	Arg	Leu	Gly	Asp	Ser	Leu	Ala	Val	Glu	Ile	Lys	Gly	Arg	Ile
245						250				255			255		
His	Phe	Asp	Leu	Phe	Pro	Val	Ile	Arg	Arg	Thr	Ile	Asn	Leu	Pro	Thr
260						265						270			
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Lys	Gln	Lys	Glu
275						280					285				
Lys	Val	Tyr	Pro	His	Glu	Ile	Ala	Glu	Ala	Trp	Glu	Thr	Gly	Lys	Gly
290						295					300				
Leu	Glu	Arg	Val	Ala	Lys	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Tyr
305						310					315			320	
Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Gln	Leu	Ala	Arg	Leu
325						330					335				
Val	Gly	Gln	Pro	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu
340						345						350			
Val	Glu	Trp	Tyr	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Leu	Ala
355						360					365				
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Tyr	Glu	Arg	Arg	Leu	Arg	Glu	Ser
370						375					380				
Tyr	Glu	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Glu	Gly
385						390				395			400		
Ile	Val	Ser	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr
405						410					415				
His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Lys	Glu	Gly	Cys	Gly	Glu	Tyr
420						425					430				
Asp	Glu	Ala	Pro	Glu	Val	Gly	His	Arg	Phe	Cys	Lys	Asp	Phe	Pro	Gly
435						440					445				
Phe	Ile	Pro	Ser	Leu	Leu	Gly	Ser	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile
450						455					460				
Lys	Lys	Arg	Met	Lys	Glu	Ser	Lys	Asp	Pro	Val	Glu	Arg	Lys	Leu	Leu
465						470				475			480		
Asp	Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Phe	Tyr	Gly
485						490					495				

-continued

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
500 505 510

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
645 650 655

Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
675 680 685

Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
705 710 715 720

Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
740 745 750

Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
755 760 765

Trp Leu Lys Val Lys Ser Gly Thr Gly Gly Gly Asn Thr Gly
770 775 780

Ala Gln Gly Val Ser Glu Met Ser Arg Met Lys Ile Ile Ser Val Gln
785 790 795 800

Leu Pro Gln Ser Leu Ile His Gly Leu Asp Ala Leu Val Lys Arg Gly
805 810 815

Ile Tyr Pro Asn Arg Ser Glu Ala Ile Arg Val Ala Ile Arg Glu Leu
820 825 830

Leu Lys Lys Glu Leu Tyr Lys Glu Glu Ile Gln Glu Glu Ile Pro Glu
835 840 845

Tyr Val Val Lys
850

<210> SEQ ID NO 129
<211> LENGTH: 856
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 129

-continued

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15
 Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
 20 25 30
 Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
 50 55 60
 Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
 85 90 95
 Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
 180 185 190
 Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220
 Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240
 Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
 275 280 285
 Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300
 Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335
 Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly
 385 390 395 400
 Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415

-continued

His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr
420 425 430

Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
435 440 445

Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile
450 455 460

Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu
465 470 475 480

Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly
485 490 495

Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
500 505 510

Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu
515 520 525

Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
530 535 540

Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg
545 550 555 560

Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
625 630 635 640

Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile
645 650 655

Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn
660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
675 680 685

Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val
690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu
705 710 715 720

Phe Asp Gly Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys
740 745 750

Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala
755 760 765

Trp Leu Lys Val Lys Lys Ser Gly Thr Gly Gly Gly Ile Ile Asn
770 775 780

Pro Gln Ala Arg Leu Thr Pro Leu Glu Leu Glu Ile Leu Glu Ile Ile
785 790 795 800

Lys Gln Lys Lys Ser Ile Thr Ile Thr Glu Ile Lys Glu Ile Leu Ser
805 810 815

Glu Arg Arg Lys Ser Glu Tyr Pro Leu Ser Leu Val Ser Glu Tyr Ile
820 825 830

Ser Arg Leu Glu Arg Lys Gly Tyr Val Lys Lys Ile Ala Lys Gly Arg

-continued

835	840	845
-----	-----	-----

Lys Lys Phe Val Glu Ala Leu Ile
850 855

<210> SEQ_ID NO 130
<211> LENGTH: 863
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic construct

<400> SEQUENCE: 130

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Leu Phe Lys Lys Glu Asn Gly Arg Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Asp Asp Val Arg Lys Ile Thr Ser Glu Arg His Gly Lys Val Val Arg
50 55 60

Val Ile Asp Val Glu Lys Val Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Met
85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Phe Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ala Asn Glu Arg Glu Met Ile Lys
180 185 190

Arg Leu Ile Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
210 215 220

Lys Leu Gly Met Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
225 230 235 240

Met Gln Arg Leu Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Gln Lys Glu
275 280 285

Lys Val Tyr Pro His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
325 330 335

Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu

US 9,963,687 B2

289**290**

-continued

340	345	350
Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
355	360	365
Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser		
370	375	380
Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Gly		
385	390	395
Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr		
405	410	415
His Asn Val Ser Pro Asp Thr Leu Asn Lys Glu Gly Cys Gly Glu Tyr		
420	425	430
Asp Glu Ala Pro Glu Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly		
435	440	445
Phe Ile Pro Ser Leu Leu Gly Ser Leu Leu Glu Glu Arg Gln Lys Ile		
450	455	460
Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Arg Lys Leu Leu		
465	470	475
Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly		
485	490	495
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu		
500	505	510
Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Leu Val Arg Arg Glu		
515	520	525
Leu Glu Glu Arg Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu		
530	535	540
Tyr Ala Thr Ile Pro Gly Glu Lys Asn Trp Glu Glu Ile Lys Arg Arg		
545	550	555
Ala Leu Glu Phe Val Asn Tyr Ile Asn Ser Lys Leu Pro Gly Ile Leu		
565	570	575
Glu Leu Glu Tyr Glu Gly Phe Tyr Thr Arg Gly Phe Phe Val Thr Lys		
580	585	590
Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly		
595	600	605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
610	615	620
Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala		
625	630	635
Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Asn Tyr Glu Ile		
645	650	655
Pro Val Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Asn		
660	665	670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala		
675	680	685
Ala Lys Gly Ile Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Val Val		
690	695	700
Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu		
705	710	715
Phe Asp Gly Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn		
725	730	735
Gln Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys		
740	745	750
Arg Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Val Gly Leu Gly Ala		
755	760	765

-continued

Trp Leu Lys Val Lys Lys Ser Gly Thr Gly Gly Gly Gly Arg Lys
770 775 780

Val Arg Thr Gln Gln Asn Glu Ile Leu Asn Leu Leu Asn Glu Lys Glu
785 790 795 800

Lys Ala Val Leu Arg Ala Ile Leu Glu His Gly Gly Glu Ile Lys Gln
805 810 815

Glu Asp Leu Pro Glu Leu Val Gly Tyr Ser Arg Pro Thr Ile Ser Lys
820 825 830

Val Ile Gln Glu Leu Glu Asn Lys Gly Leu Ile Lys Arg Glu Lys Ser
835 840 845

Gly Lys Thr Phe Val Val Lys Ile Glu Arg Lys Ile Lys Leu Asp
850 855 860

What is claimed is:

1. A composition comprising a fusion protein comprising:
(a) a DNA polymerase; and
(b) a sequence-specific DNA binding domain.
2. The composition of claim 1, wherein the fusion protein exhibits increased processivity relative to the polymerase of
(a) in the absence of the DNA binding domain of (b).
3. The composition of claim 1, wherein the sequence-specific DNA binding domain is N-terminal of the polymerase.
4. The composition of claim 1, wherein the sequence-specific DNA binding domain is C-terminal of the polymerase.
5. The composition of claim 1, wherein the DNA polymerase is a type A polymerase.
6. The composition of claim 1, wherein the DNA polymerase is a type B polymerase.
7. The composition of claim 1, wherein the sequence-specific DNA binding domain has a helix-loop-helix, ribbon-helix-helix, helix-turn-helix, winged helix, or homeodomain structure.
8. The composition of claim 1, wherein the sequence-specific DNA binding domain is from a transcriptional activator.
9. The composition of claim 1, wherein the polymerase has proofreading activity.
10. The composition of claim 1, wherein the wild type polymerase is bacterial or archaeabacterial.
11. The composition of claim 1, wherein the amino acid sequence of the sequence-specific DNA binding domain is at least 90% identical to a DNA binding domain of any of SEQ ID NOS 56-97.
- 20 12. The composition of claim 1, wherein the amino acid sequence of the polymerase is at least 90% identical to the amino acid sequence of any of SEQ ID NOS. 33-55.
13. The composition of claim 12, wherein the amino acid sequence of the polymerase is at least 90% identical to either the amino acid sequence of a Pyrococcal polymerase of any of SEQ ID NOS. 41, 47, or 48 or the amino acid sequence of a Thermococcal polymerase of any of SEQ ID NOS. 42-46, 51 or 52.
- 30 14. The composition of claim 1, wherein the polymerase is thermostable.
15. The composition of claim 1, wherein the sequence-specific DNA binding domain is thermostable.
16. A kit comprising:
(a) the composition of claim 1; and
(b) a reaction buffer.
- 35 17. The kit of claim 16, wherein the composition further comprises glycerol.
18. The kit of claim 16, wherein the buffer is in concentrated form.
19. A method comprising:
combining a DNA template, nucleotides, and the composition of claim 1 to produce a reaction mix; and
copying the DNA template.
- 40 20. The method of claim 19, wherein the DNA template is a plurality of overlapping primers.
21. The method of claim 19, wherein the DNA template is genomic DNA.
22. The method of claim 19, wherein the copying step is done using isothermal conditions.
- 45 23. The method of claim 19, wherein the copying step is done by thermocycling.

* * * * *